Genotypes B-Claim
of I-Claim
glutathione-related I-Claim
enzymes I-Claim
, I-Claim
especially I-Claim
GCLC I-Claim
, I-Claim
may I-Claim
be I-Claim
used I-Claim
as I-Claim
host I-Claim
factors I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
survival I-Claim
after I-Claim
platinum-based I-Claim
chemotherapy I-Claim
. I-Claim

Despite B-Claim
considerable I-Claim
improvement I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
, I-Claim
the I-Claim
optimization I-Claim
of I-Claim
efficacy I-Claim
and I-Claim
tolerability I-Claim
remains I-Claim
an I-Claim
important I-Claim
issue I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
self-directed I-Claim
movement I-Claim
and I-Claim
mindfulness I-Claim
, I-Claim
as I-Claim
tested I-Claim
here I-Claim
, I-Claim
may I-Claim
be I-Claim
a I-Claim
valuable I-Claim
tool I-Claim
for I-Claim
promoting I-Claim
health I-Claim
and I-Claim
well-being I-Claim
in I-Claim
older I-Claim
long-term I-Claim
survivors I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Some B-Claim
studies I-Claim
have I-Claim
also I-Claim
suggested I-Claim
that I-Claim
gemcitabine I-Claim
is I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
effective I-Claim
in I-Claim
such I-Claim
patients I-Claim
. I-Claim

Gemcitabine-carboplatin B-Claim
treatment I-Claim
significantly I-Claim
improves I-Claim
the I-Claim
PFS I-Claim
of I-Claim
patients I-Claim
with I-Claim
platinum-sensitive I-Claim
recurrent I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Laser B-Claim
treatment I-Claim
appeared I-Claim
to I-Claim
reduce I-Claim
the I-Claim
severity I-Claim
of I-Claim
facial I-Claim
hair I-Claim
and I-Claim
time I-Claim
spent I-Claim
on I-Claim
hair I-Claim
removal I-Claim
as I-Claim
well I-Claim
as I-Claim
alleviating I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
in I-Claim
women I-Claim
with I-Claim
PCOS I-Claim
. I-Claim

Given B-Claim
the I-Claim
results I-Claim
of I-Claim
the I-Claim
TEAM I-Claim
trial I-Claim
, I-Claim
upfront I-Claim
use I-Claim
of I-Claim
tamoxifen I-Claim
followed I-Claim
by I-Claim
an I-Claim
aromatase I-Claim
inhibitor I-Claim
( I-Claim
AI I-Claim
) I-Claim
may I-Claim
be I-Claim
an I-Claim
important I-Claim
option I-Claim
for I-Claim
adjuvant I-Claim
endocrine I-Claim
therapy I-Claim
in I-Claim
Japanese I-Claim
postmenopausal I-Claim
women I-Claim
. I-Claim

Patient B-Claim
preference I-Claim
, I-Claim
demographic I-Claim
variables I-Claim
, I-Claim
and I-Claim
medical I-Claim
variables I-Claim
moderated I-Claim
the I-Claim
effects I-Claim
of I-Claim
exercise I-Claim
training I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
who I-Claim
were I-Claim
receiving I-Claim
chemotherapy I-Claim
. I-Claim

In B-Claim
advanced I-Claim
not I-Claim
selected I-Claim
NSCLC I-Claim
chemotherapy I-Claim
achieved I-Claim
an I-Claim
advantage I-Claim
of I-Claim
approximately I-Claim
1-2 I-Claim
months I-Claim
on I-Claim
median I-Claim
survival I-Claim
versus I-Claim
best I-Claim
supportive I-Claim
care I-Claim
. I-Claim

This B-Claim
research I-Claim
study I-Claim
indicates I-Claim
that I-Claim
live I-Claim
music I-Claim
therapy I-Claim
using I-Claim
patient-preferred I-Claim
music I-Claim
can I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
improving I-Claim
quality I-Claim
of I-Claim
life I-Claim
indicators I-Claim
such I-Claim
as I-Claim
anxiety I-Claim
, I-Claim
perception I-Claim
of I-Claim
the I-Claim
hospitalization I-Claim
or I-Claim
procedure I-Claim
, I-Claim
relaxation I-Claim
, I-Claim
and I-Claim
stress I-Claim
in I-Claim
patients I-Claim
undergoing I-Claim
surgical I-Claim
procedures I-Claim
of I-Claim
the I-Claim
brain I-Claim
. I-Claim

The B-Claim
sequential I-Claim
addition I-Claim
of I-Claim
topotecan I-Claim
to I-Claim
carboplatin-paclitaxel I-Claim
did I-Claim
not I-Claim
result I-Claim
in I-Claim
superior I-Claim
overall I-Claim
response I-Claim
or I-Claim
progression-free I-Claim
or I-Claim
overall I-Claim
survival I-Claim
. I-Claim

Patients B-Claim
who I-Claim
performed I-Claim
prophylactic I-Claim
swallowing I-Claim
exercises I-Claim
had I-Claim
improved I-Claim
swallowing I-Claim
function I-Claim
at I-Claim
3 I-Claim
and I-Claim
6 I-Claim
months I-Claim
after I-Claim
CRT I-Claim
but I-Claim
not I-Claim
immediately I-Claim
after I-Claim
CRT I-Claim
or I-Claim
at I-Claim
9 I-Claim
and I-Claim
12 I-Claim
months I-Claim
after I-Claim
CRT I-Claim
. I-Claim

An B-Claim
antidepressant I-Claim
should I-Claim
be I-Claim
considered I-Claim
for I-Claim
early I-Claim
stage I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
depressive I-Claim
symptoms I-Claim
who I-Claim
are I-Claim
receiving I-Claim
adjuvant I-Claim
treatment I-Claim
. I-Claim

The B-Claim
global I-Claim
health I-Claim
status I-Claim
showed I-Claim
similar I-Claim
improvement I-Claim
in I-Claim
both I-Claim
arms I-Claim
during I-Claim
treatment I-Claim
. I-Claim

Whether B-Claim
such I-Claim
a I-Claim
lozenge I-Claim
would I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
treatment I-Claim
situations I-Claim
where I-Claim
rate I-Claim
of I-Claim
severe I-Claim
mucositis I-Claim
is I-Claim
higher I-Claim
( I-Claim
ie I-Claim
, I-Claim
in I-Claim
patients I-Claim
treated I-Claim
with I-Claim
unconventional I-Claim
fractionation I-Claim
or I-Claim
with I-Claim
concomitant I-Claim
chemotherapy I-Claim
) I-Claim
is I-Claim
unknown I-Claim
. I-Claim

Erlotinib B-Claim
maintenance I-Claim
therapy I-Claim
significantly I-Claim
extends I-Claim
progression-free I-Claim
survival I-Claim
without I-Claim
compromising I-Claim
patient I-Claim
HRQoL I-Claim
in I-Claim
comparison I-Claim
with I-Claim
placebo I-Claim
, I-Claim
with I-Claim
some I-Claim
improvement I-Claim
in I-Claim
symptoms I-Claim
. I-Claim

The B-Claim
use I-Claim
of I-Claim
recombinant I-Claim
human I-Claim
thyrotropin I-Claim
and I-Claim
low-dose I-Claim
( I-Claim
1.1 I-Claim
GBq I-Claim
) I-Claim
postoperative I-Claim
radioiodine I-Claim
ablation I-Claim
may I-Claim
be I-Claim
sufficient I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
low-risk I-Claim
thyroid I-Claim
cancer I-Claim
. I-Claim

Decreasing B-Claim
depression I-Claim
symptoms I-Claim
over I-Claim
the I-Claim
first I-Claim
year I-Claim
were I-Claim
associated I-Claim
with I-Claim
longer I-Claim
subsequent I-Claim
survival I-Claim
for I-Claim
women I-Claim
with I-Claim
MBC I-Claim
in I-Claim
this I-Claim
sample I-Claim
. I-Claim

Capecitabine/docetaxel B-Claim
was I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
anthracycline-pretreated I-Claim
advanced I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
and I-Claim
had I-Claim
an I-Claim
incremental I-Claim
cost-effectiveness I-Claim
ratio I-Claim
that I-Claim
compares I-Claim
very I-Claim
favorably I-Claim
with I-Claim
that I-Claim
of I-Claim
many I-Claim
other I-Claim
oncology I-Claim
therapies I-Claim
. I-Claim

The B-Claim
LV5FU2-oxaliplatin I-Claim
combination I-Claim
seems I-Claim
beneficial I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
in I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
demonstrating I-Claim
a I-Claim
prolonged I-Claim
progression-free I-Claim
survival I-Claim
with I-Claim
acceptable I-Claim
tolerability I-Claim
and I-Claim
maintenance I-Claim
of I-Claim
QoL I-Claim
. I-Claim

Moist B-Claim
desquamation I-Claim
was I-Claim
correlated I-Claim
with I-Claim
increased I-Claim
pain I-Claim
and I-Claim
reduction I-Claim
in I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Global B-Claim
quality I-Claim
of I-Claim
life I-Claim
did I-Claim
not I-Claim
differ I-Claim
within I-Claim
the I-Claim
three I-Claim
arms I-Claim
. I-Claim

Epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40,000 I-Claim
U I-Claim
once I-Claim
weekly I-Claim
( I-Claim
qw I-Claim
) I-Claim
to I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
chemotherapy I-Claim
increases I-Claim
hemoglobin I-Claim
levels I-Claim
, I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
and I-Claim
reduces I-Claim
transfusions I-Claim
. I-Claim

The B-Claim
two I-Claim
chemotherapy I-Claim
regimen I-Claim
showed I-Claim
a I-Claim
similar I-Claim
effectiveness I-Claim
in I-Claim
symptom I-Claim
palliation I-Claim
when I-Claim
evaluated I-Claim
with I-Claim
C30 I-Claim
addendum I-Claim
of I-Claim
EORTC I-Claim
QOL I-Claim
questionnaire I-Claim
. I-Claim

Pilates B-Claim
exercises I-Claim
are I-Claim
effective I-Claim
and I-Claim
safe I-Claim
in I-Claim
female I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Grade B-Claim
2 I-Claim
or I-Claim
higher I-Claim
acute I-Claim
toxicity I-Claim
was I-Claim
more I-Claim
common I-Claim
in I-Claim
the I-Claim
4 I-Claim
day I-Claim
group I-Claim
, I-Claim
approaching I-Claim
statistical I-Claim
significance I-Claim
. I-Claim

Hormone B-Claim
replacement I-Claim
therapy I-Claim
increases I-Claim
cardiovascular I-Claim
and I-Claim
thromboembolic I-Claim
risk I-Claim
when I-Claim
started I-Claim
many I-Claim
years I-Claim
after I-Claim
the I-Claim
menopause I-Claim
. I-Claim

Our B-Claim
study I-Claim
shows I-Claim
that I-Claim
despite I-Claim
the I-Claim
side-effects I-Claim
of I-Claim
treatment I-Claim
, I-Claim
patients I-Claim
who I-Claim
have I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
and I-Claim
for I-Claim
whom I-Claim
fluorouracil I-Claim
has I-Claim
failed I-Claim
, I-Claim
have I-Claim
a I-Claim
longer I-Claim
survival I-Claim
, I-Claim
fewer I-Claim
tumour-related I-Claim
symptoms I-Claim
, I-Claim
and I-Claim
a I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
when I-Claim
treated I-Claim
with I-Claim
irinotecan I-Claim
than I-Claim
with I-Claim
supportive I-Claim
care I-Claim
alone I-Claim
. I-Claim

The B-Claim
superiority I-Claim
of I-Claim
combination I-Claim
therapy I-Claim
over I-Claim
monochemotherapy I-Claim
has I-Claim
not I-Claim
been I-Claim
demonstrated I-Claim
convincingly I-Claim
. I-Claim

MBSR B-Claim
is I-Claim
recommended I-Claim
to I-Claim
support I-Claim
survivors I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

This B-Claim
confirms I-Claim
that I-Claim
the I-Claim
two-drug I-Claim
combination I-Claim
NP I-Claim
is I-Claim
a I-Claim
reference I-Claim
treatment I-Claim
for I-Claim
metastatic I-Claim
NSCLC I-Claim
. I-Claim

Those B-Claim
who I-Claim
respond I-Claim
to I-Claim
gemcitabine I-Claim
may I-Claim
experience I-Claim
a I-Claim
slight I-Claim
slowing I-Claim
of I-Claim
functional I-Claim
deterioration I-Claim
. I-Claim

Further B-Claim
investigation I-Claim
to I-Claim
define I-Claim
and I-Claim
measure I-Claim
the I-Claim
effects I-Claim
of I-Claim
these I-Claim
genes I-Claim
in I-Claim
chemotherapeutic I-Claim
regimens I-Claim
, I-Claim
drug I-Claim
toxicities I-Claim
, I-Claim
disease I-Claim
progression I-Claim
, I-Claim
and I-Claim
QOL I-Claim
are I-Claim
critical I-Claim
. I-Claim

Intrapatient B-Claim
dose I-Claim
escalation I-Claim
of I-Claim
carboplatin I-Claim
based I-Claim
on I-Claim
nadir I-Claim
blood I-Claim
counts I-Claim
is I-Claim
feasible I-Claim
and I-Claim
safe I-Claim
. I-Claim

In B-Claim
conclusion I-Claim
, I-Claim
Tomudex I-Claim
is I-Claim
more I-Claim
toxic I-Claim
and I-Claim
yields I-Claim
shorter I-Claim
PFS I-Claim
than I-Claim
infusional I-Claim
5FU I-Claim
. I-Claim

In B-Claim
view I-Claim
of I-Claim
the I-Claim
benefits I-Claim
regarding I-Claim
arm I-Claim
functioning I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
the I-Claim
data I-Claim
from I-Claim
this I-Claim
randomised I-Claim
study I-Claim
support I-Claim
the I-Claim
use I-Claim
of I-Claim
SNB I-Claim
in I-Claim
patients I-Claim
with I-Claim
clinically I-Claim
node I-Claim
negative I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Pamidronate B-Claim
treatment I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
efficaciously I-Claim
reduced I-Claim
skeletal I-Claim
morbidity I-Claim
. I-Claim

Clinical B-Claim
interventions I-Claim
to I-Claim
address I-Claim
common I-Claim
symptoms I-Claim
associated I-Claim
with I-Claim
treatment I-Claim
should I-Claim
be I-Claim
considered I-Claim
to I-Claim
improve I-Claim
physical I-Claim
and I-Claim
emotional I-Claim
functioning I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Erlotinib B-Claim
not I-Claim
only I-Claim
improves I-Claim
survival I-Claim
in I-Claim
previously I-Claim
treated I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
, I-Claim
but I-Claim
also I-Claim
improves I-Claim
tumor-related I-Claim
symptoms I-Claim
and I-Claim
important I-Claim
aspects I-Claim
of I-Claim
QOL I-Claim
. I-Claim

Response B-Claim
proportion I-Claim
and I-Claim
survival I-Claim
did I-Claim
not I-Claim
improve I-Claim
significantly I-Claim
with I-Claim
the I-Claim
addition I-Claim
of I-Claim
13-CRA I-Claim
to I-Claim
IFNalpha2a I-Claim
therapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
RCC I-Claim
. I-Claim

Epoetin B-Claim
alpha I-Claim
decreased I-Claim
the I-Claim
number I-Claim
of I-Claim
PRBC I-Claim
transfusions I-Claim
and I-Claim
did I-Claim
not I-Claim
appear I-Claim
to I-Claim
have I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
remission I-Claim
duration I-Claim
. I-Claim

Quality B-Claim
of I-Claim
life I-Claim
is I-Claim
an I-Claim
important I-Claim
issue I-Claim
in I-Claim
pancreatic I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

The B-Claim
new I-Claim
bone I-Claim
resorption I-Claim
markers I-Claim
of I-Claim
collagen I-Claim
breakdown I-Claim
were I-Claim
able I-Claim
to I-Claim
predict I-Claim
clinical I-Claim
response I-Claim
to I-Claim
pamidronate I-Claim
. I-Claim

Qualitative B-Claim
interviews I-Claim
suggested I-Claim
that I-Claim
patients I-Claim
found I-Claim
participation I-Claim
in I-Claim
the I-Claim
trial I-Claim
acceptable I-Claim
and I-Claim
that I-Claim
they I-Claim
would I-Claim
consider I-Claim
participating I-Claim
in I-Claim
a I-Claim
future I-Claim
trial I-Claim
. I-Claim

Erlotinib B-Claim
was I-Claim
effective I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
in I-Claim
Asian I-Claim
patients I-Claim
, I-Claim
producing I-Claim
benefits I-Claim
consistent I-Claim
with I-Claim
those I-Claim
observed I-Claim
in I-Claim
the I-Claim
overall I-Claim
SATURN I-Claim
population I-Claim
. I-Claim

Integration B-Claim
of I-Claim
the I-Claim
PMP I-Claim
into I-Claim
routine I-Claim
clinical I-Claim
work I-Claim
may I-Claim
help I-Claim
to I-Claim
improve I-Claim
the I-Claim
standard I-Claim
of I-Claim
care I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

However B-Claim
, I-Claim
patient I-Claim
self-assessments I-Claim
suggested I-Claim
a I-Claim
possible I-Claim
advantage I-Claim
to I-Claim
AM I-Claim
that I-Claim
is I-Claim
being I-Claim
explored I-Claim
with I-Claim
modified I-Claim
dosing I-Claim
route I-Claim
strategies I-Claim
. I-Claim

The B-Claim
study I-Claim
fails I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
of I-Claim
dl-alpha I-Claim
tocopheryl I-Claim
acetate I-Claim
plus I-Claim
pentoxifylline I-Claim
in I-Claim
patients I-Claim
with I-Claim
arm I-Claim
lymphoedema I-Claim
following I-Claim
axillary I-Claim
surgery I-Claim
and I-Claim
lymphatic I-Claim
radiotherapy I-Claim
, I-Claim
nor I-Claim
does I-Claim
it I-Claim
suggest I-Claim
any I-Claim
benefits I-Claim
of I-Claim
these I-Claim
drugs I-Claim
in I-Claim
radiation-induced I-Claim
induration I-Claim
( I-Claim
fibrosis I-Claim
) I-Claim
in I-Claim
the I-Claim
breast I-Claim
, I-Claim
chest I-Claim
wall I-Claim
, I-Claim
pectoral I-Claim
fold I-Claim
, I-Claim
axilla I-Claim
or I-Claim
supraclavicular I-Claim
fossa I-Claim
. I-Claim

Supervised B-Claim
group I-Claim
exercise I-Claim
provided I-Claim
functional I-Claim
and I-Claim
psychological I-Claim
benefit I-Claim
after I-Claim
a I-Claim
12 I-Claim
week I-Claim
intervention I-Claim
and I-Claim
six I-Claim
months I-Claim
later I-Claim
. I-Claim

Bevacizumab B-Claim
, I-Claim
a I-Claim
monoclonal I-Claim
antibody I-Claim
against I-Claim
vascular I-Claim
endothelial I-Claim
growth I-Claim
factor I-Claim
, I-Claim
increases I-Claim
survival I-Claim
when I-Claim
combined I-Claim
with I-Claim
irinotecan-based I-Claim
chemotherapy I-Claim
in I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
( I-Claim
CRC I-Claim
) I-Claim
. I-Claim

Morbidity B-Claim
associated I-Claim
with I-Claim
wound I-Claim
complications I-Claim
may I-Claim
translate I-Claim
into I-Claim
disability I-Claim
and I-Claim
quality-of-life I-Claim
disadvantages I-Claim
for I-Claim
patients I-Claim
treated I-Claim
with I-Claim
radiotherapy I-Claim
( I-Claim
RT I-Claim
) I-Claim
for I-Claim
soft I-Claim
tissue I-Claim
sarcoma I-Claim
( I-Claim
STS I-Claim
) I-Claim
of I-Claim
the I-Claim
extremities I-Claim
. I-Claim

Trials B-Claim
with I-Claim
late I-Claim
intensification I-Claim
HDCT I-Claim
have I-Claim
failed I-Claim
to I-Claim
show I-Claim
an I-Claim
advantage I-Claim
in I-Claim
overall I-Claim
survival I-Claim
. I-Claim

Compared B-Claim
with I-Claim
participants I-Claim
receiving I-Claim
usual I-Claim
oncology I-Claim
care I-Claim
, I-Claim
those I-Claim
receiving I-Claim
a I-Claim
nurse-led I-Claim
, I-Claim
palliative I-Claim
care-focused I-Claim
intervention I-Claim
addressing I-Claim
physical I-Claim
, I-Claim
psychosocial I-Claim
, I-Claim
and I-Claim
care I-Claim
coordination I-Claim
provided I-Claim
concurrently I-Claim
with I-Claim
oncology I-Claim
care I-Claim
had I-Claim
higher I-Claim
scores I-Claim
for I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
mood I-Claim
, I-Claim
but B-Claim
did I-Claim
not I-Claim
have I-Claim
improvements I-Claim
in I-Claim
symptom I-Claim
intensity I-Claim
scores I-Claim
or I-Claim
reduced I-Claim
days I-Claim
in I-Claim
the I-Claim
hospital I-Claim
or I-Claim
ICU I-Claim
or I-Claim
emergency I-Claim
department I-Claim
visits I-Claim
. I-Claim

The B-Claim
16-week I-Claim
regimen I-Claim
should I-Claim
not I-Claim
be I-Claim
used I-Claim
instead I-Claim
of I-Claim
a I-Claim
standard-dose I-Claim
regimen I-Claim
without I-Claim
careful I-Claim
consideration I-Claim
of I-Claim
the I-Claim
16-week I-Claim
regimen I-Claim
's I-Claim
pros I-Claim
and I-Claim
cons I-Claim
, I-Claim
which I-Claim
include I-Claim
its I-Claim
complicated I-Claim
schedule I-Claim
. I-Claim

In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
GCa I-Claim
chemotherapy I-Claim
was I-Claim
shown I-Claim
to I-Claim
be I-Claim
a I-Claim
better-tolerated I-Claim
treatment I-Claim
that I-Claim
conferred I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
MIC I-Claim
. I-Claim

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
switching I-Claim
patients I-Claim
to I-Claim
adjuvant I-Claim
exemestane I-Claim
treatment I-Claim
after I-Claim
at I-Claim
least I-Claim
2 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
an I-Claim
advantage I-Claim
over I-Claim
continuing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
treatment I-Claim
in I-Claim
terms I-Claim
of I-Claim
body I-Claim
composition I-Claim
. I-Claim

Its B-Claim
leakage I-Claim
rate I-Claim
was I-Claim
lower I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
was I-Claim
better I-Claim
. I-Claim

A B-Claim
combination I-Claim
regimen I-Claim
of I-Claim
MA I-Claim
and I-Claim
thalidomide I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
MA I-Claim
alone I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
CACS I-Claim
. I-Claim

A B-Claim
three-times-per-week I-Claim
dosing I-Claim
schedule I-Claim
was I-Claim
noted I-Claim
to I-Claim
be I-Claim
more I-Claim
effective I-Claim
compared I-Claim
with I-Claim
a I-Claim
once-a-week I-Claim
schedule I-Claim
without I-Claim
any I-Claim
significant I-Claim
difference I-Claim
in I-Claim
toxicity I-Claim
reported I-Claim
. I-Claim

This B-Claim
trial I-Claim
, I-Claim
also I-Claim
for I-Claim
the I-Claim
first I-Claim
time I-Claim
, I-Claim
provides I-Claim
evidence I-Claim
that I-Claim
retreatment I-Claim
after I-Claim
local I-Claim
relapse I-Claim
can I-Claim
achieve I-Claim
long-term I-Claim
second I-Claim
remissions I-Claim
. I-Claim

The B-Claim
effect I-Claim
appeared I-Claim
to I-Claim
be I-Claim
dose-dependent I-Claim
. I-Claim

Therapy B-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
or I-Claim
gastroesophageal I-Claim
junction I-Claim
cancer I-Claim
should I-Claim
provide I-Claim
symptom I-Claim
relief I-Claim
and I-Claim
improve I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
because I-Claim
most I-Claim
patients I-Claim
are I-Claim
symptomatic I-Claim
at I-Claim
baseline I-Claim
. I-Claim

Tumor B-Claim
characteristics I-Claim
and I-Claim
wound I-Claim
complications I-Claim
have I-Claim
a I-Claim
detrimental I-Claim
effect I-Claim
on I-Claim
patient I-Claim
function I-Claim
. I-Claim

13-CRA B-Claim
may I-Claim
lengthen I-Claim
response I-Claim
to I-Claim
IFNalpha2a I-Claim
therapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
IFNalpha2a-sensitive I-Claim
tumors I-Claim
. I-Claim

Intrusive B-Claim
thoughts I-Claim
are I-Claim
associated I-Claim
with I-Claim
enduring I-Claim
elevations I-Claim
in I-Claim
behavioral I-Claim
symptoms I-Claim
and I-Claim
impaired I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
the I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
and I-Claim
may I-Claim
be I-Claim
a I-Claim
risk I-Claim
factor I-Claim
for I-Claim
poor I-Claim
outcomes I-Claim
. I-Claim

AM B-Claim
did I-Claim
not I-Claim
significantly I-Claim
reduce I-Claim
esophagitis I-Claim
> I-Claim
/= I-Claim
grade I-Claim
3 I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
hyperfractionated I-Claim
radiation I-Claim
and I-Claim
chemotherapy I-Claim
. I-Claim

HDCT B-Claim
was I-Claim
associated I-Claim
with I-Claim
more I-Claim
acute I-Claim
adverse I-Claim
effects I-Claim
. I-Claim

No B-Claim
appreciable I-Claim
advantage I-Claim
to I-Claim
QoL I-Claim
with I-Claim
TMX I-Claim
was I-Claim
observed I-Claim
. I-Claim

The B-Claim
role I-Claim
of I-Claim
high-dose I-Claim
chemotherapy I-Claim
( I-Claim
HDCT I-Claim
) I-Claim
in I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
remains I-Claim
controversial I-Claim
. I-Claim

An B-Claim
unplanned I-Claim
safety I-Claim
analysis I-Claim
suggested I-Claim
decreased I-Claim
overall I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
treated I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
. I-Claim

Medical B-Claim
castration I-Claim
reduces I-Claim
TPV I-Claim
and I-Claim
could I-Claim
also I-Claim
improve I-Claim
LUTS I-Claim
in I-Claim
patients I-Claim
with I-Claim
PCa I-Claim
. I-Claim

rhTSH-prepared B-Claim
patients I-Claim
maintained I-Claim
a I-Claim
higher I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
received I-Claim
less I-Claim
radiation I-Claim
exposure I-Claim
to I-Claim
the I-Claim
blood I-Claim
. I-Claim

Surgery B-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
short-term I-Claim
negative I-Claim
impact I-Claim
in I-Claim
some I-Claim
aspects I-Claim
of I-Claim
health I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
assessments I-Claim
but B-Claim
these I-Claim
changes I-Claim
became I-Claim
insignificant I-Claim
2 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
. I-Claim

Subjective B-Claim
benefit I-Claim
after I-Claim
intravenous I-Claim
pamidronate I-Claim
is I-Claim
confirmed I-Claim
in I-Claim
this I-Claim
placebo-controlled I-Claim
study I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
paclitaxel I-Claim
improved I-Claim
progression-free I-Claim
survival I-Claim
( I-Claim
PFS I-Claim
) I-Claim
of I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
( I-Claim
MBC I-Claim
) I-Claim
. I-Claim

Although B-Claim
addition I-Claim
of I-Claim
radiotherapy I-Claim
to I-Claim
endocrine I-Claim
treatment I-Claim
significantly I-Claim
increased I-Claim
some I-Claim
treatment-related I-Claim
symptoms I-Claim
, I-Claim
none I-Claim
were I-Claim
serious I-Claim
. I-Claim

GPX1 B-Claim
may I-Claim
be I-Claim
an I-Claim
inherited I-Claim
factor I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
QOL I-Claim
. I-Claim

Preliminary B-Claim
results I-Claim
suggested I-Claim
a I-Claim
positive I-Claim
impact I-Claim
on I-Claim
survival I-Claim
. I-Claim

The B-Claim
results I-Claim
of I-Claim
this I-Claim
study I-Claim
indicate I-Claim
that I-Claim
patients I-Claim
with I-Claim
gastrointestinal I-Claim
cancer I-Claim
, I-Claim
who I-Claim
undergo I-Claim
surgery I-Claim
for I-Claim
stomach I-Claim
, I-Claim
pancreatic I-Claim
, I-Claim
primary I-Claim
liver I-Claim
, I-Claim
or I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
benefit I-Claim
from I-Claim
a I-Claim
formal I-Claim
program I-Claim
of I-Claim
psychotherapeutic I-Claim
support I-Claim
during I-Claim
the I-Claim
inpatient I-Claim
hospital I-Claim
stay I-Claim
in I-Claim
terms I-Claim
of I-Claim
long-term I-Claim
survival I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
this I-Claim
regimen I-Claim
is I-Claim
not I-Claim
recommended I-Claim
as I-Claim
standard I-Claim
of I-Claim
care I-Claim
treatment I-Claim
for I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Cisplatin B-Claim
reduces I-Claim
plasma I-Claim
ghrelin I-Claim
levels I-Claim
through I-Claim
the I-Claim
5-hydroxytryptamine I-Claim
( I-Claim
5-HT I-Claim
) I-Claim
receptor I-Claim
. I-Claim

Hormonal B-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
increases I-Claim
menopausal I-Claim
symptoms I-Claim
in I-Claim
women I-Claim
. I-Claim

The B-Claim
study I-Claim
underscores I-Claim
the I-Claim
value I-Claim
of I-Claim
undertaking I-Claim
studies I-Claim
in I-Claim
areas I-Claim
of I-Claim
disease I-Claim
prevalence I-Claim
and I-Claim
the I-Claim
necessity I-Claim
of I-Claim
selecting I-Claim
appropriate I-Claim
outcome I-Claim
measures I-Claim
. I-Claim

Abiraterone B-Claim
acetate I-Claim
plus I-Claim
prednisone I-Claim
significantly I-Claim
improves I-Claim
radiographic I-Claim
progression-free I-Claim
survival I-Claim
in I-Claim
asymptomatic I-Claim
or I-Claim
mildly I-Claim
symptomatic I-Claim
, I-Claim
chemotherapy-naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration-resistant I-Claim
prostate I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim

Although B-Claim
it I-Claim
is I-Claim
premature I-Claim
to I-Claim
make I-Claim
any I-Claim
determination I-Claim
as I-Claim
to I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
the I-Claim
interventions I-Claim
tested I-Claim
in I-Claim
this I-Claim
feasibility I-Claim
study I-Claim
, I-Claim
these B-Claim
results I-Claim
indicate I-Claim
that I-Claim
pursuing I-Claim
the I-Claim
III I-Claim
+ I-Claim
ISG I-Claim
model I-Claim
, I-Claim
as I-Claim
well I-Claim
as I-Claim
standard I-Claim
IIIs I-Claim
, I-Claim
may I-Claim
be I-Claim
fruitful I-Claim
areas I-Claim
of I-Claim
future I-Claim
research I-Claim
. I-Claim

Equivalence B-Claim
for I-Claim
three I-Claim
versus I-Claim
four I-Claim
cycles I-Claim
is I-Claim
claimed I-Claim
because I-Claim
both I-Claim
the I-Claim
upper I-Claim
and I-Claim
lower I-Claim
bounds I-Claim
of I-Claim
the I-Claim
80 I-Claim
% I-Claim
CL I-Claim
are I-Claim
less I-Claim
than I-Claim
5 I-Claim
% I-Claim
. I-Claim

Clinicians B-Claim
should I-Claim
encourage I-Claim
activity I-Claim
for I-Claim
their I-Claim
patients I-Claim
. I-Claim

This B-Claim
initial I-Claim
evidence I-Claim
involving I-Claim
a I-Claim
small I-Claim
sample I-Claim
size I-Claim
suggests I-Claim
that I-Claim
appropriately I-Claim
designed I-Claim
and I-Claim
supervised I-Claim
resistance I-Claim
exercise I-Claim
may I-Claim
be I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
bone I-Claim
metastatic I-Claim
disease I-Claim
and I-Claim
can I-Claim
lead I-Claim
to I-Claim
improvements I-Claim
in I-Claim
physical I-Claim
function I-Claim
, I-Claim
physical I-Claim
activity I-Claim
levels I-Claim
and I-Claim
lean I-Claim
mass I-Claim
. I-Claim

We B-Claim
propose I-Claim
that I-Claim
VEGF I-Claim
expression I-Claim
levels I-Claim
in I-Claim
MPE I-Claim
could I-Claim
serve I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
marker I-Claim
for I-Claim
bevacizumab I-Claim
therapy I-Claim
. I-Claim

Methods B-Claim
are I-Claim
needed I-Claim
to I-Claim
reduce I-Claim
professional I-Claim
time I-Claim
required I-Claim
while I-Claim
achieving I-Claim
sustained I-Claim
intervention I-Claim
effectiveness I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
RT I-Claim
did I-Claim
not I-Claim
negatively I-Claim
impact I-Claim
ED I-Claim
. I-Claim

Doses B-Claim
to I-Claim
the I-Claim
IUS I-Claim
and I-Claim
EUS I-Claim
on I-Claim
MRI/CT I-Claim
predicted I-Claim
worse I-Claim
urinary I-Claim
function I-Claim
, I-Claim
with I-Claim
greater I-Claim
bother I-Claim
, I-Claim
irritative I-Claim
symptoms I-Claim
, I-Claim
and I-Claim
urgency I-Claim
. I-Claim

No B-Claim
differences I-Claim
were I-Claim
observed I-Claim
between I-Claim
groups I-Claim
regarding I-Claim
HRQOL I-Claim
at I-Claim
24-month I-Claim
follow-up I-Claim
. I-Claim

ADAPt-C B-Claim
collaborative I-Claim
care I-Claim
is I-Claim
feasible I-Claim
and I-Claim
results I-Claim
in I-Claim
significant I-Claim
reduction I-Claim
in I-Claim
depressive I-Claim
symptoms I-Claim
, I-Claim
improvement I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
lower I-Claim
pain I-Claim
levels I-Claim
compared I-Claim
with I-Claim
EUC I-Claim
for I-Claim
patients I-Claim
with I-Claim
depressive I-Claim
disorders I-Claim
in I-Claim
a I-Claim
low-income I-Claim
, I-Claim
predominantly I-Claim
Hispanic I-Claim
population I-Claim
in I-Claim
public I-Claim
sector I-Claim
oncology I-Claim
clinics I-Claim
. I-Claim

The B-Claim
3-hour I-Claim
infusion I-Claim
of I-Claim
Taxol I-Claim
is I-Claim
safe I-Claim
when I-Claim
given I-Claim
with I-Claim
premedication I-Claim
and I-Claim
is I-Claim
associated I-Claim
with I-Claim
less I-Claim
neutropenia I-Claim
. I-Claim

Thus B-Claim
, I-Claim
docetaxel-carboplatin I-Claim
represents I-Claim
an I-Claim
alternative I-Claim
first-line I-Claim
chemotherapy I-Claim
regimen I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

We B-Claim
recommend I-Claim
implementation I-Claim
alongside I-Claim
evaluation I-Claim
in I-Claim
wider I-Claim
clinical I-Claim
settings I-Claim
and I-Claim
patient I-Claim
populations I-Claim
. I-Claim

The B-Claim
advantages I-Claim
of I-Claim
a I-Claim
long-lasting I-Claim
improved I-Claim
body I-Claim
image I-Claim
and I-Claim
cosmesis I-Claim
for I-Claim
this I-Claim
relatively I-Claim
young I-Claim
patient I-Claim
population I-Claim
may I-Claim
compensate I-Claim
for I-Claim
the I-Claim
longer I-Claim
operating I-Claim
times I-Claim
and I-Claim
higher I-Claim
costs I-Claim
, I-Claim
particularly I-Claim
for I-Claim
women I-Claim
. I-Claim

After B-Claim
major I-Claim
surgery I-Claim
, I-Claim
specialized I-Claim
supportive I-Claim
enteral I-Claim
and I-Claim
parenteral I-Claim
nutrition I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
oral I-Claim
nutrition I-Claim
only I-Claim
when I-Claim
guided I-Claim
by I-Claim
a I-Claim
dietitian I-Claim
. I-Claim

However B-Claim
, I-Claim
exercise I-Claim
is I-Claim
not I-Claim
better I-Claim
than I-Claim
progressive I-Claim
relaxation I-Claim
training I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
fatigue I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

Our B-Claim
findings I-Claim
showed I-Claim
no I-Claim
evidence I-Claim
of I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
with I-Claim
early I-Claim
treatment I-Claim
of I-Claim
relapse I-Claim
on I-Claim
the I-Claim
basis I-Claim
of I-Claim
a I-Claim
raised I-Claim
CA125 I-Claim
concentration I-Claim
alone I-Claim
, I-Claim
and B-Claim
therefore I-Claim
the I-Claim
value I-Claim
of I-Claim
routine I-Claim
measurement I-Claim
of I-Claim
CA125 I-Claim
in I-Claim
the I-Claim
follow-up I-Claim
of I-Claim
patients I-Claim
with I-Claim
ovarian I-Claim
cancer I-Claim
who I-Claim
attain I-Claim
a I-Claim
complete I-Claim
response I-Claim
after I-Claim
first-line I-Claim
treatment I-Claim
is I-Claim
not I-Claim
proven I-Claim
. I-Claim

The B-Claim
incidence I-Claim
and I-Claim
development I-Claim
of I-Claim
cancer I-Claim
are I-Claim
closely I-Claim
related I-Claim
to I-Claim
dysfunction I-Claim
of I-Claim
immune I-Claim
function I-Claim
. I-Claim

Measurable B-Claim
improvement I-Claim
in I-Claim
a I-Claim
general I-Claim
QOL I-Claim
measure I-Claim
was I-Claim
not I-Claim
demonstrated I-Claim
. I-Claim

Multimodality B-Claim
therapies I-Claim
for I-Claim
cachexia I-Claim
ideally I-Claim
should I-Claim
be I-Claim
introduced I-Claim
within I-Claim
a I-Claim
context I-Claim
of I-Claim
" I-Claim
best I-Claim
supportive I-Claim
care I-Claim
" I-Claim
that I-Claim
includes I-Claim
optimal I-Claim
symptom I-Claim
management I-Claim
and I-Claim
careful I-Claim
psychosocial I-Claim
counseling I-Claim
. I-Claim

Patient-caregiver B-Claim
dyads I-Claim
benefit I-Claim
when I-Claim
viewed I-Claim
as I-Claim
the I-Claim
'unit I-Claim
of I-Claim
care I-Claim
' I-Claim
. I-Claim

Compared B-Claim
with I-Claim
IFN5 I-Claim
, I-Claim
IFN1 I-Claim
is I-Claim
neither I-Claim
more I-Claim
nor I-Claim
less I-Claim
effective I-Claim
but I-Claim
is I-Claim
less I-Claim
toxic I-Claim
, I-Claim
with I-Claim
a I-Claim
better I-Claim
reported I-Claim
QOL I-Claim
. I-Claim

CRO B-Claim
is I-Claim
effective I-Claim
, I-Claim
safe I-Claim
, I-Claim
and I-Claim
cost-effective I-Claim
in I-Claim
the I-Claim
control I-Claim
of I-Claim
postoperative I-Claim
pain I-Claim
after I-Claim
transarterial I-Claim
chemoembolization I-Claim
for I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
liver I-Claim
cancer I-Claim
. I-Claim

Addition B-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
FU/LV I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
in I-Claim
CRC I-Claim
patients I-Claim
who I-Claim
were I-Claim
not I-Claim
considered I-Claim
optimal I-Claim
candidates I-Claim
for I-Claim
first-line I-Claim
irinotecan I-Claim
treatment I-Claim
provided I-Claim
clinically I-Claim
significant I-Claim
patient I-Claim
benefit I-Claim
, I-Claim
including I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
progression-free I-Claim
survival I-Claim
. I-Claim

EGFR-mutated B-Claim
patients I-Claim
had I-Claim
better I-Claim
survival I-Claim
than I-Claim
those I-Claim
with I-Claim
EGFR I-Claim
wild-type I-Claim
disease I-Claim
, I-Claim
regardless I-Claim
of I-Claim
the I-Claim
treatment I-Claim
received I-Claim
. I-Claim

Hypnosis B-Claim
appears I-Claim
to I-Claim
reduce I-Claim
perceived I-Claim
hot I-Claim
flashes I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
may I-Claim
have I-Claim
additional I-Claim
benefits I-Claim
such I-Claim
as I-Claim
reduced I-Claim
anxiety I-Claim
and I-Claim
depression I-Claim
, I-Claim
and I-Claim
improved I-Claim
sleep I-Claim
. I-Claim

However B-Claim
, I-Claim
it I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
more I-Claim
inconvenience I-Claim
in I-Claim
wound I-Claim
care I-Claim
and I-Claim
longer I-Claim
healing I-Claim
time I-Claim
than I-Claim
rhomboid I-Claim
excision I-Claim
and I-Claim
Lindberg I-Claim
flap I-Claim
. I-Claim

The B-Claim
observation I-Claim
that I-Claim
longer I-Claim
infusion I-Claim
produces I-Claim
more I-Claim
myelosuppression I-Claim
but I-Claim
does I-Claim
not I-Claim
yield I-Claim
higher I-Claim
response I-Claim
rates I-Claim
should I-Claim
lead I-Claim
to I-Claim
further I-Claim
studies I-Claim
to I-Claim
determine I-Claim
the I-Claim
optimal I-Claim
dose I-Claim
and I-Claim
schedule I-Claim
of I-Claim
this I-Claim
interesting I-Claim
new I-Claim
agent I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
mitoxantrone I-Claim
plus I-Claim
prednisone I-Claim
was I-Claim
associated I-Claim
with I-Claim
greater I-Claim
and I-Claim
longer-lasting I-Claim
improvement I-Claim
in I-Claim
several I-Claim
HQL I-Claim
domains I-Claim
and I-Claim
symptoms I-Claim
than I-Claim
treatment I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim

Leucovorin B-Claim
increases I-Claim
PFS I-Claim
if I-Claim
added I-Claim
to I-Claim
FU24h I-Claim
, I-Claim
but I-Claim
increases I-Claim
toxicity I-Claim
. I-Claim

Addition B-Claim
of I-Claim
temozolomide I-Claim
during I-Claim
and I-Claim
after I-Claim
radiotherapy I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
glioblastoma I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
without I-Claim
a I-Claim
negative I-Claim
effect I-Claim
on I-Claim
HRQOL I-Claim
. I-Claim

These B-Claim
results I-Claim
provide I-Claim
further I-Claim
support I-Claim
for I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
abiraterone I-Claim
in I-Claim
this I-Claim
population I-Claim
. I-Claim

Both B-Claim
UAE I-Claim
and I-Claim
hysterectomy I-Claim
improved I-Claim
HRQOL I-Claim
. I-Claim

This B-Claim
study I-Claim
shows I-Claim
that I-Claim
the I-Claim
higher I-Claim
frequency I-Claim
of I-Claim
toxicity I-Claim
associated I-Claim
with I-Claim
MPT I-Claim
does I-Claim
not I-Claim
translate I-Claim
into I-Claim
a I-Claim
negative I-Claim
effect I-Claim
on I-Claim
HRQoL I-Claim
and I-Claim
that I-Claim
MPT I-Claim
holds I-Claim
a I-Claim
better I-Claim
patient I-Claim
perspective I-Claim
. I-Claim

These B-Claim
results I-Claim
support I-Claim
the I-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
an I-Claim
every-2-weeks I-Claim
treatment I-Claim
with I-Claim
gemcitabine I-Claim
plus I-Claim
cisplatin I-Claim
. I-Claim

Despite B-Claim
small I-Claim
numbers I-Claim
, I-Claim
the I-Claim
main I-Claim
effect I-Claim
size I-Claim
was I-Claim
robust I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
PB+G I-Claim
increased I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
neutropenia I-Claim
and I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
the I-Claim
regimen I-Claim
generally I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Docetaxel B-Claim
monotherapy I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
the I-Claim
standard I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

New B-Claim
fibroid I-Claim
formation I-Claim
is I-Claim
significantly I-Claim
higher I-Claim
after I-Claim
myomectomy I-Claim
. I-Claim

Avoiding B-Claim
axillary I-Claim
clearance I-Claim
for I-Claim
women I-Claim
> I-Claim
or I-Claim
= I-Claim
60 I-Claim
years I-Claim
old I-Claim
who I-Claim
have I-Claim
clinically I-Claim
node-negative I-Claim
disease I-Claim
and I-Claim
receive I-Claim
Tam I-Claim
for I-Claim
endocrine-responsive I-Claim
disease I-Claim
yields I-Claim
similar I-Claim
efficacy I-Claim
with I-Claim
better I-Claim
early I-Claim
QL I-Claim
. I-Claim

Functional B-Claim
outcome I-Claim
, I-Claim
QOL I-Claim
, I-Claim
and I-Claim
morbidity I-Claim
are I-Claim
similar I-Claim
for I-Claim
the I-Claim
two I-Claim
approaches I-Claim
. I-Claim

Hot B-Claim
flashes I-Claim
can I-Claim
cause I-Claim
discomfort I-Claim
, I-Claim
disrupted I-Claim
sleep I-Claim
, I-Claim
anxiety I-Claim
, I-Claim
and I-Claim
decreased I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

No B-Claim
differences I-Claim
in I-Claim
patients I-Claim
' I-Claim
appetite I-Claim
or I-Claim
QOL I-Claim
were I-Claim
found I-Claim
either I-Claim
between I-Claim
CE I-Claim
, I-Claim
THC I-Claim
, I-Claim
and I-Claim
PL I-Claim
or I-Claim
between I-Claim
CE I-Claim
and I-Claim
THC I-Claim
at I-Claim
the I-Claim
dosages I-Claim
investigated I-Claim
. I-Claim

Letrozole B-Claim
should I-Claim
be I-Claim
considered I-Claim
for I-Claim
all I-Claim
women I-Claim
completing I-Claim
tamoxifen I-Claim
";" I-Claim
new B-Claim
results I-Claim
from I-Claim
the I-Claim
post-unblinding I-Claim
analysis I-Claim
suggest I-Claim
that I-Claim
letrozole I-Claim
treatment I-Claim
should I-Claim
also I-Claim
be I-Claim
considered I-Claim
for I-Claim
all I-Claim
disease-free I-Claim
women I-Claim
for I-Claim
periods I-Claim
up I-Claim
to I-Claim
5 I-Claim
years I-Claim
following I-Claim
completion I-Claim
of I-Claim
adjuvant I-Claim
tamoxifen I-Claim
. I-Claim

However B-Claim
, I-Claim
identification I-Claim
of I-Claim
prognostic I-Claim
factors I-Claim
from I-Claim
responses I-Claim
to I-Claim
questionnaires I-Claim
may I-Claim
be I-Claim
unstable I-Claim
, I-Claim
and I-Claim
their I-Claim
reliability I-Claim
and I-Claim
clinical I-Claim
utility I-Claim
should I-Claim
be I-Claim
tested I-Claim
prospectively I-Claim
. I-Claim

Short-term B-Claim
postoperative I-Claim
morbidity I-Claim
was I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
groups I-Claim
. I-Claim

Further B-Claim
research I-Claim
is I-Claim
needed I-Claim
into I-Claim
a I-Claim
number I-Claim
of I-Claim
areas I-Claim
including I-Claim
the I-Claim
long-term I-Claim
aspects I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
clinical I-Claim
outcomes I-Claim
, I-Claim
costs I-Claim
and I-Claim
consequences I-Claim
of I-Claim
omitting I-Claim
radiotherapy I-Claim
. I-Claim

Combined B-Claim
intrapleural I-Claim
therapy I-Claim
with I-Claim
bevacizumab I-Claim
and I-Claim
cisplatin I-Claim
was I-Claim
effective I-Claim
and I-Claim
safe I-Claim
in I-Claim
managing I-Claim
NSCLC-mediated I-Claim
MPE I-Claim
. I-Claim

Global B-Claim
health I-Claim
status/QOL I-Claim
substantially I-Claim
improved I-Claim
with I-Claim
ECF I-Claim
and I-Claim
remained I-Claim
similar I-Claim
to I-Claim
baseline I-Claim
with I-Claim
both I-Claim
docetaxel I-Claim
regimens I-Claim
. I-Claim

There B-Claim
is I-Claim
no I-Claim
rationale I-Claim
for I-Claim
the I-Claim
routine I-Claim
use I-Claim
of I-Claim
neuronavigation I-Claim
to I-Claim
improve I-Claim
the I-Claim
extent I-Claim
of I-Claim
tumor I-Claim
resection I-Claim
and I-Claim
prognosis I-Claim
in I-Claim
patients I-Claim
harboring I-Claim
a I-Claim
solitary I-Claim
enhancing I-Claim
intracerebral I-Claim
lesion I-Claim
when I-Claim
neuronavigation I-Claim
is I-Claim
not I-Claim
already I-Claim
deemed I-Claim
advantageous I-Claim
because I-Claim
of I-Claim
the I-Claim
size I-Claim
or I-Claim
location I-Claim
of I-Claim
the I-Claim
lesion I-Claim
. I-Claim

Improvement B-Claim
over I-Claim
time I-Claim
was I-Claim
evident I-Claim
in I-Claim
both I-Claim
treatment I-Claim
groups I-Claim
but I-Claim
more I-Claim
so I-Claim
for I-Claim
patients I-Claim
receiving I-Claim
placebo I-Claim
. I-Claim

In B-Claim
patients I-Claim
with I-Claim
recurrent I-Claim
or I-Claim
metastatic I-Claim
SCCHN I-Claim
, I-Claim
while I-Claim
responses I-Claim
with I-Claim
gefitinib I-Claim
were I-Claim
seen I-Claim
, I-Claim
neither I-Claim
gefitinib I-Claim
250 I-Claim
nor I-Claim
500 I-Claim
mg/day I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
compared I-Claim
with I-Claim
methotrexate I-Claim
. I-Claim

The B-Claim
combined I-Claim
treatment I-Claim
improved I-Claim
both I-Claim
immunometabolic I-Claim
alterations I-Claim
and I-Claim
patient I-Claim
QoL I-Claim
. I-Claim

The B-Claim
data I-Claim
suggest I-Claim
that I-Claim
combination I-Claim
therapy I-Claim
might I-Claim
provide I-Claim
another I-Claim
treatment I-Claim
option I-Claim
for I-Claim
SUI I-Claim
in I-Claim
men I-Claim
that I-Claim
might I-Claim
increase I-Claim
the I-Claim
percentage I-Claim
of I-Claim
early I-Claim
postsurgery I-Claim
continence I-Claim
. I-Claim

We B-Claim
can I-Claim
not I-Claim
exclude I-Claim
the I-Claim
possibility I-Claim
that I-Claim
a I-Claim
longer I-Claim
and I-Claim
more I-Claim
intense I-Claim
acupuncture I-Claim
intervention I-Claim
could I-Claim
produce I-Claim
a I-Claim
larger I-Claim
reduction I-Claim
of I-Claim
these I-Claim
symptoms I-Claim
. I-Claim

IMCP B-Claim
has I-Claim
clear I-Claim
short-term I-Claim
benefits I-Claim
for I-Claim
spiritual I-Claim
suffering I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

The B-Claim
survival I-Claim
with I-Claim
DOX I-Claim
and I-Claim
VNB I-Claim
is I-Claim
not I-Claim
superior I-Claim
to I-Claim
DOX I-Claim
alone I-Claim
in I-Claim
MBC I-Claim
. I-Claim

Efficacy B-Claim
is I-Claim
low I-Claim
but I-Claim
similar I-Claim
to I-Claim
that I-Claim
of I-Claim
other I-Claim
treatments I-Claim
used I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

Erlotinib B-Claim
was I-Claim
superior I-Claim
to I-Claim
placebo I-Claim
for I-Claim
survival I-Claim
, I-Claim
progression-free I-Claim
survival I-Claim
, I-Claim
and I-Claim
tumor I-Claim
response I-Claim
rate I-Claim
. I-Claim

Behavioral B-Claim
change I-Claim
, I-Claim
rather I-Claim
than I-Claim
immunity I-Claim
change I-Claim
, I-Claim
was I-Claim
influential I-Claim
in I-Claim
achieving I-Claim
lower I-Claim
levels I-Claim
of I-Claim
symptomatology I-Claim
and I-Claim
higher I-Claim
functional I-Claim
status I-Claim
. I-Claim

It B-Claim
is I-Claim
more I-Claim
likely I-Claim
in I-Claim
full-breasted I-Claim
women I-Claim
and I-Claim
when I-Claim
the I-Claim
radiation I-Claim
is I-Claim
distributed I-Claim
nonhomogeneously I-Claim
in I-Claim
the I-Claim
breast I-Claim
. I-Claim

However B-Claim
, I-Claim
HRQoL I-Claim
is I-Claim
not I-Claim
compromised I-Claim
in I-Claim
the I-Claim
long I-Claim
term I-Claim
, I-Claim
recovering I-Claim
by I-Claim
the I-Claim
end-of-treatment I-Claim
visit I-Claim
to I-Claim
be I-Claim
comparable I-Claim
vs. I-Claim
MP I-Claim
. I-Claim

Amenorrhea B-Claim
rates I-Claim
differed I-Claim
significantly I-Claim
by I-Claim
treatment I-Claim
arm I-Claim
, I-Claim
with I-Claim
the I-Claim
AT I-Claim
arm I-Claim
having I-Claim
the I-Claim
lowest I-Claim
rate I-Claim
. I-Claim

In B-Claim
the I-Claim
watchful-waiting I-Claim
group I-Claim
, I-Claim
side-effects I-Claim
can I-Claim
be I-Claim
caused I-Claim
by I-Claim
tumour I-Claim
progression I-Claim
. I-Claim

The B-Claim
mood I-Claim
linear I-Claim
analogue I-Claim
self-assessment I-Claim
scale I-Claim
is I-Claim
a I-Claim
valid I-Claim
indicator I-Claim
of I-Claim
emotional I-Claim
well-being I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
large I-Claim
multicenter I-Claim
, I-Claim
multicultural I-Claim
trials I-Claim
in I-Claim
which I-Claim
comprehensive I-Claim
scales I-Claim
are I-Claim
less I-Claim
feasible I-Claim
. I-Claim

Analyses B-Claim
by I-Claim
bortezomib I-Claim
dose I-Claim
intensity I-Claim
indicated I-Claim
better I-Claim
HRQoL I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
lower I-Claim
dose I-Claim
intensity I-Claim
. I-Claim

Low-dose B-Claim
radioiodine I-Claim
plus I-Claim
thyrotropin I-Claim
alfa I-Claim
was I-Claim
as I-Claim
effective I-Claim
as I-Claim
high-dose I-Claim
radioiodine I-Claim
, I-Claim
with I-Claim
a I-Claim
lower I-Claim
rate I-Claim
of I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Future B-Claim
work I-Claim
is I-Claim
needed I-Claim
to I-Claim
improve I-Claim
the I-Claim
design I-Claim
and I-Claim
the I-Claim
planning I-Claim
of I-Claim
these I-Claim
interventions I-Claim
to I-Claim
improve I-Claim
program I-Claim
adherence I-Claim
. I-Claim

Intraperitoneal B-Claim
administration I-Claim
limits I-Claim
cardiotoxicity I-Claim
of I-Claim
verapamil I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
paclitaxel I-Claim
to I-Claim
best I-Claim
supportive I-Claim
care I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
and I-Claim
time I-Claim
to I-Claim
disease I-Claim
progression I-Claim
compared I-Claim
with I-Claim
best I-Claim
supportive I-Claim
care I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
and I-Claim
may I-Claim
improve I-Claim
some I-Claim
aspects I-Claim
of I-Claim
QOL I-Claim
. I-Claim

DCb B-Claim
and I-Claim
DC I-Claim
were I-Claim
superior I-Claim
to I-Claim
VC I-Claim
in I-Claim
all I-Claim
QoL I-Claim
outcomes I-Claim
assessed I-Claim
except I-Claim
for I-Claim
the I-Claim
difference I-Claim
between I-Claim
DC I-Claim
and I-Claim
VC I-Claim
in I-Claim
LCSS I-Claim
" I-Claim
QoL I-Claim
today I-Claim
" I-Claim
, I-Claim
which I-Claim
was I-Claim
not I-Claim
significant I-Claim
. I-Claim

Postoperative B-Claim
adjuvant I-Claim
chemoradiation I-Claim
treatment I-Claim
after I-Claim
curative I-Claim
resection I-Claim
for I-Claim
rectal I-Claim
cancer I-Claim
was I-Claim
needed I-Claim
to I-Claim
reduce I-Claim
recurrence I-Claim
and I-Claim
improve I-Claim
a I-Claim
survival I-Claim
rate I-Claim
. I-Claim

GEM B-Claim
does I-Claim
not I-Claim
provide I-Claim
an I-Claim
advantage I-Claim
compared I-Claim
with I-Claim
PLD I-Claim
in I-Claim
terms I-Claim
of I-Claim
TTP I-Claim
in I-Claim
ovarian I-Claim
cancer I-Claim
patients I-Claim
who I-Claim
experience I-Claim
recurrence I-Claim
within I-Claim
12 I-Claim
months I-Claim
after I-Claim
primary I-Claim
treatment I-Claim
but I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
spectrum I-Claim
of I-Claim
drugs I-Claim
to I-Claim
be I-Claim
possibly I-Claim
used I-Claim
in I-Claim
the I-Claim
salvage I-Claim
setting I-Claim
. I-Claim

A B-Claim
more I-Claim
effective I-Claim
, I-Claim
better I-Claim
tolerated I-Claim
version I-Claim
of I-Claim
this I-Claim
FUP I-Claim
combination I-Claim
is I-Claim
needed I-Claim
. I-Claim

Strong B-Claim
opioids I-Claim
were I-Claim
safe I-Claim
and I-Claim
well-tolerated I-Claim
, I-Claim
with I-Claim
no I-Claim
development I-Claim
of I-Claim
tolerance I-Claim
or I-Claim
serious I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Future B-Claim
trials I-Claim
involving I-Claim
larger I-Claim
sample I-Claim
sizes I-Claim
are I-Claim
required I-Claim
to I-Claim
expand I-Claim
these I-Claim
preliminary I-Claim
findings I-Claim
. I-Claim

The B-Claim
number I-Claim
and I-Claim
severity I-Claim
of I-Claim
side-effects I-Claim
changes I-Claim
over I-Claim
time I-Claim
at I-Claim
a I-Claim
higher I-Claim
rate I-Claim
than I-Claim
is I-Claim
caused I-Claim
by I-Claim
normal I-Claim
ageing I-Claim
and I-Claim
a I-Claim
loss I-Claim
of I-Claim
sexual I-Claim
ability I-Claim
is I-Claim
a I-Claim
persistent I-Claim
psychological I-Claim
problem I-Claim
for I-Claim
both I-Claim
interventions I-Claim
. I-Claim

Docetaxel-carboplatin B-Claim
appears I-Claim
to I-Claim
be I-Claim
similar I-Claim
to I-Claim
paclitaxel-carboplatin I-Claim
in I-Claim
terms I-Claim
of I-Claim
progression-free I-Claim
survival I-Claim
and I-Claim
response I-Claim
, I-Claim
although B-Claim
longer I-Claim
follow-up I-Claim
is I-Claim
required I-Claim
for I-Claim
a I-Claim
definitive I-Claim
statement I-Claim
on I-Claim
survival I-Claim
. I-Claim

The B-Claim
results I-Claim
of I-Claim
this I-Claim
brief I-Claim
pilot I-Claim
counseling I-Claim
intervention I-Claim
demonstrated I-Claim
significant I-Claim
gains I-Claim
in I-Claim
sexual I-Claim
function I-Claim
and I-Claim
satisfaction I-Claim
and I-Claim
increased I-Claim
utilization I-Claim
of I-Claim
treatments I-Claim
for I-Claim
ED I-Claim
. I-Claim

With B-Claim
the I-Claim
exception I-Claim
of I-Claim
tumor I-Claim
hemorrhage-type I-Claim
events I-Claim
with I-Claim
gefitinib I-Claim
, I-Claim
the I-Claim
adverse I-Claim
event I-Claim
profiles I-Claim
were I-Claim
generally I-Claim
consistent I-Claim
with I-Claim
those I-Claim
previously I-Claim
observed I-Claim
. I-Claim

IMRT B-Claim
results I-Claim
in I-Claim
clinically I-Claim
meaningful I-Claim
and I-Claim
statistically I-Claim
better I-Claim
QOL I-Claim
scores I-Claim
for I-Claim
some I-Claim
domains I-Claim
compared I-Claim
to I-Claim
3D-CRT I-Claim
at I-Claim
several I-Claim
time I-Claim
points I-Claim
with I-Claim
comparable I-Claim
disease I-Claim
outcomes I-Claim
that I-Claim
could I-Claim
support I-Claim
its I-Claim
widespread I-Claim
adoption I-Claim
in I-Claim
routine I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

Acupuncture B-Claim
is I-Claim
an I-Claim
effective I-Claim
intervention I-Claim
for I-Claim
managing I-Claim
the I-Claim
symptom I-Claim
of I-Claim
CRF I-Claim
and I-Claim
improving I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

In B-Claim
contrast I-Claim
, I-Claim
if I-Claim
their I-Claim
cancer I-Claim
was I-Claim
ER-positive I-Claim
( I-Claim
i.e. I-Claim
, I-Claim
endocrine-responsive I-Claim
) I-Claim
, I-Claim
they I-Claim
obtained I-Claim
no I-Claim
benefit I-Claim
from I-Claim
the I-Claim
combination I-Claim
treatment I-Claim
compared I-Claim
with I-Claim
tamoxifen I-Claim
alone I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
either I-Claim
paclitaxel I-Claim
or I-Claim
PLD I-Claim
appears I-Claim
to I-Claim
produce I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
pain I-Claim
and I-Claim
swelling I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
, I-Claim
symptomatic I-Claim
, I-Claim
HIV-associated I-Claim
KS I-Claim
treated I-Claim
in I-Claim
the I-Claim
HAART I-Claim
era I-Claim
. I-Claim

This B-Claim
is I-Claim
the I-Claim
first I-Claim
prospective I-Claim
, I-Claim
randomized I-Claim
controlled I-Claim
trial I-Claim
to I-Claim
report I-Claim
that I-Claim
participation I-Claim
in I-Claim
a I-Claim
home I-Claim
walking I-Claim
program I-Claim
confers I-Claim
a I-Claim
significant I-Claim
benefit I-Claim
in I-Claim
resected I-Claim
PPC I-Claim
patients I-Claim
with I-Claim
regard I-Claim
to I-Claim
fatigue I-Claim
levels I-Claim
, I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
and I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

The B-Claim
IMPACT I-Claim
collaborative I-Claim
care I-Claim
program I-Claim
appears I-Claim
to I-Claim
be I-Claim
feasible I-Claim
and I-Claim
effective I-Claim
for I-Claim
depression I-Claim
among I-Claim
older I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
diverse I-Claim
primary I-Claim
care I-Claim
settings I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
trend I-Claim
in I-Claim
RR I-Claim
, I-Claim
PFS I-Claim
, I-Claim
and I-Claim
OS I-Claim
favors I-Claim
PC I-Claim
. I-Claim

HDC B-Claim
has I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QOL I-Claim
even I-Claim
after I-Claim
treatment I-Claim
phase I-Claim
. I-Claim

After B-Claim
validation I-Claim
of I-Claim
our I-Claim
data I-Claim
in I-Claim
a I-Claim
larger I-Claim
group I-Claim
TS I-Claim
determination I-Claim
may I-Claim
have I-Claim
the I-Claim
potential I-Claim
to I-Claim
better I-Claim
help I-Claim
direct I-Claim
systemic I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
primarily I-Claim
non-resectable I-Claim
mCRC I-Claim
. I-Claim

Imatinib B-Claim
interruption I-Claim
results I-Claim
in I-Claim
rapid I-Claim
progression I-Claim
in I-Claim
most I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
GIST I-Claim
, I-Claim
and I-Claim
can I-Claim
not I-Claim
be I-Claim
recommended I-Claim
in I-Claim
routine I-Claim
practice I-Claim
unless I-Claim
patient I-Claim
experience I-Claim
significant I-Claim
toxicity I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
marimastat I-Claim
after I-Claim
induction I-Claim
therapy I-Claim
for I-Claim
SCLC I-Claim
did I-Claim
not I-Claim
result I-Claim
in I-Claim
improved I-Claim
survival I-Claim
and I-Claim
had I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

There B-Claim
is I-Claim
a I-Claim
need I-Claim
for I-Claim
further I-Claim
studies I-Claim
so I-Claim
that I-Claim
its I-Claim
effect I-Claim
can I-Claim
be I-Claim
confirmed I-Claim
. I-Claim

Since B-Claim
the I-Claim
cost I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
treatments I-Claim
was I-Claim
only I-Claim
small I-Claim
, I-Claim
cost B-Claim
should I-Claim
not I-Claim
play I-Claim
a I-Claim
predominant I-Claim
role I-Claim
when I-Claim
deciding I-Claim
on I-Claim
the I-Claim
type I-Claim
of I-Claim
treatment I-Claim
assigned I-Claim
to I-Claim
patients I-Claim
with I-Claim
malignant I-Claim
GOO I-Claim
. I-Claim

Abiraterone B-Claim
plus I-Claim
prednisone I-Claim
delays I-Claim
patient-reported I-Claim
pain I-Claim
progression I-Claim
and I-Claim
HRQoL I-Claim
deterioration I-Claim
in I-Claim
chemotherapy-naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration-resistant I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

Participation B-Claim
in I-Claim
an I-Claim
upper-body I-Claim
exercise I-Claim
program I-Claim
caused I-Claim
no I-Claim
changes I-Claim
in I-Claim
arm I-Claim
circumference I-Claim
or I-Claim
arm I-Claim
volume I-Claim
in I-Claim
women I-Claim
with I-Claim
lymphedema I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
and I-Claim
they I-Claim
may I-Claim
have I-Claim
experienced I-Claim
an I-Claim
increase I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

No B-Claim
difference I-Claim
in I-Claim
QOL I-Claim
was I-Claim
observed I-Claim
. I-Claim

LLLT B-Claim
was I-Claim
effective I-Claim
in I-Claim
improving I-Claim
the I-Claim
patient I-Claim
's I-Claim
subjective I-Claim
experience I-Claim
of I-Claim
OM I-Claim
and I-Claim
QOL I-Claim
in I-Claim
HNC I-Claim
patients I-Claim
receiving I-Claim
CRT I-Claim
. I-Claim

Patients B-Claim
with I-Claim
bone-cancer I-Claim
pain I-Claim
, I-Claim
already I-Claim
on I-Claim
opioids I-Claim
, I-Claim
obtain I-Claim
clinically I-Claim
important I-Claim
, I-Claim
additional I-Claim
pain-control I-Claim
, I-Claim
with I-Claim
regular I-Claim
oxycodone/paracetamol I-Claim
dosing I-Claim
. I-Claim

Short-term B-Claim
administration I-Claim
of I-Claim
exogenous I-Claim
ghrelin I-Claim
at I-Claim
the I-Claim
start I-Claim
of I-Claim
cisplatin-based I-Claim
chemotherapy I-Claim
stimulated I-Claim
food I-Claim
intake I-Claim
and I-Claim
minimized I-Claim
adverse I-Claim
events I-Claim
. I-Claim

These B-Claim
analyses I-Claim
confirm I-Claim
that I-Claim
EVE I-Claim
+ I-Claim
EXE I-Claim
provides I-Claim
clinical I-Claim
benefit I-Claim
without I-Claim
adversely I-Claim
impacting I-Claim
HRQOL I-Claim
in I-Claim
patients I-Claim
with I-Claim
HR I-Claim
( I-Claim
+ I-Claim
) I-Claim
ABC I-Claim
who I-Claim
recurred/progressed I-Claim
on I-Claim
prior I-Claim
NSAIs I-Claim
versus I-Claim
endocrine I-Claim
therapy I-Claim
alone I-Claim
. I-Claim

These B-Claim
findings I-Claim
demonstrate I-Claim
clinically I-Claim
meaningful I-Claim
, I-Claim
transitory I-Claim
HRQoL I-Claim
decrements I-Claim
with I-Claim
VMP I-Claim
and I-Claim
relatively I-Claim
lower I-Claim
HRQoL I-Claim
vs. I-Claim
MP I-Claim
during I-Claim
early I-Claim
treatment I-Claim
cycles I-Claim
, I-Claim
associated I-Claim
with I-Claim
the I-Claim
expected I-Claim
additional I-Claim
toxicities I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
isotretinoin I-Claim
to I-Claim
an I-Claim
adjuvant I-Claim
treatment I-Claim
of I-Claim
low-dose I-Claim
IFNalpha I-Claim
in I-Claim
patients I-Claim
with I-Claim
stage I-Claim
IIA I-Claim
and I-Claim
IIB I-Claim
melanoma I-Claim
had I-Claim
no I-Claim
significant I-Claim
effect I-Claim
on I-Claim
disease-free I-Claim
or I-Claim
overall I-Claim
survival I-Claim
and I-Claim
is I-Claim
therefore I-Claim
not I-Claim
recommended I-Claim
. I-Claim

Erlotinib B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
had I-Claim
no I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QoL I-Claim
in I-Claim
this I-Claim
subpopulation I-Claim
. I-Claim

The B-Claim
survival I-Claim
was I-Claim
similar I-Claim
to I-Claim
that I-Claim
of I-Claim
transthoracic I-Claim
approach I-Claim
. I-Claim

Prophylactic B-Claim
alpha-blockers I-Claim
gave I-Claim
significantly I-Claim
lower I-Claim
maximum I-Claim
dysuria I-Claim
scores I-Claim
but B-Claim
did I-Claim
not I-Claim
affect I-Claim
the I-Claim
time I-Claim
to I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim

In B-Claim
summary I-Claim
, I-Claim
this I-Claim
six-week I-Claim
supervised I-Claim
multimodal I-Claim
exercise I-Claim
intervention I-Claim
can I-Claim
lead I-Claim
to I-Claim
significant I-Claim
reduction I-Claim
in I-Claim
self-reported I-Claim
CRF I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
undergoing I-Claim
chemotherapy I-Claim
. I-Claim

Subcutaneous B-Claim
interleukin-2 I-Claim
and/or I-Claim
interferon-alfa I-Claim
provide I-Claim
no I-Claim
survival I-Claim
benefit I-Claim
in I-Claim
metastatic I-Claim
renal I-Claim
cancers I-Claim
of I-Claim
intermediate I-Claim
prognosis I-Claim
, I-Claim
and I-Claim
they I-Claim
induce I-Claim
a I-Claim
significant I-Claim
risk I-Claim
of I-Claim
toxicity I-Claim
. I-Claim

Replacement B-Claim
of I-Claim
most I-Claim
hospital I-Claim
follow-up I-Claim
visits I-Claim
in I-Claim
the I-Claim
first I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
by I-Claim
nurse-led I-Claim
telephone I-Claim
follow-up I-Claim
does I-Claim
not I-Claim
impede I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

Thalidomide B-Claim
, I-Claim
which I-Claim
is I-Claim
an I-Claim
inhibitor I-Claim
of I-Claim
TNF-alpha I-Claim
synthesis I-Claim
, I-Claim
may I-Claim
represent I-Claim
a I-Claim
novel I-Claim
and I-Claim
rational I-Claim
approach I-Claim
to I-Claim
the I-Claim
treatment I-Claim
of I-Claim
cancer I-Claim
cachexia I-Claim
. I-Claim

During B-Claim
RT I-Claim
, I-Claim
nutritional I-Claim
interventions I-Claim
positively I-Claim
influenced I-Claim
outcomes I-Claim
, I-Claim
and I-Claim
counseling I-Claim
was I-Claim
of I-Claim
similar/higher I-Claim
benefit I-Claim
";" I-Claim
in B-Claim
the I-Claim
medium I-Claim
term I-Claim
, I-Claim
only I-Claim
counseling I-Claim
exerted I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

However B-Claim
, I-Claim
combination I-Claim
modalities I-Claim
including I-Claim
IPC I-Claim
and I-Claim
SLD I-Claim
may I-Claim
be I-Claim
the I-Claim
preferred I-Claim
choices I-Claim
for I-Claim
their I-Claim
applicability I-Claim
at I-Claim
home I-Claim
. I-Claim

There B-Claim
is I-Claim
a I-Claim
paucity I-Claim
of I-Claim
high-level I-Claim
evidence I-Claim
on I-Claim
potentially I-Claim
useful I-Claim
interventions I-Claim
and I-Claim
a I-Claim
continued I-Claim
need I-Claim
for I-Claim
new I-Claim
and I-Claim
innovative I-Claim
research I-Claim
, I-Claim
incorporating I-Claim
quality-of-life I-Claim
measurements I-Claim
, I-Claim
in I-Claim
patients I-Claim
experiencing I-Claim
radiation-induced I-Claim
mucositis I-Claim
. I-Claim

Erlotinib B-Claim
is I-Claim
highly I-Claim
effective I-Claim
compared I-Claim
with I-Claim
oral I-Claim
vinorelbine I-Claim
in I-Claim
elderly I-Claim
, I-Claim
chemonaive I-Claim
, I-Claim
Taiwanese I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
. I-Claim

An B-Claim
Internet-based I-Claim
education I-Claim
program I-Claim
based I-Claim
on I-Claim
NCCN I-Claim
guidelines I-Claim
and I-Claim
TTM I-Claim
may I-Claim
help I-Claim
patients I-Claim
manage I-Claim
CRF I-Claim
. I-Claim

Breast B-Claim
and I-Claim
colorectal I-Claim
cancer I-Claim
survivors I-Claim
enrolled I-Claim
in I-Claim
a I-Claim
multicenter I-Claim
, I-Claim
telephone-based I-Claim
physical I-Claim
activity I-Claim
intervention I-Claim
increased I-Claim
physical I-Claim
activity I-Claim
and I-Claim
experienced I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
fitness I-Claim
and I-Claim
physical I-Claim
functioning I-Claim
. I-Claim

Chemotherapy B-Claim
is I-Claim
moderately I-Claim
efficient I-Claim
as I-Claim
a I-Claim
treatment I-Claim
for I-Claim
pancreatic I-Claim
adenocarcinoma I-Claim
, I-Claim
but B-Claim
patient I-Claim
survival I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
has I-Claim
improved I-Claim
with I-Claim
this I-Claim
modality I-Claim
in I-Claim
some I-Claim
trials I-Claim
. I-Claim

The B-Claim
findings I-Claim
of I-Claim
this I-Claim
trial I-Claim
indicate I-Claim
that I-Claim
the I-Claim
negative I-Claim
effects I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
on I-Claim
QOL I-Claim
appear I-Claim
to I-Claim
be I-Claim
temporary I-Claim
, I-Claim
and I-Claim
that I-Claim
improvements I-Claim
( I-Claim
with I-Claim
a I-Claim
return I-Claim
to I-Claim
baseline I-Claim
function I-Claim
) I-Claim
are I-Claim
likely I-Claim
in I-Claim
most I-Claim
patients I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
cisplatin-based I-Claim
chemotherapy I-Claim
provides I-Claim
a I-Claim
modest I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
supportive I-Claim
care I-Claim
alone I-Claim
in I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
statistically I-Claim
significant I-Claim
difference I-Claim
in I-Claim
treatment I-Claim
response I-Claim
when I-Claim
the I-Claim
100 I-Claim
% I-Claim
or I-Claim
75 I-Claim
% I-Claim
clearance I-Claim
rate I-Claim
cutoff I-Claim
was I-Claim
used I-Claim
, I-Claim
but B-Claim
our I-Claim
secondary I-Claim
outcome I-Claim
suggests I-Claim
that I-Claim
two I-Claim
sessions I-Claim
of I-Claim
ALA-PDT I-Claim
is I-Claim
superior I-Claim
to I-Claim
imiquimod I-Claim
5 I-Claim
% I-Claim
cream I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
AKs I-Claim
. I-Claim

Clinically B-Claim
, I-Claim
HBO I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
adjunct I-Claim
to I-Claim
ONJ I-Claim
treatment I-Claim
, I-Claim
particularly I-Claim
for I-Claim
more I-Claim
severe I-Claim
cases I-Claim
, I-Claim
although I-Claim
this I-Claim
study I-Claim
was I-Claim
underpowered I-Claim
to I-Claim
fully I-Claim
support I-Claim
this I-Claim
claim I-Claim
. I-Claim

GC B-Claim
is I-Claim
as I-Claim
effective I-Claim
as I-Claim
PE I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression-free I-Claim
survival I-Claim
and I-Claim
has I-Claim
a I-Claim
toxicity I-Claim
profile I-Claim
more I-Claim
acceptable I-Claim
to I-Claim
patients I-Claim
. I-Claim

Relapse B-Claim
after I-Claim
completing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
therapy I-Claim
is I-Claim
a I-Claim
persistent I-Claim
threat I-Claim
for I-Claim
women I-Claim
with I-Claim
hormone-responsive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

SLN B-Claim
biopsy I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well-tolerated I-Claim
procedure I-Claim
. I-Claim

Coloplasty B-Claim
pouches I-Claim
resulted I-Claim
in I-Claim
more I-Claim
anastomotic I-Claim
leaks I-Claim
and I-Claim
minimal I-Claim
differences I-Claim
in I-Claim
bowel I-Claim
function I-Claim
. I-Claim

To B-Claim
our I-Claim
knowledge I-Claim
, I-Claim
this I-Claim
study I-Claim
provided I-Claim
novel I-Claim
evidence I-Claim
that I-Claim
MBSR I-Claim
can I-Claim
help I-Claim
alleviate I-Claim
long-term I-Claim
emotional I-Claim
and I-Claim
physical I-Claim
adverse I-Claim
effects I-Claim
of I-Claim
medical I-Claim
treatments I-Claim
, I-Claim
including I-Claim
endocrine I-Claim
treatments I-Claim
. I-Claim

The B-Claim
-3 I-Claim
and I-Claim
5-year I-Claim
survival I-Claim
rates I-Claim
of I-Claim
nonsurgical I-Claim
therapy I-Claim
were I-Claim
comparable I-Claim
to I-Claim
published I-Claim
surgical I-Claim
trials I-Claim
of I-Claim
N2 I-Claim
disease I-Claim
. I-Claim

The B-Claim
behaviorally I-Claim
oriented I-Claim
intervention I-Claim
brought I-Claim
about I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
indicated I-Claim
a I-Claim
trend I-Claim
toward I-Claim
improved I-Claim
CRF I-Claim
, I-Claim
but I-Claim
detected I-Claim
no I-Claim
effect I-Claim
for I-Claim
fatigue-related I-Claim
distress I-Claim
. I-Claim

Of B-Claim
the I-Claim
three I-Claim
regimens I-Claim
tested I-Claim
, I-Claim
the I-Claim
combination I-Claim
of I-Claim
LV5FU2-irinotecan I-Claim
is I-Claim
the I-Claim
most I-Claim
promising I-Claim
and I-Claim
will I-Claim
be I-Claim
assessed I-Claim
in I-Claim
a I-Claim
phase I-Claim
III I-Claim
trial I-Claim
. I-Claim

The B-Claim
maximum I-Claim
IPSS I-Claim
after I-Claim
the I-Claim
implant I-Claim
was I-Claim
the I-Claim
best I-Claim
predictor I-Claim
of I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim

Radiation B-Claim
therapy I-Claim
for I-Claim
prostate I-Claim
carcinoma I-Claim
causes I-Claim
persistent I-Claim
GI I-Claim
toxicity I-Claim
that I-Claim
is I-Claim
largely I-Claim
independent I-Claim
of I-Claim
the I-Claim
two I-Claim
dose I-Claim
schedules I-Claim
. I-Claim

CBT-I B-Claim
delivered I-Claim
through I-Claim
an I-Claim
interactive I-Claim
, I-Claim
individually I-Claim
tailored I-Claim
Internet I-Claim
intervention I-Claim
may I-Claim
be I-Claim
a I-Claim
viable I-Claim
treatment I-Claim
option I-Claim
for I-Claim
cancer I-Claim
survivors I-Claim
experiencing I-Claim
insomnia I-Claim
. I-Claim

Taking B-Claim
a I-Claim
pre-treatment I-Claim
biopsy I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
feasible I-Claim
procedure I-Claim
in I-Claim
mCRC I-Claim
. I-Claim

These B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
ways I-Claim
of I-Claim
making I-Claim
this I-Claim
method I-Claim
of I-Claim
hair I-Claim
removal I-Claim
more I-Claim
widely I-Claim
available I-Claim
to I-Claim
women I-Claim
with I-Claim
facial I-Claim
hirsutism I-Claim
should I-Claim
be I-Claim
considered I-Claim
. I-Claim

No B-Claim
substantive I-Claim
differences I-Claim
were I-Claim
detected I-Claim
between I-Claim
outcomes I-Claim
of I-Claim
embolization I-Claim
with I-Claim
PVA I-Claim
particles I-Claim
or I-Claim
tris-acryl I-Claim
gelatin I-Claim
microspheres I-Claim
. I-Claim

Le B-Claim
( I-Claim
y I-Claim
) I-Claim
is I-Claim
an I-Claim
attractive I-Claim
target I-Claim
since I-Claim
it I-Claim
is I-Claim
expressed I-Claim
by I-Claim
most I-Claim
NSCLC I-Claim
. I-Claim

During B-Claim
radiotherapy I-Claim
, I-Claim
both I-Claim
interventions I-Claim
positively I-Claim
influenced I-Claim
outcomes I-Claim
";" I-Claim
dietary B-Claim
counseling I-Claim
was I-Claim
of I-Claim
similar I-Claim
or I-Claim
higher I-Claim
benefit I-Claim
, I-Claim
whereas I-Claim
even I-Claim
3 I-Claim
months I-Claim
after I-Claim
RT I-Claim
, I-Claim
it I-Claim
was I-Claim
the I-Claim
only I-Claim
method I-Claim
to I-Claim
sustain I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

Tamoxifen B-Claim
decreases I-Claim
the I-Claim
incidence I-Claim
of I-Claim
invasive I-Claim
and I-Claim
noninvasive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Symptoms B-Claim
were I-Claim
common I-Claim
in I-Claim
both I-Claim
groups I-Claim
. I-Claim

This B-Claim
study I-Claim
demonstrates I-Claim
that I-Claim
a I-Claim
brief I-Claim
, I-Claim
predominantly I-Claim
group-based I-Claim
resilience I-Claim
training I-Claim
intervention I-Claim
is I-Claim
feasible I-Claim
in I-Claim
patients I-Claim
with I-Claim
previous I-Claim
breast I-Claim
cancer I-Claim
";" I-Claim
also I-Claim
, I-Claim
it I-Claim
may I-Claim
be I-Claim
efficacious I-Claim
. I-Claim

The B-Claim
efficacy I-Claim
of I-Claim
5-FU I-Claim
, I-Claim
modulated I-Claim
with I-Claim
6S-LV I-Claim
, I-Claim
is I-Claim
moderate I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
, I-Claim
similar I-Claim
to I-Claim
cisplatin-containing I-Claim
regimens I-Claim
. I-Claim

Sunitinib B-Claim
37.5 I-Claim
mg I-Claim
, I-Claim
administered I-Claim
on I-Claim
a I-Claim
continuous I-Claim
once-daily I-Claim
dosing I-Claim
regimen I-Claim
, I-Claim
has I-Claim
a I-Claim
manageable I-Claim
safety I-Claim
profile I-Claim
as I-Claim
second-line I-Claim
mRCC I-Claim
therapy I-Claim
, I-Claim
providing I-Claim
flexible I-Claim
dosing I-Claim
, I-Claim
which I-Claim
can I-Claim
be I-Claim
explored I-Claim
in I-Claim
combination I-Claim
studies I-Claim
. I-Claim

In B-Claim
conclusion I-Claim
, I-Claim
this I-Claim
first I-Claim
randomized I-Claim
study I-Claim
did I-Claim
not I-Claim
demonstrate I-Claim
any I-Claim
significant I-Claim
improvement I-Claim
of I-Claim
using I-Claim
estramustine I-Claim
in I-Claim
addition I-Claim
to I-Claim
conventional I-Claim
radiotherapy I-Claim
, I-Claim
however B-Claim
, I-Claim
a I-Claim
trend I-Claim
for I-Claim
a I-Claim
positive I-Claim
response I-Claim
for I-Claim
the I-Claim
estramustine I-Claim
group I-Claim
was I-Claim
found I-Claim
in I-Claim
patients I-Claim
with I-Claim
grade I-Claim
III I-Claim
glioma I-Claim
. I-Claim

Somatostatin B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
have I-Claim
antimitotic I-Claim
activity I-Claim
in I-Claim
endocrine I-Claim
as I-Claim
well I-Claim
as I-Claim
in I-Claim
a I-Claim
variety I-Claim
of I-Claim
nonendocrine I-Claim
tumors I-Claim
. I-Claim

Exercise B-Claim
training I-Claim
to I-Claim
improve I-Claim
cardiovascular I-Claim
fitness I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
management I-Claim
of I-Claim
lymphoma I-Claim
patients I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
MEV I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
demonstrated I-Claim
clinical I-Claim
activity I-Claim
in I-Claim
patients I-Claim
with I-Claim
CRPC I-Claim
. I-Claim

QOL B-Claim
was I-Claim
similar I-Claim
for I-Claim
both I-Claim
arms I-Claim
. I-Claim

Results B-Claim
showed I-Claim
a I-Claim
significant I-Claim
increase I-Claim
in I-Claim
pain I-Claim
knowledge I-Claim
in I-Claim
patients I-Claim
who I-Claim
received I-Claim
the I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
and I-Claim
a I-Claim
significant I-Claim
decrease I-Claim
in I-Claim
pain I-Claim
intensity I-Claim
. I-Claim

CBT B-Claim
and I-Claim
PE I-Claim
can I-Claim
have I-Claim
salutary I-Claim
effects I-Claim
on I-Claim
endocrine I-Claim
symptoms I-Claim
and I-Claim
, I-Claim
to I-Claim
a I-Claim
lesser I-Claim
degree I-Claim
, I-Claim
on I-Claim
sexuality I-Claim
and I-Claim
physical I-Claim
functioning I-Claim
of I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
experiencing I-Claim
treatment-induced I-Claim
menopause I-Claim
. I-Claim

Bevacizumab B-Claim
, I-Claim
a I-Claim
humanized I-Claim
monoclonal I-Claim
antibody I-Claim
against I-Claim
vascular I-Claim
endothelial I-Claim
growth I-Claim
factor I-Claim
( I-Claim
VEGF I-Claim
) I-Claim
, I-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
efficient I-Claim
in I-Claim
suppressing I-Claim
the I-Claim
accumulation I-Claim
of I-Claim
pleural I-Claim
fluid I-Claim
. I-Claim

However B-Claim
, I-Claim
monitoring I-Claim
the I-Claim
lymphocyte I-Claim
count I-Claim
is I-Claim
advisable I-Claim
. I-Claim

Improvements B-Claim
in I-Claim
total I-Claim
quality-of-life I-Claim
change I-Claim
scores I-Claim
demonstrated I-Claim
that I-Claim
at I-Claim
6 I-Claim
months I-Claim
, I-Claim
improvements I-Claim
were I-Claim
more I-Claim
than I-Claim
twice I-Claim
as I-Claim
large I-Claim
and I-Claim
clinically I-Claim
significant I-Claim
in I-Claim
the I-Claim
intervention I-Claim
compared I-Claim
with I-Claim
the I-Claim
control I-Claim
group I-Claim
. I-Claim

Switching B-Claim
to I-Claim
anastrozole I-Claim
strongly I-Claim
decreased I-Claim
the I-Claim
endometrial I-Claim
thickness I-Claim
and I-Claim
uterine I-Claim
volume I-Claim
but I-Claim
increased I-Claim
sexual I-Claim
disturbances I-Claim
. I-Claim

The B-Claim
use I-Claim
of I-Claim
the I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
by I-Claim
nurses I-Claim
should I-Claim
be I-Claim
seriously I-Claim
considered I-Claim
on I-Claim
oncology I-Claim
units I-Claim
. I-Claim

Lifestyle B-Claim
intervention I-Claim
research I-Claim
is I-Claim
feasible I-Claim
in I-Claim
a I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim

However B-Claim
, I-Claim
many I-Claim
patients I-Claim
develop I-Claim
clinically I-Claim
relevant I-Claim
neurotoxicity I-Claim
, I-Claim
frequently I-Claim
resulting I-Claim
in I-Claim
treatment I-Claim
discontinuation I-Claim
. I-Claim

Dysuria B-Claim
is I-Claim
common I-Claim
after I-Claim
brachytherapy I-Claim
but I-Claim
is I-Claim
typically I-Claim
mild I-Claim
. I-Claim

For B-Claim
malignant I-Claim
pleural I-Claim
mesothelioma I-Claim
( I-Claim
MPM I-Claim
) I-Claim
patients I-Claim
with I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
, I-Claim
maintaining I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
HRQOL I-Claim
) I-Claim
is I-Claim
important I-Claim
. I-Claim

Cancer B-Claim
patients I-Claim
should I-Claim
be I-Claim
empowered I-Claim
with I-Claim
pain I-Claim
management I-Claim
education I-Claim
to I-Claim
gain I-Claim
knowledge I-Claim
and I-Claim
correct I-Claim
misconceptions I-Claim
in I-Claim
managing I-Claim
their I-Claim
cancer I-Claim
pain I-Claim
. I-Claim

More B-Claim
patients I-Claim
treated I-Claim
on I-Claim
4 I-Claim
consecutive I-Claim
days I-Claim
reported I-Claim
a I-Claim
clinically I-Claim
meaningful I-Claim
increase I-Claim
in I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
interpretation I-Claim
of I-Claim
these I-Claim
results I-Claim
is I-Claim
challenging I-Claim
due I-Claim
to I-Claim
baseline I-Claim
imbalance I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
statistically I-Claim
significant I-Claim
difference I-Claim
in I-Claim
effect I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
assessed I-Claim
using I-Claim
the I-Claim
DLQI I-Claim
. I-Claim

Nocturnal B-Claim
administration I-Claim
of I-Claim
BCAA I-Claim
granules I-Claim
in I-Claim
patients I-Claim
with I-Claim
cirrhosis I-Claim
reduced I-Claim
the I-Claim
occurrence I-Claim
of I-Claim
muscle I-Claim
cramps I-Claim
in I-Claim
the I-Claim
leg I-Claim
but I-Claim
did I-Claim
not I-Claim
improve I-Claim
the I-Claim
patients I-Claim
' I-Claim
QOL I-Claim
. I-Claim

MA.17 B-Claim
showed I-Claim
that I-Claim
letrozole I-Claim
is I-Claim
extremely I-Claim
well-tolerated I-Claim
relative I-Claim
to I-Claim
placebo I-Claim
. I-Claim

For B-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
treatment I-Claim
is I-Claim
primarily I-Claim
palliative I-Claim
, I-Claim
relying I-Claim
mainly I-Claim
on I-Claim
the I-Claim
suppression I-Claim
of I-Claim
systemic I-Claim
androgen I-Claim
hormone I-Claim
levels I-Claim
. I-Claim

Patients B-Claim
given I-Claim
targeted I-Claim
intervention I-Claim
following I-Claim
a I-Claim
detailed I-Claim
clinical I-Claim
algorithm I-Claim
had I-Claim
better I-Claim
improvements I-Claim
in I-Claim
radiotherapy-induced I-Claim
gastrointestinal I-Claim
symptoms I-Claim
than I-Claim
did I-Claim
patients I-Claim
given I-Claim
usual I-Claim
care I-Claim
. I-Claim

For B-Claim
men I-Claim
with I-Claim
localised I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
surgery I-Claim
provides I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
watchful I-Claim
waiting I-Claim
. I-Claim

Dermatitis B-Claim
is I-Claim
a I-Claim
frequent I-Claim
adverse I-Claim
effect I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
radiotherapy I-Claim
. I-Claim

Although B-Claim
this I-Claim
trial I-Claim
met I-Claim
the I-Claim
pre-determined I-Claim
criteria I-Claim
for I-Claim
equivalence I-Claim
between I-Claim
the I-Claim
two I-Claim
palliative I-Claim
regimens I-Claim
, I-Claim
significantly B-Claim
more I-Claim
patients I-Claim
achieved I-Claim
complete I-Claim
resolution I-Claim
of I-Claim
symptoms I-Claim
and I-Claim
palliation I-Claim
of I-Claim
chest I-Claim
pain I-Claim
and I-Claim
dyspnoea I-Claim
with I-Claim
the I-Claim
fractionated I-Claim
regimen I-Claim
. I-Claim

Subgroup B-Claim
analyses I-Claim
suggested I-Claim
a I-Claim
dose-dependent I-Claim
treatment I-Claim
effect I-Claim
. I-Claim

Standard B-Claim
chemotherapy I-Claim
was I-Claim
superior I-Claim
to I-Claim
capecitabine I-Claim
in I-Claim
improving I-Claim
relapse-free I-Claim
and I-Claim
overall I-Claim
survival I-Claim
for I-Claim
older I-Claim
women I-Claim
with I-Claim
early-stage I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Patients B-Claim
treated I-Claim
with I-Claim
single-agent I-Claim
E I-Claim
followed I-Claim
by I-Claim
single-agent I-Claim
M I-Claim
had I-Claim
similar I-Claim
survival I-Claim
, I-Claim
but I-Claim
less I-Claim
treatment-related I-Claim
toxicity I-Claim
and I-Claim
better I-Claim
QOL I-Claim
as I-Claim
compared I-Claim
with I-Claim
those I-Claim
treated I-Claim
with I-Claim
CEF I-Claim
followed I-Claim
by I-Claim
MV I-Claim
. I-Claim

These B-Claim
data I-Claim
demonstrated I-Claim
a I-Claim
significant I-Claim
4.5-month I-Claim
median I-Claim
OS I-Claim
advantage I-Claim
with I-Claim
the I-Claim
lapatinib I-Claim
and I-Claim
trastuzumab I-Claim
combination I-Claim
and I-Claim
support I-Claim
dual I-Claim
HER2 I-Claim
blockade I-Claim
in I-Claim
patients I-Claim
with I-Claim
heavily I-Claim
pretreated I-Claim
HER2-positive I-Claim
MBC I-Claim
. I-Claim

Safe B-Claim
, I-Claim
effective I-Claim
non-hormonal I-Claim
treatments I-Claim
are I-Claim
needed I-Claim
. I-Claim

Larger B-Claim
studies I-Claim
are I-Claim
required I-Claim
to I-Claim
validate I-Claim
these I-Claim
results I-Claim
. I-Claim

Gemcitabine B-Claim
plus I-Claim
carboplatin I-Claim
significantly I-Claim
improves I-Claim
PFS I-Claim
and I-Claim
response I-Claim
rate I-Claim
without I-Claim
worsening I-Claim
quality I-Claim
of I-Claim
life I-Claim
for I-Claim
patients I-Claim
with I-Claim
platinum-sensitive I-Claim
recurrent I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Although B-Claim
the I-Claim
ability I-Claim
of I-Claim
dignity I-Claim
therapy I-Claim
to I-Claim
mitigate I-Claim
outright I-Claim
distress I-Claim
, I-Claim
such I-Claim
as I-Claim
depression I-Claim
, I-Claim
desire I-Claim
for I-Claim
death I-Claim
or I-Claim
suicidality I-Claim
, I-Claim
has I-Claim
yet I-Claim
to I-Claim
be I-Claim
proven I-Claim
, I-Claim
its B-Claim
benefits I-Claim
in I-Claim
terms I-Claim
of I-Claim
self-reported I-Claim
end-of-life I-Claim
experiences I-Claim
support I-Claim
its I-Claim
clinical I-Claim
application I-Claim
for I-Claim
patients I-Claim
nearing I-Claim
death I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
significant I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
schedules I-Claim
examined I-Claim
in I-Claim
terms I-Claim
of I-Claim
improvement I-Claim
in I-Claim
KP I-Claim
or I-Claim
QOL I-Claim
, I-Claim
but I-Claim
there I-Claim
seemed I-Claim
to I-Claim
be I-Claim
a I-Claim
trend I-Claim
in I-Claim
favor I-Claim
of I-Claim
the I-Claim
3w4 I-Claim
schedule I-Claim
. I-Claim

Preparatory B-Claim
education I-Claim
and I-Claim
support I-Claim
has I-Claim
the I-Claim
potential I-Claim
to I-Claim
assist I-Claim
women I-Claim
to I-Claim
cope I-Claim
with I-Claim
cancer-related I-Claim
fatigue I-Claim
in I-Claim
the I-Claim
short I-Claim
term I-Claim
. I-Claim

However B-Claim
, I-Claim
it I-Claim
provided I-Claim
no I-Claim
improvement I-Claim
in I-Claim
PFS I-Claim
or I-Claim
OS I-Claim
compared I-Claim
with I-Claim
flat I-Claim
dosing I-Claim
. I-Claim

In B-Claim
nonrandomized I-Claim
studies I-Claim
involving I-Claim
patients I-Claim
with I-Claim
different I-Claim
tumor I-Claim
types I-Claim
including I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
, I-Claim
ATP I-Claim
infusion I-Claim
appeared I-Claim
to I-Claim
inhibit I-Claim
loss I-Claim
of I-Claim
weight I-Claim
and I-Claim
deterioration I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
and I-Claim
performance I-Claim
status I-Claim
. I-Claim

We B-Claim
could I-Claim
not I-Claim
identify I-Claim
any I-Claim
significant I-Claim
difference I-Claim
in I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
mucositis I-Claim
based I-Claim
on I-Claim
whether I-Claim
patients I-Claim
were I-Claim
allocated I-Claim
to I-Claim
receive I-Claim
misoprostol I-Claim
or I-Claim
placebo I-Claim
. I-Claim

Two B-Claim
months I-Claim
after I-Claim
starting I-Claim
treatment I-Claim
there I-Claim
were I-Claim
no I-Claim
significant I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
between I-Claim
the I-Claim
arms I-Claim
. I-Claim

The B-Claim
analgesic I-Claim
effects I-Claim
of I-Claim
amitriptyline I-Claim
were I-Claim
slight I-Claim
and I-Claim
associated I-Claim
with I-Claim
adverse I-Claim
effects I-Claim
. I-Claim

The B-Claim
treatment I-Claim
choice I-Claim
for I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
esophageal I-Claim
cancer I-Claim
should I-Claim
be I-Claim
between I-Claim
a I-Claim
SEMS I-Claim
or I-Claim
a I-Claim
non-stent I-Claim
treatment I-Claim
after I-Claim
consideration I-Claim
has I-Claim
been I-Claim
given I-Claim
to I-Claim
both I-Claim
patient I-Claim
and I-Claim
tumor I-Claim
characteristics I-Claim
and I-Claim
clinician I-Claim
and I-Claim
patient I-Claim
preferences I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
pemetrexed I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
can I-Claim
be I-Claim
used I-Claim
as I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
drug I-Claim
for I-Claim
clinical I-Claim
first-line I-Claim
treatment I-Claim
for I-Claim
previously I-Claim
untreated I-Claim
NSCLC I-Claim
. I-Claim

Abatacept B-Claim
demonstrated I-Claim
acceptable I-Claim
safety I-Claim
and I-Claim
tolerability I-Claim
and I-Claim
clinically I-Claim
meaningful I-Claim
efficacy I-Claim
over I-Claim
6 I-Claim
months I-Claim
in I-Claim
patients I-Claim
with I-Claim
inadequate I-Claim
response I-Claim
to I-Claim
anti-TNF I-Claim
therapy I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
radiotherapy I-Claim
and I-Claim
5-fluorouracil I-Claim
changed I-Claim
only I-Claim
some I-Claim
aspects I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
did I-Claim
not I-Claim
have I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Newly B-Claim
available I-Claim
angiogenesis I-Claim
inhibitors I-Claim
should I-Claim
be I-Claim
preferred I-Claim
for I-Claim
these I-Claim
patients I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
ASA404 I-Claim
to I-Claim
carboplatin I-Claim
and I-Claim
paclitaxel I-Claim
, I-Claim
although I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
failed I-Claim
to I-Claim
improve I-Claim
frontline I-Claim
efficacy I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
interferon I-Claim
alfa I-Claim
( I-Claim
IFNalpha I-Claim
) I-Claim
and I-Claim
isotretinoin I-Claim
has I-Claim
shown I-Claim
a I-Claim
direct I-Claim
antiproliferative I-Claim
effect I-Claim
on I-Claim
human I-Claim
melanoma I-Claim
cell I-Claim
lines I-Claim
, I-Claim
but B-Claim
it I-Claim
remained I-Claim
unclear I-Claim
whether I-Claim
this I-Claim
combination I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
IFNalpha I-Claim
alone I-Claim
in I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
melanoma I-Claim
. I-Claim

Overall B-Claim
survival I-Claim
was I-Claim
not I-Claim
statistically I-Claim
significantly I-Claim
improved I-Claim
at I-Claim
this I-Claim
time I-Claim
. I-Claim

Further B-Claim
research I-Claim
is I-Claim
necessary I-Claim
to I-Claim
confirm I-Claim
this I-Claim
hypothesis I-Claim
in I-Claim
other I-Claim
samples I-Claim
, I-Claim
and I-Claim
causation I-Claim
can I-Claim
not I-Claim
be I-Claim
assumed I-Claim
based I-Claim
on I-Claim
this I-Claim
analysis I-Claim
. I-Claim

Epoetin B-Claim
beta I-Claim
30,000 I-Claim
IU I-Claim
once I-Claim
weekly I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well-tolerated I-Claim
treatment I-Claim
of I-Claim
anaemia I-Claim
in I-Claim
patients I-Claim
with I-Claim
solid I-Claim
tumours I-Claim
. I-Claim

In B-Claim
this I-Claim
, I-Claim
the I-Claim
first I-Claim
report I-Claim
of I-Claim
HRQoL I-Claim
over I-Claim
5 I-Claim
years I-Claim
of I-Claim
initial I-Claim
adjuvant I-Claim
therapy I-Claim
with I-Claim
an I-Claim
aromatase I-Claim
inhibitor I-Claim
, I-Claim
we I-Claim
conclude I-Claim
that I-Claim
anastrozole I-Claim
and I-Claim
tamoxifen I-Claim
had I-Claim
similar I-Claim
impacts I-Claim
on I-Claim
HRQoL I-Claim
, I-Claim
which I-Claim
was I-Claim
maintained I-Claim
or I-Claim
slightly I-Claim
improved I-Claim
during I-Claim
the I-Claim
treatment I-Claim
period I-Claim
for I-Claim
both I-Claim
groups I-Claim
. I-Claim

Vandetanib B-Claim
failed I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
as I-Claim
maintenance I-Claim
therapy I-Claim
for I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
. I-Claim

The B-Claim
results I-Claim
of I-Claim
this I-Claim
randomized I-Claim
clinical I-Claim
trial I-Claim
indicate I-Claim
that I-Claim
daunomycin-cytosine I-Claim
arabinoside I-Claim
plus I-Claim
GM-CSF I-Claim
is I-Claim
not I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
strategy I-Claim
when I-Claim
compared I-Claim
with I-Claim
daunomycin-cytosine I-Claim
arabinoside I-Claim
alone I-Claim
. I-Claim

PVI B-Claim
5-FU I-Claim
+ I-Claim
MMC I-Claim
results I-Claim
in I-Claim
failure-free I-Claim
survival I-Claim
and I-Claim
response I-Claim
advantage I-Claim
, I-Claim
tolerable I-Claim
toxicity I-Claim
and I-Claim
better I-Claim
QL I-Claim
when I-Claim
compared I-Claim
to I-Claim
PVI I-Claim
5-FU I-Claim
alone I-Claim
but I-Claim
no I-Claim
overall I-Claim
survival I-Claim
advantage I-Claim
. I-Claim

A B-Claim
supervised I-Claim
multimodal I-Claim
exercise I-Claim
intervention I-Claim
including I-Claim
high I-Claim
and I-Claim
low I-Claim
intensity I-Claim
components I-Claim
was I-Claim
feasible I-Claim
and I-Claim
could I-Claim
safely I-Claim
be I-Claim
used I-Claim
in I-Claim
patients I-Claim
with I-Claim
various I-Claim
cancers I-Claim
who I-Claim
were I-Claim
receiving I-Claim
adjuvant I-Claim
chemotherapy I-Claim
or I-Claim
treatment I-Claim
for I-Claim
advanced I-Claim
disease I-Claim
. I-Claim

Although B-Claim
there I-Claim
are I-Claim
no I-Claim
significant I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
changes I-Claim
, I-Claim
the B-Claim
observed I-Claim
trend I-Claim
towards I-Claim
a I-Claim
better I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
is I-Claim
remarkable I-Claim
in I-Claim
low-frequency I-Claim
low-intensity I-Claim
electrotherapy I-Claim
. I-Claim

Despite B-Claim
side I-Claim
effects I-Claim
resulting I-Claim
from I-Claim
administration I-Claim
of I-Claim
tamoxifen I-Claim
, I-Claim
its I-Claim
use I-Claim
as I-Claim
a I-Claim
breast I-Claim
cancer I-Claim
preventive I-Claim
agent I-Claim
is I-Claim
appropriate I-Claim
in I-Claim
many I-Claim
women I-Claim
at I-Claim
increased I-Claim
risk I-Claim
for I-Claim
the I-Claim
disease I-Claim
. I-Claim

Incorporating B-Claim
MRI-based I-Claim
dose-volume I-Claim
histogram I-Claim
analysis I-Claim
into I-Claim
the I-Claim
treatment I-Claim
planning I-Claim
process I-Claim
may I-Claim
reduce I-Claim
acute I-Claim
urinary I-Claim
morbidity I-Claim
after I-Claim
brachytherapy I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
VNR I-Claim
on I-Claim
day I-Claim
1-8 I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
a I-Claim
reference I-Claim
regimen I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
disease I-Claim
and I-Claim
those I-Claim
who I-Claim
deserve I-Claim
a I-Claim
postoperative I-Claim
therapy I-Claim
, I-Claim
and I-Claim
for I-Claim
future I-Claim
studies I-Claim
. I-Claim

Sentinel B-Claim
lymph I-Claim
node I-Claim
biopsy I-Claim
in I-Claim
women I-Claim
with I-Claim
operable I-Claim
breast I-Claim
cancer I-Claim
is I-Claim
routinely I-Claim
used I-Claim
in I-Claim
some I-Claim
countries I-Claim
for I-Claim
staging I-Claim
the I-Claim
axilla I-Claim
despite I-Claim
limited I-Claim
data I-Claim
from I-Claim
randomized I-Claim
trials I-Claim
on I-Claim
morbidity I-Claim
and I-Claim
mortality I-Claim
outcomes I-Claim
. I-Claim

DC/CIK B-Claim
treatment I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
method I-Claim
for I-Claim
maintenance I-Claim
therapy I-Claim
of I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
. I-Claim

The B-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
uterine-artery I-Claim
embolization I-Claim
, I-Claim
as I-Claim
compared I-Claim
with I-Claim
standard I-Claim
surgical I-Claim
methods I-Claim
, I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
symptomatic I-Claim
uterine I-Claim
fibroids I-Claim
remain I-Claim
uncertain I-Claim
. I-Claim

Adding B-Claim
E I-Claim
to I-Claim
G I-Claim
did I-Claim
not I-Claim
increase I-Claim
hematologic I-Claim
toxicities I-Claim
. I-Claim

On B-Claim
the I-Claim
basis I-Claim
of I-Claim
these I-Claim
findings I-Claim
, I-Claim
the I-Claim
policy I-Claim
of I-Claim
EOF I-Claim
should I-Claim
be I-Claim
used I-Claim
after I-Claim
a I-Claim
complex I-Claim
gynecologic I-Claim
oncologic I-Claim
laparotomy I-Claim
. I-Claim

Rigorous B-Claim
standard I-Claim
operating I-Claim
procedures I-Claim
for I-Claim
data I-Claim
collection I-Claim
are I-Claim
required I-Claim
. I-Claim

In B-Claim
advanced I-Claim
pancreatic I-Claim
carcinomas I-Claim
with I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
, I-Claim
FUP I-Claim
was I-Claim
superior I-Claim
to I-Claim
FU I-Claim
in I-Claim
terms I-Claim
of I-Claim
response I-Claim
and I-Claim
progression-free I-Claim
survival I-Claim
, I-Claim
but I-Claim
not I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
. I-Claim

We B-Claim
found I-Claim
a I-Claim
consistent I-Claim
pattern I-Claim
of I-Claim
better I-Claim
QOL I-Claim
outcomes I-Claim
at I-Claim
each I-Claim
follow-up I-Claim
assessment I-Claim
during I-Claim
the I-Claim
first I-Claim
6 I-Claim
months I-Claim
of I-Claim
treatment I-Claim
for I-Claim
orchiectomized I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
who I-Claim
received I-Claim
placebo I-Claim
versus I-Claim
flutamide I-Claim
. I-Claim

HDCT B-Claim
did I-Claim
not I-Claim
improve I-Claim
OS I-Claim
in I-Claim
women I-Claim
with I-Claim
MBC I-Claim
when I-Claim
used I-Claim
as I-Claim
consolidation I-Claim
after I-Claim
response I-Claim
to I-Claim
induction I-Claim
chemotherapy I-Claim
. I-Claim

The B-Claim
role I-Claim
of I-Claim
three-drug I-Claim
combinations I-Claim
remains I-Claim
questionable I-Claim
in I-Claim
this I-Claim
subset I-Claim
of I-Claim
patients I-Claim
. I-Claim

The B-Claim
effect I-Claim
of I-Claim
grape I-Claim
juice I-Claim
flavonoids I-Claim
on I-Claim
CINV I-Claim
should I-Claim
be I-Claim
investigated I-Claim
further I-Claim
with I-Claim
a I-Claim
larger I-Claim
sample I-Claim
to I-Claim
determine I-Claim
whether I-Claim
preliminary I-Claim
findings I-Claim
are I-Claim
supported I-Claim
. I-Claim

VC B-Claim
, I-Claim
GC I-Claim
, I-Claim
and I-Claim
TC I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
PC I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
( I-Claim
OS I-Claim
) I-Claim
. I-Claim

We B-Claim
found I-Claim
no I-Claim
evidence I-Claim
that I-Claim
the I-Claim
addition I-Claim
of I-Claim
TPZ I-Claim
to I-Claim
chemoradiotherapy I-Claim
, I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
not I-Claim
selected I-Claim
for I-Claim
the I-Claim
presence I-Claim
of I-Claim
hypoxia I-Claim
, I-Claim
improves I-Claim
OS I-Claim
. I-Claim

A B-Claim
colonic I-Claim
J-pouch I-Claim
may I-Claim
reduce I-Claim
excessive I-Claim
stool I-Claim
frequency I-Claim
and I-Claim
incontinence I-Claim
after I-Claim
anterior I-Claim
resection I-Claim
, I-Claim
but I-Claim
at I-Claim
the I-Claim
risk I-Claim
of I-Claim
evacuation I-Claim
problems I-Claim
. I-Claim

The B-Claim
hypofractionated I-Claim
schedule I-Claim
is I-Claim
equivalent I-Claim
in I-Claim
efficacy I-Claim
to I-Claim
the I-Claim
conventional I-Claim
schedule I-Claim
. I-Claim

These B-Claim
interim I-Claim
data I-Claim
indicate I-Claim
no I-Claim
early I-Claim
evidence I-Claim
of I-Claim
detriment I-Claim
to I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
overall I-Claim
survival I-Claim
or I-Claim
QALYs I-Claim
for I-Claim
patients I-Claim
allocated I-Claim
to I-Claim
OSC I-Claim
alone I-Claim
. I-Claim

There B-Premise
were I-Premise
no I-Premise
other I-Premise
significant I-Premise
associations I-Premise
between I-Premise
attrition I-Premise
and I-Premise
any I-Premise
demographic I-Premise
, I-Premise
medical I-Premise
, I-Premise
psychiatric I-Premise
, I-Premise
or I-Premise
study-related I-Premise
variables I-Premise
. I-Premise

In B-Premise
an I-Premise
intent-to-treat I-Premise
analysis I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatments I-Premise
in I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
11.1 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
10.6 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.67 I-Premise
) I-Premise
, I-Premise
duration I-Premise
of I-Premise
response I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
13.9 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
14.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.98 I-Premise
) I-Premise
, I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
26.9 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
23.4 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.60 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
was I-Premise
similar I-Premise
for I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
, I-Premise
except B-Premise
for I-Premise
the I-Premise
functional I-Premise
activity I-Premise
score I-Premise
of I-Premise
the I-Premise
Rotterdam I-Premise
Symptom I-Premise
Checklist I-Premise
, I-Premise
where I-Premise
QOL I-Premise
data I-Premise
statistically I-Premise
significantly I-Premise
favored I-Premise
the I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
arm I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
=.043 I-Premise
) I-Premise
. I-Premise

Sentinel B-Premise
nodes I-Premise
were I-Premise
found I-Premise
in I-Premise
95 I-Premise
% I-Premise
of I-Premise
the I-Premise
SNBM I-Premise
group I-Premise
( I-Premise
29 I-Premise
% I-Premise
positive I-Premise
) I-Premise
and I-Premise
93 I-Premise
% I-Premise
of I-Premise
the I-Premise
RAC I-Premise
group I-Premise
( I-Premise
25 I-Premise
% I-Premise
positive I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
the I-Premise
number I-Premise
of I-Premise
enrolled I-Premise
patients I-Premise
was I-Premise
not I-Premise
sufficient I-Premise
to I-Premise
draw I-Premise
definitive I-Premise
conclusions I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rates I-Premise
, I-Premise
which I-Premise
were I-Premise
confirmed I-Premise
by I-Premise
an I-Premise
independent I-Premise
expert I-Premise
panel I-Premise
, I-Premise
were I-Premise
13 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
% I-Premise
to I-Premise
23.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
27 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
14.1 I-Premise
% I-Premise
to I-Premise
40.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
40 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
25.7 I-Premise
% I-Premise
to I-Premise
54.3 I-Premise
% I-Premise
) I-Premise
for I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
16 I-Premise
and I-Premise
21 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
C3 I-Premise
and I-Premise
C6 I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P=0.21 I-Premise
, I-Premise
HR I-Premise
0.86 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.68-1.08 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
RR I-Premise
, I-Premise
RD I-Premise
, I-Premise
or I-Premise
PFS I-Premise
between I-Premise
arms I-Premise
. I-Premise

Opioid B-Premise
escalation I-Premise
index I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
methadone I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
, I-Premise
although I-Premise
requiring I-Premise
up I-Premise
and I-Premise
down I-Premise
changes I-Premise
in I-Premise
doses I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
non-stent-treated I-Premise
patients I-Premise
( I-Premise
log-rank I-Premise
statistic=4.21 I-Premise
, I-Premise
P=0.04 I-Premise
) I-Premise
. I-Premise

At B-Premise
enrollment I-Premise
, I-Premise
mood I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
were I-Premise
similar I-Premise
among I-Premise
all I-Premise
patients I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
by I-Premise
type I-Premise
of I-Premise
treatment I-Premise
received I-Premise
. I-Premise

After B-Premise
the I-Premise
rehabilitation I-Premise
program I-Premise
, I-Premise
cancer I-Premise
survivors I-Premise
( I-Premise
n=63 I-Premise
) I-Premise
displayed I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
on I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
with I-Premise
effect I-Premise
sizes I-Premise
( I-Premise
ES I-Premise
) I-Premise
varying I-Premise
from I-Premise
0.38 I-Premise
to I-Premise
0.99 I-Premise
( I-Premise
RAND-36 I-Premise
) I-Premise
and I-Premise
from I-Premise
-0.34 I-Premise
to I-Premise
-0.57 I-Premise
( I-Premise
RSCL I-Premise
) I-Premise
, I-Premise
most I-Premise
persistent I-Premise
at I-Premise
3-month I-Premise
follow-up I-Premise
. I-Premise

OS B-Premise
, I-Premise
PFS I-Premise
, I-Premise
QOL I-Premise
, I-Premise
and I-Premise
RR I-Premise
were I-Premise
comparable I-Premise
between I-Premise
arms I-Premise
. I-Premise

The B-Premise
dyspnoea I-Premise
palliation I-Premise
rate I-Premise
was I-Premise
lower I-Premise
in I-Premise
the I-Premise
C3 I-Premise
arm I-Premise
at I-Premise
18 I-Premise
and I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
finding I-Premise
was I-Premise
inconsistent I-Premise
across I-Premise
different I-Premise
methods I-Premise
of I-Premise
analysis I-Premise
. I-Premise

Overall B-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
scores I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
arms I-Premise
at I-Premise
the I-Premise
fourth I-Premise
assessment I-Premise
( I-Premise
C I-Premise
= I-Premise
70.3 I-Premise
( I-Premise
19.6 I-Premise
) I-Premise
";" I-Premise
CP I-Premise
= I-Premise
72.8 I-Premise
( I-Premise
17.4 I-Premise
) I-Premise
) I-Premise
. I-Premise

The B-Premise
CP I-Premise
arm I-Premise
produced I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
response I-Premise
rate I-Premise
and I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
but B-Premise
not I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
. I-Premise

Eighty B-Premise
percent I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
second-line I-Premise
chemotherapy I-Premise
in I-Premise
control I-Premise
arm I-Premise
were I-Premise
treated I-Premise
with I-Premise
continuous I-Premise
infusion I-Premise
5-FU I-Premise
. I-Premise

Patients B-Premise
reported I-Premise
increased I-Premise
leakage I-Premise
with I-Premise
a I-Premise
full I-Premise
bladder I-Premise
( I-Premise
urge I-Premise
incontinence I-Premise
) I-Premise
between I-Premise
the I-Premise
2 I-Premise
and I-Premise
3-year I-Premise
questionnaires I-Premise
( I-Premise
42 I-Premise
% I-Premise
versus I-Premise
50 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

No B-Premise
other I-Premise
patient I-Premise
outcomes I-Premise
( I-Premise
symptom I-Premise
distress I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
or I-Premise
caregiver I-Premise
outcomes I-Premise
( I-Premise
depression I-Premise
, I-Premise
support I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
were I-Premise
significantly I-Premise
different I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
eight I-Premise
components I-Premise
of I-Premise
the I-Premise
SF-36 I-Premise
scores I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

Time B-Premise
to I-Premise
pain I-Premise
and I-Premise
time I-Premise
to I-Premise
analgesic I-Premise
use I-Premise
were I-Premise
significantly I-Premise
delayed I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
HR=0.61 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.42-0.88 I-Premise
] I-Premise
";" I-Premise
p=0.0080 I-Premise
and I-Premise
HR=0.66 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.46-0.94 I-Premise
] I-Premise
";" I-Premise
p=0.0199 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Physical B-Premise
performance I-Premise
of I-Premise
the I-Premise
training I-Premise
group I-Premise
improved I-Premise
significantly I-Premise
during I-Premise
the I-Premise
programme I-Premise
( I-Premise
9.4+/-20 I-Premise
watts I-Premise
, I-Premise
p=0.01 I-Premise
) I-Premise
but I-Premise
remained I-Premise
unchanged I-Premise
in I-Premise
the I-Premise
relaxation I-Premise
group I-Premise
( I-Premise
1.5+/-14.8 I-Premise
watts I-Premise
, I-Premise
p=0.37 I-Premise
) I-Premise
. I-Premise

Improvement B-Premise
over I-Premise
time I-Premise
and I-Premise
time I-Premise
x I-Premise
treatment I-Premise
effects I-Premise
only I-Premise
reached I-Premise
trend I-Premise
significance I-Premise
levels I-Premise
( I-Premise
ps I-Premise
= I-Premise
0.07 I-Premise
& I-Premise
amp I-Premise
";" I-Premise
0.12 I-Premise
) I-Premise
as I-Premise
this I-Premise
pilot I-Premise
was I-Premise
not I-Premise
powered I-Premise
to I-Premise
detect I-Premise
these I-Premise
differences I-Premise
. I-Premise

Neither B-Premise
surgery I-Premise
nor I-Premise
definitive I-Premise
CRT I-Premise
significantly I-Premise
impaired I-Premise
the I-Premise
global I-Premise
health I-Premise
status I-Premise
of I-Premise
patients I-Premise
. I-Premise

In B-Premise
G1/G2 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
improvement/deterioration I-Premise
of I-Premise
QoL I-Premise
correlated I-Premise
with I-Premise
better I-Premise
or I-Premise
poorer I-Premise
intake I-Premise
or I-Premise
nutritional I-Premise
status I-Premise
( I-Premise
P I-Premise
< I-Premise
.003 I-Premise
) I-Premise
. I-Premise

A B-Premise
response I-Premise
to I-Premise
CEF I-Premise
tended I-Premise
to I-Premise
last I-Premise
longer I-Premise
than I-Premise
a I-Premise
response I-Premise
to I-Premise
E I-Premise
( I-Premise
median I-Premise
, I-Premise
12 I-Premise
v I-Premise
10.5 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.07 I-Premise
) I-Premise
. I-Premise

Following B-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
was I-Premise
variable I-Premise
, I-Premise
with I-Premise
15 I-Premise
% I-Premise
electing I-Premise
to I-Premise
continue I-Premise
or I-Premise
restart I-Premise
HRT I-Premise
and I-Premise
7 I-Premise
% I-Premise
resuming I-Premise
at I-Premise
follow-up I-Premise
. I-Premise

Multivariate B-Premise
analysis I-Premise
showed I-Premise
a I-Premise
significant I-Premise
impact I-Premise
of I-Premise
duration I-Premise
of I-Premise
response/CR I-Premise
on I-Premise
improving I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
pain I-Premise
, I-Premise
and I-Premise
appetite I-Premise
loss I-Premise
scores I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
rates I-Premise
for I-Premise
both I-Premise
arms I-Premise
were I-Premise
comparable I-Premise
( I-Premise
AM I-Premise
, I-Premise
17.3 I-Premise
v I-Premise
no I-Premise
AM I-Premise
, I-Premise
17.9 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.87 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
this I-Premise
difference I-Premise
did I-Premise
not I-Premise
translate I-Premise
into I-Premise
a I-Premise
worse I-Premise
feeling I-Premise
of I-Premise
general I-Premise
well-being I-Premise
as I-Premise
measured I-Premise
by I-Premise
a I-Premise
simple I-Premise
visual I-Premise
analogue I-Premise
scale I-Premise
( I-Premise
5.8 I-Premise
vs I-Premise
5.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.3 I-Premise
) I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
lymphedema I-Premise
during I-Premise
the I-Premise
study I-Premise
was I-Premise
low I-Premise
for I-Premise
both I-Premise
groups I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
groups I-Premise
. I-Premise

The B-Premise
response I-Premise
rate I-Premise
was I-Premise
low I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
but I-Premise
superior I-Premise
in I-Premise
the I-Premise
FUP I-Premise
arm I-Premise
: I-Premise
12 I-Premise
% I-Premise
versus I-Premise
0 I-Premise
% I-Premise
( I-Premise
intention-to-treat I-Premise
analysis I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Additional B-Premise
analyses I-Premise
yielded I-Premise
quadratic I-Premise
interactions I-Premise
for I-Premise
exercise I-Premise
activity I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.022 I-Premise
) I-Premise
, I-Premise
with I-Premise
positive I-Premise
changes I-Premise
in I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
, I-Premise
and I-Premise
for I-Premise
stress I-Premise
management I-Premise
activity I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SM I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
, I-Premise
with I-Premise
positive I-Premise
changes I-Premise
in I-Premise
SM I-Premise
and I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
. I-Premise

Fibroid B-Premise
infarction I-Premise
at I-Premise
6 I-Premise
months I-Premise
was I-Premise
complete I-Premise
in I-Premise
35 I-Premise
% I-Premise
of I-Premise
women I-Premise
, I-Premise
almost I-Premise
complete I-Premise
in I-Premise
29 I-Premise
% I-Premise
, I-Premise
and I-Premise
partial I-Premise
in I-Premise
36 I-Premise
% I-Premise
. I-Premise

However B-Premise
, I-Premise
DPPE I-Premise
is I-Premise
associated I-Premise
with I-Premise
unusual I-Premise
toxicity I-Premise
in I-Premise
the I-Premise
form I-Premise
of I-Premise
hallucinations I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
which I-Premise
were I-Premise
anticipated I-Premise
to I-Premise
impact I-Premise
on I-Premise
short-term I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
. I-Premise

A B-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
resilience I-Premise
, I-Premise
perceived I-Premise
stress I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
12 I-Premise
weeks I-Premise
, I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
study I-Premise
arm I-Premise
. I-Premise

In B-Premise
response I-Premise
to I-Premise
training I-Premise
, I-Premise
QOL I-Premise
, I-Premise
VO2peak I-Premise
( I-Premise
mean I-Premise
3.9 I-Premise
ml/kg/min I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.93 I-Premise
, I-Premise
6.90 I-Premise
) I-Premise
performance I-Premise
in I-Premise
leg I-Premise
press I-Premise
( I-Premise
17.9 I-Premise
kg I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.8 I-Premise
, I-Premise
22.4 I-Premise
) I-Premise
and I-Premise
sit-stand I-Premise
test I-Premise
( I-Premise
- I-Premise
0.67 I-Premise
s I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
- I-Premise
0.52 I-Premise
, I-Premise
- I-Premise
1.2 I-Premise
) I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
rates I-Premise
of I-Premise
attrition I-Premise
at I-Premise
these I-Premise
time I-Premise
points I-Premise
were I-Premise
28.1 I-Premise
% I-Premise
, I-Premise
17.7 I-Premise
% I-Premise
, I-Premise
and I-Premise
11.1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
43.1 I-Premise
% I-Premise
of I-Premise
the I-Premise
participants I-Premise
( I-Premise
66 I-Premise
of I-Premise
153 I-Premise
) I-Premise
completed I-Premise
the I-Premise
entire I-Premise
study I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
FACT-Anemia I-Premise
or I-Premise
ESAS I-Premise
instruments I-Premise
. I-Premise

Secondary B-Premise
analyses I-Premise
found I-Premise
that I-Premise
differences I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
experimental I-Premise
group I-Premise
occurred I-Premise
in I-Premise
patients I-Premise
with I-Premise
stomach I-Premise
, I-Premise
pancreatic I-Premise
, I-Premise
primary I-Premise
liver I-Premise
, I-Premise
or I-Premise
colorectal I-Premise
cancer I-Premise
. I-Premise

Body B-Premise
cell I-Premise
mass I-Premise
was I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
study I-Premise
in I-Premise
group I-Premise
B I-Premise
, I-Premise
but I-Premise
declined I-Premise
significantly I-Premise
up I-Premise
to I-Premise
weeks I-Premise
4 I-Premise
and I-Premise
8 I-Premise
in I-Premise
group I-Premise
A I-Premise
( I-Premise
intergroup I-Premise
difference I-Premise
: I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
and I-Premise
0.01 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

QOL B-Premise
was I-Premise
poorer I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
AC→T I-Premise
at I-Premise
6 I-Premise
months I-Premise
but I-Premise
similar I-Premise
to I-Premise
others I-Premise
by I-Premise
12 I-Premise
months I-Premise
. I-Premise

Older B-Premise
adult I-Premise
patients I-Premise
reported I-Premise
better I-Premise
overall I-Premise
QOL I-Premise
( I-Premise
LASA I-Premise
74.4 I-Premise
vs. I-Premise
62.9 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.040 I-Premise
) I-Premise
, I-Premise
higher I-Premise
social I-Premise
well-being I-Premise
( I-Premise
FACT-G I-Premise
91.1 I-Premise
vs. I-Premise
83.3 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.045 I-Premise
) I-Premise
, I-Premise
and I-Premise
fewer I-Premise
problems I-Premise
with I-Premise
anger I-Premise
( I-Premise
POMS I-Premise
anger-hostility I-Premise
95.0 I-Premise
vs. I-Premise
86.4 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.028 I-Premise
) I-Premise
. I-Premise

Distress B-Premise
caused I-Premise
by I-Premise
these I-Premise
symptoms I-Premise
was I-Premise
reported I-Premise
significantly I-Premise
more I-Premise
often I-Premise
by I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
than I-Premise
by I-Premise
men I-Premise
assigned I-Premise
to I-Premise
watchful I-Premise
waiting I-Premise
. I-Premise

The B-Premise
median I-Premise
OS I-Premise
was I-Premise
24 I-Premise
months I-Premise
for I-Premise
the I-Premise
HDCT I-Premise
arm I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
21 I-Premise
to I-Premise
35 I-Premise
months I-Premise
) I-Premise
and I-Premise
28 I-Premise
months I-Premise
for I-Premise
ST I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
22 I-Premise
to I-Premise
33 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.9 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.6 I-Premise
to I-Premise
1.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.43 I-Premise
) I-Premise
. I-Premise

These B-Premise
results I-Premise
show I-Premise
an I-Premise
improvement I-Premise
over I-Premise
previous I-Premise
SIOP I-Premise
study I-Premise
( I-Premise
RMS75 I-Premise
) I-Premise
in I-Premise
which I-Premise
survival I-Premise
was I-Premise
52 I-Premise
% I-Premise
and I-Premise
event-free I-Premise
survival I-Premise
was I-Premise
47 I-Premise
% I-Premise
. I-Premise

In B-Premise
patients I-Premise
in I-Premise
group I-Premise
1 I-Premise
who I-Premise
had I-Premise
gynecomastia I-Premise
or I-Premise
breast I-Premise
pain I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
symptoms I-Premise
was I-Premise
achieved I-Premise
in I-Premise
those I-Premise
receiving I-Premise
tamoxifen I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

These B-Premise
benefits I-Premise
were I-Premise
seen I-Premise
with I-Premise
no I-Premise
increase I-Premise
in I-Premise
anxiety I-Premise
levels I-Premise
in I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
( I-Premise
P I-Premise
> I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Only B-Premise
1 I-Premise
patient I-Premise
in I-Premise
each I-Premise
group I-Premise
had I-Premise
acute I-Premise
nonhematologic I-Premise
toxicity I-Premise
greater I-Premise
than I-Premise
Grade I-Premise
3 I-Premise
( I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
community I-Premise
locations I-Premise
in I-Premise
favour I-Premise
of I-Premise
home I-Premise
( I-Premise
+15·2 I-Premise
, I-Premise
1·3 I-Premise
to I-Premise
29·1 I-Premise
, I-Premise
P=0.033 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
with I-Premise
complete I-Premise
or I-Premise
partial I-Premise
response I-Premise
were I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
improvement I-Premise
in I-Premise
the I-Premise
QOL I-Premise
response I-Premise
than I-Premise
patients I-Premise
with I-Premise
stable I-Premise
or I-Premise
progressive I-Premise
disease I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Variables B-Premise
such I-Premise
as I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
analgesic I-Premise
and I-Premise
antiemetic I-Premise
requirement I-Premise
as I-Premise
well I-Premise
as I-Premise
level I-Premise
of I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
were I-Premise
not I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise

Neither B-Premise
group I-Premise
had I-Premise
a I-Premise
survival I-Premise
advantage I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0.95 I-Premise
, I-Premise
0.73 I-Premise
to I-Premise
1.24 I-Premise
";" I-Premise
P=0.71 I-Premise
) I-Premise
. I-Premise

Eighteen B-Premise
patients I-Premise
receiving I-Premise
IFN5 I-Premise
and I-Premise
4 I-Premise
patients I-Premise
receiving I-Premise
IFN1 I-Premise
had I-Premise
dose I-Premise
reductions I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
latter I-Premise
patients I-Premise
the I-Premise
received I-Premise
dose I-Premise
intensities I-Premise
( I-Premise
RDI I-Premise
) I-Premise
of I-Premise
cisplatin I-Premise
, I-Premise
adriamycin I-Premise
and I-Premise
etoposide I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
late-alternation I-Premise
arm I-Premise
. I-Premise

The B-Premise
-1 I-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
25 I-Premise
% I-Premise
and I-Premise
7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median B-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
4.3 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
0.2-13.8 I-Premise
months I-Premise
) I-Premise
. I-Premise

The B-Premise
total I-Premise
clinical I-Premise
effective I-Premise
rates I-Premise
in I-Premise
PP I-Premise
group I-Premise
and I-Premise
GP I-Premise
group I-Premise
were I-Premise
25.20 I-Premise
% I-Premise
and I-Premise
17.74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
final I-Premise
multivariate I-Premise
model I-Premise
predicted I-Premise
poor I-Premise
survival I-Premise
with I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
( I-Premise
P=0.003 I-Premise
) I-Premise
, I-Premise
DFI I-Premise
< I-Premise
/=2 I-Premise
years I-Premise
( I-Premise
P=0.026 I-Premise
) I-Premise
and I-Premise
pain I-Premise
( I-Premise
P=0.003 I-Premise
) I-Premise
. I-Premise

Toxicities B-Premise
were I-Premise
generally I-Premise
mild I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

With B-Premise
median I-Premise
follow-up I-Premise
of I-Premise
15.8 I-Premise
months I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
1-year I-Premise
survival I-Premise
( I-Premise
46 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.42 I-Premise
) I-Premise
, I-Premise
median I-Premise
survival I-Premise
( I-Premise
9.9 I-Premise
v I-Premise
9.9 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.43 I-Premise
) I-Premise
, I-Premise
or I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
4.0 I-Premise
v I-Premise
3.0 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.54 I-Premise
) I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
. I-Premise

More B-Premise
major I-Premise
complications I-Premise
( I-Premise
stent I-Premise
: I-Premise
6 I-Premise
in I-Premise
4 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
0 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
recurrent I-Premise
obstructive I-Premise
symptoms I-Premise
( I-Premise
stent I-Premise
: I-Premise
8 I-Premise
in I-Premise
5 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
1 I-Premise
in I-Premise
1 I-Premise
patient I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
and I-Premise
reinterventions I-Premise
( I-Premise
stent I-Premise
: I-Premise
10 I-Premise
in I-Premise
7 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
2 I-Premise
in I-Premise
2 I-Premise
patients I-Premise
";" I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
were I-Premise
observed I-Premise
after I-Premise
stent I-Premise
placement I-Premise
compared I-Premise
with I-Premise
GJJ I-Premise
. I-Premise

Mean B-Premise
( I-Premise
s.d I-Premise
. I-Premise
) I-Premise
pain I-Premise
scores I-Premise
on I-Premise
the I-Premise
day I-Premise
of I-Premise
discharge I-Premise
were I-Premise
1·9 I-Premise
( I-Premise
3·1 I-Premise
) I-Premise
in I-Premise
the I-Premise
epidural I-Premise
group I-Premise
and I-Premise
0·7 I-Premise
( I-Premise
0·7 I-Premise
) I-Premise
in I-Premise
the I-Premise
WIC I-Premise
group I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
6.9 I-Premise
( I-Premise
4.6-10.1 I-Premise
) I-Premise
and I-Premise
9.2 I-Premise
( I-Premise
7.9-11.5 I-Premise
) I-Premise
months I-Premise
and I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
17.4 I-Premise
( I-Premise
12.6-23.0+ I-Premise
) I-Premise
and I-Premise
24.7 I-Premise
( I-Premise
16.3-26.4+ I-Premise
) I-Premise
months I-Premise
. I-Premise

As B-Premise
for I-Premise
the I-Premise
secondary I-Premise
efficacy I-Premise
endpoints I-Premise
, I-Premise
patient I-Premise
appetite I-Premise
increased I-Premise
, I-Premise
and I-Premise
ECOG I-Premise
PS I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

While B-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
pain I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
functional I-Premise
and I-Premise
cognitive I-Premise
functioning I-Premise
scores I-Premise
appeared I-Premise
to I-Premise
be I-Premise
improved I-Premise
only I-Premise
in I-Premise
patients I-Premise
of I-Premise
group I-Premise
I I-Premise
. I-Premise

Significant B-Premise
differences I-Premise
of I-Premise
FACT-B I-Premise
score I-Premise
( I-Premise
p=0.008 I-Premise
) I-Premise
and I-Premise
FACT-G I-Premise
score I-Premise
( I-Premise
p=0.019 I-Premise
) I-Premise
were I-Premise
observed I-Premise
at I-Premise
that I-Premise
time I-Premise
point I-Premise
. I-Premise

Women B-Premise
with I-Premise
advanced I-Premise
breast I-Premise
cancer I-Premise
randomized I-Premise
to I-Premise
the I-Premise
seated I-Premise
exercise I-Premise
intervention I-Premise
had I-Premise
a I-Premise
slower I-Premise
decline I-Premise
in I-Premise
total I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
and I-Premise
less I-Premise
increase I-Premise
in I-Premise
fatigue I-Premise
scores I-Premise
starting I-Premise
with I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
noted I-Premise
between I-Premise
study I-Premise
arms I-Premise
for I-Premise
patients I-Premise
with I-Premise
mutated I-Premise
KRAS I-Premise
tumors I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
TTP I-Premise
) I-Premise
curves I-Premise
according I-Premise
to I-Premise
treatment I-Premise
allocation I-Premise
was I-Premise
documented I-Premise
( I-Premise
P I-Premise
= I-Premise
.411 I-Premise
) I-Premise
. I-Premise

Prevalence B-Premise
of I-Premise
erectile I-Premise
dysfunction I-Premise
was I-Premise
84 I-Premise
% I-Premise
( I-Premise
146 I-Premise
of I-Premise
173 I-Premise
men I-Premise
) I-Premise
in I-Premise
the I-Premise
radical I-Premise
prostatectomy I-Premise
group I-Premise
, I-Premise
80 I-Premise
% I-Premise
( I-Premise
122 I-Premise
of I-Premise
153 I-Premise
) I-Premise
in I-Premise
the I-Premise
watchful-waiting I-Premise
group I-Premise
, I-Premise
and I-Premise
46 I-Premise
% I-Premise
( I-Premise
95 I-Premise
of I-Premise
208 I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
prevalence I-Premise
of I-Premise
urinary I-Premise
leakage I-Premise
was I-Premise
41 I-Premise
% I-Premise
( I-Premise
71 I-Premise
of I-Premise
173 I-Premise
) I-Premise
, I-Premise
11 I-Premise
% I-Premise
( I-Premise
18 I-Premise
of I-Premise
164 I-Premise
) I-Premise
, I-Premise
and I-Premise
3 I-Premise
% I-Premise
( I-Premise
six I-Premise
of I-Premise
209 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
change I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
0.067 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.33 I-Premise
) I-Premise
and I-Premise
strength I-Premise
of I-Premise
external I-Premise
rotation I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.55 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
in I-Premise
the I-Premise
scapula-oriented I-Premise
exercise I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
general I-Premise
exercise I-Premise
and I-Premise
control I-Premise
group I-Premise
. I-Premise

The B-Premise
relative I-Premise
risks I-Premise
of I-Premise
any I-Premise
lymphedema I-Premise
and I-Premise
sensory I-Premise
loss I-Premise
for I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
axillary I-Premise
treatment I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
were I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.23 I-Premise
to I-Premise
0.60 I-Premise
";" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
5 I-Premise
% I-Premise
versus I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.27 I-Premise
to I-Premise
0.50 I-Premise
";" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
11 I-Premise
% I-Premise
versus I-Premise
31 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Premise
an I-Premise
intent-to-treat I-Premise
analysis I-Premise
, I-Premise
the I-Premise
2-year I-Premise
OS I-Premise
rates I-Premise
were I-Premise
65.7 I-Premise
% I-Premise
for I-Premise
CIS I-Premise
and I-Premise
66.2 I-Premise
% I-Premise
for I-Premise
TPZ/CIS I-Premise
( I-Premise
TPZ/CIS I-Premise
-- I-Premise
CIS I-Premise
: I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-5.9 I-Premise
% I-Premise
to I-Premise
6.9 I-Premise
% I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
16.6 I-Premise
months I-Premise
for I-Premise
the I-Premise
FU/LV/bevacizumab I-Premise
group I-Premise
and I-Premise
12.9 I-Premise
months I-Premise
for I-Premise
the I-Premise
FU/LV/placebo I-Premise
group I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.79 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.16 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
intake I-Premise
per I-Premise
kilogram I-Premise
of I-Premise
body I-Premise
weight I-Premise
for I-Premise
the I-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
ranged I-Premise
from I-Premise
28 I-Premise
to I-Premise
31 I-Premise
kcal/kg/day I-Premise
compared I-Premise
with I-Premise
25 I-Premise
to I-Premise
29 I-Premise
kcal/kg/day I-Premise
for I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
( I-Premise
P=0.022 I-Premise
) I-Premise
. I-Premise

The B-Premise
saving I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
was I-Premise
$ I-Premise
1,396 I-Premise
per I-Premise
patient I-Premise
randomized I-Premise
( I-Premise
$ I-Premise
647 I-Premise
the I-Premise
result I-Premise
of I-Premise
shorter I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
and I-Premise
$ I-Premise
749 I-Premise
the I-Premise
result I-Premise
of I-Premise
the I-Premise
lower I-Premise
cost I-Premise
of I-Premise
postoperative I-Premise
complications I-Premise
) I-Premise
. I-Premise

Dignity B-Premise
therapy I-Premise
was I-Premise
significantly I-Premise
better I-Premise
than I-Premise
client-centred I-Premise
care I-Premise
in I-Premise
improving I-Premise
spiritual I-Premise
wellbeing I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=10·35 I-Premise
";" I-Premise
p=0·006 I-Premise
) I-Premise
, I-Premise
and I-Premise
was I-Premise
significantly I-Premise
better I-Premise
than I-Premise
standard I-Premise
palliative I-Premise
care I-Premise
in I-Premise
terms I-Premise
of I-Premise
lessening I-Premise
sadness I-Premise
or I-Premise
depression I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=9·38 I-Premise
";" I-Premise
p=0·009 I-Premise
) I-Premise
";" I-Premise
significantly B-Premise
more I-Premise
patients I-Premise
who I-Premise
had I-Premise
received I-Premise
dignity I-Premise
therapy I-Premise
reported I-Premise
that I-Premise
the I-Premise
study I-Premise
group I-Premise
had I-Premise
been I-Premise
satisfactory I-Premise
, I-Premise
compared I-Premise
with I-Premise
those I-Premise
who I-Premise
received I-Premise
standard I-Premise
palliative I-Premise
care I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=29·58 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
the I-Premise
magnitude I-Premise
of I-Premise
the I-Premise
benefits I-Premise
was I-Premise
small I-Premise
. I-Premise

Increased B-Premise
appetite I-Premise
was I-Premise
reported I-Premise
by I-Premise
73 I-Premise
% I-Premise
, I-Premise
58 I-Premise
% I-Premise
, I-Premise
and I-Premise
69 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
CE I-Premise
, I-Premise
THC I-Premise
, I-Premise
or I-Premise
PL I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Seventeen B-Premise
of I-Premise
25 I-Premise
HBO-treated I-Premise
patients I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
improved I-Premise
versus I-Premise
8 I-Premise
of I-Premise
21 I-Premise
controls I-Premise
( I-Premise
38.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.043 I-Premise
, I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
) I-Premise
. I-Premise

In B-Premise
planned I-Premise
subgroup I-Premise
analyses I-Premise
, I-Premise
statistically I-Premise
significant I-Premise
or I-Premise
borderline I-Premise
significant I-Premise
interactions I-Premise
were I-Premise
identified I-Premise
for I-Premise
type I-Premise
of I-Premise
lymphoma I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
, I-Premise
current I-Premise
treatment I-Premise
status I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.036 I-Premise
) I-Premise
, I-Premise
time I-Premise
since I-Premise
diagnosis I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.010 I-Premise
) I-Premise
, I-Premise
body I-Premise
mass I-Premise
index I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.075 I-Premise
) I-Premise
, I-Premise
and I-Premise
baseline I-Premise
sleep I-Premise
quality I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.041 I-Premise
) I-Premise
. I-Premise

The B-Premise
most I-Premise
frequent I-Premise
World I-Premise
Health I-Premise
Organization I-Premise
Grade I-Premise
3-4 I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
gastrointestinal I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
hematologic I-Premise
in I-Premise
Study I-Premise
B I-Premise
. I-Premise

Sexual B-Premise
functioning I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
improved I-Premise
( I-Premise
P I-Premise
=.04 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual-care I-Premise
group I-Premise
. I-Premise

Diarrhea B-Premise
was I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
. I-Premise

Mean B-Premise
utility I-Premise
scores I-Premise
in I-Premise
the I-Premise
DTX I-Premise
group I-Premise
were I-Premise
lowest I-Premise
at I-Premise
7 I-Premise
months I-Premise
and I-Premise
tended I-Premise
to I-Premise
remain I-Premise
low I-Premise
for I-Premise
a I-Premise
long I-Premise
time I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
( I-Premise
ORR I-Premise
) I-Premise
was I-Premise
significantly I-Premise
greater I-Premise
for I-Premise
patients I-Premise
taking I-Premise
AT I-Premise
( I-Premise
59 I-Premise
% I-Premise
, I-Premise
with I-Premise
10 I-Premise
% I-Premise
complete I-Premise
response I-Premise
[ I-Premise
CR I-Premise
] I-Premise
, I-Premise
49 I-Premise
% I-Premise
partial I-Premise
response I-Premise
[ I-Premise
PR I-Premise
] I-Premise
) I-Premise
than I-Premise
for I-Premise
those I-Premise
taking I-Premise
AC I-Premise
( I-Premise
47 I-Premise
% I-Premise
, I-Premise
with I-Premise
7 I-Premise
% I-Premise
CR I-Premise
, I-Premise
39 I-Premise
% I-Premise
PR I-Premise
) I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
placebo I-Premise
, I-Premise
erlotinib I-Premise
maintenance I-Premise
therapy I-Premise
prolonged I-Premise
progression-free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
by I-Premise
41 I-Premise
% I-Premise
and I-Premise
23 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Grades B-Premise
3/4 I-Premise
toxicities I-Premise
occurred I-Premise
infrequently I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

The B-Premise
incremental I-Premise
cost-effectiveness I-Premise
ratio I-Premise
was I-Premise
19,39£ I-Premise
per I-Premise
quality-adjusted I-Premise
life I-Premise
year I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
reported I-Premise
better I-Premise
overall I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
symptom I-Premise
control I-Premise
compared I-Premise
with I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
. I-Premise

Median B-Premise
TTP I-Premise
was I-Premise
4.5 I-Premise
and I-Premise
4.6 I-Premise
months I-Premise
respectively I-Premise
for I-Premise
weekly I-Premise
VNR/CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
one I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
and I-Premise
overall I-Premise
survival I-Premise
times I-Premise
were I-Premise
3.2 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.8 I-Premise
to I-Premise
4.6 I-Premise
months I-Premise
) I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.6 I-Premise
to I-Premise
11.1 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
4.9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.5 I-Premise
to I-Premise
6.3 I-Premise
months I-Premise
) I-Premise
and I-Premise
9.5 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
6.9 I-Premise
to I-Premise
12.2 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2-cisplatin I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
and I-Premise
6.9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
5.5 I-Premise
to I-Premise
8.3 I-Premise
months I-Premise
) I-Premise
and I-Premise
11.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9.3 I-Premise
to I-Premise
13.3 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2-irinotecan I-Premise
, I-Premise
respectively I-Premise
. I-Premise

No B-Premise
difference I-Premise
in I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
detected I-Premise
( I-Premise
57 I-Premise
months I-Premise
for I-Premise
fludarabine I-Premise
v I-Premise
44 I-Premise
months I-Premise
for I-Premise
CVP I-Premise
";" I-Premise
P I-Premise
=.95 I-Premise
) I-Premise
. I-Premise

A B-Premise
greater I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
had I-Premise
skeletal-related I-Premise
events I-Premise
than I-Premise
those I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
4 I-Premise
mg I-Premise
( I-Premise
44.2 I-Premise
% I-Premise
versus I-Premise
33.2 I-Premise
% I-Premise
";" I-Premise
difference I-Premise
= I-Premise
-11.0 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
-20.3 I-Premise
% I-Premise
to I-Premise
-1.8 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.021 I-Premise
) I-Premise
or I-Premise
those I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
8/4 I-Premise
mg I-Premise
( I-Premise
38.5 I-Premise
% I-Premise
";" I-Premise
difference I-Premise
versus I-Premise
placebo I-Premise
= I-Premise
-5.8 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-15.1 I-Premise
% I-Premise
to I-Premise
3.6 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.222 I-Premise
) I-Premise
. I-Premise

Evidence B-Premise
of I-Premise
a I-Premise
homeopathic I-Premise
" I-Premise
drug I-Premise
proving I-Premise
" I-Premise
in I-Premise
the I-Premise
subjects I-Premise
receiving I-Premise
the I-Premise
homeopathic I-Premise
combination I-Premise
medicine I-Premise
who I-Premise
were I-Premise
not I-Premise
taking I-Premise
tamoxifen I-Premise
also I-Premise
was I-Premise
found I-Premise
. I-Premise

The B-Premise
differences I-Premise
in I-Premise
tumor I-Premise
response I-Premise
( I-Premise
35.5 I-Premise
and I-Premise
46.5 I-Premise
% I-Premise
for I-Premise
GE I-Premise
and I-Premise
GP I-Premise
, I-Premise
respectively I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
. I-Premise

Cross-sectional B-Premise
comparisons I-Premise
showed I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
for I-Premise
some I-Premise
domains/items I-Premise
at I-Premise
specific I-Premise
assessment I-Premise
times I-Premise
with I-Premise
all I-Premise
differences I-Premise
favoring I-Premise
the I-Premise
DOX I-Premise
alone I-Premise
arm I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
failure-free I-Premise
survival I-Premise
, I-Premise
time I-Premise
to I-Premise
locoregional I-Premise
failure I-Premise
, I-Premise
or I-Premise
quality I-Premise
of I-Premise
life I-Premise
as I-Premise
measured I-Premise
by I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Head I-Premise
and I-Premise
Neck I-Premise
. I-Premise

A B-Premise
multivariate I-Premise
analysis I-Premise
found I-Premise
the I-Premise
use I-Premise
of I-Premise
breast I-Premise
IMRT I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
and I-Premise
smaller I-Premise
breast I-Premise
size I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
a I-Premise
decreased I-Premise
risk I-Premise
of I-Premise
moist I-Premise
desquamation I-Premise
. I-Premise

Pain B-Premise
decreased I-Premise
faster I-Premise
for I-Premise
HBO-treated I-Premise
subjects I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
, I-Premise
linear I-Premise
regression I-Premise
) I-Premise
. I-Premise

Changes B-Premise
in I-Premise
the I-Premise
average I-Premise
QOL I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
study I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
P I-Premise
= I-Premise
not I-Premise
significant I-Premise
) I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
mean I-Premise
hot I-Premise
flash I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
with I-Premise
daily I-Premise
hot I-Premise
flashes I-Premise
increasing I-Premise
from I-Premise
baseline I-Premise
by I-Premise
33 I-Premise
% I-Premise
compared I-Premise
with I-Premise
a I-Premise
7 I-Premise
% I-Premise
increase I-Premise
from I-Premise
baseline I-Premise
with I-Premise
exemestane I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
1.01 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.77 I-Premise
to I-Premise
1.32 I-Premise
) I-Premise
. I-Premise

Concerning B-Premise
the I-Premise
eating I-Premise
function I-Premise
, I-Premise
both I-Premise
groups I-Premise
had I-Premise
improvements I-Premise
in I-Premise
dysphagia I-Premise
but I-Premise
there I-Premise
were I-Premise
frequent I-Premise
need I-Premise
for I-Premise
endoscopic I-Premise
intervention I-Premise
. I-Premise

No B-Premise
pain I-Premise
training I-Premise
patients I-Premise
reported I-Premise
severe I-Premise
pain I-Premise
( I-Premise
> I-Premise
6 I-Premise
on I-Premise
a I-Premise
0-10 I-Premise
scale I-Premise
) I-Premise
at I-Premise
1-month I-Premise
outcomes I-Premise
( I-Premise
P=.03 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
with I-Premise
UM I-Premise
had I-Premise
lower I-Premise
levels I-Premise
of I-Premise
pain I-Premise
one I-Premise
week I-Premise
after I-Premise
surgery I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
FOIS I-Premise
scores I-Premise
between I-Premise
intervention I-Premise
and I-Premise
control I-Premise
patients I-Premise
immediately I-Premise
after I-Premise
CRT I-Premise
( I-Premise
immediately I-Premise
after I-Premise
CRT I-Premise
: I-Premise
intervention I-Premise
group I-Premise
median I-Premise
score I-Premise
, I-Premise
3 I-Premise
[ I-Premise
range I-Premise
, I-Premise
1-7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
4 I-Premise
[ I-Premise
range I-Premise
, I-Premise
1-6 I-Premise
] I-Premise
( I-Premise
P I-Premise
= I-Premise
.88 I-Premise
) I-Premise
. I-Premise

The B-Premise
intervention I-Premise
demonstrated I-Premise
a I-Premise
trend I-Premise
toward I-Premise
improved I-Premise
CRF I-Premise
, I-Premise
although B-Premise
this I-Premise
effect I-Premise
was I-Premise
reduced I-Premise
once I-Premise
confounders I-Premise
had I-Premise
been I-Premise
controlled I-Premise
statistically I-Premise
. I-Premise

Decreased B-Premise
quality I-Premise
of I-Premise
life I-Premise
later I-Premise
after I-Premise
treatment I-Premise
was I-Premise
also I-Premise
observed I-Premise
in I-Premise
patients I-Premise
diagnosed I-Premise
with I-Premise
unresectable I-Premise
pancreatic I-Premise
cancer I-Premise
and I-Premise
treated I-Premise
with I-Premise
the I-Premise
same I-Premise
regimen I-Premise
. I-Premise

At B-Premise
3 I-Premise
years I-Premise
, I-Premise
33 I-Premise
% I-Premise
of I-Premise
patients I-Premise
reported I-Premise
rectal I-Premise
bleeding I-Premise
compared I-Premise
with I-Premise
47 I-Premise
% I-Premise
at I-Premise
2 I-Premise
years I-Premise
( I-Premise
P I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
. I-Premise

The B-Premise
occurrence I-Premise
of I-Premise
adverse I-Premise
reaction I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
was I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
was I-Premise
4.57 I-Premise
months I-Premise
in I-Premise
E I-Premise
and I-Premise
2.53 I-Premise
months I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0287 I-Premise
) I-Premise
, I-Premise
with I-Premise
an I-Premise
80.6 I-Premise
% I-Premise
increase I-Premise
in I-Premise
median I-Premise
PFS I-Premise
for I-Premise
E I-Premise
compared I-Premise
with I-Premise
V. I-Premise
Median B-Premise
survival I-Premise
time I-Premise
was I-Premise
11.67 I-Premise
months I-Premise
in I-Premise
E I-Premise
and I-Premise
9.3 I-Premise
months I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.6975 I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
difference I-Premise
in I-Premise
total I-Premise
societal I-Premise
costs I-Premise
was I-Premise
larger I-Premise
, I-Premise
also I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
single-fraction I-Premise
schedule I-Premise
, I-Premise
but B-Premise
it I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
$ I-Premise
4700 I-Premise
versus I-Premise
$ I-Premise
6453 I-Premise
, I-Premise
difference I-Premise
= I-Premise
$ I-Premise
1753 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
on I-Premise
the I-Premise
difference I-Premise
= I-Premise
- I-Premise
$ I-Premise
99 I-Premise
to I-Premise
$ I-Premise
3604 I-Premise
";" I-Premise
P I-Premise
=.06 I-Premise
) I-Premise
. I-Premise

Hemoglobin B-Premise
responses I-Premise
defined I-Premise
as I-Premise
mean I-Premise
hemoglobin I-Premise
> I-Premise
or I-Premise
= I-Premise
12 I-Premise
g/dL I-Premise
or I-Premise
a I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g/dL I-Premise
increase I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
SOC I-Premise
: I-Premise
52.0 I-Premise
% I-Premise
v I-Premise
5.1 I-Premise
% I-Premise
and I-Premise
65.7 I-Premise
% I-Premise
v I-Premise
6.3 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
for I-Premise
both I-Premise
comparisons I-Premise
) I-Premise
. I-Premise

Increased B-Premise
symptoms I-Premise
were I-Premise
reflected I-Premise
by I-Premise
the I-Premise
frequent I-Premise
use I-Premise
of I-Premise
incontinence I-Premise
materials I-Premise
after I-Premise
EBRT I-Premise
( I-Premise
day I-Premise
and I-Premise
night I-Premise
use I-Premise
, I-Premise
42.9 I-Premise
% I-Premise
v I-Premise
15.2 I-Premise
% I-Premise
for I-Premise
NAT I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Peripheral B-Premise
neuropathy I-Premise
and I-Premise
alopecia I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
CVP I-Premise
. I-Premise

No B-Premise
unique I-Premise
safety I-Premise
observations I-Premise
were I-Premise
reported I-Premise
during I-Premise
open-label I-Premise
exposure I-Premise
. I-Premise

Statistically B-Premise
significantly I-Premise
higher I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
PLD-treated I-Premise
patients I-Premise
at I-Premise
the I-Premise
first I-Premise
and I-Premise
second I-Premise
postbaseline I-Premise
QOL I-Premise
assessments I-Premise
. I-Premise

The B-Premise
night I-Premise
awakenings I-Premise
( I-Premise
Actigraph I-Premise
) I-Premise
pattern I-Premise
was I-Premise
significantly I-Premise
different I-Premise
by I-Premise
group I-Premise
over I-Premise
time I-Premise
( I-Premise
P I-Premise
= I-Premise
.046 I-Premise
) I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
between I-Premise
groups I-Premise
at I-Premise
90 I-Premise
days I-Premise
or I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

These B-Premise
findings I-Premise
are I-Premise
consistent I-Premise
with I-Premise
evidence I-Premise
that I-Premise
only I-Premise
the I-Premise
combined I-Premise
intervention I-Premise
yielded I-Premise
increases I-Premise
in I-Premise
both I-Premise
exercise I-Premise
and I-Premise
stress I-Premise
management I-Premise
activity I-Premise
. I-Premise

Excess B-Premise
limb I-Premise
size I-Premise
( I-Premise
circumference I-Premise
and I-Premise
water I-Premise
displacement I-Premise
) I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
bandage I-Premise
group I-Premise
";" I-Premise
excess B-Premise
circumference I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
tape I-Premise
group I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
of I-Premise
all I-Premise
406 I-Premise
eligible I-Premise
patients I-Premise
was I-Premise
346 I-Premise
days I-Premise
with I-Premise
15 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
alive I-Premise
at I-Premise
two I-Premise
years I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
14.6 I-Premise
months I-Premise
( I-Premise
temozolomide I-Premise
+ I-Premise
radiotherapy I-Premise
) I-Premise
versus I-Premise
12.1 I-Premise
months I-Premise
( I-Premise
radiotherapy I-Premise
alone I-Premise
) I-Premise
. I-Premise

No B-Premise
adverse I-Premise
events I-Premise
or I-Premise
skeletal I-Premise
complications I-Premise
occurred I-Premise
during I-Premise
the I-Premise
supervised I-Premise
exercise I-Premise
sessions I-Premise
. I-Premise

The B-Premise
proportion I-Premise
of I-Premise
patients I-Premise
without I-Premise
progression I-Premise
at I-Premise
2 I-Premise
years I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
40.0 I-Premise
% I-Premise
for I-Premise
PT I-Premise
versus I-Premise
37.5 I-Premise
% I-Premise
for I-Premise
TC I-Premise
, I-Premise
difference I-Premise
= I-Premise
2.5 I-Premise
% I-Premise
, I-Premise
one-sided I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
- I-Premise
infinity I-Premise
to I-Premise
8.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Most B-Premise
frequent I-Premise
non-hematological I-Premise
toxicities I-Premise
were I-Premise
nausea I-Premise
( I-Premise
76 I-Premise
% I-Premise
) I-Premise
, I-Premise
constipation I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
for I-Premise
PSA I-Premise
nadir I-Premise
≤ I-Premise
0.2 I-Premise
ng/ml I-Premise
, I-Premise
and I-Premise
> I-Premise
0.2 I-Premise
to I-Premise
4 I-Premise
ng/ml I-Premise
in I-Premise
CAD I-Premise
was I-Premise
31 I-Premise
% I-Premise
and I-Premise
70 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
mean I-Premise
level I-Premise
of I-Premise
postoperative I-Premise
satisfaction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
EOF I-Premise
group I-Premise
( I-Premise
82.8 I-Premise
vs. I-Premise
71.7 I-Premise
mm I-Premise
, I-Premise
P I-Premise
B I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

No B-Premise
consistent I-Premise
influence I-Premise
on I-Premise
QOL I-Premise
was I-Premise
detected I-Premise
. I-Premise

Furthermore B-Premise
, I-Premise
letrozole I-Premise
significantly I-Premise
improved I-Premise
distant I-Premise
DFS I-Premise
( I-Premise
HR=0.60 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.43 I-Premise
, I-Premise
0.84 I-Premise
";" I-Premise
P=0.002 I-Premise
) I-Premise
and I-Premise
, I-Premise
in I-Premise
women I-Premise
with I-Premise
node-positive I-Premise
tumors I-Premise
, I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR=0.61 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.38 I-Premise
, I-Premise
0.98 I-Premise
";" I-Premise
P=0.04 I-Premise
) I-Premise
. I-Premise

The B-Premise
operation I-Premise
time I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
, I-Premise
and I-Premise
the I-Premise
leakage I-Premise
rate I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
transthoracic I-Premise
group I-Premise
( I-Premise
Student I-Premise
's I-Premise
t-test I-Premise
and I-Premise
Fischer I-Premise
's I-Premise
exact I-Premise
test I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Mean B-Premise
( I-Premise
+/- I-Premise
SD I-Premise
) I-Premise
increase I-Premise
in I-Premise
Hb I-Premise
from I-Premise
baseline I-Premise
to I-Premise
week I-Premise
12 I-Premise
was I-Premise
1.75 I-Premise
+/- I-Premise
2.15 I-Premise
g/dL I-Premise
in I-Premise
the I-Premise
30,000 I-Premise
IU I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.008 I-Premise
vs. I-Premise
baseline I-Premise
) I-Premise
and I-Premise
1.04 I-Premise
+/- I-Premise
1.75 I-Premise
g/dL I-Premise
in I-Premise
the I-Premise
20,000 I-Premise
IU I-Premise
group I-Premise
( I-Premise
non-significant I-Premise
) I-Premise
. I-Premise

At B-Premise
first I-Premise
follow-up I-Premise
, I-Premise
groups I-Premise
differed I-Premise
only I-Premise
in I-Premise
social I-Premise
functioning I-Premise
, I-Premise
favouring I-Premise
the I-Premise
radiotherapy-only I-Premise
group I-Premise
( I-Premise
mean I-Premise
score I-Premise
79.0 I-Premise
[ I-Premise
SD I-Premise
3.2 I-Premise
] I-Premise
for I-Premise
patients I-Premise
assigned I-Premise
radiotherapy I-Premise
vs I-Premise
67.4 I-Premise
[ I-Premise
2.7 I-Premise
] I-Premise
for I-Premise
those I-Premise
assigned I-Premise
radiotherapy I-Premise
and I-Premise
temozolomide I-Premise
";" I-Premise
difference I-Premise
between I-Premise
groups I-Premise
11.6 I-Premise
points I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
3.5-19.7 I-Premise
] I-Premise
, I-Premise
p=0.0052 I-Premise
) I-Premise
. I-Premise

Absolute B-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
2.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.40 I-Premise
to I-Premise
5.3 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
to I-Premise
1.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-2.8 I-Premise
to I-Premise
5.1 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

The B-Premise
estimated I-Premise
treatment I-Premise
effects I-Premise
( I-Premise
intervention I-Premise
minus I-Premise
usual I-Premise
care I-Premise
) I-Premise
for I-Premise
all I-Premise
participants I-Premise
were I-Premise
a I-Premise
mean I-Premise
( I-Premise
SE I-Premise
) I-Premise
of I-Premise
4.6 I-Premise
( I-Premise
2 I-Premise
) I-Premise
for I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
-27.8 I-Premise
( I-Premise
15 I-Premise
) I-Premise
for I-Premise
symptom I-Premise
intensity I-Premise
( I-Premise
P I-Premise
= I-Premise
.06 I-Premise
) I-Premise
, I-Premise
and I-Premise
-1.8 I-Premise
( I-Premise
0.81 I-Premise
) I-Premise
for I-Premise
depressed I-Premise
mood I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

We B-Premise
found I-Premise
no I-Premise
difference I-Premise
in I-Premise
severe I-Premise
ARSR I-Premise
between I-Premise
the I-Premise
groups I-Premise
at I-Premise
any I-Premise
point I-Premise
of I-Premise
assessment I-Premise
. I-Premise

No B-Premise
significant I-Premise
effect I-Premise
was I-Premise
seen I-Premise
for I-Premise
general I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
, I-Premise
which I-Premise
was I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
. I-Premise

From B-Premise
the I-Premise
1-year I-Premise
survival I-Premise
analysis I-Premise
, I-Premise
the I-Premise
hazard I-Premise
ratio I-Premise
for I-Premise
probability I-Premise
of I-Premise
death I-Premise
was I-Premise
1.29 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.96 I-Premise
to I-Premise
1.72 I-Premise
) I-Premise
. I-Premise

Two B-Premise
patients I-Premise
( I-Premise
1.3 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
gefitinib I-Premise
arm I-Premise
developed I-Premise
interstitial I-Premise
lung I-Premise
disease I-Premise
and I-Premise
died I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
( I-Premise
33.8 I-Premise
and I-Premise
40.7 I-Premise
weeks I-Premise
, I-Premise
respectively I-Premise
) I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
41.4 I-Premise
and I-Premise
57.3 I-Premise
weeks I-Premise
, I-Premise
respectively I-Premise
) I-Premise
were I-Premise
of I-Premise
borderline I-Premise
significance I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
GP I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
0.055 I-Premise
) I-Premise
. I-Premise

Cosmetic B-Premise
results I-Premise
were I-Premise
better I-Premise
in I-Premise
those I-Premise
not I-Premise
receiving I-Premise
radiotherapy I-Premise
but B-Premise
this I-Premise
did I-Premise
not I-Premise
appear I-Premise
to I-Premise
be I-Premise
an I-Premise
important I-Premise
issue I-Premise
to I-Premise
the I-Premise
patients I-Premise
. I-Premise

Toxicity B-Premise
profiles I-Premise
were I-Premise
similar I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
of I-Premise
the I-Premise
study I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
episode I-Premise
of I-Premise
arm I-Premise
infection I-Premise
or I-Premise
aggravation I-Premise
in I-Premise
limb I-Premise
volume I-Premise
during I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
3.9 I-Premise
years I-Premise
, I-Premise
the I-Premise
estimated I-Premise
4-year I-Premise
recurrence-free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
67.5 I-Premise
% I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
versus I-Premise
62.7 I-Premise
% I-Premise
with I-Premise
CAF I-Premise
( I-Premise
P I-Premise
= I-Premise
.19 I-Premise
, I-Premise
two-sided I-Premise
";" I-Premise
P I-Premise
= I-Premise
.095 I-Premise
, I-Premise
one-sided I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
RELP I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
UM I-Premise
had I-Premise
significantly I-Premise
shorter I-Premise
duration I-Premise
of I-Premise
operation I-Premise
and I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
shorter I-Premise
time I-Premise
periods I-Premise
to I-Premise
walk I-Premise
, I-Premise
return I-Premise
to I-Premise
daily I-Premise
activities I-Premise
, I-Premise
or I-Premise
sit I-Premise
without I-Premise
pain I-Premise
and I-Premise
to I-Premise
return I-Premise
to I-Premise
work I-Premise
or I-Premise
school I-Premise
, I-Premise
and I-Premise
fewer I-Premise
complications I-Premise
. I-Premise

Overall B-Premise
response I-Premise
rates I-Premise
were I-Premise
similar I-Premise
( I-Premise
42 I-Premise
% I-Premise
for I-Premise
GCa I-Premise
v I-Premise
41 I-Premise
% I-Premise
for I-Premise
MIC I-Premise
";" I-Premise
P I-Premise
= I-Premise
.84 I-Premise
) I-Premise
. I-Premise

GEM-CAP B-Premise
significantly I-Premise
improved I-Premise
objective I-Premise
response I-Premise
rate I-Premise
( I-Premise
19.1 I-Premise
% I-Premise
v I-Premise
12.4 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.034 I-Premise
) I-Premise
and I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.78 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.66 I-Premise
to I-Premise
0.93 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
and I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
trend I-Premise
toward I-Premise
improved I-Premise
OS I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.72 I-Premise
to I-Premise
1.02 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.08 I-Premise
) I-Premise
compared I-Premise
with I-Premise
GEM I-Premise
alone I-Premise
. I-Premise

Without B-Premise
ADT I-Premise
testosterone I-Premise
remained I-Premise
at I-Premise
castrate I-Premise
level I-Premise
for I-Premise
4 I-Premise
months I-Premise
. I-Premise

At B-Premise
four I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
who I-Premise
received I-Premise
thalidomide I-Premise
had I-Premise
gained I-Premise
on I-Premise
average I-Premise
0.37 I-Premise
kg I-Premise
in I-Premise
weight I-Premise
and I-Premise
1.0 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
in I-Premise
arm I-Premise
muscle I-Premise
mass I-Premise
( I-Premise
AMA I-Premise
) I-Premise
compared I-Premise
with I-Premise
a I-Premise
loss I-Premise
of I-Premise
2.21 I-Premise
kg I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-2.59 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
-4.3 I-Premise
to I-Premise
-0.8 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
and I-Premise
4.46 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-5.6 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-8.9 I-Premise
to I-Premise
-2.2 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

A B-Premise
similar I-Premise
change I-Premise
was I-Premise
seen I-Premise
for I-Premise
mean I-Premise
anxiety I-Premise
scores I-Premise
: I-Premise
intervention I-Premise
11.1 I-Premise
to I-Premise
8.2 I-Premise
, I-Premise
control I-Premise
9.6 I-Premise
to I-Premise
9.3 I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,84 I-Premise
) I-Premise
) I-Premise
= I-Premise
17.8 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

HDCT B-Premise
was I-Premise
associated I-Premise
with I-Premise
significantly I-Premise
more I-Premise
myelosuppression I-Premise
, I-Premise
infection I-Premise
, I-Premise
diarrhea I-Premise
, I-Premise
stomatitis I-Premise
, I-Premise
and I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
treated I-Premise
with I-Premise
AT I-Premise
developed I-Premise
more I-Premise
neurotoxicity I-Premise
. I-Premise

Hospital B-Premise
stay I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
EOF I-Premise
( I-Premise
n=71 I-Premise
) I-Premise
was I-Premise
4.7 I-Premise
vs. I-Premise
5.8 I-Premise
days I-Premise
for I-Premise
the I-Premise
TOF I-Premise
group I-Premise
( I-Premise
n=72 I-Premise
) I-Premise
( I-Premise
P=0.006 I-Premise
) I-Premise
. I-Premise

When B-Premise
group I-Premise
1 I-Premise
with I-Premise
group I-Premise
2 I-Premise
were I-Premise
compared I-Premise
, I-Premise
numeric I-Premise
rating I-Premise
scale I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
group I-Premise
1 I-Premise
than I-Premise
in I-Premise
group I-Premise
2 I-Premise
during I-Premise
the I-Premise
period I-Premise
of I-Premise
T I-Premise
( I-Premise
0-12 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
but B-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
at I-Premise
T I-Premise
( I-Premise
12-24 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.68 I-Premise
) I-Premise
and I-Premise
T I-Premise
( I-Premise
24-48 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.10 I-Premise
) I-Premise
. I-Premise

HRQOL B-Premise
and I-Premise
symptom I-Premise
relief I-Premise
were I-Premise
equivalent I-Premise
in I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

Fat B-Premise
mass I-Premise
had I-Premise
significantly I-Premise
decreased I-Premise
by I-Premise
month I-Premise
12 I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
, I-Premise
but I-Premise
not I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
";" I-Premise
the B-Premise
between-group I-Premise
difference I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
SNBM I-Premise
group I-Premise
gave I-Premise
lower I-Premise
ratings I-Premise
for I-Premise
arm I-Premise
swelling I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
dysfunctions I-Premise
( I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
but I-Premise
not I-Premise
disabilities I-Premise
( I-Premise
P I-Premise
= I-Premise
0.5 I-Premise
) I-Premise
. I-Premise

Incontinence B-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
EUS I-Premise
or I-Premise
IUS I-Premise
dose I-Premise
. I-Premise

The B-Premise
1-year I-Premise
PFS I-Premise
rates I-Premise
were I-Premise
16.7 I-Premise
% I-Premise
with I-Premise
gefitinib I-Premise
and I-Premise
2.8 I-Premise
% I-Premise
with I-Premise
GP I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.198 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.944 I-Premise
to I-Premise
1.520 I-Premise
) I-Premise
. I-Premise

ORR B-Premise
was I-Premise
25.0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
13 I-Premise
% I-Premise
to I-Premise
41 I-Premise
% I-Premise
) I-Premise
for I-Premise
ECF I-Premise
, I-Premise
18.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9 I-Premise
% I-Premise
to I-Premise
34 I-Premise
% I-Premise
) I-Premise
for I-Premise
TC I-Premise
, I-Premise
and I-Premise
36.6 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
23 I-Premise
% I-Premise
to I-Premise
53 I-Premise
% I-Premise
) I-Premise
for I-Premise
TCF I-Premise
( I-Premise
n I-Premise
= I-Premise
119 I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
treatment I-Premise
effects I-Premise
in I-Premise
participants I-Premise
who I-Premise
died I-Premise
during I-Premise
the I-Premise
study I-Premise
were I-Premise
a I-Premise
mean I-Premise
( I-Premise
SE I-Premise
) I-Premise
of I-Premise
8.6 I-Premise
( I-Premise
3.6 I-Premise
) I-Premise
for I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
-24.2 I-Premise
( I-Premise
20.5 I-Premise
) I-Premise
for I-Premise
symptom I-Premise
intensity I-Premise
( I-Premise
P I-Premise
= I-Premise
.24 I-Premise
) I-Premise
, I-Premise
and I-Premise
-2.7 I-Premise
( I-Premise
1.2 I-Premise
) I-Premise
for I-Premise
depressed I-Premise
mood I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

Seventy-one B-Premise
percent I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
EDS I-Premise
group I-Premise
and I-Premise
76 I-Premise
% I-Premise
in I-Premise
the I-Premise
QW I-Premise
group I-Premise
achieved I-Premise
the I-Premise
target I-Premise
hemoglobin I-Premise
of I-Premise
≥11.0 I-Premise
g/dL I-Premise
. I-Premise

Symptomatic B-Premise
response I-Premise
during I-Premise
the I-Premise
first I-Premise
four I-Premise
weeks I-Premise
was I-Premise
seen I-Premise
after I-Premise
pamidronate I-Premise
, I-Premise
but I-Premise
not I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

During B-Premise
the I-Premise
last I-Premise
decade I-Premise
, I-Premise
survival I-Premise
rates I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
have I-Premise
increased I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
earlier I-Premise
detection I-Premise
and I-Premise
increased I-Premise
use I-Premise
of I-Premise
adjuvant I-Premise
therapy I-Premise
. I-Premise

ES B-Premise
scores I-Premise
and I-Premise
CES-D I-Premise
scores I-Premise
were I-Premise
similar I-Premise
in I-Premise
all I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

16 B-Premise
( I-Premise
29 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
had I-Premise
pulmonary I-Premise
infection I-Premise
in I-Premise
the I-Premise
first I-Premise
2 I-Premise
weeks I-Premise
compared I-Premise
with I-Premise
five I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
( I-Premise
relative I-Premise
risk I-Premise
[ I-Premise
RR I-Premise
] I-Premise
0·30 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·12-0·76 I-Premise
";" I-Premise
p=0·005 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
time I-Premise
for I-Premise
all I-Premise
patients I-Premise
was I-Premise
15 I-Premise
months I-Premise
, I-Premise
with I-Premise
no I-Premise
difference I-Premise
in I-Premise
survival I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
P I-Premise
=.26 I-Premise
) I-Premise
. I-Premise

The B-Premise
tumor I-Premise
progression I-Premise
duration I-Premise
in I-Premise
these I-Premise
two I-Premise
groups I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
5.6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Multivariable B-Premise
repeated I-Premise
measures I-Premise
modeling I-Premise
demonstrated I-Premise
that I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
time I-Premise
point I-Premise
, I-Premise
age I-Premise
, I-Premise
and I-Premise
tamoxifen I-Premise
use I-Premise
were I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
symptom I-Premise
severity I-Premise
( I-Premise
all I-Premise
P I-Premise
values I-Premise
< I-Premise
.002 I-Premise
) I-Premise
. I-Premise

The B-Premise
response I-Premise
rates I-Premise
in I-Premise
the I-Premise
subgroup I-Premise
of I-Premise
patients I-Premise
with I-Premise
measurable I-Premise
disease I-Premise
were I-Premise
12 I-Premise
% I-Premise
, I-Premise
10 I-Premise
% I-Premise
, I-Premise
and I-Premise
17 I-Premise
% I-Premise
for I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
FU24h I-Premise
, I-Premise
and I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
, I-Premise
respectively I-Premise
( I-Premise
not I-Premise
significant I-Premise
) I-Premise
. I-Premise

Nadir B-Premise
prostate-specific I-Premise
antigen I-Premise
values I-Premise
occurred I-Premise
at I-Premise
a I-Premise
median I-Premise
of I-Premise
18.0 I-Premise
( I-Premise
3.0-54.0 I-Premise
) I-Premise
months I-Premise
after I-Premise
RT I-Premise
. I-Premise

The B-Premise
Breast I-Premise
Cancer I-Premise
Subscale I-Premise
scores I-Premise
in I-Premise
group I-Premise
A I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
of I-Premise
group I-Premise
C I-Premise
patients I-Premise
( I-Premise
p=0.021 I-Premise
) I-Premise
. I-Premise

This B-Premise
was I-Premise
accompanied I-Premise
by I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
the I-Premise
physical I-Premise
function I-Premise
( I-Premise
31 I-Premise
% I-Premise
erlotinib I-Premise
v I-Premise
19 I-Premise
% I-Premise
placebo I-Premise
, I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
global I-Premise
QOL I-Premise
( I-Premise
35 I-Premise
% I-Premise
v I-Premise
26 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

After B-Premise
the I-Premise
first I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
14 I-Premise
women I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
13 I-Premise
% I-Premise
) I-Premise
required I-Premise
hospitalization I-Premise
, I-Premise
3 I-Premise
of I-Premise
them I-Premise
for I-Premise
major I-Premise
adverse I-Premise
events I-Premise
and I-Premise
11 I-Premise
for I-Premise
reintervention I-Premise
for I-Premise
treatment I-Premise
failure I-Premise
. I-Premise

The B-Premise
3-year I-Premise
progression-free I-Premise
survival I-Premise
for I-Premise
neoadjuvant I-Premise
versus I-Premise
control I-Premise
arm I-Premise
was I-Premise
88.2 I-Premise
% I-Premise
and I-Premise
59.5 I-Premise
% I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
0.49 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.20 I-Premise
to I-Premise
1.19 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.12 I-Premise
) I-Premise
. I-Premise

No B-Premise
liver I-Premise
cancers I-Premise
or I-Premise
increase I-Premise
in I-Premise
colon I-Premise
, I-Premise
rectal I-Premise
, I-Premise
ovarian I-Premise
, I-Premise
or I-Premise
other I-Premise
tumors I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
. I-Premise

The B-Premise
groups I-Premise
that I-Premise
included I-Premise
CBT I-Premise
also I-Premise
showed I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
perceived I-Premise
burden I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
and I-Premise
night I-Premise
sweats I-Premise
( I-Premise
problem I-Premise
rating I-Premise
scale I-Premise
of I-Premise
the I-Premise
Hot I-Premise
Flush I-Premise
Rating I-Premise
Scale I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.39-0.56 I-Premise
) I-Premise
and I-Premise
an I-Premise
increase I-Premise
in I-Premise
sexual I-Premise
activity I-Premise
( I-Premise
Sexual I-Premise
Activity I-Premise
Questionnaire I-Premise
habit I-Premise
subscale I-Premise
";" I-Premise
P=.027 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.65 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
was I-Premise
noted I-Premise
in I-Premise
the I-Premise
time I-Premise
to I-Premise
local I-Premise
failure I-Premise
between I-Premise
the I-Premise
surgical I-Premise
and I-Premise
RT I-Premise
arms I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
risk I-Premise
of I-Premise
death I-Premise
in I-Premise
the I-Premise
TMX120 I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
P I-Premise
group I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.39 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
1.07-1.81 I-Premise
) I-Premise
. I-Premise

Fatigue B-Premise
and I-Premise
global I-Premise
health I-Premise
scores I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
during I-Premise
the I-Premise
intervention I-Premise
( I-Premise
fatigue I-Premise
: I-Premise
training I-Premise
group I-Premise
21 I-Premise
% I-Premise
, I-Premise
relaxation I-Premise
group I-Premise
19 I-Premise
% I-Premise
";" I-Premise
global I-Premise
health I-Premise
of I-Premise
both I-Premise
groups I-Premise
19 I-Premise
% I-Premise
, I-Premise
p I-Premise
for I-Premise
all I-Premise
< I-Premise
or I-Premise
=0.01 I-Premise
) I-Premise
";" I-Premise
however B-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
changes I-Premise
in I-Premise
the I-Premise
scores I-Premise
of I-Premise
both I-Premise
groups I-Premise
( I-Premise
p=0.67 I-Premise
) I-Premise
. I-Premise

Need B-Premise
for I-Premise
reintervention I-Premise
was I-Premise
19 I-Premise
, I-Premise
10 I-Premise
, I-Premise
and I-Premise
33 I-Premise
% I-Premise
in I-Premise
these I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.123 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
EBRT I-Premise
reported I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
and I-Premise
clinically I-Premise
relevant I-Premise
higher I-Premise
rates I-Premise
of I-Premise
urinary I-Premise
incontinence I-Premise
, I-Premise
diarrhea I-Premise
, I-Premise
and I-Premise
fecal I-Premise
leakage I-Premise
leading I-Premise
to I-Premise
more I-Premise
limitations I-Premise
in I-Premise
daily I-Premise
activities I-Premise
. I-Premise

Complete B-Premise
and I-Premise
partial I-Premise
response I-Premise
rates I-Premise
to I-Premise
induction I-Premise
PE I-Premise
were I-Premise
3 I-Premise
% I-Premise
and I-Premise
32 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
total I-Premise
medical-resource I-Premise
utilization I-Premise
cost I-Premise
per I-Premise
patient I-Premise
was I-Premise
8.9 I-Premise
% I-Premise
higher I-Premise
with I-Premise
the I-Premise
combination I-Premise
: I-Premise
24,475 I-Premise
dollars I-Premise
for I-Premise
combination I-Premise
therapy I-Premise
versus I-Premise
22,477 I-Premise
dollars I-Premise
for I-Premise
single-agent I-Premise
docetaxel I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ratio I-Premise
was I-Premise
0.63 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
0.52-0.75 I-Premise
";" I-Premise
log-rank I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

HRQOL B-Premise
ratings I-Premise
improved I-Premise
with I-Premise
ccHRT I-Premise
, I-Premise
irrespective I-Premise
of I-Premise
dosage I-Premise
, I-Premise
including I-Premise
depressed I-Premise
mood I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
health I-Premise
perception I-Premise
and I-Premise
sexual I-Premise
interest I-Premise
. I-Premise

Patients B-Premise
with I-Premise
an I-Premise
objective I-Premise
tumor I-Premise
response I-Premise
reported I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
functional I-Premise
performance I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
less I-Premise
effort I-Premise
to I-Premise
cope I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
non-responders I-Premise
and I-Premise
stable I-Premise
disease I-Premise
patients I-Premise
. I-Premise

The B-Premise
ORR I-Premise
was I-Premise
also I-Premise
higher I-Premise
with I-Premise
AT I-Premise
in I-Premise
patients I-Premise
with I-Premise
visceral I-Premise
involvement I-Premise
( I-Premise
58 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
";" I-Premise
liver I-Premise
, I-Premise
62 I-Premise
% I-Premise
v I-Premise
42 I-Premise
% I-Premise
";" I-Premise
lung I-Premise
, I-Premise
58 I-Premise
% I-Premise
v I-Premise
35 I-Premise
% I-Premise
) I-Premise
, I-Premise
three I-Premise
or I-Premise
more I-Premise
organs I-Premise
involved I-Premise
( I-Premise
59 I-Premise
% I-Premise
v I-Premise
40 I-Premise
% I-Premise
) I-Premise
, I-Premise
or I-Premise
prior I-Premise
adjuvant I-Premise
CT I-Premise
( I-Premise
53 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
pad I-Premise
use I-Premise
in I-Premise
group I-Premise
A I-Premise
. I-Premise

Mean B-Premise
hemoglobin I-Premise
levels I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
placebo I-Premise
group I-Premise
after I-Premise
4 I-Premise
cycles I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

Patients B-Premise
had I-Premise
significant I-Premise
concerns I-Premise
about I-Premise
the I-Premise
delivery I-Premise
of I-Premise
radiotherapy I-Premise
services I-Premise
, I-Premise
such I-Premise
as I-Premise
transport I-Premise
, I-Premise
accommodation I-Premise
and I-Premise
travel I-Premise
costs I-Premise
associated I-Premise
with I-Premise
receiving I-Premise
radiotherapy I-Premise
. I-Premise

The B-Premise
15-year I-Premise
actuarial I-Premise
locoregional I-Premise
recurrence I-Premise
rates I-Premise
were I-Premise
5.8 I-Premise
% I-Premise
for I-Premise
EBRT I-Premise
versus I-Premise
15.5 I-Premise
% I-Premise
for I-Premise
NAT I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
15-year I-Premise
overall I-Premise
survival I-Premise
was I-Premise
52 I-Premise
% I-Premise
versus I-Premise
60 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
.14 I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
maintained I-Premise
better I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
three I-Premise
cycles I-Premise
";" I-Premise
no B-Premise
differences I-Premise
were I-Premise
detected I-Premise
between I-Premise
3 I-Premise
and I-Premise
5 I-Premise
days I-Premise
of I-Premise
treatment I-Premise
. I-Premise

These B-Premise
findings I-Premise
were I-Premise
associated I-Premise
with I-Premise
higher I-Premise
post-procedure I-Premise
pain I-Premise
scores I-Premise
in I-Premise
the I-Premise
SEMS I-Premise
patient I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
of I-Premise
the I-Premise
European I-Premise
Organisation I-Premise
for I-Premise
Research I-Premise
and I-Premise
Treatment I-Premise
of I-Premise
Cancer I-Premise
QLQ I-Premise
C-30 I-Premise
pain I-Premise
symptom I-Premise
score I-Premise
at I-Premise
week I-Premise
1=11.13 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
2.89-19.4 I-Premise
";" I-Premise
P=0.01 I-Premise
) I-Premise
. I-Premise

When B-Premise
evaluated I-Premise
with I-Premise
the I-Premise
EORTC I-Premise
questionnaire I-Premise
there I-Premise
was I-Premise
significantly I-Premise
less I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
P=0.0001 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
P=0.03 I-Premise
) I-Premise
, I-Premise
constipation I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
and I-Premise
peripheral I-Premise
neuropathy I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
in I-Premise
favour I-Premise
of I-Premise
MVC I-Premise
, I-Premise
and I-Premise
a I-Premise
trend I-Premise
for I-Premise
less I-Premise
hair I-Premise
loss I-Premise
( I-Premise
P=0.05 I-Premise
) I-Premise
. I-Premise

CR B-Premise
after I-Premise
remission I-Premise
induction I-Premise
treatment I-Premise
was I-Premise
achieved I-Premise
in I-Premise
55 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
in I-Premise
56 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
GM-CSF I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
NS I-Premise
) I-Premise
. I-Premise

Visual B-Premise
analogue I-Premise
scale I-Premise
scores I-Premise
trended I-Premise
downward I-Premise
over I-Premise
time I-Premise
irrespective I-Premise
of I-Premise
chemotherapy I-Premise
response I-Premise
status I-Premise
, I-Premise
with I-Premise
a I-Premise
statistically I-Premise
meaningful I-Premise
deterioration I-Premise
in I-Premise
patients I-Premise
who I-Premise
progressed I-Premise
( I-Premise
68.9 I-Premise
vs. I-Premise
64.4 I-Premise
, I-Premise
P=0.029 I-Premise
) I-Premise
. I-Premise

By B-Premise
the I-Premise
end I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
radiotherapy I-Premise
were I-Premise
expressing I-Premise
less I-Premise
anxiety I-Premise
about I-Premise
recurrence I-Premise
than I-Premise
those I-Premise
who I-Premise
had I-Premise
not I-Premise
received I-Premise
radiotherapy I-Premise
. I-Premise

More B-Premise
patients I-Premise
survived I-Premise
> I-Premise
/= I-Premise
3 I-Premise
years I-Premise
in I-Premise
the I-Premise
D3P I-Premise
and I-Premise
D1P I-Premise
arms I-Premise
( I-Premise
18.6 I-Premise
% I-Premise
and I-Premise
16.6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
MP I-Premise
arm I-Premise
( I-Premise
13.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
29 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
weekly I-Premise
and I-Premise
34 I-Premise
% I-Premise
of I-Premise
those I-Premise
treated I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.35 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
NGT I-Premise
group I-Premise
reported I-Premise
significantly I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
better I-Premise
scores I-Premise
of I-Premise
QoL I-Premise
at I-Premise
both I-Premise
6 I-Premise
months I-Premise
and I-Premise
1 I-Premise
year I-Premise
. I-Premise

PF B-Premise
change I-Premise
scores I-Premise
were I-Premise
-3.9 I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
-8.6 I-Premise
for I-Premise
BSC I-Premise
( I-Premise
P I-Premise
= I-Premise
.046 I-Premise
) I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
and I-Premise
were I-Premise
-5.9 I-Premise
and I-Premise
-12.5 I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
BSC I-Premise
, I-Premise
respectively I-Premise
, I-Premise
( I-Premise
P I-Premise
= I-Premise
.027 I-Premise
) I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
. I-Premise

These B-Premise
differences I-Premise
were I-Premise
not I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
T3 I-Premise
and I-Premise
T4 I-Premise
assessments I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
non-hematological I-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
Arm I-Premise
B I-Premise
( I-Premise
31 I-Premise
% I-Premise
versus I-Premise
22 I-Premise
% I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

No B-Premise
interactions I-Premise
were I-Premise
found I-Premise
between I-Premise
other I-Premise
domains I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
functioning I-Premise
, I-Premise
psychological I-Premise
distress I-Premise
and I-Premise
CBT I-Premise
. I-Premise

Many B-Premise
patients I-Premise
( I-Premise
24 I-Premise
% I-Premise
) I-Premise
failed I-Premise
to I-Premise
complete I-Premise
at I-Premise
least I-Premise
6 I-Premise
weeks I-Premise
of I-Premise
therapy I-Premise
, I-Premise
including I-Premise
five I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
treatment-related I-Premise
early I-Premise
deaths I-Premise
. I-Premise

A B-Premise
complete I-Premise
resolution I-Premise
of I-Premise
all I-Premise
symptoms I-Premise
was I-Premise
achieved I-Premise
in I-Premise
three I-Premise
( I-Premise
5 I-Premise
% I-Premise
) I-Premise
on I-Premise
regimen I-Premise
1 I-Premise
, I-Premise
and I-Premise
in I-Premise
14 I-Premise
( I-Premise
23 I-Premise
% I-Premise
) I-Premise
patients I-Premise
on I-Premise
regimen I-Premise
2 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
a I-Premise
difference I-Premise
in I-Premise
the I-Premise
proportion I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
of I-Premise
21 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
10-33 I-Premise
) I-Premise
. I-Premise

A B-Premise
mean I-Premise
of I-Premise
10.6 I-Premise
units I-Premise
of I-Premise
PRBCs I-Premise
over I-Premise
5 I-Premise
months I-Premise
were I-Premise
administered I-Premise
to I-Premise
those I-Premise
who I-Premise
received I-Premise
epoetin I-Premise
alpha I-Premise
compared I-Premise
with I-Premise
13 I-Premise
units I-Premise
for I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
receive I-Premise
epoetin I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
score I-Premise
changes I-Premise
per I-Premise
4-week I-Premise
period I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
showed I-Premise
overall I-Premise
less I-Premise
deterioration I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group-physical I-Premise
scores I-Premise
( I-Premise
-0.2 I-Premise
% I-Premise
versus I-Premise
-2.4 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
2 I-Premise
) I-Premise
";" I-Premise
functional I-Premise
scores I-Premise
( I-Premise
+0.4 I-Premise
% I-Premise
versus I-Premise
-5.5 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
";" I-Premise
psychologic I-Premise
scores I-Premise
( I-Premise
-0.7 I-Premise
% I-Premise
versus I-Premise
-2.4 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.11 I-Premise
) I-Premise
";" I-Premise
overall I-Premise
QOL I-Premise
score I-Premise
( I-Premise
+0.1 I-Premise
% I-Premise
versus I-Premise
-3.5 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
. I-Premise

Small B-Premise
( I-Premise
< I-Premise
0.2 I-Premise
standard I-Premise
deviations I-Premise
) I-Premise
but I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
mean I-Premise
change I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
were I-Premise
seen I-Premise
for I-Premise
the I-Premise
SF-36 I-Premise
domains I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
12 I-Premise
months I-Premise
) I-Premise
, I-Premise
bodily I-Premise
pain I-Premise
( I-Premise
6 I-Premise
months I-Premise
) I-Premise
and I-Premise
vitality I-Premise
( I-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
MENQOL I-Premise
vasomotor I-Premise
( I-Premise
6 I-Premise
, I-Premise
12 I-Premise
, I-Premise
and I-Premise
24 I-Premise
months I-Premise
) I-Premise
and I-Premise
sexual I-Premise
domains I-Premise
( I-Premise
12 I-Premise
and I-Premise
24 I-Premise
months I-Premise
) I-Premise
. I-Premise

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0.96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.75 I-Premise
to1.23 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.7349 I-Premise
) I-Premise
. I-Premise

High B-Premise
self-assessed I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
reported I-Premise
by I-Premise
62 I-Premise
( I-Premise
35 I-Premise
% I-Premise
) I-Premise
of I-Premise
179 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
, I-Premise
55 I-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
of I-Premise
160 I-Premise
men I-Premise
assigned I-Premise
to I-Premise
watchful I-Premise
waiting I-Premise
, I-Premise
and I-Premise
93 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
208 I-Premise
men I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

CRF B-Premise
was I-Premise
significantly I-Premise
reduced I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
corresponding I-Premise
to I-Premise
a I-Premise
Fatigue I-Premise
score I-Premise
reduction I-Premise
of I-Premise
3.04 I-Premise
( I-Premise
effect I-Premise
size I-Premise
of I-Premise
0.44 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.17-0.72 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
, I-Premise
the I-Premise
FACT-An I-Premise
score I-Premise
by I-Premise
5.40 I-Premise
( I-Premise
P I-Premise
= I-Premise
.015 I-Premise
) I-Premise
, I-Premise
the I-Premise
FACT-An I-Premise
Toi I-Premise
score I-Premise
by I-Premise
5.22 I-Premise
( I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
and I-Premise
the I-Premise
Anaemia-ANS I-Premise
by I-Premise
3.76 I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Exploratory B-Premise
analyses I-Premise
showed I-Premise
that I-Premise
the I-Premise
difference I-Premise
nearly I-Premise
reached I-Premise
significance I-Premise
until I-Premise
7 I-Premise
months I-Premise
postintervention I-Premise
. I-Premise

However B-Premise
, I-Premise
at I-Premise
the I-Premise
final I-Premise
analysis I-Premise
in I-Premise
July I-Premise
2006 I-Premise
of I-Premise
all I-Premise
patients I-Premise
( I-Premise
n=189 I-Premise
) I-Premise
and I-Premise
with I-Premise
longer I-Premise
follow-up I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
1.35 I-Premise
[ I-Premise
0.95-1.91 I-Premise
] I-Premise
, I-Premise
log-rank I-Premise
p=0.09 I-Premise
";" I-Premise
adjusted I-Premise
hazard I-Premise
ratio I-Premise
1.27 I-Premise
[ I-Premise
0.87-1.84 I-Premise
] I-Premise
, I-Premise
Cox I-Premise
model I-Premise
p=0.20 I-Premise
) I-Premise
. I-Premise

Operative B-Premise
time I-Premise
was I-Premise
53 I-Premise
minutes I-Premise
longer I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
was I-Premise
preserved I-Premise
longer I-Premise
for I-Premise
patients I-Premise
on I-Premise
DCF I-Premise
than I-Premise
those I-Premise
on I-Premise
CF I-Premise
for I-Premise
all I-Premise
time I-Premise
to I-Premise
deterioration I-Premise
analyses I-Premise
, I-Premise
demonstrating I-Premise
the I-Premise
statistical I-Premise
superiority I-Premise
of I-Premise
DCF I-Premise
compared I-Premise
with I-Premise
CF I-Premise
. I-Premise

Climacteric B-Premise
symptoms I-Premise
remained I-Premise
significantly I-Premise
below I-Premise
baseline I-Premise
values I-Premise
after I-Premise
dosage I-Premise
reduction I-Premise
";" I-Premise
some B-Premise
symptoms I-Premise
recurred I-Premise
after I-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
. I-Premise

The B-Premise
scores I-Premise
of I-Premise
TCM I-Premise
efficacy I-Premise
( I-Premise
24.52 I-Premise
+/- I-Premise
8.98 I-Premise
vs I-Premise
29.76 I-Premise
+/- I-Premise
7.09 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
the I-Premise
6-min I-Premise
walking I-Premise
distance I-Premise
( I-Premise
233.4 I-Premise
+/- I-Premise
29.2 I-Premise
m I-Premise
vs I-Premise
205.8 I-Premise
+/- I-Premise
31.9 I-Premise
m I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
. I-Premise

Decreases B-Premise
in I-Premise
IPSS I-Premise
were I-Premise
greater I-Premise
in I-Premise
degarelix I-Premise
than I-Premise
in I-Premise
goserelin-treated I-Premise
patients I-Premise
, I-Premise
differences I-Premise
being I-Premise
statistically I-Premise
significant I-Premise
in I-Premise
patients I-Premise
with I-Premise
baseline I-Premise
IPSS I-Premise
> I-Premise
13 I-Premise
( I-Premise
-6.7 I-Premise
± I-Premise
1.8 I-Premise
vs I-Premise
-4.0 I-Premise
± I-Premise
1.0 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
cumulative I-Premise
survival I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
recurrence I-Premise
was I-Premise
9/74 I-Premise
( I-Premise
12.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
6/92 I-Premise
( I-Premise
6.5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.937 I-Premise
) I-Premise
. I-Premise

A B-Premise
model I-Premise
measuring I-Premise
effectiveness I-Premise
of I-Premise
CCSP I-Premise
on I-Premise
QOL I-Premise
( I-Premise
total I-Premise
and I-Premise
subscale I-Premise
) I-Premise
at I-Premise
1-year I-Premise
follow-up I-Premise
showed I-Premise
that I-Premise
the I-Premise
CCSP I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
had I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
health I-Premise
and I-Premise
functioning I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
and I-Premise
socioeconomic I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
psychological/spiritual I-Premise
well-being I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
35 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
for I-Premise
appetite I-Premise
( I-Premise
P I-Premise
= I-Premise
.78 I-Premise
) I-Premise
or I-Premise
other I-Premise
symptoms I-Premise
, I-Premise
weight I-Premise
( I-Premise
P I-Premise
= I-Premise
.17 I-Premise
) I-Premise
, I-Premise
FAACT I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
.95 I-Premise
) I-Premise
, I-Premise
toxicity I-Premise
, I-Premise
or I-Premise
survival I-Premise
from I-Premise
baseline I-Premise
to I-Premise
day I-Premise
28 I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
severe I-Premise
ARSR I-Premise
( I-Premise
RTOG/EORTC I-Premise
grade I-Premise
≤2 I-Premise
) I-Premise
at I-Premise
the I-Premise
follow-up I-Premise
visit I-Premise
was I-Premise
23 I-Premise
% I-Premise
( I-Premise
n I-Premise
= I-Premise
45 I-Premise
) I-Premise
in I-Premise
the I-Premise
Calendula I-Premise
group I-Premise
and I-Premise
19 I-Premise
% I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
in I-Premise
the I-Premise
Essex I-Premise
group I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
better I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
only I-Premise
in I-Premise
the I-Premise
first I-Premise
year I-Premise
after I-Premise
surgery I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
QLQ-C30 I-Premise
subscales I-Premise
pain I-Premise
( I-Premise
P=0.12 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
P=0.068 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
P=0.074 I-Premise
) I-Premise
and I-Premise
the I-Premise
QLQ-MY24 I-Premise
item I-Premise
sick I-Premise
( I-Premise
P=0.086 I-Premise
) I-Premise
scored I-Premise
marginally I-Premise
better I-Premise
during I-Premise
thalidomide I-Premise
maintenance I-Premise
. I-Premise

At B-Premise
4 I-Premise
months I-Premise
, I-Premise
J-pouch I-Premise
patients I-Premise
had I-Premise
10.3 I-Premise
% I-Premise
less I-Premise
stool I-Premise
fragmentation I-Premise
but I-Premise
poorer I-Premise
stool I-Premise
deferment I-Premise
and I-Premise
more I-Premise
nocturnal I-Premise
leakage I-Premise
. I-Premise

We B-Premise
recorded I-Premise
the I-Premise
following I-Premise
pair-wise I-Premise
mean I-Premise
difference I-Premise
in I-Premise
change I-Premise
in I-Premise
IBDQ-B I-Premise
score I-Premise
between I-Premise
groups I-Premise
: I-Premise
nurse I-Premise
versus I-Premise
booklet I-Premise
4·12 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·04-8·19 I-Premise
";" I-Premise
p=0·04 I-Premise
) I-Premise
, I-Premise
gastroenterologist I-Premise
versus I-Premise
booklet I-Premise
5·47 I-Premise
( I-Premise
1·14-9·81 I-Premise
";" I-Premise
p=0·01 I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
34.6 I-Premise
% I-Premise
for I-Premise
NP I-Premise
and I-Premise
35.7 I-Premise
% I-Premise
for I-Premise
NIP I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
either I-Premise
docetaxel I-Premise
regimen I-Premise
had I-Premise
more I-Premise
favorable I-Premise
changes I-Premise
in I-Premise
performance I-Premise
status I-Premise
( I-Premise
P=0.065 I-Premise
for I-Premise
DC I-Premise
and I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
for I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
) I-Premise
and I-Premise
mean I-Premise
weight I-Premise
loss I-Premise
( I-Premise
0.06 I-Premise
kg I-Premise
, I-Premise
gain I-Premise
of I-Premise
0.08 I-Premise
kg I-Premise
, I-Premise
and I-Premise
2.27 I-Premise
kg I-Premise
for I-Premise
DC I-Premise
, I-Premise
DCb I-Premise
, I-Premise
and I-Premise
VC I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
for I-Premise
both I-Premise
DC I-Premise
versus I-Premise
VC I-Premise
and I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
) I-Premise
. I-Premise

Both B-Premise
epoetin I-Premise
beta I-Premise
regiments I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
and I-Premise
there I-Premise
were I-Premise
no I-Premise
dose-dependent I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Median B-Premise
overall I-Premise
survival I-Premise
was I-Premise
43.1 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
versus I-Premise
44.5 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
stratum-adjusted I-Premise
HR I-Premise
= I-Premise
1.01 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.86 I-Premise
to I-Premise
1.18 I-Premise
] I-Premise
";" I-Premise
P I-Premise
= I-Premise
.885 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
the I-Premise
proportion I-Premise
of I-Premise
NK I-Premise
cells I-Premise
, I-Premise
T-cell I-Premise
subgroups I-Premise
CD3+ I-Premise
, I-Premise
CD4+ I-Premise
and I-Premise
CD8+ I-Premise
had I-Premise
a I-Premise
significant I-Premise
change I-Premise
before I-Premise
and I-Premise
after I-Premise
treatment I-Premise
. I-Premise

This B-Premise
translated I-Premise
into I-Premise
a I-Premise
lower I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
experiencing I-Premise
moist I-Premise
desquamation I-Premise
during I-Premise
or I-Premise
up I-Premise
to I-Premise
6 I-Premise
weeks I-Premise
after I-Premise
their I-Premise
radiation I-Premise
treatment I-Premise
";" I-Premise
31.2 I-Premise
% I-Premise
with I-Premise
IMRT I-Premise
compared I-Premise
with I-Premise
47.8 I-Premise
% I-Premise
with I-Premise
standard I-Premise
treatment I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Six-month B-Premise
survival I-Premise
rates I-Premise
were I-Premise
41 I-Premise
% I-Premise
for I-Premise
octreotide I-Premise
patients I-Premise
and I-Premise
42 I-Premise
% I-Premise
for I-Premise
control I-Premise
patients I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
effects I-Premise
of I-Premise
ATP I-Premise
on I-Premise
body I-Premise
weight I-Premise
, I-Premise
muscle I-Premise
strength I-Premise
, I-Premise
and I-Premise
albumin I-Premise
concentration I-Premise
were I-Premise
especially I-Premise
marked I-Premise
in I-Premise
cachectic I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.0002 I-Premise
, I-Premise
P I-Premise
=.0001 I-Premise
, I-Premise
and I-Premise
P I-Premise
= I-Premise
. I-Premise
1 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
ATP I-Premise
versus I-Premise
no I-Premise
ATP I-Premise
) I-Premise
. I-Premise

The B-Premise
change I-Premise
in I-Premise
physical I-Premise
function I-Premise
( I-Premise
muscle I-Premise
strength I-Premise
∼11 I-Premise
% I-Premise
";" I-Premise
submaximal I-Premise
aerobic I-Premise
exercise I-Premise
capacity I-Premise
∼5 I-Premise
% I-Premise
and I-Premise
ambulation I-Premise
∼12 I-Premise
% I-Premise
) I-Premise
, I-Premise
physical I-Premise
activity I-Premise
level I-Premise
( I-Premise
∼24 I-Premise
% I-Premise
) I-Premise
and I-Premise
lean I-Premise
mass I-Premise
( I-Premise
∼3 I-Premise
% I-Premise
) I-Premise
differed I-Premise
significantly I-Premise
between I-Premise
groups I-Premise
following I-Premise
the I-Premise
intervention I-Premise
, I-Premise
with I-Premise
favorable I-Premise
changes I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
. I-Premise

Sertraline B-Premise
had I-Premise
no I-Premise
significant I-Premise
effect I-Premise
( I-Premise
scale I-Premise
, I-Premise
benefit I-Premise
over I-Premise
placebo I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
) I-Premise
on I-Premise
depression I-Premise
( I-Premise
CES-D I-Premise
0.4 I-Premise
[ I-Premise
-2.6 I-Premise
to I-Premise
3.4 I-Premise
] I-Premise
) I-Premise
, I-Premise
anxiety I-Premise
( I-Premise
HADS-A I-Premise
2.0 I-Premise
[ I-Premise
-1.5 I-Premise
to I-Premise
5.5 I-Premise
] I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
FACT-F I-Premise
0.3 I-Premise
[ I-Premise
-4.3 I-Premise
to I-Premise
4.9 I-Premise
] I-Premise
) I-Premise
, I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FACT-G I-Premise
1.7 I-Premise
[ I-Premise
-1.3 I-Premise
to I-Premise
4.7 I-Premise
] I-Premise
) I-Premise
, I-Premise
or I-Premise
clinicians I-Premise
' I-Premise
ratings I-Premise
( I-Premise
SQLI I-Premise
2.0 I-Premise
[ I-Premise
-2.5 I-Premise
to I-Premise
6.5 I-Premise
] I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
95 I-Premise
% I-Premise
CI I-Premise
ruled I-Premise
out I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
benefit I-Premise
for I-Premise
all I-Premise
main I-Premise
outcomes I-Premise
. I-Premise

No B-Premise
difference I-Premise
in I-Premise
the I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
( I-Premise
70 I-Premise
% I-Premise
vs. I-Premise
66 I-Premise
% I-Premise
) I-Premise
or I-Premise
median I-Premise
survival I-Premise
time I-Premise
( I-Premise
19.4 I-Premise
vs. I-Premise
17.4 I-Premise
months I-Premise
) I-Premise
between I-Premise
the I-Premise
surgery I-Premise
and I-Premise
RT I-Premise
arms I-Premise
. I-Premise

QOL B-Premise
decreased I-Premise
during I-Premise
the I-Premise
first I-Premise
8 I-Premise
weeks I-Premise
of I-Premise
treatment I-Premise
, I-Premise
and I-Premise
a I-Premise
partial I-Premise
recovery I-Premise
followed I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
subdomain I-Premise
( I-Premise
P=0.40 I-Premise
) I-Premise
between I-Premise
the I-Premise
two I-Premise
regimen I-Premise
. I-Premise

The B-Premise
mean I-Premise
cost I-Premise
per I-Premise
QALY I-Premise
gained I-Premise
with I-Premise
combination I-Premise
therapy I-Premise
was I-Premise
13,558 I-Premise
dollars I-Premise
( I-Premise
standard I-Premise
deviation I-Premise
, I-Premise
6742 I-Premise
dollars I-Premise
) I-Premise
. I-Premise

The B-Premise
main I-Premise
nonhematologic I-Premise
adverse I-Premise
effect I-Premise
was I-Premise
fatigue I-Premise
( I-Premise
grade I-Premise
3/4 I-Premise
in I-Premise
18 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise

Anemia B-Premise
was I-Premise
the I-Premise
most I-Premise
common I-Premise
hematological I-Premise
toxicity I-Premise
( I-Premise
88 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
ghrelin I-Premise
group I-Premise
had I-Premise
fewer I-Premise
adverse I-Premise
events I-Premise
during I-Premise
chemotherapy I-Premise
related I-Premise
to I-Premise
anorexia I-Premise
and I-Premise
nausea I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

No B-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
were I-Premise
evident I-Premise
with I-Premise
respect I-Premise
to I-Premise
quality I-Premise
of I-Premise
life I-Premise
according I-Premise
to I-Premise
the I-Premise
EORTC I-Premise
QLQ-protocol I-Premise
. I-Premise

Analysing B-Premise
response I-Premise
to I-Premise
FUFA I-Premise
and I-Premise
FOLFIRI I-Premise
in I-Premise
the I-Premise
per I-Premise
protocol I-Premise
set I-Premise
( I-Premise
n=119 I-Premise
) I-Premise
after I-Premise
un-blinding I-Premise
TS I-Premise
in I-Premise
the I-Premise
data I-Premise
base I-Premise
revealed I-Premise
a I-Premise
trend I-Premise
to I-Premise
better I-Premise
overall I-Premise
response I-Premise
to I-Premise
FOLFIRI I-Premise
( I-Premise
9/19 I-Premise
, I-Premise
47 I-Premise
% I-Premise
) I-Premise
in I-Premise
TS I-Premise
high I-Premise
compared I-Premise
to I-Premise
FUFA I-Premise
( I-Premise
5/23 I-Premise
, I-Premise
22 I-Premise
% I-Premise
, I-Premise
p=0.077 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
docetaxel-carboplatin I-Premise
was I-Premise
associated I-Premise
with I-Premise
substantially I-Premise
less I-Premise
overall I-Premise
and I-Premise
grade I-Premise
2 I-Premise
or I-Premise
higher I-Premise
neurotoxicity I-Premise
than I-Premise
paclitaxel-carboplatin I-Premise
( I-Premise
grade I-Premise
> I-Premise
or I-Premise
2 I-Premise
neurosensory I-Premise
toxicity I-Premise
in I-Premise
11 I-Premise
% I-Premise
versus I-Premise
30 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
19 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
15 I-Premise
% I-Premise
to I-Premise
24 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
grade I-Premise
> I-Premise
or I-Premise
2 I-Premise
neuromotor I-Premise
toxicity I-Premise
in I-Premise
3 I-Premise
% I-Premise
versus I-Premise
7 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
4 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1 I-Premise
% I-Premise
to I-Premise
7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
fludarabine I-Premise
had I-Premise
higher I-Premise
scores I-Premise
for I-Premise
social I-Premise
function I-Premise
( I-Premise
P I-Premise
=.008 I-Premise
) I-Premise
";" I-Premise
no B-Premise
other I-Premise
differences I-Premise
in I-Premise
QoL I-Premise
were I-Premise
detected I-Premise
. I-Premise

As B-Premise
reflected I-Premise
in I-Premise
the I-Premise
hot I-Premise
flashes I-Premise
scores I-Premise
, I-Premise
patients I-Premise
in I-Premise
all I-Premise
three I-Premise
treatment I-Premise
groups I-Premise
experienced I-Premise
induced I-Premise
amenorrhea I-Premise
, I-Premise
but B-Premise
the I-Premise
onset I-Premise
of I-Premise
ovarian I-Premise
function I-Premise
suppression I-Premise
was I-Premise
slightly I-Premise
delayed I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
chemotherapy I-Premise
. I-Premise

We B-Premise
found I-Premise
no I-Premise
difference I-Premise
in I-Premise
follow-up I-Premise
costs I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
noted I-Premise
in I-Premise
the I-Premise
distress I-Premise
levels I-Premise
before I-Premise
and I-Premise
after I-Premise
completion I-Premise
of I-Premise
the I-Premise
study I-Premise
in I-Premise
the I-Premise
three I-Premise
groups I-Premise
. I-Premise

Nine B-Premise
CR I-Premise
and I-Premise
twenty-seven I-Premise
PR I-Premise
were I-Premise
obtained I-Premise
on I-Premise
one I-Premise
hundred I-Premise
eleven I-Premise
evaluable I-Premise
patients I-Premise
treated I-Premise
in I-Premise
experimental I-Premise
arm I-Premise
( I-Premise
RR I-Premise
= I-Premise
32 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
) I-Premise
: I-Premise
24 I-Premise
% I-Premise
-42 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
two I-Premise
CR I-Premise
and I-Premise
eleven I-Premise
PR I-Premise
were I-Premise
observed I-Premise
among I-Premise
one I-Premise
hundred I-Premise
three I-Premise
evaluable I-Premise
patients I-Premise
in I-Premise
control I-Premise
arm I-Premise
( I-Premise
RR I-Premise
= I-Premise
13 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
7 I-Premise
% I-Premise
-21 I-Premise
% I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
significantly I-Premise
shorter I-Premise
in I-Premise
the I-Premise
SN I-Premise
group I-Premise
( I-Premise
5.6 I-Premise
months I-Premise
compared I-Premise
with I-Premise
9 I-Premise
months I-Premise
, I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
1.6 I-Premise
) I-Premise
";" I-Premise
however B-Premise
, I-Premise
this I-Premise
difference I-Premise
may I-Premise
be I-Premise
attributable I-Premise
to I-Premise
the I-Premise
coincidental I-Premise
early I-Premise
death I-Premise
of I-Premise
three I-Premise
patients I-Premise
in I-Premise
the I-Premise
SN I-Premise
group I-Premise
. I-Premise

No B-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
was I-Premise
observed I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
activity I-Premise
level I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
and I-Premise
psychological I-Premise
distress I-Premise
, I-Premise
as I-Premise
recorded I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
severe I-Premise
neutropenia I-Premise
( I-Premise
34 I-Premise
% I-Premise
versus I-Premise
68 I-Premise
% I-Premise
";" I-Premise
p=0.0001 I-Premise
) I-Premise
and I-Premise
of I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
5 I-Premise
% I-Premise
versus I-Premise
12 I-Premise
% I-Premise
";" I-Premise
p=0.026 I-Premise
) I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
the I-Premise
rate I-Premise
of I-Premise
therapy I-Premise
omissions I-Premise
( I-Premise
10 I-Premise
% I-Premise
versus I-Premise
24 I-Premise
% I-Premise
";" I-Premise
p=0.0037 I-Premise
) I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
weekly I-Premise
VNR/CDDP I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
one I-Premise
. I-Premise

Patients B-Premise
allocated I-Premise
to I-Premise
oxaliplatin I-Premise
plus I-Premise
LV5FU2 I-Premise
had I-Premise
significantly I-Premise
longer I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
median I-Premise
, I-Premise
9.0 I-Premise
v I-Premise
6.2 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.0003 I-Premise
) I-Premise
and I-Premise
better I-Premise
response I-Premise
rate I-Premise
( I-Premise
50.7 I-Premise
% I-Premise
v I-Premise
22.3 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
when I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
arm I-Premise
. I-Premise

A B-Premise
small I-Premise
decline I-Premise
in I-Premise
visual I-Premise
analogue I-Premise
scale I-Premise
scores I-Premise
was I-Premise
observed I-Premise
( I-Premise
70.7 I-Premise
vs. I-Premise
68.2 I-Premise
, I-Premise
P=0.026 I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
4-year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
78.1 I-Premise
% I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
versus I-Premise
71.4 I-Premise
% I-Premise
with I-Premise
CAF I-Premise
( I-Premise
P I-Premise
= I-Premise
.10 I-Premise
, I-Premise
two-sided I-Premise
";" I-Premise
P I-Premise
= I-Premise
.05 I-Premise
, I-Premise
one-sided I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
with I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
24 I-Premise
% I-Premise
versus I-Premise
5 I-Premise
% I-Premise
";" I-Premise
p=0.0025 I-Premise
) I-Premise
. I-Premise

When B-Premise
the I-Premise
two I-Premise
exercise I-Premise
groups I-Premise
were I-Premise
compared I-Premise
, I-Premise
there I-Premise
were I-Premise
significant I-Premise
differences I-Premise
in I-Premise
6MWT I-Premise
in I-Premise
pilates-exercise I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

At B-Premise
6-month I-Premise
follow-up I-Premise
, I-Premise
AET I-Premise
was I-Premise
still I-Premise
borderline I-Premise
or I-Premise
significantly I-Premise
superior I-Premise
to I-Premise
UC I-Premise
for I-Premise
overall I-Premise
QoL I-Premise
( I-Premise
P I-Premise
= I-Premise
.054 I-Premise
) I-Premise
, I-Premise
happiness I-Premise
( I-Premise
P I-Premise
= I-Premise
.034 I-Premise
) I-Premise
, I-Premise
and I-Premise
depression I-Premise
( I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
without I-Premise
an I-Premise
increased I-Premise
risk I-Premise
of I-Premise
disease I-Premise
recurrence/progression I-Premise
. I-Premise

When B-Premise
adjusted I-Premise
for I-Premise
Okuda I-Premise
, I-Premise
CTP I-Premise
, I-Premise
and I-Premise
Cancer I-Premise
of I-Premise
the I-Premise
Liver I-Premise
Italian I-Premise
Program I-Premise
( I-Premise
CLIP I-Premise
) I-Premise
scores I-Premise
, I-Premise
the I-Premise
relative I-Premise
risk I-Premise
for I-Premise
octreotide I-Premise
did I-Premise
not I-Premise
change I-Premise
markedly I-Premise
and I-Premise
was I-Premise
1.05 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.71-1.55 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.83 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
time I-Premise
was I-Premise
53.6 I-Premise
months I-Premise
for I-Premise
women I-Premise
with I-Premise
decreasing I-Premise
CES-D I-Premise
scores I-Premise
over I-Premise
1 I-Premise
year I-Premise
and I-Premise
25.1 I-Premise
months I-Premise
for I-Premise
women I-Premise
with I-Premise
increasing I-Premise
CES-D I-Premise
scores I-Premise
. I-Premise

Complete B-Premise
or I-Premise
partial I-Premise
responses I-Premise
were I-Premise
achieved I-Premise
by I-Premise
12 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
plus I-Premise
13-CRA I-Premise
and I-Premise
6 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
( I-Premise
P I-Premise
=.14 I-Premise
) I-Premise
. I-Premise

For B-Premise
astrocytoma I-Premise
grade I-Premise
III I-Premise
the I-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
10.6 I-Premise
( I-Premise
1.3-92.7 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
radiotherapy I-Premise
only I-Premise
group I-Premise
and I-Premise
17.3 I-Premise
( I-Premise
0.4-96.9+ I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
estramustine I-Premise
+ I-Premise
radiotherapy I-Premise
group I-Premise
. I-Premise

A B-Premise
significantly I-Premise
lower I-Premise
serum I-Premise
interleukin-6 I-Premise
level I-Premise
was I-Premise
found I-Premise
in I-Premise
comparing I-Premise
glutamine-enriched I-Premise
with I-Premise
standard I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
but B-Premise
not I-Premise
in I-Premise
interleukin-10 I-Premise
( I-Premise
P I-Premise
= I-Premise
0.374 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-α I-Premise
levels I-Premise
( I-Premise
P I-Premise
= I-Premise
0.653 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
other I-Premise
treatment-related I-Premise
side I-Premise
effects I-Premise
between I-Premise
groups I-Premise
. I-Premise

These B-Premise
effects I-Premise
remained I-Premise
when I-Premise
statistically I-Premise
controlling I-Premise
for I-Premise
baseline I-Premise
levels I-Premise
of I-Premise
distress I-Premise
, I-Premise
immunity I-Premise
, I-Premise
and I-Premise
health I-Premise
as I-Premise
well I-Premise
as I-Premise
sociodemographic I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
cancer I-Premise
treatment I-Premise
variables I-Premise
. I-Premise

TSS B-Premise
improved I-Premise
in I-Premise
49 I-Premise
patients I-Premise
( I-Premise
77 I-Premise
% I-Premise
) I-Premise
on I-Premise
regimen I-Premise
1 I-Premise
, I-Premise
and I-Premise
in I-Premise
57 I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
patients I-Premise
on I-Premise
regimen I-Premise
2 I-Premise
, I-Premise
a I-Premise
difference I-Premise
of I-Premise
15 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
3-28 I-Premise
) I-Premise
in I-Premise
the I-Premise
proportion I-Premise
improving I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
. I-Premise

Upon B-Premise
the I-Premise
completion I-Premise
of I-Premise
PMP I-Premise
, I-Premise
pain I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
reduced I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
yet B-Premise
patients I-Premise
in I-Premise
the I-Premise
experimental I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
the I-Premise
use I-Premise
of I-Premise
PRN I-Premise
analgesics I-Premise
and I-Premise
nonpharmacological I-Premise
strategies I-Premise
to I-Premise
relieve I-Premise
pain I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
reduce I-Premise
barriers I-Premise
to I-Premise
managing I-Premise
their I-Premise
cancer I-Premise
pain I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
> I-Premise
/= I-Premise
grade I-Premise
3 I-Premise
esophagitis I-Premise
was I-Premise
30 I-Premise
% I-Premise
with I-Premise
AM I-Premise
versus I-Premise
34 I-Premise
% I-Premise
without I-Premise
AM I-Premise
( I-Premise
P I-Premise
= I-Premise
.9 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
functional I-Premise
outcome I-Premise
, I-Premise
morbidity I-Premise
, I-Premise
or I-Premise
QOL I-Premise
between I-Premise
LRP I-Premise
and I-Premise
ORP I-Premise
. I-Premise

Dizziness B-Premise
( I-Premise
3.1 I-Premise
% I-Premise
vs. I-Premise
5.4 I-Premise
% I-Premise
) I-Premise
and I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
1.2 I-Premise
% I-Premise
vs. I-Premise
5.2 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
less I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise

Although B-Premise
improvements I-Premise
in I-Premise
the I-Premise
UC I-Premise
group I-Premise
occurred I-Premise
by I-Premise
12-months I-Premise
post-surgery I-Premise
, I-Premise
the B-Premise
change I-Premise
did I-Premise
not I-Premise
meet I-Premise
the I-Premise
clinically I-Premise
relevant I-Premise
threshold I-Premise
. I-Premise

Intent-to-treat B-Premise
analysis I-Premise
showed I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
three I-Premise
arms I-Premise
for I-Premise
appetite I-Premise
, I-Premise
QOL I-Premise
, I-Premise
or I-Premise
cannabinoid-related I-Premise
toxicity I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
8 I-Premise
years I-Premise
, I-Premise
the I-Premise
5-year I-Premise
overall I-Premise
survival I-Premise
was I-Premise
68 I-Premise
% I-Premise
( I-Premise
+/- I-Premise
3 I-Premise
% I-Premise
standard I-Premise
error I-Premise
of I-Premise
the I-Premise
mean I-Premise
( I-Premise
SEM I-Premise
) I-Premise
and I-Premise
the I-Premise
5-year I-Premise
event-free I-Premise
survival I-Premise
53 I-Premise
% I-Premise
( I-Premise
+/- I-Premise
4 I-Premise
% I-Premise
SEM I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
evaluated I-Premise
6 I-Premise
months I-Premise
after I-Premise
random I-Premise
assignment I-Premise
using I-Premise
the I-Premise
30-item I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
Questionnaire I-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
of I-Premise
randomly I-Premise
assigned I-Premise
patients I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
in I-Premise
disease-free I-Premise
survival I-Premise
( I-Premise
DFS I-Premise
) I-Premise
( I-Premise
2-year I-Premise
DFS I-Premise
79.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
76.4 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.527 I-Premise
) I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
( I-Premise
2-year I-Premise
OS I-Premise
83.1 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
84.3 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.925 I-Premise
) I-Premise
. I-Premise

Postoperative B-Premise
side I-Premise
effects I-Premise
were I-Premise
significantly I-Premise
less I-Premise
in I-Premise
the I-Premise
SLN I-Premise
group I-Premise
and I-Premise
there I-Premise
was I-Premise
no I-Premise
negative I-Premise
impact I-Premise
of I-Premise
the I-Premise
SLN I-Premise
procedure I-Premise
on I-Premise
psychologic I-Premise
well I-Premise
being I-Premise
. I-Premise

Mean B-Premise
physical I-Premise
function I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
66 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
62·9-70·0 I-Premise
) I-Premise
in I-Premise
the I-Premise
90 I-Premise
mg I-Premise
group I-Premise
and I-Premise
68 I-Premise
points I-Premise
( I-Premise
64·6-71·4 I-Premise
) I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
of I-Premise
difference I-Premise
-6·6 I-Premise
to I-Premise
3·3 I-Premise
";" I-Premise
p=0·52 I-Premise
) I-Premise
. I-Premise

A B-Premise
higher I-Premise
rate I-Premise
of I-Premise
persistent I-Premise
thyroid I-Premise
remnants I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
rhTSH I-Premise
arm I-Premise
, I-Premise
although B-Premise
in I-Premise
most I-Premise
cases I-Premise
uptake I-Premise
was I-Premise
< I-Premise
0.1 I-Premise
% I-Premise
and I-Premise
of I-Premise
no I-Premise
clinical I-Premise
significance I-Premise
. I-Premise

QoL B-Premise
was I-Premise
better I-Premise
preserved I-Premise
in I-Premise
rhTSH I-Premise
Group I-Premise
than I-Premise
in I-Premise
T4-WD I-Premise
and I-Premise
T3-WD I-Premise
Groups I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
42 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
( I-Premise
11 I-Premise
months I-Premise
v I-Premise
9.1 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
and I-Premise
TFS I-Premise
( I-Premise
15 I-Premise
months I-Premise
v I-Premise
11 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
were I-Premise
superior I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
fludarabine I-Premise
. I-Premise

In B-Premise
the I-Premise
IAD I-Premise
group I-Premise
, I-Premise
a I-Premise
similar I-Premise
trend I-Premise
was I-Premise
seen I-Premise
. I-Premise

In B-Premise
a I-Premise
multinational I-Premise
trial I-Premise
of I-Premise
anaemic I-Premise
patients I-Premise
with I-Premise
cancer I-Premise
receiving I-Premise
nonplatinum-containing I-Premise
chemotherapy I-Premise
, I-Premise
epoetin-alfa I-Premise
effectively I-Premise
increased I-Premise
haemoglobin I-Premise
levels I-Premise
, I-Premise
reduced I-Premise
red I-Premise
blood I-Premise
cell I-Premise
transfusion I-Premise
requirements I-Premise
, I-Premise
and I-Premise
improved I-Premise
QOL I-Premise
. I-Premise

These B-Premise
changes I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
indicating I-Premise
that I-Premise
acupuncture I-Premise
was I-Premise
as I-Premise
effective I-Premise
as I-Premise
venlafaxine I-Premise
. I-Premise

In B-Premise
the I-Premise
whole I-Premise
population I-Premise
of I-Premise
patients I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
with I-Premise
a I-Premise
PS I-Premise
of I-Premise
0-1 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Breast B-Premise
symptoms I-Premise
increased I-Premise
for I-Premise
both I-Premise
groups I-Premise
during I-Premise
radiotherapy I-Premise
, I-Premise
without I-Premise
loss I-Premise
of I-Premise
strength I-Premise
or I-Premise
range I-Premise
of I-Premise
movement I-Premise
. I-Premise

In B-Premise
the I-Premise
pamidronate I-Premise
group I-Premise
, I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
hypercalcemia I-Premise
, I-Premise
severe I-Premise
bone I-Premise
pain I-Premise
, I-Premise
and I-Premise
symptomatic I-Premise
impending I-Premise
fractures I-Premise
decreased I-Premise
by I-Premise
65 I-Premise
% I-Premise
, I-Premise
30 I-Premise
% I-Premise
, I-Premise
and I-Premise
50 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
event-rates I-Premise
of I-Premise
systemic I-Premise
treatment I-Premise
and I-Premise
radiotherapy I-Premise
decreased I-Premise
by I-Premise
35 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

Thalidomide B-Premise
was I-Premise
associated I-Premise
with I-Premise
an I-Premise
increased I-Premise
risk I-Premise
of I-Premise
having I-Premise
a I-Premise
thrombotic I-Premise
event I-Premise
, I-Premise
mainly I-Premise
pulmonary I-Premise
embolus I-Premise
and I-Premise
deep I-Premise
vein I-Premise
thrombosis I-Premise
( I-Premise
19 I-Premise
% I-Premise
thalidomide I-Premise
vs I-Premise
10 I-Premise
% I-Premise
placebo I-Premise
";" I-Premise
HR I-Premise
= I-Premise
2.13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1.41 I-Premise
to I-Premise
3.20 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
HRQoL I-Premise
between I-Premise
nurse-led I-Premise
telephone I-Premise
and I-Premise
hospital I-Premise
follow-up I-Premise
at I-Premise
12 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
( I-Premise
p I-Premise
= I-Premise
0.42 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
for I-Premise
difference I-Premise
: I-Premise
-1.93-4.64 I-Premise
) I-Premise
and I-Premise
neither I-Premise
between I-Premise
follow-up I-Premise
with I-Premise
or I-Premise
without I-Premise
EGP I-Premise
( I-Premise
p I-Premise
= I-Premise
0.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
for I-Premise
difference I-Premise
: I-Premise
-3.59-3.00 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
hematologic I-Premise
toxicity I-Premise
did I-Premise
not I-Premise
exceed I-Premise
15 I-Premise
% I-Premise
in I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

Results B-Premise
showed I-Premise
improved I-Premise
patient I-Premise
depression I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
the I-Premise
intervention I-Premise
and I-Premise
improvement I-Premise
in I-Premise
both I-Premise
groups I-Premise
in I-Premise
patients I-Premise
' I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Men B-Premise
with I-Premise
prostate I-Premise
cancer I-Premise
and I-Premise
their I-Premise
spouses I-Premise
reported I-Premise
positive I-Premise
outcomes I-Premise
from I-Premise
a I-Premise
family I-Premise
intervention I-Premise
that I-Premise
offered I-Premise
them I-Premise
information I-Premise
and I-Premise
support I-Premise
. I-Premise

Intervention B-Premise
patients I-Premise
also I-Premise
experienced I-Premise
greater I-Premise
remission I-Premise
rates I-Premise
( I-Premise
P I-Premise
= I-Premise
0.031 I-Premise
) I-Premise
, I-Premise
more I-Premise
depression-free I-Premise
days I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
less I-Premise
functional I-Premise
impairment I-Premise
( I-Premise
P I-Premise
= I-Premise
0.011 I-Premise
) I-Premise
, I-Premise
and I-Premise
greater I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
0.039 I-Premise
) I-Premise
at I-Premise
12 I-Premise
months I-Premise
than I-Premise
usual I-Premise
care I-Premise
participants I-Premise
. I-Premise

The B-Premise
additional I-Premise
charge I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
was I-Premise
$ I-Premise
1,748 I-Premise
per I-Premise
patient I-Premise
randomized I-Premise
( I-Premise
$ I-Premise
1,194 I-Premise
the I-Premise
result I-Premise
of I-Premise
surgical I-Premise
instruments I-Premise
and I-Premise
$ I-Premise
554 I-Premise
the I-Premise
result I-Premise
of I-Premise
longer I-Premise
operative I-Premise
time I-Premise
) I-Premise
. I-Premise

Tamoxifen B-Premise
reduced I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
estrogen I-Premise
receptor-positive I-Premise
tumors I-Premise
by I-Premise
69 I-Premise
% I-Premise
, I-Premise
but I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
estrogen I-Premise
receptor-negative I-Premise
tumors I-Premise
was I-Premise
seen I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
numbers I-Premise
of I-Premise
breast I-Premise
or I-Premise
other I-Premise
cancers I-Premise
( I-Premise
22 I-Premise
v I-Premise
25 I-Premise
, I-Premise
hazard I-Premise
ratio I-Premise
0.88 I-Premise
( I-Premise
0.49 I-Premise
to I-Premise
1.56 I-Premise
) I-Premise
) I-Premise
, I-Premise
cerebrovascular I-Premise
events I-Premise
( I-Premise
14 I-Premise
v I-Premise
19 I-Premise
, I-Premise
0.73 I-Premise
( I-Premise
0.37 I-Premise
to I-Premise
1.46 I-Premise
) I-Premise
) I-Premise
, I-Premise
fractures I-Premise
( I-Premise
40 I-Premise
v I-Premise
58 I-Premise
, I-Premise
0.69 I-Premise
( I-Premise
0.46 I-Premise
to I-Premise
1.03 I-Premise
) I-Premise
) I-Premise
, I-Premise
and I-Premise
overall I-Premise
deaths I-Premise
( I-Premise
8 I-Premise
v I-Premise
5 I-Premise
, I-Premise
1.60 I-Premise
( I-Premise
0.52 I-Premise
to I-Premise
4.89 I-Premise
) I-Premise
) I-Premise
. I-Premise

Treatment-related B-Premise
mortality I-Premise
occurred I-Premise
in I-Premise
five I-Premise
patients I-Premise
( I-Premise
5.3 I-Premise
% I-Premise
) I-Premise
receiving I-Premise
irinotecan I-Premise
weekly I-Premise
and I-Premise
three I-Premise
patients I-Premise
( I-Premise
1.6 I-Premise
% I-Premise
) I-Premise
given I-Premise
therapy I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.12 I-Premise
) I-Premise
. I-Premise

Intention-to-treat B-Premise
analysis I-Premise
based I-Premise
on I-Premise
participants I-Premise
with I-Premise
follow-up I-Premise
data I-Premise
indicated I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
total I-Premise
exercise I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
recommendation-only I-Premise
group I-Premise
over I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
3.4 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
0.7-6.1 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
p I-Premise
= I-Premise
.011 I-Premise
) I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
exemestane I-Premise
was I-Premise
associated I-Premise
with I-Premise
fewer I-Premise
hot I-Premise
flashes I-Premise
and I-Premise
less I-Premise
vaginal I-Premise
discharge I-Premise
than I-Premise
tamoxifen I-Premise
, I-Premise
but I-Premise
with I-Premise
more I-Premise
vaginal I-Premise
dryness I-Premise
, I-Premise
bone/muscle I-Premise
aches I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
sleeping I-Premise
. I-Premise

Among B-Premise
patients I-Premise
with I-Premise
limited-stage I-Premise
disease I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
survival I-Premise
difference I-Premise
( I-Premise
HR I-Premise
for I-Premise
death I-Premise
= I-Premise
0.91 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.73 I-Premise
to I-Premise
1.15 I-Premise
) I-Premise
, I-Premise
but B-Premise
among I-Premise
patients I-Premise
with I-Premise
extensive I-Premise
disease I-Premise
, I-Premise
survival I-Premise
was I-Premise
worse I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
( I-Premise
HR I-Premise
for I-Premise
death I-Premise
= I-Premise
1.36 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1.10 I-Premise
to I-Premise
1.68 I-Premise
) I-Premise
. I-Premise

Postoperative B-Premise
morbidity I-Premise
rate I-Premise
was I-Premise
28.9 I-Premise
percent I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
vs. I-Premise
40 I-Premise
percent I-Premise
in I-Premise
the I-Premise
open I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.18 I-Premise
) I-Premise
. I-Premise

Incidence B-Premise
of I-Premise
adverse I-Premise
events I-Premise
was I-Premise
consistent I-Premise
with I-Premise
previously I-Premise
reported I-Premise
rates I-Premise
. I-Premise

However B-Premise
, I-Premise
utilization I-Premise
of I-Premise
ED I-Premise
treatments I-Premise
increased I-Premise
from I-Premise
31 I-Premise
% I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
study I-Premise
entry I-Premise
to I-Premise
49 I-Premise
% I-Premise
at I-Premise
the I-Premise
6-month I-Premise
follow-up I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
. I-Premise

This B-Premise
revealed I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
median I-Premise
survival I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
patients I-Premise
on I-Premise
the I-Premise
placebo I-Premise
arm I-Premise
of I-Premise
the I-Premise
trial I-Premise
( I-Premise
63 I-Premise
v I-Premise
129 I-Premise
days I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.84 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

AET B-Premise
did I-Premise
not I-Premise
interfere I-Premise
with I-Premise
chemotherapy I-Premise
completion I-Premise
rate I-Premise
or I-Premise
treatment I-Premise
response I-Premise
. I-Premise

The B-Premise
sample I-Premise
size I-Premise
was I-Premise
small I-Premise
, I-Premise
and I-Premise
patients I-Premise
applied I-Premise
a I-Premise
small I-Premise
amount I-Premise
of I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
half I-Premise
a I-Premise
sachet I-Premise
) I-Premise
to I-Premise
a I-Premise
large I-Premise
surface I-Premise
area I-Premise
. I-Premise

Considering B-Premise
the I-Premise
short-term I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
the I-Premise
administration I-Premise
of I-Premise
GM-CSF I-Premise
resulted I-Premise
in I-Premise
more I-Premise
problems I-Premise
with I-Premise
regard I-Premise
to I-Premise
depressed I-Premise
mood I-Premise
, I-Premise
diarrhoea I-Premise
and I-Premise
rash/eczema I-Premise
. I-Premise

The B-Premise
relative I-Premise
hazard I-Premise
of I-Premise
death I-Premise
for I-Premise
vinorelbine-treated I-Premise
patients I-Premise
was I-Premise
0.65 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.45-0.93 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
early I-Premise
alternating I-Premise
chemotherapy I-Premise
rated I-Premise
their I-Premise
tumor I-Premise
symptoms I-Premise
, I-Premise
functional I-Premise
states I-Premise
, I-Premise
fatigue/malaise I-Premise
and I-Premise
restriction I-Premise
of I-Premise
social I-Premise
activity I-Premise
significantly I-Premise
better I-Premise
, I-Premise
reflecting I-Premise
an I-Premise
improved I-Premise
subjective I-Premise
adjustment I-Premise
. I-Premise

For B-Premise
patients I-Premise
with I-Premise
ER-negative I-Premise
tumors I-Premise
, I-Premise
the I-Premise
addition I-Premise
of I-Premise
CMF I-Premise
statistically I-Premise
significantly I-Premise
improved I-Premise
DFS I-Premise
( I-Premise
5-year I-Premise
DFS I-Premise
= I-Premise
84 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
69 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
15 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
6 I-Premise
% I-Premise
to I-Premise
24 I-Premise
% I-Premise
";" I-Premise
risk I-Premise
ratio I-Premise
[ I-Premise
RR I-Premise
] I-Premise
= I-Premise
0.52 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.34 I-Premise
to I-Premise
0.79 I-Premise
";" I-Premise
P I-Premise
=.003 I-Premise
) I-Premise
and I-Premise
OS I-Premise
( I-Premise
5-year I-Premise
OS I-Premise
= I-Premise
89 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
81 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
8 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0 I-Premise
% I-Premise
to I-Premise
16 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.51 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.30 I-Premise
to I-Premise
0.87 I-Premise
";" I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
reduction I-Premise
in I-Premise
AK I-Premise
count I-Premise
was I-Premise
59.2 I-Premise
% I-Premise
for I-Premise
ALA-PDT I-Premise
and I-Premise
41.4 I-Premise
% I-Premise
for I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
p I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

When B-Premise
combined I-Premise
hormone I-Premise
therapy I-Premise
( I-Premise
n=2196 I-Premise
) I-Premise
was I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
n=2189 I-Premise
) I-Premise
, I-Premise
there I-Premise
was I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
the I-Premise
number I-Premise
of I-Premise
major I-Premise
cardiovascular I-Premise
events I-Premise
( I-Premise
7 I-Premise
v I-Premise
0 I-Premise
, I-Premise
P=0.016 I-Premise
) I-Premise
and I-Premise
venous I-Premise
thromboembolisms I-Premise
( I-Premise
22 I-Premise
v I-Premise
3 I-Premise
, I-Premise
hazard I-Premise
ratio I-Premise
7.36 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
2.20 I-Premise
to I-Premise
24.60 I-Premise
) I-Premise
) I-Premise
. I-Premise

Similarly B-Premise
, I-Premise
both I-Premise
groups I-Premise
showed I-Premise
a I-Premise
decline I-Premise
in I-Premise
physical I-Premise
and I-Premise
functional I-Premise
well I-Premise
being I-Premise
but I-Premise
recovered I-Premise
in I-Premise
the I-Premise
3 I-Premise
months I-Premise
posttreatment I-Premise
follow-up I-Premise
, I-Premise
with I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
exhibiting I-Premise
speedier I-Premise
recovery I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
G1 I-Premise
patients I-Premise
maintained/improved I-Premise
function I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
and I-Premise
single-item I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
.02 I-Premise
) I-Premise
";" I-Premise
in I-Premise
G2 I-Premise
, I-Premise
only I-Premise
few I-Premise
function I-Premise
and I-Premise
symptom I-Premise
scales I-Premise
improved I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
in I-Premise
G3 I-Premise
, I-Premise
QoL I-Premise
remained I-Premise
as I-Premise
poor I-Premise
as I-Premise
after I-Premise
radiotherapy I-Premise
. I-Premise

LV5FU2 B-Premise
plus I-Premise
oxaliplatin I-Premise
gave I-Premise
higher I-Premise
frequencies I-Premise
of I-Premise
National I-Premise
Cancer I-Premise
Institute I-Premise
common I-Premise
toxicity I-Premise
criteria I-Premise
grade I-Premise
3/4 I-Premise
neutropenia I-Premise
( I-Premise
41 I-Premise
. I-Premise
7 I-Premise
% I-Premise
v I-Premise
5.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
, I-Premise
grade I-Premise
3/4 I-Premise
diarrhea I-Premise
( I-Premise
11.9 I-Premise
% I-Premise
v I-Premise
5.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
neurosensory I-Premise
toxicity I-Premise
( I-Premise
18.2 I-Premise
% I-Premise
v I-Premise
0 I-Premise
% I-Premise
) I-Premise
, I-Premise
but I-Premise
this I-Premise
did I-Premise
not I-Premise
result I-Premise
in I-Premise
impairment I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
QoL I-Premise
) I-Premise
. I-Premise

Arm B-Premise
volume I-Premise
measured I-Premise
by I-Premise
water I-Premise
displacement I-Premise
was I-Premise
correlated I-Premise
with I-Premise
calculated I-Premise
arm I-Premise
volume I-Premise
( I-Premise
r I-Premise
=.973 I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
although B-Premise
the I-Premise
exercise I-Premise
and I-Premise
control I-Premise
group I-Premise
means I-Premise
were I-Premise
significantly I-Premise
different I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Intrusions B-Premise
were I-Premise
not I-Premise
associated I-Premise
with I-Premise
the I-Premise
trajectory I-Premise
of I-Premise
fatigue I-Premise
, I-Premise
sleep I-Premise
, I-Premise
breast I-Premise
cancer-specific I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
mental I-Premise
functioning I-Premise
";" I-Premise
women B-Premise
with I-Premise
higher I-Premise
intrusions I-Premise
at I-Premise
baseline I-Premise
started I-Premise
worse I-Premise
and I-Premise
remained I-Premise
worse I-Premise
over I-Premise
time I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
toxicity I-Premise
. I-Premise

Pairwise B-Premise
comparisons I-Premise
revealed I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
at I-Premise
90 I-Premise
days I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
but B-Premise
not I-Premise
at I-Premise
1 I-Premise
year I-Premise
( I-Premise
P I-Premise
= I-Premise
.052 I-Premise
) I-Premise
. I-Premise

Reported B-Premise
adverse I-Premise
events I-Premise
were I-Premise
similar I-Premise
between I-Premise
groups I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
adverse I-Premise
reactions I-Premise
, I-Premise
including I-Premise
white I-Premise
blood I-Premise
cell I-Premise
reduction I-Premise
, I-Premise
lower I-Premise
platelet I-Premise
count I-Premise
, I-Premise
lower I-Premise
hemoglobin I-Premise
, I-Premise
and I-Premise
hair I-Premise
loss I-Premise
in I-Premise
the I-Premise
PP I-Premise
group I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
GP I-Premise
group I-Premise
. I-Premise

The B-Premise
weekly I-Premise
VNR/CDDP I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
lower I-Premise
received I-Premise
dose I-Premise
intensity I-Premise
in I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
fashion I-Premise
( I-Premise
9 I-Premise
% I-Premise
versus I-Premise
22 I-Premise
% I-Premise
";" I-Premise
p=0.0001 I-Premise
) I-Premise
and I-Premise
with I-Premise
a I-Premise
lower I-Premise
non-statistically I-Premise
significant I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
as I-Premise
compared I-Premise
to I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
schedule I-Premise
. I-Premise

Despite B-Premise
difficulties I-Premise
in I-Premise
carrying I-Premise
out I-Premise
and I-Premise
analysing I-Premise
QoL I-Premise
items I-Premise
in I-Premise
such I-Premise
patients I-Premise
, I-Premise
the I-Premise
global I-Premise
QoL I-Premise
evaluated I-Premise
by I-Premise
the I-Premise
Spitzer I-Premise
's I-Premise
questionnaire I-Premise
suggested I-Premise
an I-Premise
advantage I-Premise
for I-Premise
MVC I-Premise
regimen I-Premise
( I-Premise
P=0.05 I-Premise
) I-Premise
and I-Premise
a I-Premise
significant I-Premise
difference I-Premise
was I-Premise
observed I-Premise
in I-Premise
global I-Premise
health I-Premise
subdomain I-Premise
( I-Premise
P=0.04 I-Premise
) I-Premise
. I-Premise

Fifty-nine B-Premise
percent I-Premise
of I-Premise
those I-Premise
initially I-Premise
receiving I-Premise
duloxetine I-Premise
vs I-Premise
38 I-Premise
% I-Premise
of I-Premise
those I-Premise
initially I-Premise
receiving I-Premise
placebo I-Premise
reported I-Premise
decreased I-Premise
pain I-Premise
of I-Premise
any I-Premise
amount I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
worst I-Premise
pain I-Premise
was I-Premise
also I-Premise
longer I-Premise
with I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26·7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
19·4-not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
with I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
19·4 I-Premise
months I-Premise
[ I-Premise
16·6-not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
, I-Premise
but I-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
significant I-Premise
( I-Premise
HR I-Premise
0·85 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·69-1·04 I-Premise
";" I-Premise
p=0·109 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
postoperative I-Premise
RT I-Premise
had I-Premise
better I-Premise
function I-Premise
with I-Premise
higher I-Premise
MSTS I-Premise
( I-Premise
25.8 I-Premise
v I-Premise
21.3 I-Premise
, I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
, I-Premise
TESS I-Premise
( I-Premise
69.8 I-Premise
v I-Premise
60.6 I-Premise
, I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
SF-36 I-Premise
bodily I-Premise
pain I-Premise
( I-Premise
67.7 I-Premise
v I-Premise
58.5 I-Premise
, I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
scores I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
after I-Premise
surgery I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
in I-Premise
the I-Premise
patients I-Premise
receiving I-Premise
induction I-Premise
chemotherapy I-Premise
only I-Premise
was I-Premise
8.9 I-Premise
months I-Premise
. I-Premise

Comparison B-Premise
of I-Premise
combined I-Premise
hormone I-Premise
therapy I-Premise
( I-Premise
n=815 I-Premise
) I-Premise
versus I-Premise
oestrogen I-Premise
therapy I-Premise
( I-Premise
n=826 I-Premise
) I-Premise
outcomes I-Premise
revealed I-Premise
no I-Premise
significant I-Premise
differences I-Premise
. I-Premise

Compared B-Premise
with I-Premise
baseline I-Premise
, I-Premise
the I-Premise
QoL I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
but I-Premise
to I-Premise
different I-Premise
degrees I-Premise
. I-Premise

Response B-Premise
rates I-Premise
( I-Premise
RRs I-Premise
) I-Premise
for I-Premise
PC I-Premise
, I-Premise
VC I-Premise
, I-Premise
GC I-Premise
, I-Premise
and I-Premise
TC I-Premise
were I-Premise
29.1 I-Premise
% I-Premise
, I-Premise
25.9 I-Premise
% I-Premise
, I-Premise
22.3 I-Premise
% I-Premise
, I-Premise
and I-Premise
23.4 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
assessed I-Premise
using I-Premise
EQ-5D I-Premise
showed I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
. I-Premise

Seventy-eight B-Premise
percent I-Premise
of I-Premise
patients I-Premise
expressed I-Premise
satisfaction I-Premise
with I-Premise
their I-Premise
treatment I-Premise
whatever I-Premise
their I-Premise
location I-Premise
, I-Premise
whereas I-Premise
57 I-Premise
% I-Premise
of I-Premise
patients I-Premise
preferred I-Premise
future I-Premise
treatment I-Premise
to I-Premise
continue I-Premise
at I-Premise
the I-Premise
hospital I-Premise
, I-Premise
81 I-Premise
% I-Premise
at I-Premise
GP I-Premise
surgeries I-Premise
and I-Premise
90 I-Premise
% I-Premise
at I-Premise
home I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
gender I-Premise
and I-Premise
KPS I-Premise
using I-Premise
FLIC I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
) I-Premise
, I-Premise
which I-Premise
also I-Premise
showed I-Premise
a I-Premise
trend I-Premise
toward I-Premise
significance I-Premise
with I-Premise
FACT I-Premise
( I-Premise
P I-Premise
= I-Premise
0.09 I-Premise
) I-Premise
. I-Premise

No B-Premise
adverse I-Premise
effects I-Premise
were I-Premise
noted I-Premise
. I-Premise

At B-Premise
4 I-Premise
years I-Premise
, I-Premise
64 I-Premise
( I-Premise
18 I-Premise
% I-Premise
) I-Premise
of I-Premise
353 I-Premise
patients I-Premise
on I-Premise
combined I-Premise
therapy I-Premise
and I-Premise
39 I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
of I-Premise
337 I-Premise
on I-Premise
endocrine-alone I-Premise
therapy I-Premise
had I-Premise
moderate I-Premise
to I-Premise
severe I-Premise
urinary I-Premise
bother I-Premise
( I-Premise
p=0.005 I-Premise
) I-Premise
, I-Premise
and I-Premise
16 I-Premise
( I-Premise
4 I-Premise
% I-Premise
) I-Premise
of I-Premise
355 I-Premise
on I-Premise
combined I-Premise
therapy I-Premise
and I-Premise
five I-Premise
( I-Premise
2 I-Premise
% I-Premise
) I-Premise
of I-Premise
338 I-Premise
on I-Premise
endocrine I-Premise
treatment I-Premise
alone I-Premise
had I-Premise
pain I-Premise
while I-Premise
urinating I-Premise
( I-Premise
p=0.024 I-Premise
) I-Premise
. I-Premise

Neither B-Premise
gefitinib I-Premise
250 I-Premise
nor I-Premise
500 I-Premise
mg/day I-Premise
improved I-Premise
overall I-Premise
survival I-Premise
compared I-Premise
with I-Premise
methotrexate I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1.22 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.95 I-Premise
to I-Premise
1.57 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.12 I-Premise
";" I-Premise
and I-Premise
HR I-Premise
, I-Premise
1.12 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.87 I-Premise
to I-Premise
1.43 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.39 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Global B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
not I-Premise
statistically I-Premise
different I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

An B-Premise
average I-Premise
weight I-Premise
gain I-Premise
in I-Premise
group I-Premise
B I-Premise
contrasted I-Premise
with I-Premise
an I-Premise
average I-Premise
weight I-Premise
loss I-Premise
in I-Premise
group I-Premise
A I-Premise
after I-Premise
four I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
eight I-Premise
weeks I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
CCSP I-Premise
improved I-Premise
QOL I-Premise
for I-Premise
patients I-Premise
at I-Premise
1-year I-Premise
follow-up I-Premise
. I-Premise

No B-Premise
survival I-Premise
differences I-Premise
were I-Premise
noted I-Premise
. I-Premise

According B-Premise
to I-Premise
the I-Premise
Radiation I-Premise
Therapy I-Premise
Oncology I-Premise
Group I-Premise
scale I-Premise
, I-Premise
the I-Premise
Grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
rectal I-Premise
toxicity I-Premise
rate I-Premise
was I-Premise
14 I-Premise
% I-Premise
and I-Premise
19.5 I-Premise
% I-Premise
for I-Premise
the I-Premise
-70 I-Premise
and I-Premise
80-Gy I-Premise
arms I-Premise
( I-Premise
p I-Premise
= I-Premise
.22 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
recommendation-plus-referral I-Premise
group I-Premise
and I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.5 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.0 I-Premise
to I-Premise
4.0 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
p I-Premise
= I-Premise
.244 I-Premise
) I-Premise
. I-Premise

A B-Premise
significantly I-Premise
higher I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
experienced I-Premise
palliation I-Premise
and I-Premise
complete I-Premise
resolution I-Premise
of I-Premise
chest I-Premise
pain I-Premise
and I-Premise
dyspnoea I-Premise
with I-Premise
regimen I-Premise
2 I-Premise
. I-Premise

The B-Premise
Grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
urinary I-Premise
toxicity I-Premise
was I-Premise
10 I-Premise
% I-Premise
at I-Premise
70 I-Premise
Gy I-Premise
and I-Premise
17.5 I-Premise
% I-Premise
at I-Premise
80 I-Premise
Gy I-Premise
( I-Premise
p I-Premise
= I-Premise
.046 I-Premise
) I-Premise
. I-Premise

At B-Premise
postintervention I-Premise
, I-Premise
AET I-Premise
was I-Premise
superior I-Premise
to I-Premise
UC I-Premise
for I-Premise
patient-rated I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
mean I-Premise
group I-Premise
difference I-Premise
, I-Premise
+9.0 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.0 I-Premise
to I-Premise
16.0 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.012 I-Premise
) I-Premise
, I-Premise
overall I-Premise
QoL I-Premise
( I-Premise
P I-Premise
= I-Premise
.021 I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
, I-Premise
happiness I-Premise
( I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
, I-Premise
depression I-Premise
( I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
, I-Premise
general I-Premise
health I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
cardiovascular I-Premise
fitness I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
lean I-Premise
body I-Premise
mass I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
. I-Premise

Intervention B-Premise
patients I-Premise
also I-Premise
experienced I-Premise
greater I-Premise
rates I-Premise
of I-Premise
depression I-Premise
treatment I-Premise
( I-Premise
72.3 I-Premise
% I-Premise
v I-Premise
10.4 I-Premise
% I-Premise
of I-Premise
EUC I-Premise
patients I-Premise
";" I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
better I-Premise
quality-of-life I-Premise
outcomes I-Premise
, I-Premise
including I-Premise
social/family I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
between I-Premise
groups I-Premise
, I-Premise
2.7 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.22 I-Premise
to I-Premise
4.17 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
emotional I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.29 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.26 I-Premise
to I-Premise
2.22 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
, I-Premise
functional I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.34 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.08 I-Premise
to I-Premise
2.59 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
2.79 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.49 I-Premise
to I-Premise
5.1 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
treatment-related I-Premise
adverse I-Premise
events I-Premise
were I-Premise
rash I-Premise
, I-Premise
diarrhea I-Premise
and I-Premise
pruritus I-Premise
. I-Premise

Significant B-Premise
improvements I-Premise
in I-Premise
self-reported I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
interference I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
on I-Premise
daily I-Premise
activities I-Premise
, I-Premise
and I-Premise
sleep I-Premise
were I-Premise
observed I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
the I-Premise
hypnosis I-Premise
intervention I-Premise
( I-Premise
P I-Premise
< I-Premise
.005 I-Premise
) I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
no I-Premise
treatment I-Premise
control I-Premise
group I-Premise
. I-Premise

In B-Premise
QoL I-Premise
questionnaires I-Premise
, I-Premise
more I-Premise
patients I-Premise
receiving I-Premise
PE I-Premise
reported I-Premise
being I-Premise
upset I-Premise
by I-Premise
hair I-Premise
loss I-Premise
( I-Premise
p I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
and I-Premise
impaired I-Premise
cognitive I-Premise
functioning I-Premise
( I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

The B-Premise
response I-Premise
rate I-Premise
for I-Premise
the I-Premise
gemcitabine-carboplatin I-Premise
group I-Premise
was I-Premise
47.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
39.9-54.5 I-Premise
% I-Premise
) I-Premise
and I-Premise
30.9 I-Premise
% I-Premise
for I-Premise
carboplatin I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
24.1-37.7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.0016 I-Premise
) I-Premise
. I-Premise

Toxicity B-Premise
was I-Premise
mild I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

For B-Premise
the I-Premise
chemoradiation I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
was I-Premise
7.1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
6.0 I-Premise
, I-Premise
9.0 I-Premise
) I-Premise
months I-Premise
compared I-Premise
with I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
of I-Premise
8.1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
7.0 I-Premise
, I-Premise
10.0 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
no I-Premise
chemoradiation I-Premise
group I-Premise
. I-Premise

Concomitant B-Premise
or I-Premise
prior I-Premise
use I-Premise
of I-Premise
protease I-Premise
inhibitors I-Premise
did I-Premise
not I-Premise
appear I-Premise
to I-Premise
affect I-Premise
the I-Premise
patient I-Premise
's I-Premise
response I-Premise
to I-Premise
treatment I-Premise
( I-Premise
P I-Premise
= I-Premise
0.183 I-Premise
) I-Premise
. I-Premise

Symptomatic B-Premise
response I-Premise
to I-Premise
pamidronate I-Premise
correlated I-Premise
closely I-Premise
with I-Premise
the I-Premise
rate I-Premise
of I-Premise
bone I-Premise
resorption I-Premise
";" I-Premise
it B-Premise
was I-Premise
more I-Premise
frequent I-Premise
in I-Premise
those I-Premise
patients I-Premise
with I-Premise
an I-Premise
initial I-Premise
NTx I-Premise
value I-Premise
of I-Premise
< I-Premise
2 I-Premise
times I-Premise
the I-Premise
upper I-Premise
limit I-Premise
of I-Premise
normal I-Premise
( I-Premise
17 I-Premise
of I-Premise
27 I-Premise
, I-Premise
62 I-Premise
% I-Premise
) I-Premise
and I-Premise
in I-Premise
those I-Premise
where I-Premise
the I-Premise
level I-Premise
of I-Premise
Ntx I-Premise
returned I-Premise
to I-Premise
normal I-Premise
( I-Premise
19 I-Premise
of I-Premise
32 I-Premise
, I-Premise
59 I-Premise
% I-Premise
) I-Premise
, I-Premise
than I-Premise
in I-Premise
the I-Premise
patients I-Premise
with I-Premise
either I-Premise
high I-Premise
baseline I-Premise
values I-Premise
of I-Premise
NTx I-Premise
( I-Premise
> I-Premise
2 I-Premise
times I-Premise
the I-Premise
upper I-Premise
limit I-Premise
of I-Premise
normal I-Premise
) I-Premise
or I-Premise
Ntx I-Premise
levels I-Premise
which I-Premise
failed I-Premise
to I-Premise
normalise I-Premise
for I-Premise
whom I-Premise
the I-Premise
response I-Premise
frequencies I-Premise
were I-Premise
2 I-Premise
of I-Premise
16 I-Premise
( I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
0 I-Premise
of I-Premise
11 I-Premise
( I-Premise
0 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
PFS I-Premise
between I-Premise
three I-Premise
and I-Premise
four I-Premise
cycles I-Premise
is I-Premise
-1.0 I-Premise
% I-Premise
( I-Premise
80 I-Premise
% I-Premise
confidence I-Premise
limit I-Premise
[ I-Premise
CL I-Premise
] I-Premise
, I-Premise
-3.8 I-Premise
% I-Premise
, I-Premise
+1.8 I-Premise
% I-Premise
) I-Premise
. I-Premise

Liposomal B-Premise
tretinoin I-Premise
is I-Premise
a I-Premise
new I-Premise
therapeutic I-Premise
agent I-Premise
that I-Premise
has I-Premise
been I-Premise
reported I-Premise
to I-Premise
have I-Premise
some I-Premise
clinical I-Premise
activity I-Premise
in I-Premise
patients I-Premise
with I-Premise
AIDS-associated I-Premise
Kaposi I-Premise
sarcoma I-Premise
. I-Premise

After B-Premise
intervention I-Premise
, I-Premise
EG I-Premise
participants I-Premise
showed I-Premise
improved I-Premise
QOL I-Premise
via I-Premise
decreased I-Premise
fear I-Premise
of I-Premise
recurrence I-Premise
and I-Premise
increased I-Premise
mindfulness I-Premise
attitude I-Premise
. I-Premise

A B-Premise
second I-Premise
infusion I-Premise
of I-Premise
pamidronate I-Premise
did I-Premise
not I-Premise
decrease I-Premise
resorption I-Premise
further I-Premise
, I-Premise
but B-Premise
maintained I-Premise
the I-Premise
suppression I-Premise
of I-Premise
resorption I-Premise
at I-Premise
similar I-Premise
levels I-Premise
for I-Premise
a I-Premise
further I-Premise
four I-Premise
weeks I-Premise
. I-Premise

Sensitivity B-Premise
analyses I-Premise
showed I-Premise
that I-Premise
varying I-Premise
the I-Premise
mean I-Premise
hospital I-Premise
cost I-Premise
per I-Premise
day I-Premise
from I-Premise
the I-Premise
5th I-Premise
to I-Premise
the I-Premise
95th I-Premise
percentile I-Premise
resulted I-Premise
in I-Premise
cost-utility I-Premise
ratios I-Premise
ranging I-Premise
from I-Premise
20,326 I-Premise
dollars I-Premise
to I-Premise
as I-Premise
low I-Premise
as I-Premise
6360 I-Premise
dollars I-Premise
. I-Premise

Sleep B-Premise
quality I-Premise
differed I-Premise
over I-Premise
1 I-Premise
years I-Premise
time I-Premise
( I-Premise
F I-Premise
[ I-Premise
4,162 I-Premise
] I-Premise
= I-Premise
7.7 I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
by I-Premise
group I-Premise
, I-Premise
F I-Premise
[ I-Premise
1,173 I-Premise
] I-Premise
= I-Premise
4.8 I-Premise
, I-Premise
P I-Premise
= I-Premise
.029 I-Premise
";" I-Premise
and I-Premise
over I-Premise
time I-Premise
by I-Premise
group I-Premise
, I-Premise
F I-Premise
[ I-Premise
4,162 I-Premise
] I-Premise
= I-Premise
3.3 I-Premise
, I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
. I-Premise

Exemestane B-Premise
patients I-Premise
reported I-Premise
more I-Premise
bone/muscle I-Premise
aches I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
P I-Premise
= I-Premise
.0004 I-Premise
) I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
sleeping I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

The B-Premise
projected I-Premise
2-year I-Premise
PFS I-Premise
is I-Premise
90.4 I-Premise
% I-Premise
on I-Premise
three I-Premise
cycles I-Premise
and I-Premise
89.4 I-Premise
% I-Premise
on I-Premise
four I-Premise
cycles I-Premise
. I-Premise

More B-Premise
than I-Premise
90 I-Premise
% I-Premise
of I-Premise
patients I-Premise
did I-Premise
not I-Premise
require I-Premise
a I-Premise
dose I-Premise
increase I-Premise
and I-Premise
28.7 I-Premise
% I-Premise
had I-Premise
a I-Premise
dose I-Premise
reduction I-Premise
. I-Premise

No B-Premise
statistical I-Premise
significance I-Premise
was I-Premise
found I-Premise
in I-Premise
the I-Premise
FACT-G I-Premise
scores I-Premise
and I-Premise
FACT-B I-Premise
scores I-Premise
among I-Premise
different I-Premise
groups I-Premise
at I-Premise
baseline I-Premise
, I-Premise
week I-Premise
4 I-Premise
, I-Premise
week I-Premise
8 I-Premise
and I-Premise
week I-Premise
12 I-Premise
after I-Premise
NHT I-Premise
. I-Premise

Nonsignificant B-Premise
differences I-Premise
between I-Premise
groups I-Premise
were I-Premise
found I-Premise
for I-Premise
all I-Premise
unmet I-Premise
supportive I-Premise
care I-Premise
need I-Premise
and I-Premise
quality-of-life I-Premise
scores I-Premise
, I-Premise
change I-Premise
scores I-Premise
, I-Premise
and I-Premise
trends I-Premise
. I-Premise

The B-Premise
female I-Premise
patients I-Premise
in I-Premise
the I-Premise
ORP I-Premise
group I-Premise
had I-Premise
significantly I-Premise
lower I-Premise
body I-Premise
image I-Premise
scores I-Premise
than I-Premise
the I-Premise
male I-Premise
patients I-Premise
( I-Premise
14.9 I-Premise
vs I-Premise
18.3 I-Premise
) I-Premise
. I-Premise

The B-Premise
group I-Premise
treated I-Premise
with I-Premise
oral I-Premise
Etoposide I-Premise
had I-Premise
a I-Premise
significantly I-Premise
better I-Premise
QOL I-Premise
than I-Premise
the I-Premise
radiotherapy I-Premise
group I-Premise
for I-Premise
the I-Premise
total I-Premise
FLI-C I-Premise
score I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
plus I-Premise
standard I-Premise
error I-Premise
at I-Premise
3-months I-Premise
89 I-Premise
+/- I-Premise
3 I-Premise
vs. I-Premise
76 I-Premise
+/- I-Premise
3 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
and I-Premise
for I-Premise
the I-Premise
hardship I-Premise
( I-Premise
11 I-Premise
+/- I-Premise
0.4 I-Premise
vs. I-Premise
9 I-Premise
+/- I-Premise
0.4 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
";" I-Premise
social I-Premise
( I-Premise
10 I-Premise
+/- I-Premise
0.4 I-Premise
vs. I-Premise
8 I-Premise
+/- I-Premise
0.4 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
nausea I-Premise
( I-Premise
9 I-Premise
+/- I-Premise
0.4 I-Premise
vs. I-Premise
8 I-Premise
+/- I-Premise
0.4 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
subscales I-Premise
. I-Premise

At B-Premise
1 I-Premise
and I-Premise
4 I-Premise
months I-Premise
, I-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
4 I-Premise
day I-Premise
group I-Premise
experienced I-Premise
a I-Premise
clinically I-Premise
meaningful I-Premise
worsening I-Premise
in I-Premise
the I-Premise
dyspnea I-Premise
QOL I-Premise
domain I-Premise
compared I-Premise
to I-Premise
the I-Premise
11 I-Premise
day I-Premise
group I-Premise
( I-Premise
44.5 I-Premise
% I-Premise
vs I-Premise
15.4 I-Premise
% I-Premise
, I-Premise
p=0.02 I-Premise
";" I-Premise
38.5 I-Premise
% I-Premise
vs I-Premise
12.0 I-Premise
% I-Premise
, I-Premise
p=0.03 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Of B-Premise
group I-Premise
1 I-Premise
patients I-Premise
67 I-Premise
% I-Premise
had I-Premise
gynecomastia I-Premise
compared I-Premise
with I-Premise
8 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
and I-Premise
34 I-Premise
% I-Premise
in I-Premise
group I-Premise
3 I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
seen I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
, I-Premise
except B-Premise
for I-Premise
hair I-Premise
loss I-Premise
. I-Premise

Comparing B-Premise
survival I-Premise
for I-Premise
the I-Premise
two I-Premise
dose I-Premise
levels I-Premise
of I-Premise
paclitaxel I-Premise
revealed I-Premise
no I-Premise
significant I-Premise
difference I-Premise
. I-Premise

There B-Premise
were I-Premise
also I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
frequency I-Premise
of I-Premise
incompletely I-Premise
infarcted I-Premise
leiomyomas I-Premise
, I-Premise
degree I-Premise
of I-Premise
improvement I-Premise
in I-Premise
symptom I-Premise
score I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
, I-Premise
or I-Premise
QOL I-Premise
. I-Premise

Similar B-Premise
results I-Premise
were I-Premise
observed I-Premise
using I-Premise
the I-Premise
LENT-SOMA I-Premise
scale I-Premise
. I-Premise

No B-Premise
significant I-Premise
effect I-Premise
was I-Premise
seen I-Premise
on I-Premise
global I-Premise
health I-Premise
status/quality I-Premise
of I-Premise
life I-Premise
. I-Premise

After B-Premise
a I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
the I-Premise
effect I-Premise
of I-Premise
CBT I-Premise
for I-Premise
fatigue I-Premise
was I-Premise
no I-Premise
longer I-Premise
observed I-Premise
, I-Premise
and I-Premise
the I-Premise
effect I-Premise
on I-Premise
fatigue I-Premise
seemed I-Premise
to I-Premise
be I-Premise
diminished I-Premise
7 I-Premise
months I-Premise
postintervention I-Premise
. I-Premise

No B-Premise
relevant I-Premise
differences I-Premise
in I-Premise
adverse I-Premise
effects I-Premise
were I-Premise
observed I-Premise
among I-Premise
the I-Premise
groups I-Premise
during I-Premise
either I-Premise
the I-Premise
titration I-Premise
phase I-Premise
and I-Premise
chronic I-Premise
treatment I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
was I-Premise
longest I-Premise
for I-Premise
epidermal I-Premise
growth I-Premise
factor I-Premise
receptor I-Premise
gene I-Premise
( I-Premise
EGFR I-Premise
) I-Premise
-mutated I-Premise
patients I-Premise
in I-Premise
the I-Premise
E I-Premise
group I-Premise
, I-Premise
followed I-Premise
by I-Premise
EGFR-mutated I-Premise
patients I-Premise
in I-Premise
V I-Premise
, I-Premise
EGFR I-Premise
wild I-Premise
type I-Premise
in I-Premise
E I-Premise
, I-Premise
and I-Premise
EGFR I-Premise
wild I-Premise
type I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0034 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
VBT I-Premise
group I-Premise
reported I-Premise
better I-Premise
social I-Premise
functioning I-Premise
( I-Premise
P I-Premise
< I-Premise
.002 I-Premise
) I-Premise
and I-Premise
lower I-Premise
symptom I-Premise
scores I-Premise
for I-Premise
diarrhea I-Premise
, I-Premise
fecal I-Premise
leakage I-Premise
, I-Premise
the I-Premise
need I-Premise
to I-Premise
stay I-Premise
close I-Premise
to I-Premise
the I-Premise
toilet I-Premise
, I-Premise
and I-Premise
limitation I-Premise
in I-Premise
daily I-Premise
activities I-Premise
because I-Premise
of I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

A B-Premise
significant I-Premise
improvement I-Premise
in I-Premise
symptoms I-Premise
after I-Premise
treatment I-Premise
was I-Premise
found I-Premise
on I-Premise
day I-Premise
5 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
on I-Premise
day I-Premise
10 I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0002 I-Premise
) I-Premise
. I-Premise

Sexual B-Premise
functioning I-Premise
was I-Premise
worse I-Premise
for I-Premise
women I-Premise
who I-Premise
received I-Premise
chemotherapy I-Premise
than I-Premise
for I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
, I-Premise
regardless I-Premise
of I-Premise
type I-Premise
of I-Premise
surgery I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
14 I-Premise
months I-Premise
with I-Premise
MMC I-Premise
and I-Premise
15 I-Premise
months I-Premise
in I-Premise
5-FU I-Premise
alone I-Premise
";" I-Premise
one-year I-Premise
survival I-Premise
51.7 I-Premise
% I-Premise
vs. I-Premise
57.2 I-Premise
% I-Premise
. I-Premise

The B-Premise
treatment I-Premise
groups I-Premise
reported I-Premise
improved I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
over I-Premise
time I-Premise
and I-Premise
changes I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
post-intervention I-Premise
were I-Premise
clinically I-Premise
relevant I-Premise
. I-Premise

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0.96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.75-1.23 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.7349 I-Premise
) I-Premise
. I-Premise

Improvement B-Premise
was I-Premise
also I-Premise
found I-Premise
for I-Premise
5-point I-Premise
decrease I-Premise
in I-Premise
PHQ-9 I-Premise
score I-Premise
among I-Premise
72.2 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
compared I-Premise
with I-Premise
59.7 I-Premise
% I-Premise
of I-Premise
EUC I-Premise
patients I-Premise
( I-Premise
OR I-Premise
= I-Premise
1.99 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.14 I-Premise
to I-Premise
3.50 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

For B-Premise
response I-Premise
, I-Premise
age I-Premise
, I-Premise
dyspnoea I-Premise
, I-Premise
fatigue I-Premise
and I-Premise
global I-Premise
QL I-Premise
were I-Premise
significant I-Premise
predictive I-Premise
factors I-Premise
in I-Premise
the I-Premise
univariate I-Premise
analysis I-Premise
. I-Premise

During B-Premise
treatment I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
declined I-Premise
significantly I-Premise
more I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
than I-Premise
CAF I-Premise
, I-Premise
but B-Premise
by I-Premise
4 I-Premise
months I-Premise
posttreatment I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
difference I-Premise
. I-Premise

The B-Premise
KPS I-Premise
score I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
after I-Premise
treatment I-Premise
was I-Premise
improved I-Premise
in I-Premise
13 I-Premise
patients I-Premise
( I-Premise
23.6 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
27 I-Premise
( I-Premise
49.6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
15 I-Premise
( I-Premise
27.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
it I-Premise
was I-Premise
improved I-Premise
in I-Premise
7 I-Premise
( I-Premise
13.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
21 I-Premise
( I-Premise
39.6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
25 I-Premise
( I-Premise
47.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
the I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Median B-Premise
relative I-Premise
dose I-Premise
intensity I-Premise
over I-Premise
eight I-Premise
cycles I-Premise
( I-Premise
DI8 I-Premise
) I-Premise
was I-Premise
78 I-Premise
% I-Premise
for I-Premise
CPT-11 I-Premise
and I-Premise
82 I-Premise
% I-Premise
for I-Premise
5-FU I-Premise
. I-Premise

A B-Premise
decrease I-Premise
in I-Premise
transfusion I-Premise
requirement I-Premise
did I-Premise
not I-Premise
reach I-Premise
significance I-Premise
over I-Premise
all I-Premise
3 I-Premise
months I-Premise
, I-Premise
but I-Premise
there I-Premise
was I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
the I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
transfused I-Premise
in I-Premise
the I-Premise
second I-Premise
and I-Premise
third I-Premise
months I-Premise
( I-Premise
27 I-Premise
% I-Premise
r-HuEPO I-Premise
vs. I-Premise
56 I-Premise
% I-Premise
placebo I-Premise
) I-Premise
and I-Premise
a I-Premise
trend I-Premise
toward I-Premise
reduction I-Premise
in I-Premise
the I-Premise
mean I-Premise
total I-Premise
number I-Premise
of I-Premise
units I-Premise
transfused I-Premise
( I-Premise
1.20 I-Premise
units I-Premise
r-HuEPO I-Premise
vs. I-Premise
2.02 I-Premise
units I-Premise
placebo I-Premise
) I-Premise
, I-Premise
suggesting I-Premise
a I-Premise
lag I-Premise
of I-Premise
1 I-Premise
month I-Premise
before I-Premise
r-HuEPO I-Premise
can I-Premise
affect I-Premise
the I-Premise
transfusion I-Premise
requirement I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
median I-Premise
overall I-Premise
survival I-Premise
time I-Premise
between I-Premise
the I-Premise
5-FU+low-dose I-Premise
CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
5-FU I-Premise
arm I-Premise
( I-Premise
479 I-Premise
and I-Premise
491 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Mean B-Premise
scores I-Premise
were I-Premise
generally I-Premise
improved I-Premise
by I-Premise
the I-Premise
end-of-treatment I-Premise
assessment I-Premise
vs. I-Premise
baseline I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

In B-Premise
the I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
, I-Premise
500 I-Premise
mg/day I-Premise
, I-Premise
and I-Premise
methotrexate I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
5.6 I-Premise
, I-Premise
6.0 I-Premise
, I-Premise
and I-Premise
6.7 I-Premise
months I-Premise
";" I-Premise
ORRs I-Premise
( I-Premise
Response I-Premise
Evaluation I-Premise
Criteria I-Premise
in I-Premise
Solid I-Premise
Tumors I-Premise
) I-Premise
were I-Premise
2.7 I-Premise
% I-Premise
, I-Premise
7.6 I-Premise
% I-Premise
and I-Premise
3.9 I-Premise
% I-Premise
, I-Premise
with I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
between I-Premise
either I-Premise
gefitinib I-Premise
arm I-Premise
and I-Premise
methotrexate I-Premise
. I-Premise

For B-Premise
those I-Premise
patients I-Premise
who I-Premise
have I-Premise
recurrence I-Premise
of I-Premise
disease I-Premise
at I-Premise
least I-Premise
6 I-Premise
months I-Premise
after I-Premise
initial I-Premise
therapy I-Premise
, I-Premise
the I-Premise
paclitaxel-platinum I-Premise
combination I-Premise
has I-Premise
been I-Premise
shown I-Premise
to I-Premise
be I-Premise
a I-Premise
superior I-Premise
treatment I-Premise
to I-Premise
platinum I-Premise
monotherapy I-Premise
. I-Premise

Time B-Premise
to I-Premise
5 I-Premise
% I-Premise
deterioration I-Premise
of I-Premise
global I-Premise
health I-Premise
status I-Premise
( I-Premise
primary I-Premise
end I-Premise
point I-Premise
) I-Premise
significantly I-Premise
favored I-Premise
DCF I-Premise
over I-Premise
CF I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

At B-Premise
eight I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
had I-Premise
lost I-Premise
0.06 I-Premise
kg I-Premise
in I-Premise
weight I-Premise
and I-Premise
0.5 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
in I-Premise
AMA I-Premise
compared I-Premise
with I-Premise
a I-Premise
loss I-Premise
of I-Premise
3.62 I-Premise
kg I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-3.57 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-6.8 I-Premise
to I-Premise
-0.3 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.034 I-Premise
) I-Premise
and I-Premise
8.4 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-7.9 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-14.0 I-Premise
to I-Premise
-1.8 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.014 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
5.5 I-Premise
months I-Premise
v I-Premise
3.1 I-Premise
months I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
grade I-Premise
III/IV I-Premise
adverse I-Premise
events I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

Transient B-Premise
grade I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
18 I-Premise
and I-Premise
2 I-Premise
patients I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
thrombosis I-Premise
in I-Premise
7 I-Premise
patients I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
Arm I-Premise
B I-Premise
respectively I-Premise
. I-Premise

The B-Premise
survival I-Premise
benefit I-Premise
, I-Premise
adjusted I-Premise
for I-Premise
prognostic I-Premise
factors I-Premise
in I-Premise
a I-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
remained I-Premise
significant I-Premise
( I-Premise
p=0.001 I-Premise
) I-Premise
. I-Premise

Ancillary B-Premise
" I-Premise
on-treatment I-Premise
" I-Premise
analyzes I-Premise
showed I-Premise
that I-Premise
participants I-Premise
who I-Premise
recalled I-Premise
an I-Premise
exercise I-Premise
recommendation I-Premise
reported I-Premise
significantly I-Premise
more I-Premise
total I-Premise
exercise I-Premise
than I-Premise
participants I-Premise
who I-Premise
did I-Premise
not I-Premise
recall I-Premise
an I-Premise
exercise I-Premise
recommendation I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
4.1 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
: I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.9-6.4 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
p I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

With B-Premise
a I-Premise
mixed I-Premise
modeling I-Premise
approach I-Premise
, I-Premise
total I-Premise
FACIT I-Premise
F I-Premise
scores I-Premise
for I-Premise
the I-Premise
entire I-Premise
sample I-Premise
declined I-Premise
at I-Premise
a I-Premise
significant I-Premise
rate I-Premise
( I-Premise
p I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
beginning I-Premise
with I-Premise
cycle I-Premise
3 I-Premise
but B-Premise
at I-Premise
a I-Premise
slower I-Premise
rate I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
serious I-Premise
events I-Premise
with I-Premise
the I-Premise
1 I-Premise
+ I-Premise
2.5 I-Premise
dosage I-Premise
or I-Premise
after I-Premise
ccHRT I-Premise
discontinuation I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
the I-Premise
mean I-Premise
General I-Premise
Fatigue I-Premise
score I-Premise
, I-Premise
between I-Premise
those I-Premise
who I-Premise
received I-Premise
the I-Premise
intervention I-Premise
and I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
, I-Premise
was I-Premise
-3.11 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-3.97 I-Premise
to I-Premise
-2.25 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Systemic B-Premise
recurrence I-Premise
was I-Premise
7/74 I-Premise
( I-Premise
stage I-Premise
III I-Premise
";" I-Premise
9.4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
5/92 I-Premise
( I-Premise
stage I-Premise
III I-Premise
";" I-Premise
5.4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Toxicity B-Premise
of I-Premise
HDC I-Premise
has I-Premise
a I-Premise
strong I-Premise
negative I-Premise
impact I-Premise
on I-Premise
patients I-Premise
' I-Premise
QOL I-Premise
during I-Premise
the I-Premise
treatment I-Premise
phase I-Premise
. I-Premise

Over B-Premise
subsequent I-Premise
assessments I-Premise
, I-Premise
HRQOL I-Premise
was I-Premise
much I-Premise
the I-Premise
same I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Individuals B-Premise
receiving I-Premise
duloxetine I-Premise
as I-Premise
their I-Premise
initial I-Premise
5-week I-Premise
treatment I-Premise
reported I-Premise
a I-Premise
mean I-Premise
decrease I-Premise
in I-Premise
average I-Premise
pain I-Premise
of I-Premise
1.06 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.72-1.40 I-Premise
) I-Premise
vs I-Premise
0.34 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.01-0.66 I-Premise
) I-Premise
among I-Premise
those I-Premise
who I-Premise
received I-Premise
placebo I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.513 I-Premise
) I-Premise
. I-Premise

At B-Premise
2 I-Premise
weeks I-Premise
, I-Premise
assignment I-Premise
to I-Premise
TEC I-Premise
was I-Premise
associated I-Premise
with I-Premise
improvement I-Premise
in I-Premise
pain-related I-Premise
impairment I-Premise
( I-Premise
-0.25 I-Premise
points I-Premise
on I-Premise
a I-Premise
5-point I-Premise
scale I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-0.43 I-Premise
to I-Premise
-0.06 I-Premise
, I-Premise
P=.01 I-Premise
) I-Premise
but B-Premise
not I-Premise
in I-Premise
pain I-Premise
severity I-Premise
( I-Premise
-0.21 I-Premise
points I-Premise
on I-Premise
an I-Premise
11-point I-Premise
scale I-Premise
, I-Premise
-0.60 I-Premise
to I-Premise
0.17 I-Premise
, I-Premise
P=.27 I-Premise
) I-Premise
. I-Premise

Conversely B-Premise
, I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
exhibited I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
muscle I-Premise
cramps I-Premise
in I-Premise
the I-Premise
legs I-Premise
( I-Premise
P I-Premise
= I-Premise
0.014 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
improved I-Premise
Fisher I-Premise
's I-Premise
ratio I-Premise
after I-Premise
3 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

Differences B-Premise
were I-Premise
significant I-Premise
between I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
OR I-Premise
0.12 I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
groups I-Premise
1 I-Premise
and I-Premise
3 I-Premise
( I-Premise
OR I-Premise
0.52 I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

High B-Premise
baseline I-Premise
plasma I-Premise
vascular I-Premise
endothelial I-Premise
growth I-Premise
factor I-Premise
A I-Premise
( I-Premise
VEGF-A I-Premise
) I-Premise
concentrations I-Premise
were I-Premise
associated I-Premise
with I-Premise
greater I-Premise
bevacizumab I-Premise
benefit I-Premise
( I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
their I-Premise
controls I-Premise
, I-Premise
in I-Premise
pamidronate I-Premise
HD/LD I-Premise
patients I-Premise
, I-Premise
events I-Premise
occurred I-Premise
60 I-Premise
% I-Premise
to I-Premise
90 I-Premise
% I-Premise
less I-Premise
frequently I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.03 I-Premise
) I-Premise
and I-Premise
the I-Premise
EFP I-Premise
was I-Premise
prolonged I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Greater B-Premise
myelosuppression I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
. I-Premise

Adjusted B-Premise
for I-Premise
baseline I-Premise
score I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
demographic I-Premise
covariates I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
showed I-Premise
an I-Premise
estimated I-Premise
improvement I-Premise
at I-Premise
six I-Premise
weeks I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
of I-Premise
-6.6 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-12.3 I-Premise
to I-Premise
-0.9 I-Premise
, I-Premise
P=0.02 I-Premise
";" I-Premise
effect I-Premise
size=0.33 I-Premise
, I-Premise
0.04 I-Premise
to I-Premise
0.61 I-Premise
) I-Premise
. I-Premise

These B-Premise
differences I-Premise
were I-Premise
not I-Premise
significant I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
response I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
was I-Premise
found I-Premise
for I-Premise
any I-Premise
domain I-Premise
or I-Premise
item I-Premise
except I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
favor I-Premise
of I-Premise
PPT I-Premise
were I-Premise
also I-Premise
found I-Premise
for I-Premise
the I-Premise
following I-Premise
secondary I-Premise
outcomes I-Premise
: I-Premise
fatigue I-Premise
dimensions I-Premise
" I-Premise
reduced I-Premise
activity I-Premise
" I-Premise
and I-Premise
" I-Premise
reduced I-Premise
motivation I-Premise
, I-Premise
" I-Premise
fatigue I-Premise
NRS I-Premise
, I-Premise
symptom I-Premise
burden I-Premise
, I-Premise
interference I-Premise
of I-Premise
fatigue I-Premise
with I-Premise
daily I-Premise
life I-Premise
, I-Premise
and I-Premise
anxiety I-Premise
( I-Premise
all I-Premise
P I-Premise
≤ I-Premise
.03 I-Premise
) I-Premise
. I-Premise

Both B-Premise
treatments I-Premise
led I-Premise
to I-Premise
an I-Premise
improvement I-Premise
, I-Premise
over I-Premise
time I-Premise
, I-Premise
in I-Premise
dyspnoea I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
63 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
had I-Premise
a I-Premise
50 I-Premise
% I-Premise
or I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
from I-Premise
baseline I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
Patient I-Premise
Health I-Premise
Questionnaire-9 I-Premise
( I-Premise
PHQ-9 I-Premise
) I-Premise
depression I-Premise
scale I-Premise
compared I-Premise
with I-Premise
50 I-Premise
% I-Premise
of I-Premise
EUC I-Premise
patients I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
[ I-Premise
OR I-Premise
] I-Premise
= I-Premise
1.98 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.16 I-Premise
to I-Premise
3.38 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Tamoxifen B-Premise
reduced I-Premise
the I-Premise
risk I-Premise
of I-Premise
invasive I-Premise
breast I-Premise
cancer I-Premise
by I-Premise
49 I-Premise
% I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
< I-Premise
.00001 I-Premise
) I-Premise
, I-Premise
with I-Premise
cumulative I-Premise
incidence I-Premise
through I-Premise
69 I-Premise
months I-Premise
of I-Premise
follow-up I-Premise
of I-Premise
43.4 I-Premise
versus I-Premise
22.0 I-Premise
per I-Premise
1000 I-Premise
women I-Premise
in I-Premise
the I-Premise
placebo I-Premise
and I-Premise
tamoxifen I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
two I-Premise
groups I-Premise
were I-Premise
comparable I-Premise
, I-Premise
with I-Premise
low I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
and I-Premise
significant I-Premise
symptom I-Premise
burden I-Premise
, I-Premise
especially I-Premise
pain I-Premise
and I-Premise
fatigue I-Premise
, I-Premise
after I-Premise
thoracotomy I-Premise
. I-Premise

Grade B-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
27 I-Premise
% I-Premise
v I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
infusion I-Premise
site I-Premise
pain I-Premise
( I-Premise
10 I-Premise
% I-Premise
v I-Premise
0.5 I-Premise
% I-Premise
) I-Premise
were I-Premise
reported I-Premise
more I-Premise
frequently I-Premise
in I-Premise
the I-Premise
ASA404 I-Premise
arm I-Premise
. I-Premise

The B-Premise
RR I-Premise
was I-Premise
70 I-Premise
% I-Premise
versus I-Premise
74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.3492 I-Premise
) I-Premise
. I-Premise

Similarly B-Premise
, I-Premise
ASES I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
( I-Premise
p=0.001 I-Premise
) I-Premise
improved I-Premise
in I-Premise
both I-Premise
Group I-Premise
I I-Premise
and I-Premise
II I-Premise
without I-Premise
any I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
groups I-Premise
. I-Premise

In B-Premise
all I-Premise
study I-Premise
groups I-Premise
, I-Premise
serum I-Premise
TSH I-Premise
levels I-Premise
showed I-Premise
very I-Premise
good I-Premise
stimulation I-Premise
( I-Premise
mean I-Premise
, I-Premise
82.24 I-Premise
+/- I-Premise
18.21 I-Premise
mU/L I-Premise
) I-Premise
, I-Premise
without I-Premise
significant I-Premise
between-group I-Premise
differences I-Premise
( I-Premise
p I-Premise
= I-Premise
0.5213 I-Premise
) I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ratio I-Premise
for I-Premise
investigator-assessed I-Premise
PFS I-Premise
was I-Premise
0.82 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.65 I-Premise
to I-Premise
1.02 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0775 I-Premise
";" I-Premise
median I-Premise
PFS I-Premise
, I-Premise
13.7 I-Premise
v I-Premise
16.5 I-Premise
months I-Premise
in I-Premise
the I-Premise
non-bevacizumab I-Premise
and I-Premise
bevacizumab I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
PFS I-Premise
events I-Premise
in I-Premise
72 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
SF-6D I-Premise
score I-Premise
decreased I-Premise
to I-Premise
21·2 I-Premise
± I-Premise
2·5 I-Premise
in I-Premise
the I-Premise
oxycodone/paracetamol I-Premise
group I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
phase I-Premise
( I-Premise
P I-Premise
= I-Premise
0·001 I-Premise
) I-Premise
. I-Premise

Thus B-Premise
far I-Premise
, I-Premise
with I-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
86 I-Premise
weeks I-Premise
, I-Premise
median I-Premise
survival I-Premise
has I-Premise
not I-Premise
been I-Premise
reached I-Premise
in I-Premise
either I-Premise
group I-Premise
. I-Premise

The B-Premise
experimental-to-PC I-Premise
hazard I-Premise
ratios I-Premise
of I-Premise
death I-Premise
were I-Premise
1.15 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.79 I-Premise
to I-Premise
1.67 I-Premise
) I-Premise
for I-Premise
VC I-Premise
, I-Premise
1.32 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.91 I-Premise
to I-Premise
1.92 I-Premise
) I-Premise
for I-Premise
GC I-Premise
, I-Premise
and I-Premise
1.26 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.86 I-Premise
to I-Premise
1.82 I-Premise
) I-Premise
for I-Premise
TC I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
were I-Premise
found I-Premise
for I-Premise
mood I-Premise
( I-Premise
p I-Premise
> I-Premise
.05 I-Premise
) I-Premise
or I-Premise
pain I-Premise
( I-Premise
p I-Premise
> I-Premise
.05 I-Premise
) I-Premise
levels I-Premise
. I-Premise

Gastrointestinal B-Premise
and I-Premise
GU I-Premise
toxicity I-Premise
persisted I-Premise
5 I-Premise
years I-Premise
after I-Premise
RT I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
dose I-Premise
schedules I-Premise
other I-Premise
than I-Premise
in I-Premise
regard I-Premise
to I-Premise
urgency I-Premise
of I-Premise
defecation I-Premise
. I-Premise

No B-Premise
decrease I-Premise
in I-Premise
fatigue-related I-Premise
distress I-Premise
was I-Premise
detected I-Premise
. I-Premise

Response B-Premise
rate I-Premise
, I-Premise
survival I-Premise
, I-Premise
and I-Premise
duration I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Self-reported B-Premise
severity I-Premise
of I-Premise
facial I-Premise
hair I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
51 I-Premise
) I-Premise
fell I-Premise
from I-Premise
7.3 I-Premise
to I-Premise
3.6 I-Premise
over I-Premise
the I-Premise
6-month I-Premise
study I-Premise
period I-Premise
";" I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
37 I-Premise
) I-Premise
the I-Premise
corresponding I-Premise
scores I-Premise
were I-Premise
7.1 I-Premise
and I-Premise
6.1 I-Premise
. I-Premise

Objective B-Premise
response I-Premise
rates I-Premise
were I-Premise
22.8 I-Premise
% I-Premise
( I-Premise
13 I-Premise
of I-Premise
57 I-Premise
) I-Premise
in I-Premise
E I-Premise
and I-Premise
8.9 I-Premise
% I-Premise
( I-Premise
5 I-Premise
of I-Premise
56 I-Premise
) I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0388 I-Premise
) I-Premise
. I-Premise

Numeric B-Premise
rating I-Premise
scale I-Premise
scores I-Premise
for I-Premise
pain I-Premise
intensity I-Premise
in I-Premise
group I-Premise
1 I-Premise
and I-Premise
group I-Premise
2 I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
those I-Premise
in I-Premise
group I-Premise
3 I-Premise
at I-Premise
T I-Premise
( I-Premise
0-12 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
T I-Premise
( I-Premise
12-24 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
and I-Premise
T I-Premise
( I-Premise
24-48 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
follow-up I-Premise
in I-Premise
this I-Premise
study I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
recurrences I-Premise
, I-Premise
and I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
utilities I-Premise
from I-Premise
EuroQol I-Premise
were I-Premise
almost I-Premise
identical I-Premise
. I-Premise

Resorption B-Premise
markers I-Premise
did I-Premise
not I-Premise
decrease I-Premise
after I-Premise
placebo I-Premise
, I-Premise
but B-Premise
NTx I-Premise
and I-Premise
Crosslaps I-Premise
both I-Premise
decreased I-Premise
by I-Premise
70 I-Premise
% I-Premise
after I-Premise
pamidronate I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
78-Gy I-Premise
arm I-Premise
reported I-Premise
more I-Premise
frequent I-Premise
bowel I-Premise
movements I-Premise
at I-Premise
3 I-Premise
years I-Premise
and I-Premise
less I-Premise
change I-Premise
in I-Premise
bowel I-Premise
function I-Premise
at I-Premise
2 I-Premise
years I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
70-Gy I-Premise
arm I-Premise
. I-Premise

Eighteen B-Premise
months I-Premise
after I-Premise
surgery I-Premise
, I-Premise
any I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
patients I-Premise
randomized I-Premise
to I-Premise
LAC I-Premise
or I-Premise
open I-Premise
colectomy I-Premise
favored I-Premise
LAC I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
significantly I-Premise
more I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

PFS B-Premise
was I-Premise
significantly I-Premise
prolonged I-Premise
in I-Premise
the I-Premise
erlotinib I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
both I-Premise
overall I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
: I-Premise
0.57 I-Premise
";" I-Premise
p=0.0067 I-Premise
) I-Premise
and I-Premise
in I-Premise
patients I-Premise
with I-Premise
EGFR I-Premise
IHC-positive I-Premise
disease I-Premise
( I-Premise
HR=0.50 I-Premise
";" I-Premise
p=0.0057 I-Premise
) I-Premise
. I-Premise

An B-Premise
objective I-Premise
response I-Premise
( I-Premise
complete I-Premise
[ I-Premise
CR I-Premise
] I-Premise
or I-Premise
partial I-Premise
[ I-Premise
PR I-Premise
] I-Premise
) I-Premise
was I-Premise
obtained I-Premise
in I-Premise
55 I-Premise
% I-Premise
, I-Premise
48 I-Premise
% I-Premise
, I-Premise
16 I-Premise
% I-Premise
, I-Premise
and I-Premise
7 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CEF I-Premise
, I-Premise
E I-Premise
, I-Premise
M I-Premise
, I-Premise
and I-Premise
MV I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Results B-Premise
from I-Premise
the I-Premise
non-randomised I-Premise
patients I-Premise
did I-Premise
not I-Premise
confirm I-Premise
this I-Premise
effect I-Premise
, I-Premise
however I-Premise
. I-Premise

Comparing B-Premise
the I-Premise
single- I-Premise
and I-Premise
multiple-fraction I-Premise
radiotherapy I-Premise
schedules I-Premise
, I-Premise
no I-Premise
differences I-Premise
were I-Premise
found I-Premise
in I-Premise
life I-Premise
expectancy I-Premise
( I-Premise
43.0 I-Premise
versus I-Premise
40.4 I-Premise
weeks I-Premise
, I-Premise
P I-Premise
=.20 I-Premise
) I-Premise
or I-Premise
quality-adjusted I-Premise
life I-Premise
expectancy I-Premise
( I-Premise
17.7 I-Premise
versus I-Premise
16.0 I-Premise
weeks I-Premise
, I-Premise
P I-Premise
=.21 I-Premise
) I-Premise
. I-Premise

Tumor B-Premise
response I-Premise
rates I-Premise
were I-Premise
comparable I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
10.2 I-Premise
% I-Premise
v I-Premise
8.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Intrusive B-Premise
thoughts I-Premise
also I-Premise
influenced I-Premise
the I-Premise
trajectory I-Premise
of I-Premise
pain I-Premise
, I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
negative I-Premise
affect I-Premise
, I-Premise
and I-Premise
physical I-Premise
functioning I-Premise
over I-Premise
time I-Premise
";" I-Premise
women B-Premise
with I-Premise
higher I-Premise
intrusions I-Premise
at I-Premise
baseline I-Premise
started I-Premise
worse I-Premise
and I-Premise
improved I-Premise
over I-Premise
time I-Premise
, I-Premise
whereas I-Premise
those I-Premise
with I-Premise
lower I-Premise
intrusions I-Premise
remained I-Premise
at I-Premise
a I-Premise
constant I-Premise
, I-Premise
lower I-Premise
level I-Premise
over I-Premise
time I-Premise
. I-Premise

The B-Premise
proportions I-Premise
of I-Premise
patients I-Premise
with I-Premise
adverse I-Premise
events I-Premise
were I-Premise
21 I-Premise
% I-Premise
in I-Premise
the I-Premise
low-dose I-Premise
group I-Premise
versus I-Premise
33 I-Premise
% I-Premise
in I-Premise
the I-Premise
high-dose I-Premise
group I-Premise
( I-Premise
P=0.007 I-Premise
) I-Premise
and I-Premise
23 I-Premise
% I-Premise
in I-Premise
the I-Premise
thyrotropin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
30 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
undergoing I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
( I-Premise
P=0.11 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
the I-Premise
800-mg/d I-Premise
dose I-Premise
fell I-Premise
between I-Premise
the I-Premise
low- I-Premise
and I-Premise
high-dose I-Premise
arms I-Premise
in I-Premise
reported I-Premise
intensity I-Premise
of I-Premise
drug I-Premise
side I-Premise
effects I-Premise
, I-Premise
but B-Premise
responded I-Premise
similarly I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
160-mg/d I-Premise
group I-Premise
in I-Premise
terms I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
, I-Premise
psychologic I-Premise
distress I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
10 I-Premise
months I-Premise
with I-Premise
GCa I-Premise
and I-Premise
7.6 I-Premise
months I-Premise
with I-Premise
MIC I-Premise
( I-Premise
difference I-Premise
, I-Premise
2.4 I-Premise
months I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.0 I-Premise
to I-Premise
4.0 I-Premise
) I-Premise
, I-Premise
and I-Premise
1-year I-Premise
survival I-Premise
was I-Premise
40 I-Premise
% I-Premise
with I-Premise
GCa I-Premise
and I-Premise
30 I-Premise
% I-Premise
with I-Premise
MIC I-Premise
( I-Premise
difference I-Premise
, I-Premise
10 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3 I-Premise
% I-Premise
to I-Premise
18 I-Premise
% I-Premise
) I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
post-randomisation I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
and I-Premise
control I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
arm I-Premise
volume I-Premise
. I-Premise

Significantly B-Premise
more I-Premise
neutropenia I-Premise
was I-Premise
seen I-Premise
when I-Premise
Taxol I-Premise
was I-Premise
administered I-Premise
as I-Premise
a I-Premise
24-hour I-Premise
infusion I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
at I-Premise
4 I-Premise
years I-Premise
was I-Premise
similar I-Premise
, I-Premise
with I-Premise
the I-Premise
exception I-Premise
of I-Premise
decreased I-Premise
social I-Premise
function I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
endocrine I-Premise
treatment I-Premise
plus I-Premise
radiotherapy I-Premise
. I-Premise

Efficacy B-Premise
, I-Premise
tolerability I-Premise
, I-Premise
and I-Premise
quality-of-life I-Premise
results I-Premise
were I-Premise
similar I-Premise
between I-Premise
patients I-Premise
dosed I-Premise
in I-Premise
the I-Premise
AM I-Premise
or I-Premise
PM I-Premise
. I-Premise

Taxol B-Premise
( I-Premise
paclitaxel I-Premise
";" I-Premise
Bristol-Myers I-Premise
Squibb I-Premise
, I-Premise
Wallingford I-Premise
, I-Premise
CT I-Premise
) I-Premise
is I-Premise
a I-Premise
new I-Premise
anticancer I-Premise
agent I-Premise
with I-Premise
activity I-Premise
in I-Premise
a I-Premise
number I-Premise
of I-Premise
human I-Premise
tumors I-Premise
, I-Premise
including I-Premise
epithelial I-Premise
ovarian I-Premise
cancer I-Premise
. I-Premise

Mean B-Premise
time I-Premise
to I-Premise
improvement I-Premise
was I-Premise
39.7 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
22.4 I-Premise
to I-Premise
57.0 I-Premise
weeks I-Premise
) I-Premise
for I-Premise
HBO-treated I-Premise
patients I-Premise
versus I-Premise
67.9 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
CI I-Premise
, I-Premise
48.4 I-Premise
to I-Premise
87.5 I-Premise
weeks I-Premise
) I-Premise
for I-Premise
controls I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
, I-Premise
log-rank I-Premise
test I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
duration I-Premise
for I-Premise
the I-Premise
stage I-Premise
IIIB I-Premise
subgroup I-Premise
was I-Premise
7.9 I-Premise
months I-Premise
for I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
patients I-Premise
versus I-Premise
13.1 I-Premise
months I-Premise
for I-Premise
all I-Premise
paclitaxel I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.152 I-Premise
) I-Premise
. I-Premise

Utility B-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
DTX I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
ACP I-Premise
and I-Premise
ACD I-Premise
groups I-Premise
. I-Premise

The B-Premise
3-drug I-Premise
combination I-Premise
, I-Premise
supportive I-Premise
care I-Premise
and I-Premise
radiotherapy I-Premise
groups I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
from I-Premise
each I-Premise
other I-Premise
with I-Premise
respect I-Premise
to I-Premise
the I-Premise
total I-Premise
FLI-C I-Premise
score I-Premise
or I-Premise
its I-Premise
subscales I-Premise
. I-Premise

With B-Premise
regard I-Premise
to I-Premise
the I-Premise
long-term I-Premise
quality I-Premise
of I-Premise
life I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

Similar B-Premise
trends I-Premise
in I-Premise
survival I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
were I-Premise
seen I-Premise
for I-Premise
men I-Premise
greater I-Premise
than I-Premise
and I-Premise
less I-Premise
than I-Premise
65 I-Premise
years I-Premise
of I-Premise
age I-Premise
, I-Premise
for I-Premise
those I-Premise
with I-Premise
and I-Premise
without I-Premise
pain I-Premise
at I-Premise
baseline I-Premise
, I-Premise
and I-Premise
for I-Premise
those I-Premise
with I-Premise
baseline I-Premise
PSA I-Premise
greater I-Premise
than I-Premise
and I-Premise
less I-Premise
than I-Premise
the I-Premise
median I-Premise
value I-Premise
of I-Premise
115 I-Premise
ng/mL I-Premise
. I-Premise

For B-Premise
sexually I-Premise
active I-Premise
female I-Premise
rectal I-Premise
and I-Premise
anal I-Premise
cancer I-Premise
survivors I-Premise
enrolled I-Premise
in I-Premise
a I-Premise
sexual I-Premise
health I-Premise
intervention I-Premise
, I-Premise
sexual I-Premise
dysfunction I-Premise
was I-Premise
significantly I-Premise
and I-Premise
consistently I-Premise
associated I-Premise
with I-Premise
specific I-Premise
measures I-Premise
of I-Premise
psychological I-Premise
well-being I-Premise
, I-Premise
most I-Premise
notably I-Premise
Sexual/Relationship I-Premise
Satisfaction I-Premise
. I-Premise

Although B-Premise
the I-Premise
intervention I-Premise
simultaneously I-Premise
improved I-Premise
patients I-Premise
' I-Premise
T-cell I-Premise
blastogenesis I-Premise
in I-Premise
response I-Premise
to I-Premise
phytohemagglutinin I-Premise
( I-Premise
PHA I-Premise
) I-Premise
, I-Premise
the B-Premise
latter I-Premise
increases I-Premise
were I-Premise
unrelated I-Premise
to I-Premise
improved I-Premise
health I-Premise
. I-Premise

Three B-Premise
treatment-related I-Premise
deaths I-Premise
occurred I-Premise
: I-Premise
2 I-Premise
patients I-Premise
in I-Premise
the I-Premise
surgical I-Premise
arms I-Premise
( I-Premise
one I-Premise
late I-Premise
pulmonary I-Premise
toxicity I-Premise
and I-Premise
one I-Premise
pulmonary I-Premise
embolus I-Premise
) I-Premise
, I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
the I-Premise
radiation I-Premise
arm I-Premise
( I-Premise
radiation I-Premise
pneumonitis I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
any I-Premise
outcome I-Premise
between I-Premise
groups I-Premise
. I-Premise

The B-Premise
CCSP I-Premise
patients I-Premise
frequently I-Premise
used I-Premise
the I-Premise
CCSP I-Premise
to I-Premise
manage I-Premise
psychological I-Premise
( I-Premise
51 I-Premise
% I-Premise
) I-Premise
and I-Premise
sleep I-Premise
problems I-Premise
( I-Premise
60 I-Premise
% I-Premise
) I-Premise
. I-Premise

Kaplan-Meier B-Premise
survival I-Premise
analysis I-Premise
did I-Premise
not I-Premise
indicate I-Premise
an I-Premise
overall I-Premise
survival I-Premise
benefit I-Premise
for I-Premise
the I-Premise
IG I-Premise
. I-Premise

The B-Premise
SF-36 I-Premise
MCS I-Premise
and I-Premise
PCS I-Premise
, I-Premise
Health I-Premise
Utilities I-Premise
Index I-Premise
Mark I-Premise
3 I-Premise
, I-Premise
EuroQol I-Premise
5D I-Premise
, I-Premise
and I-Premise
UDI I-Premise
scores I-Premise
were I-Premise
improved I-Premise
significantly I-Premise
in I-Premise
both I-Premise
groups I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
afterward I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
with I-Premise
PSA I-Premise
nadir I-Premise
≤ I-Premise
0.2 I-Premise
ng/ml I-Premise
, I-Premise
though I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
compared I-Premise
to I-Premise
CAD I-Premise
( I-Premise
53 I-Premise
% I-Premise
vs. I-Premise
31 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
adherence I-Premise
rate I-Premise
to I-Premise
ALT I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
the I-Premise
adherence I-Premise
to I-Premise
self-management I-Premise
therapy I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
QoL I-Premise
from I-Premise
baseline I-Premise
( I-Premise
t0 I-Premise
) I-Premise
to I-Premise
t1 I-Premise
( I-Premise
RRA I-Premise
period I-Premise
) I-Premise
in I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
with I-Premise
significant I-Premise
differences I-Premise
in I-Premise
FACIT-F I-Premise
TOI I-Premise
( I-Premise
P I-Premise
< I-Premise
10 I-Premise
( I-Premise
-3 I-Premise
) I-Premise
) I-Premise
, I-Premise
FACT-G I-Premise
total I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
and I-Premise
FACIT-F I-Premise
total I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
remission I-Premise
rate I-Premise
was I-Premise
87 I-Premise
% I-Premise
with I-Premise
31 I-Premise
% I-Premise
complete I-Premise
remissions I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
at I-Premise
3 I-Premise
years I-Premise
after I-Premise
random I-Premise
assignment I-Premise
according I-Premise
to I-Premise
treatment I-Premise
except I-Premise
for I-Premise
hot I-Premise
flashes I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
in I-Premise
ES I-Premise
total I-Premise
scores I-Premise
. I-Premise

Vinorelbine-treated B-Premise
patients I-Premise
scored I-Premise
better I-Premise
than I-Premise
control I-Premise
patients I-Premise
on I-Premise
QoL I-Premise
functioning I-Premise
scales I-Premise
, I-Premise
and I-Premise
they I-Premise
reported I-Premise
fewer I-Premise
lung I-Premise
cancer-related I-Premise
symptoms I-Premise
but I-Premise
reported I-Premise
worse I-Premise
toxicity-related I-Premise
symptoms I-Premise
. I-Premise

ALT B-Premise
had I-Premise
a I-Premise
positive I-Premise
, I-Premise
statistically I-Premise
and I-Premise
clinically I-Premise
significant I-Premise
immediate I-Premise
effect I-Premise
on I-Premise
limb I-Premise
volume I-Premise
but B-Premise
no I-Premise
long-term I-Premise
effect I-Premise
was I-Premise
noted I-Premise
. I-Premise

Patients B-Premise
who I-Premise
preferred I-Premise
RET I-Premise
improved I-Premise
QoL I-Premise
when I-Premise
they I-Premise
were I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
RET I-Premise
compared I-Premise
with I-Premise
UC I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
16.5 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
4.3-28.7 I-Premise
";" I-Premise
P= I-Premise
.008 I-Premise
) I-Premise
or I-Premise
AET I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
11 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.1-23.4 I-Premise
";" I-Premise
P= I-Premise
.076 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
16.9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
10.5 I-Premise
to I-Premise
21.2 I-Premise
months I-Premise
) I-Premise
in I-Premise
the I-Premise
TEE I-Premise
arm I-Premise
and I-Premise
23.4 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.9 I-Premise
to I-Premise
30.6 I-Premise
months I-Premise
) I-Premise
for I-Premise
patients I-Premise
treated I-Premise
with I-Premise
KA/VE I-Premise
. I-Premise

With B-Premise
the I-Premise
exceptions I-Premise
of I-Premise
increased I-Premise
granulocytopenia I-Premise
on I-Premise
the I-Premise
low-dose I-Premise
paclitaxel I-Premise
regimen I-Premise
and I-Premise
increased I-Premise
myalgias I-Premise
, I-Premise
neurotoxicity I-Premise
, I-Premise
and I-Premise
, I-Premise
possibly I-Premise
, I-Premise
increased I-Premise
treatment-related I-Premise
cardiac I-Premise
events I-Premise
with I-Premise
high-dose I-Premise
paclitaxel I-Premise
, I-Premise
toxicity I-Premise
was I-Premise
similar I-Premise
across I-Premise
all I-Premise
three I-Premise
arms I-Premise
. I-Premise

Patients B-Premise
with I-Premise
wild-type I-Premise
status I-Premise
who I-Premise
received I-Premise
cetuximab I-Premise
experienced I-Premise
improved I-Premise
GHS I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
who I-Premise
received I-Premise
BSC I-Premise
alone I-Premise
deteriorated I-Premise
( I-Premise
3.2 I-Premise
v I-Premise
-7.7 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
groups I-Premise
in I-Premise
all I-Premise
outcome I-Premise
variables I-Premise
( I-Premise
P I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
through I-Premise
the I-Premise
whole I-Premise
study I-Premise
period I-Premise
. I-Premise

QOL B-Premise
, I-Premise
except I-Premise
for I-Premise
symptoms I-Premise
of I-Premise
sensory I-Premise
neuropathy I-Premise
and I-Premise
hearing I-Premise
loss I-Premise
, I-Premise
in I-Premise
those I-Premise
treated I-Premise
with I-Premise
chemotherapy I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
by I-Premise
9 I-Premise
months I-Premise
. I-Premise

While B-Premise
under I-Premise
treatment I-Premise
, I-Premise
responders I-Premise
reported I-Premise
significantly I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
months I-Premise
3 I-Premise
to I-Premise
11 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
months I-Premise
5 I-Premise
to I-Premise
11 I-Premise
) I-Premise
, I-Premise
coping I-Premise
( I-Premise
months I-Premise
5 I-Premise
to I-Premise
9 I-Premise
) I-Premise
, I-Premise
and I-Premise
appetite I-Premise
( I-Premise
months I-Premise
7 I-Premise
to I-Premise
11 I-Premise
) I-Premise
and I-Premise
less I-Premise
dizziness I-Premise
( I-Premise
month I-Premise
9 I-Premise
) I-Premise
than I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
treatments I-Premise
in I-Premise
hematological I-Premise
and I-Premise
nonhematological I-Premise
toxic I-Premise
effects I-Premise
, I-Premise
except B-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
had I-Premise
rash I-Premise
, I-Premise
constipation I-Premise
, I-Premise
or I-Premise
neuropathy I-Premise
. I-Premise

For B-Premise
survival I-Premise
, I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
, I-Premise
pain I-Premise
, I-Premise
global I-Premise
QL I-Premise
and I-Premise
fatigue I-Premise
were I-Premise
significant I-Premise
prognostic I-Premise
factors I-Premise
in I-Premise
the I-Premise
univariate I-Premise
analysis I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
groups I-Premise
in I-Premise
mean I-Premise
change I-Premise
in I-Premise
EXIT25 I-Premise
score I-Premise
from I-Premise
baseline I-Premise
to I-Premise
6-month I-Premise
follow-up I-Premise
assessment I-Premise
. I-Premise

Participants B-Premise
completing I-Premise
the I-Premise
intervention I-Premise
demonstrated I-Premise
improvement I-Premise
in I-Premise
male I-Premise
overall I-Premise
distress I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
male I-Premise
global I-Premise
sexual I-Premise
function I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
, I-Premise
and I-Premise
female I-Premise
global I-Premise
sexual I-Premise
function I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
at I-Premise
3-month I-Premise
follow-up I-Premise
, I-Premise
but B-Premise
regression I-Premise
toward I-Premise
baseline I-Premise
was I-Premise
noted I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
. I-Premise

HRQOL B-Premise
changes I-Premise
within I-Premise
chemotherapy I-Premise
response I-Premise
strata I-Premise
revealed I-Premise
stable I-Premise
index I-Premise
scores I-Premise
but B-Premise
a I-Premise
trend I-Premise
of I-Premise
worsened I-Premise
physical I-Premise
function I-Premise
among I-Premise
patients I-Premise
with I-Premise
disease I-Premise
progression I-Premise
compared I-Premise
with I-Premise
those I-Premise
with I-Premise
stable I-Premise
or I-Premise
improved I-Premise
disease I-Premise
. I-Premise

Maintenance B-Premise
therapy I-Premise
with I-Premise
erlotinib I-Premise
did I-Premise
not I-Premise
impact I-Premise
on I-Premise
deterioration I-Premise
in I-Premise
HRQoL I-Premise
: I-Premise
TSP I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
=0.91 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
0.74-1.12 I-Premise
] I-Premise
";" I-Premise
n=785 I-Premise
) I-Premise
, I-Premise
TTD I-Premise
in I-Premise
TOI I-Premise
( I-Premise
HR=1.06 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.87-1.31 I-Premise
] I-Premise
";" I-Premise
n=781 I-Premise
) I-Premise
and I-Premise
TTD I-Premise
in I-Premise
HRQoL I-Premise
( I-Premise
HR=0.96 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.79-1.16 I-Premise
] I-Premise
";" I-Premise
n=776 I-Premise
) I-Premise
. I-Premise

At B-Premise
4-month I-Premise
follow-up I-Premise
, I-Premise
intervention I-Premise
patients I-Premise
reported I-Premise
less I-Premise
uncertainty I-Premise
and I-Premise
better I-Premise
communication I-Premise
with I-Premise
spouses I-Premise
than I-Premise
control I-Premise
patients I-Premise
, I-Premise
but B-Premise
they I-Premise
reported I-Premise
no I-Premise
other I-Premise
effects I-Premise
. I-Premise

However B-Premise
, I-Premise
raw I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
not I-Premise
different I-Premise
at I-Premise
these I-Premise
time-points I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Mitomycin-C B-Premise
had I-Premise
no I-Premise
impact I-Premise
on I-Premise
survival I-Premise
( I-Premise
p I-Premise
= I-Premise
0.75 I-Premise
) I-Premise
. I-Premise

Results B-Premise
indicated I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
for I-Premise
4 I-Premise
of I-Premise
the I-Premise
6 I-Premise
quality I-Premise
of I-Premise
life I-Premise
measures I-Premise
: I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
perception I-Premise
of I-Premise
hospitalization I-Premise
( I-Premise
p I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
relaxation I-Premise
( I-Premise
p I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
stress I-Premise
( I-Premise
p I-Premise
= I-Premise
.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
is I-Premise
a I-Premise
further I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
both I-Premise
uterine I-Premise
volume I-Premise
and I-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
between I-Premise
6 I-Premise
months I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
UAE I-Premise
. I-Premise

Regarding B-Premise
the I-Premise
postoperative I-Premise
complication I-Premise
, I-Premise
there I-Premise
were I-Premise
more I-Premise
cases I-Premise
of I-Premise
postoperative I-Premise
reflux I-Premise
oesophagitis I-Premise
and I-Premise
impairment I-Premise
of I-Premise
pulmonary I-Premise
function I-Premise
in I-Premise
the I-Premise
WS I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

At B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
energy I-Premise
intake I-Premise
increased I-Premise
in I-Premise
G1/G2 I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
G1 I-Premise
more I-Premise
than I-Premise
G2 I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
decreased I-Premise
in I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
both I-Premise
treatment I-Premise
conditions I-Premise
showed I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
depression I-Premise
, I-Premise
QOL I-Premise
, I-Premise
and I-Premise
self-efficacy I-Premise
, I-Premise
and I-Premise
caregivers I-Premise
in I-Premise
both I-Premise
conditions I-Premise
showed I-Premise
improvements I-Premise
in I-Premise
anxiety I-Premise
and I-Premise
self-efficacy I-Premise
from I-Premise
baseline I-Premise
to I-Premise
four-month I-Premise
follow-up I-Premise
. I-Premise

The B-Premise
results I-Premise
from I-Premise
evaluation I-Premise
with I-Premise
QLQ-C30 I-Premise
questionnaire I-Premise
and I-Premise
LC30 I-Premise
scale I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
was I-Premise
also I-Premise
superior I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
1 I-Premise
case I-Premise
suffered I-Premise
from I-Premise
chest I-Premise
distress I-Premise
, I-Premise
3 I-Premise
cases I-Premise
suffered I-Premise
from I-Premise
acratia I-Premise
, I-Premise
and I-Premise
4 I-Premise
cases I-Premise
suffered I-Premise
from I-Premise
pyrexia I-Premise
. I-Premise

Significant B-Premise
deterioration I-Premise
was I-Premise
noted I-Premise
after I-Premise
chemotherapy I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
in I-Premise
QoL I-Premise
scores I-Premise
, I-Premise
appetite I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
global I-Premise
health I-Premise
status I-Premise
. I-Premise

Significant B-Premise
group I-Premise
by I-Premise
time I-Premise
interactions I-Premise
showed I-Premise
that I-Premise
there I-Premise
was I-Premise
an I-Premise
improvement I-Premise
in I-Premise
dyads I-Premise
' I-Premise
coping I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
self-efficacy I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
and I-Premise
social I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
in I-Premise
caregivers I-Premise
' I-Premise
emotional I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

More B-Premise
thrombocytopenia I-Premise
occurred I-Premise
with I-Premise
GCa I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admission I-Premise
or I-Premise
fatality I-Premise
. I-Premise

Among B-Premise
these I-Premise
32 I-Premise
patients I-Premise
, I-Premise
8 I-Premise
had I-Premise
a I-Premise
partial I-Premise
response I-Premise
( I-Premise
intent-to-treat I-Premise
response I-Premise
rate I-Premise
, I-Premise
20 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
10 I-Premise
( I-Premise
25 I-Premise
% I-Premise
) I-Premise
had I-Premise
stable I-Premise
disease I-Premise
. I-Premise

Significant B-Premise
KPS-by-gender I-Premise
interactions I-Premise
were I-Premise
noted I-Premise
for I-Premise
FACT-L I-Premise
in I-Premise
the I-Premise
physical I-Premise
well-being I-Premise
and I-Premise
additional I-Premise
concerns-lung I-Premise
subscales I-Premise
( I-Premise
P I-Premise
= I-Premise
0.012 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.0003 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
postoperative I-Premise
QOL I-Premise
and I-Premise
complication I-Premise
scores I-Premise
at I-Premise
60 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
were I-Premise
significantly I-Premise
better I-Premise
than I-Premise
those I-Premise
at I-Premise
3 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
in I-Premise
each I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
QoL I-Premise
difference I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
ablation I-Premise
between I-Premise
T4-WD I-Premise
and I-Premise
T3-WD I-Premise
Groups I-Premise
. I-Premise

Fatigue B-Premise
was I-Premise
lower I-Premise
at I-Premise
1 I-Premise
year I-Premise
than I-Premise
before I-Premise
CTX I-Premise
";" I-Premise
no B-Premise
group I-Premise
effects I-Premise
were I-Premise
found I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistical I-Premise
difference I-Premise
in I-Premise
median I-Premise
overall I-Premise
survival I-Premise
with I-Premise
docetaxel I-Premise
versus I-Premise
vinorelbine I-Premise
( I-Premise
14.3 I-Premise
months I-Premise
v I-Premise
9.9 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.780 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.561 I-Premise
to I-Premise
1.085 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.138 I-Premise
) I-Premise
. I-Premise

Global B-Premise
health I-Premise
scores I-Premise
showed I-Premise
continuous I-Premise
improvement I-Premise
in I-Premise
QoL I-Premise
after I-Premise
both I-Premise
treatments I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Regarding B-Premise
the I-Premise
QoL I-Premise
investigation I-Premise
, I-Premise
the I-Premise
scores I-Premise
of I-Premise
QoL I-Premise
dropped I-Premise
for I-Premise
all I-Premise
patients I-Premise
at I-Premise
3 I-Premise
weeks I-Premise
after I-Premise
surgery I-Premise
. I-Premise

Rates B-Premise
of I-Premise
resource I-Premise
use I-Premise
were I-Premise
statistically I-Premise
higher I-Premise
for I-Premise
pemetrexed I-Premise
than I-Premise
for I-Premise
placebo I-Premise
: I-Premise
admissions I-Premise
to I-Premise
hospital I-Premise
for I-Premise
drug-related I-Premise
adverse I-Premise
events I-Premise
( I-Premise
19 I-Premise
[ I-Premise
4 I-Premise
% I-Premise
] I-Premise
vs I-Premise
none I-Premise
";" I-Premise
p=0·001 I-Premise
) I-Premise
, I-Premise
transfusions I-Premise
( I-Premise
42 I-Premise
[ I-Premise
10 I-Premise
% I-Premise
] I-Premise
vs I-Premise
seven I-Premise
[ I-Premise
3 I-Premise
% I-Premise
] I-Premise
";" I-Premise
p=0·003 I-Premise
) I-Premise
, I-Premise
and I-Premise
erythropoiesis-stimulating I-Premise
agents I-Premise
( I-Premise
26 I-Premise
[ I-Premise
6 I-Premise
% I-Premise
] I-Premise
vs I-Premise
four I-Premise
[ I-Premise
2 I-Premise
% I-Premise
] I-Premise
";" I-Premise
p=0·017 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
had I-Premise
an I-Premise
improvement I-Premise
in I-Premise
fatigue I-Premise
as I-Premise
shown I-Premise
by I-Premise
a I-Premise
significantly I-Premise
greater I-Premise
decrease I-Premise
in I-Premise
BFI I-Premise
global I-Premise
score I-Premise
( I-Premise
-0.66 I-Premise
points I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-1.04 I-Premise
to I-Premise
-0.27 I-Premise
) I-Premise
and I-Premise
FSS I-Premise
total I-Premise
score I-Premise
( I-Premise
-0.49 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-0.78 I-Premise
to I-Premise
-0.21 I-Premise
) I-Premise
. I-Premise

Frequent B-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
for I-Premise
DCF I-Premise
v I-Premise
CF I-Premise
were I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
82 I-Premise
% I-Premise
v I-Premise
57 I-Premise
% I-Premise
) I-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
21 I-Premise
% I-Premise
v I-Premise
27 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
8 I-Premise
% I-Premise
) I-Premise
, I-Premise
lethargy I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
14 I-Premise
% I-Premise
) I-Premise
. I-Premise

Interaction B-Premise
effects I-Premise
for I-Premise
mental I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
scores I-Premise
were I-Premise
not I-Premise
significant I-Premise
. I-Premise

Based B-Premise
on I-Premise
the I-Premise
results I-Premise
of I-Premise
the I-Premise
area I-Premise
under I-Premise
the I-Premise
curve I-Premise
( I-Premise
AUC I-Premise
) I-Premise
analysis I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
HMB/Arg/Gln I-Premise
had I-Premise
a I-Premise
strong I-Premise
trend I-Premise
higher I-Premise
LBM I-Premise
throughout I-Premise
the I-Premise
study I-Premise
as I-Premise
measured I-Premise
by I-Premise
both I-Premise
bioimpedance I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
and I-Premise
skin-fold I-Premise
measurements I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
without I-Premise
pain I-Premise
had I-Premise
a I-Premise
significantly I-Premise
lower I-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

The B-Premise
global I-Premise
HRQOL I-Premise
scale I-Premise
was I-Premise
comparable I-Premise
at I-Premise
baseline I-Premise
on I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
P I-Premise
= I-Premise
.848 I-Premise
) I-Premise
";" I-Premise
at B-Premise
no I-Premise
point I-Premise
was I-Premise
any I-Premise
significant I-Premise
difference I-Premise
apparent I-Premise
on I-Premise
this I-Premise
end I-Premise
point I-Premise
. I-Premise

Gefitinib B-Premise
did I-Premise
not I-Premise
show I-Premise
better I-Premise
OS I-Premise
compared I-Premise
with I-Premise
GP I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.932 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.716 I-Premise
to I-Premise
1.213 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.604 I-Premise
";" I-Premise
median I-Premise
OS I-Premise
, I-Premise
22.3 I-Premise
v I-Premise
22.9 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Vandetanib B-Premise
patients I-Premise
had I-Premise
more I-Premise
toxicity I-Premise
and I-Premise
required I-Premise
more I-Premise
dose I-Premise
modifications I-Premise
for I-Premise
gastrointestinal I-Premise
toxicity I-Premise
and I-Premise
rash I-Premise
. I-Premise

The B-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
for I-Premise
marimastat I-Premise
patients I-Premise
was I-Premise
4.3 I-Premise
months I-Premise
compared I-Premise
with I-Premise
4.4 I-Premise
months I-Premise
for I-Premise
placebo I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.81 I-Premise
) I-Premise
. I-Premise

Pretreatment B-Premise
serum I-Premise
erythropoietin I-Premise
levels I-Premise
were I-Premise
lower I-Premise
in I-Premise
responders I-Premise
than I-Premise
in I-Premise
nonresponders I-Premise
( I-Premise
73.5 I-Premise
IU/L I-Premise
and I-Premise
86.3 I-Premise
IU/L I-Premise
means I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
FLOT I-Premise
exhibited I-Premise
higher I-Premise
response I-Premise
rates I-Premise
and I-Premise
had I-Premise
improved I-Premise
disease-free I-Premise
and I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
the I-Premise
magnitude I-Premise
of I-Premise
this I-Premise
difference I-Premise
was I-Premise
not I-Premise
helpful I-Premise
in I-Premise
defining I-Premise
which I-Premise
patients I-Premise
were I-Premise
likely I-Premise
to I-Premise
respond I-Premise
. I-Premise

Significantly B-Premise
greater I-Premise
improvements I-Premise
for I-Premise
IMCP I-Premise
patients I-Premise
were I-Premise
also I-Premise
observed I-Premise
for I-Premise
the I-Premise
secondary I-Premise
outcomes I-Premise
of I-Premise
symptom I-Premise
burden I-Premise
( I-Premise
b I-Premise
= I-Premise
-6.56 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
symptom-related I-Premise
distress I-Premise
( I-Premise
b I-Premise
= I-Premise
-0.47 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
but I-Premise
not I-Premise
for I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
or I-Premise
hopelessness I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
82.9 I-Premise
% I-Premise
for I-Premise
docetaxel I-Premise
";" I-Premise
69.2 I-Premise
% I-Premise
for I-Premise
vinorelbine I-Premise
";" I-Premise
P I-Premise
= I-Premise
.031 I-Premise
) I-Premise
and I-Premise
leukopenia I-Premise
( I-Premise
58.0 I-Premise
% I-Premise
for I-Premise
docetaxel I-Premise
";" I-Premise
51.7 I-Premise
% I-Premise
for I-Premise
vinorelbine I-Premise
) I-Premise
. I-Premise

Regarding B-Premise
the I-Premise
mechanisms I-Premise
for I-Premise
achieving I-Premise
better I-Premise
health I-Premise
, I-Premise
support I-Premise
was I-Premise
found I-Premise
for I-Premise
an I-Premise
indirect I-Premise
effect I-Premise
of I-Premise
distress I-Premise
reduction I-Premise
. I-Premise

The B-Premise
median I-Premise
duration I-Premise
of I-Premise
response I-Premise
was I-Premise
8.8 I-Premise
and I-Premise
8.3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
Study I-Premise
B I-Premise
. I-Premise

The B-Premise
combined I-Premise
treatment I-Premise
group I-Premise
demonstrated I-Premise
13 I-Premise
cases I-Premise
of I-Premise
complete I-Premise
remission I-Premise
and I-Premise
22 I-Premise
cases I-Premise
of I-Premise
partial I-Premise
remission I-Premise
. I-Premise

Both B-Premise
groups I-Premise
exhibited I-Premise
significant I-Premise
decreases I-Premise
in I-Premise
hot I-Premise
flashes I-Premise
, I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
and I-Premise
other I-Premise
quality-of-life I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
mental I-Premise
health I-Premise
from I-Premise
pre- I-Premise
to I-Premise
post-treatment I-Premise
. I-Premise

Anxiety B-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
SPCG-4 I-Premise
groups I-Premise
( I-Premise
77 I-Premise
[ I-Premise
43 I-Premise
% I-Premise
] I-Premise
of I-Premise
178 I-Premise
and I-Premise
69 I-Premise
[ I-Premise
43 I-Premise
% I-Premise
] I-Premise
of I-Premise
161 I-Premise
men I-Premise
) I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
68 I-Premise
[ I-Premise
33 I-Premise
% I-Premise
] I-Premise
of I-Premise
208 I-Premise
men I-Premise
";" I-Premise
relative I-Premise
risk I-Premise
1·42 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1·07-1·88 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
IG I-Premise
had I-Premise
significantly I-Premise
improved I-Premise
scores I-Premise
on I-Premise
the I-Premise
FACIT-Fatigue I-Premise
Scale I-Premise
at I-Premise
study I-Premise
completion I-Premise
, I-Premise
improved I-Premise
fatigue I-Premise
and I-Premise
pain I-Premise
scores I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
overall I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
mental I-Premise
health I-Premise
composite I-Premise
scores I-Premise
. I-Premise

Although B-Premise
there I-Premise
was I-Premise
a I-Premise
tendency I-Premise
for I-Premise
improved I-Premise
survival I-Premise
in I-Premise
grade I-Premise
III I-Premise
, I-Premise
no I-Premise
statistical I-Premise
significant I-Premise
differences I-Premise
were I-Premise
found I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progress I-Premise
for I-Premise
radiotherapy I-Premise
only I-Premise
and I-Premise
radiotherapy I-Premise
and I-Premise
estramustin I-Premise
group I-Premise
in I-Premise
grade I-Premise
III I-Premise
tumours I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
10.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

DPPE B-Premise
plus I-Premise
DOX I-Premise
was I-Premise
statistically I-Premise
superior I-Premise
to I-Premise
DOX I-Premise
in I-Premise
OS I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.66 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.48 I-Premise
to I-Premise
0.91 I-Premise
";" I-Premise
P I-Premise
=.021 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
three I-Premise
treatment-related I-Premise
deaths I-Premise
with I-Premise
CAF I-Premise
but B-Premise
none I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
. I-Premise

Functionality B-Premise
was I-Premise
not I-Premise
greatly I-Premise
affected I-Premise
by I-Premise
treatment I-Premise
. I-Premise

The B-Premise
QLQ-C30 I-Premise
subscales I-Premise
physical I-Premise
function I-Premise
( I-Premise
P=0.044 I-Premise
) I-Premise
and I-Premise
constipation I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
during I-Premise
induction I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
MP I-Premise
arm I-Premise
. I-Premise

In B-Premise
secondary I-Premise
outcomes I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
experienced I-Premise
a I-Premise
significantly I-Premise
greater I-Premise
decrease I-Premise
in I-Premise
HADS I-Premise
anxiety I-Premise
score I-Premise
( I-Premise
-0.90 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.51 I-Premise
to I-Premise
-0.29 I-Premise
) I-Premise
as I-Premise
well I-Premise
as I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
5.22 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.93 I-Premise
to I-Premise
9.50 I-Premise
) I-Premise
and I-Premise
several I-Premise
functioning I-Premise
scores I-Premise
of I-Premise
the I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
. I-Premise

Global B-Premise
QL I-Premise
scores I-Premise
were I-Premise
lower I-Premise
at I-Premise
both I-Premise
1 I-Premise
and I-Premise
6 I-Premise
weeks I-Premise
following I-Premise
treatment I-Premise
for I-Premise
patients I-Premise
treated I-Premise
by I-Premise
SEMSs I-Premise
( I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
1=-0.66 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
-0.02 I-Premise
to I-Premise
-1.30 I-Premise
, I-Premise
P=0.04 I-Premise
";" I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
6=-1.01 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.30 I-Premise
to I-Premise
-1.72 I-Premise
, I-Premise
P=0.006 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
, I-Premise
the I-Premise
levels I-Premise
of I-Premise
VEGF I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
compared I-Premise
to I-Premise
those I-Premise
of I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
after I-Premise
treatment I-Premise
, I-Premise
which I-Premise
showed I-Premise
greater I-Premise
efficacy I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
after I-Premise
the I-Premise
end I-Premise
of I-Premise
RT I-Premise
, I-Premise
global I-Premise
HRQOL I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
TPF I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
PF I-Premise
arm I-Premise
, I-Premise
but B-Premise
the I-Premise
low I-Premise
compliance I-Premise
does I-Premise
not I-Premise
allow I-Premise
to I-Premise
draw I-Premise
definitive I-Premise
conclusions I-Premise
. I-Premise

Objective B-Premise
response I-Premise
rate I-Premise
was I-Premise
similar I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
and I-Premise
250 I-Premise
mg I-Premise
( I-Premise
9.1 I-Premise
% I-Premise
v I-Premise
10.2 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
changes I-Premise
between I-Premise
baseline I-Premise
and I-Premise
months I-Premise
5 I-Premise
and I-Premise
7 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
indicated I-Premise
improvement I-Premise
in I-Premise
responders I-Premise
but I-Premise
heterogeneous I-Premise
patterns I-Premise
in I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
and I-Premise
survival I-Premise
outcomes I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
randomised I-Premise
and I-Premise
non-randomised I-Premise
patients I-Premise
receiving I-Premise
chemotherapy I-Premise
. I-Premise

Multiple B-Premise
baseline I-Premise
factors I-Premise
, I-Premise
including I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
of I-Premise
0 I-Premise
, I-Premise
nonvisceral I-Premise
disease I-Premise
, I-Premise
< I-Premise
three I-Premise
metastatic I-Premise
sites I-Premise
, I-Premise
and I-Premise
less I-Premise
time I-Premise
from I-Premise
initial I-Premise
diagnosis I-Premise
until I-Premise
random I-Premise
assignment I-Premise
, I-Premise
were I-Premise
associated I-Premise
with I-Premise
improved I-Premise
OS I-Premise
. I-Premise

In B-Premise
the I-Premise
Gefitinib I-Premise
group I-Premise
, I-Premise
ORR I-Premise
was I-Premise
17.3 I-Premise
% I-Premise
( I-Premise
4/23 I-Premise
) I-Premise
, I-Premise
DCR I-Premise
was I-Premise
39.1 I-Premise
% I-Premise
( I-Premise
9/23 I-Premise
) I-Premise
, I-Premise
and I-Premise
mPFS I-Premise
was I-Premise
4.4 I-Premise
months I-Premise
. I-Premise

Improvement B-Premise
was I-Premise
noted I-Premise
in I-Premise
physical I-Premise
capacity I-Premise
: I-Premise
estimated I-Premise
mean I-Premise
difference I-Premise
between I-Premise
groups I-Premise
for I-Premise
maximum I-Premise
oxygen I-Premise
consumption I-Premise
was I-Premise
0.16 I-Premise
l/min I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.1 I-Premise
to I-Premise
0.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
for I-Premise
muscular I-Premise
strength I-Premise
( I-Premise
leg I-Premise
press I-Premise
) I-Premise
was I-Premise
29.7 I-Premise
kg I-Premise
( I-Premise
23.4 I-Premise
to I-Premise
34.9 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
30 I-Premise
months I-Premise
, I-Premise
letrozole I-Premise
significantly I-Premise
improved I-Premise
disease-free I-Premise
survival I-Premise
( I-Premise
DFS I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
the I-Premise
primary I-Premise
end I-Premise
point I-Premise
, I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
for I-Premise
recurrence I-Premise
or I-Premise
contralateral I-Premise
breast I-Premise
cancer I-Premise
0.58 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
0.45 I-Premise
, I-Premise
0.76 I-Premise
] I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
IMRT I-Premise
group I-Premise
, I-Premise
there I-Premise
was I-Premise
consistent I-Premise
improvement I-Premise
over I-Premise
time I-Premise
with I-Premise
xerostomia-related I-Premise
symptoms I-Premise
significantly I-Premise
less I-Premise
common I-Premise
than I-Premise
in I-Premise
the I-Premise
CRT I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
postradiotherapy I-Premise
. I-Premise

A B-Premise
similar I-Premise
pattern I-Premise
was I-Premise
observed I-Premise
for I-Premise
knee I-Premise
extensor I-Premise
muscles I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
. I-Premise

The B-Premise
quality I-Premise
of I-Premise
life I-Premise
improved I-Premise
in I-Premise
control I-Premise
group I-Premise
by I-Premise
13.7 I-Premise
% I-Premise
, I-Premise
while I-Premise
combined I-Premise
treatment I-Premise
group I-Premise
showed I-Premise
improvement I-Premise
of I-Premise
83.5 I-Premise
% I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
vs. I-Premise
control I-Premise
group I-Premise
) I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
toxicity I-Premise
in I-Premise
the I-Premise
groups I-Premise
was I-Premise
similar I-Premise
. I-Premise

CPT-11 B-Premise
+ I-Premise
LFA-5-FU I-Premise
compares I-Premise
favorably I-Premise
in I-Premise
term I-Premise
of I-Premise
activity I-Premise
and I-Premise
toxicity I-Premise
with I-Premise
other I-Premise
combination I-Premise
regimens I-Premise
including I-Premise
CPT-11 I-Premise
and I-Premise
continuous I-Premise
infusional I-Premise
5-FU I-Premise
. I-Premise

Three-month B-Premise
survival I-Premise
rates I-Premise
for I-Premise
the I-Premise
P I-Premise
, I-Premise
TMX60 I-Premise
, I-Premise
and I-Premise
TMX120 I-Premise
groups I-Premise
were I-Premise
44 I-Premise
% I-Premise
, I-Premise
41 I-Premise
% I-Premise
, I-Premise
and I-Premise
35 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
with I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
trend I-Premise
difference I-Premise
in I-Premise
survival I-Premise
across I-Premise
the I-Premise
3 I-Premise
treatment I-Premise
regimens I-Premise
( I-Premise
P I-Premise
=.011 I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
grade I-Premise
2 I-Premise
or I-Premise
above I-Premise
nausea I-Premise
was I-Premise
numerically I-Premise
higher I-Premise
in I-Premise
the I-Premise
GP I-Premise
arm I-Premise
, I-Premise
but B-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
GE I-Premise
15.5 I-Premise
% I-Premise
, I-Premise
GP I-Premise
27.7 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0.20 I-Premise
) I-Premise
. I-Premise

Results B-Premise
analysis I-Premise
revealed I-Premise
that I-Premise
OMWQ-HN I-Premise
( I-Premise
F I-Premise
= I-Premise
12.199 I-Premise
, I-Premise
df I-Premise
= I-Premise
6,1314 I-Premise
, I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
FACT-HN I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
LLLT I-Premise
than I-Premise
placebo I-Premise
group I-Premise
patients I-Premise
. I-Premise

Scores B-Premise
on I-Premise
the I-Premise
physical I-Premise
function I-Premise
, I-Premise
role-physical I-Premise
, I-Premise
and I-Premise
general I-Premise
health I-Premise
subscales I-Premise
of I-Premise
the I-Premise
SF-36 I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
Canadian I-Premise
normative I-Premise
data I-Premise
at I-Premise
all I-Premise
time I-Premise
points I-Premise
. I-Premise

In B-Premise
a I-Premise
longitudinal I-Premise
analysis I-Premise
of I-Premise
men I-Premise
in I-Premise
SPCG-4 I-Premise
who I-Premise
provided I-Premise
information I-Premise
at I-Premise
two I-Premise
follow-up I-Premise
points I-Premise
9 I-Premise
years I-Premise
apart I-Premise
, I-Premise
38 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
85 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
and I-Premise
48 I-Premise
( I-Premise
60 I-Premise
% I-Premise
) I-Premise
of I-Premise
80 I-Premise
men I-Premise
allocated I-Premise
watchful I-Premise
waiting I-Premise
reported I-Premise
an I-Premise
increase I-Premise
in I-Premise
number I-Premise
of I-Premise
physical I-Premise
symptoms I-Premise
";" I-Premise
50 I-Premise
( I-Premise
61 I-Premise
% I-Premise
) I-Premise
of I-Premise
82 I-Premise
and I-Premise
47 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
of I-Premise
74 I-Premise
men I-Premise
, I-Premise
respectively I-Premise
, I-Premise
reported I-Premise
a I-Premise
reduction I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Therapy B-Premise
with I-Premise
combined I-Premise
bevacizumab I-Premise
plus I-Premise
cisplatin I-Premise
significantly I-Premise
reduced I-Premise
VEGF I-Premise
levels I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Scores B-Premise
were I-Premise
stable I-Premise
over I-Premise
time I-Premise
and I-Premise
considerably I-Premise
lower I-Premise
than I-Premise
the I-Premise
general I-Premise
population I-Premise
norms I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
effect I-Premise
on I-Premise
the I-Premise
General I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
score I-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
or I-Premise
on I-Premise
any I-Premise
of I-Premise
the I-Premise
individual I-Premise
wellbeing I-Premise
scores I-Premise
";" I-Premise
Physical I-Premise
( I-Premise
P I-Premise
= I-Premise
.13 I-Premise
) I-Premise
, I-Premise
Emotional I-Premise
( I-Premise
P I-Premise
= I-Premise
.87 I-Premise
) I-Premise
, I-Premise
Social I-Premise
( I-Premise
P I-Premise
= I-Premise
.83 I-Premise
) I-Premise
and I-Premise
Functional I-Premise
( I-Premise
P I-Premise
= I-Premise
.26 I-Premise
) I-Premise
. I-Premise

The B-Premise
change I-Premise
in I-Premise
total I-Premise
FACT-B+4 I-Premise
scores I-Premise
( I-Premise
measuring I-Premise
global I-Premise
QOL I-Premise
) I-Premise
closely I-Premise
resembled I-Premise
the I-Premise
TOI I-Premise
results I-Premise
. I-Premise

At B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
initial I-Premise
effects I-Premise
were I-Premise
retained I-Premise
. I-Premise

A B-Premise
positive I-Premise
longitudinal I-Premise
impact I-Premise
of I-Premise
the I-Premise
intervention I-Premise
on I-Premise
symptom I-Premise
discussion I-Premise
was I-Premise
observed I-Premise
, I-Premise
but B-Premise
not I-Premise
for I-Premise
function I-Premise
discussion I-Premise
, I-Premise
suggesting I-Premise
that I-Premise
potentially I-Premise
serious I-Premise
problems I-Premise
may I-Premise
remain I-Premise
unaddressed I-Premise
. I-Premise

Similarly B-Premise
, I-Premise
no I-Premise
difference I-Premise
in I-Premise
survival I-Premise
was I-Premise
found I-Premise
when I-Premise
the I-Premise
patients I-Premise
who I-Premise
received I-Premise
both I-Premise
the I-Premise
planned I-Premise
first-and I-Premise
second-line I-Premise
treatments I-Premise
were I-Premise
compared I-Premise
or I-Premise
when I-Premise
survival I-Premise
was I-Premise
calculated I-Premise
from I-Premise
the I-Premise
beginning I-Premise
of I-Premise
the I-Premise
second-line I-Premise
therapy I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
5.9 I-Premise
months I-Premise
with I-Premise
GC I-Premise
and I-Premise
6.3 I-Premise
months I-Premise
with I-Premise
PE I-Premise
. I-Premise

Placebo-treated B-Premise
patients I-Premise
had I-Premise
a I-Premise
mean I-Premise
increase I-Premise
in I-Premise
HgB I-Premise
of I-Premise
0.9 I-Premise
g/dL I-Premise
( I-Premise
range I-Premise
, I-Premise
-3.8 I-Premise
to I-Premise
+5.3 I-Premise
) I-Premise
compared I-Premise
with I-Premise
2.8 I-Premise
g/dL I-Premise
( I-Premise
range I-Premise
, I-Premise
-2.2 I-Premise
to I-Premise
+7.5 I-Premise
) I-Premise
for I-Premise
epoetin-treated I-Premise
patients I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
grade I-Premise
3-4 I-Premise
late I-Premise
radiation I-Premise
toxicities I-Premise
. I-Premise

Frequencies B-Premise
of I-Premise
hematologic I-Premise
and I-Premise
nonhematologic I-Premise
toxicities I-Premise
were I-Premise
essentially I-Premise
similar I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
and I-Premise
OS I-Premise
were I-Premise
8.2 I-Premise
and I-Premise
19.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
at I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
26.4 I-Premise
months I-Premise
. I-Premise

Toxicity B-Premise
was I-Premise
generally I-Premise
limited I-Premise
to I-Premise
musculoskeletal I-Premise
symptoms I-Premise
( I-Premise
18 I-Premise
% I-Premise
grade I-Premise
3/4 I-Premise
for I-Premise
marimastat I-Premise
) I-Premise
. I-Premise

Similar B-Premise
results I-Premise
were I-Premise
found I-Premise
for I-Premise
low-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyrotropin I-Premise
alfa I-Premise
( I-Premise
84.3 I-Premise
% I-Premise
) I-Premise
versus I-Premise
high-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
( I-Premise
87.6 I-Premise
% I-Premise
) I-Premise
or I-Premise
high-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyrotropin I-Premise
alfa I-Premise
( I-Premise
90.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

By B-Premise
cycle I-Premise
4 I-Premise
, I-Premise
mean I-Premise
differences I-Premise
were I-Premise
clinically I-Premise
meaningful I-Premise
for I-Premise
most I-Premise
domains I-Premise
, I-Premise
indicating I-Premise
poorer I-Premise
health I-Premise
status I-Premise
with I-Premise
VMP I-Premise
. I-Premise

Drowsiness B-Premise
, I-Premise
confusion I-Premise
and I-Premise
dry I-Premise
mouth I-Premise
were I-Premise
significantly I-Premise
more I-Premise
intense I-Premise
with I-Premise
amitriptyline I-Premise
than I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.036 I-Premise
, I-Premise
0.003 I-Premise
, I-Premise
and I-Premise
0.034 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Among B-Premise
patients I-Premise
who I-Premise
had I-Premise
measurable I-Premise
disease I-Premise
( I-Premise
TC I-Premise
, I-Premise
n I-Premise
= I-Premise
147 I-Premise
";" I-Premise
TC-Top I-Premise
, I-Premise
n I-Premise
= I-Premise
145 I-Premise
) I-Premise
, I-Premise
overall I-Premise
( I-Premise
i.e. I-Premise
, I-Premise
complete I-Premise
or I-Premise
partial I-Premise
) I-Premise
response I-Premise
was I-Premise
69.0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
61.4 I-Premise
% I-Premise
to I-Premise
76.5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
and I-Premise
76.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
69.3 I-Premise
% I-Premise
to I-Premise
83.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.166 I-Premise
) I-Premise
. I-Premise

The B-Premise
use I-Premise
of I-Premise
prophylactic I-Premise
tamsulosin I-Premise
resulted I-Premise
in I-Premise
a I-Premise
statistically I-Premise
lower I-Premise
dysuria I-Premise
severity I-Premise
score I-Premise
( I-Premise
difference I-Premise
of I-Premise
2.7 I-Premise
vs I-Premise
4.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.005 I-Premise
) I-Premise
at I-Premise
1 I-Premise
month I-Premise
, I-Premise
with I-Premise
no I-Premise
discernible I-Premise
differences I-Premise
at I-Premise
3 I-Premise
, I-Premise
6 I-Premise
, I-Premise
12 I-Premise
and I-Premise
18 I-Premise
months I-Premise
. I-Premise

Two B-Premise
patients I-Premise
treated I-Premise
with I-Premise
a I-Premise
cumulative I-Premise
dose I-Premise
of I-Premise
MMC I-Premise
of I-Premise
40 I-Premise
mg/m2 I-Premise
developed I-Premise
haemolytic I-Premise
uraemic I-Premise
syndrome I-Premise
warranting I-Premise
the I-Premise
reduction I-Premise
in I-Premise
cumulative I-Premise
MMC I-Premise
dose I-Premise
to I-Premise
28 I-Premise
mg/m2 I-Premise
. I-Premise

The B-Premise
use I-Premise
of I-Premise
fluoxetine I-Premise
for I-Premise
6 I-Premise
months I-Premise
resulted I-Premise
in I-Premise
an I-Premise
improvement I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
a I-Premise
higher I-Premise
completion I-Premise
of I-Premise
adjuvant I-Premise
treatment I-Premise
( I-Premise
chemotherapy I-Premise
, I-Premise
hormonal I-Premise
therapy I-Premise
, I-Premise
chemotherapy I-Premise
plus I-Premise
hormonal I-Premise
therapy I-Premise
) I-Premise
, I-Premise
and I-Premise
a I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
compared I-Premise
to I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
. I-Premise

No B-Premise
differences I-Premise
in I-Premise
overall I-Premise
survival I-Premise
or I-Premise
imatinib I-Premise
resistance I-Premise
were I-Premise
observed I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
was I-Premise
7.8 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
4-11.6 I-Premise
months I-Premise
) I-Premise
. I-Premise

The B-Premise
combined I-Premise
anthracycline I-Premise
followed I-Premise
by I-Premise
taxane I-Premise
group I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
utility I-Premise
scores I-Premise
that I-Premise
the I-Premise
taxane-alone I-Premise
group I-Premise
, I-Premise
with I-Premise
no I-Premise
significant I-Premise
difference I-Premise
depending I-Premise
on I-Premise
the I-Premise
type I-Premise
of I-Premise
taxane I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
17 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
was I-Premise
8.6 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
7.9 I-Premise
to I-Premise
9.7 I-Premise
months I-Premise
) I-Premise
for I-Premise
gemcitabine I-Premise
plus I-Premise
carboplatin I-Premise
and I-Premise
5.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
5.2 I-Premise
to I-Premise
7.1 I-Premise
months I-Premise
) I-Premise
for I-Premise
carboplatin I-Premise
. I-Premise

GHRQL B-Premise
was I-Premise
initially I-Premise
worse I-Premise
for I-Premise
the I-Premise
RP+RT I-Premise
arm I-Premise
but I-Premise
improved I-Premise
over I-Premise
time I-Premise
and I-Premise
was I-Premise
better I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
period I-Premise
than I-Premise
the I-Premise
GHRQL I-Premise
reported I-Premise
for I-Premise
RP I-Premise
alone I-Premise
( I-Premise
treatment I-Premise
arm I-Premise
x I-Premise
time I-Premise
interaction I-Premise
, I-Premise
P I-Premise
= I-Premise
.0004 I-Premise
) I-Premise
. I-Premise

Additionally B-Premise
, I-Premise
patients I-Premise
started I-Premise
on I-Premise
strong I-Premise
opioids I-Premise
required I-Premise
significantly I-Premise
fewer I-Premise
changes I-Premise
in I-Premise
therapy I-Premise
, I-Premise
had I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
pain I-Premise
when I-Premise
a I-Premise
change I-Premise
was I-Premise
initiated I-Premise
, I-Premise
and I-Premise
reported I-Premise
greater I-Premise
satisfaction I-Premise
with I-Premise
treatment I-Premise
than I-Premise
the I-Premise
comparator I-Premise
group I-Premise
( I-Premise
P=0.041 I-Premise
) I-Premise
. I-Premise

Complicated B-Premise
neutropenia I-Premise
was I-Premise
more I-Premise
frequent I-Premise
with I-Premise
DCF I-Premise
than I-Premise
CF I-Premise
( I-Premise
29 I-Premise
% I-Premise
v I-Premise
12 I-Premise
% I-Premise
) I-Premise
. I-Premise

QOL B-Premise
improvement I-Premise
rates I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Head I-Premise
& I-Premise
amp I-Premise
";" I-Premise
Neck I-Premise
total I-Premise
score I-Premise
) I-Premise
were I-Premise
13.4 I-Premise
% I-Premise
, I-Premise
18.0 I-Premise
% I-Premise
, I-Premise
and I-Premise
6.0 I-Premise
% I-Premise
for I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
, I-Premise
500 I-Premise
mg/day I-Premise
, I-Premise
and I-Premise
methotrexate I-Premise
, I-Premise
respectively I-Premise
. I-Premise

However B-Premise
, I-Premise
1-month I-Premise
GI I-Premise
toxicity I-Premise
was I-Premise
not I-Premise
only I-Premise
worse I-Premise
in I-Premise
patients I-Premise
with I-Premise
the I-Premise
hypofractionated I-Premise
RT I-Premise
schedule I-Premise
but I-Premise
also I-Premise
adversely I-Premise
affected I-Premise
daily I-Premise
activities I-Premise
. I-Premise

The B-Premise
exercise I-Premise
program I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
as I-Premise
evidenced I-Premise
by I-Premise
high I-Premise
attendance I-Premise
( I-Premise
83 I-Premise
% I-Premise
) I-Premise
and I-Premise
compliance I-Premise
rates I-Premise
( I-Premise
93 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
ability I-Premise
of I-Premise
the I-Premise
participants I-Premise
to I-Premise
exercise I-Premise
at I-Premise
an I-Premise
intensity I-Premise
within I-Premise
the I-Premise
target I-Premise
range I-Premise
for I-Premise
cancer I-Premise
survivors I-Premise
( I-Premise
rating I-Premise
of I-Premise
perceived I-Premise
exertion I-Premise
=13.8±1.5 I-Premise
) I-Premise
. I-Premise

Both B-Premise
EBRT I-Premise
and I-Premise
cryoablation I-Premise
participants I-Premise
reported I-Premise
decreases I-Premise
in I-Premise
sexual I-Premise
function I-Premise
at I-Premise
3 I-Premise
months I-Premise
with I-Premise
the I-Premise
cryoablation I-Premise
patients I-Premise
reporting I-Premise
poorer I-Premise
functioning I-Premise
( I-Premise
mean I-Premise
cryoablation=7.2 I-Premise
: I-Premise
mean I-Premise
EBRT=32.9 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
the I-Premise
six I-Premise
month I-Premise
follow-up I-Premise
, I-Premise
most I-Premise
of I-Premise
these I-Premise
effects I-Premise
were I-Premise
maintained I-Premise
and I-Premise
an I-Premise
intervention I-Premise
effect I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
specific I-Premise
quality I-Premise
of I-Premise
life I-Premise
emerged I-Premise
. I-Premise

No B-Premise
QOL I-Premise
differences I-Premise
were I-Premise
noted I-Premise
between I-Premise
arms I-Premise
. I-Premise

No B-Premise
differences I-Premise
in I-Premise
opioid I-Premise
doses I-Premise
during I-Premise
the I-Premise
period I-Premise
of I-Premise
study I-Premise
were I-Premise
found I-Premise
. I-Premise

After B-Premise
radiotherapy I-Premise
and I-Premise
at I-Premise
3 I-Premise
months I-Premise
, I-Premise
rates I-Premise
of I-Premise
anorexia I-Premise
, I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
diarrhea I-Premise
were I-Premise
higher I-Premise
in I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

MSBR B-Premise
improved I-Premise
mood I-Premise
, I-Premise
breast- I-Premise
and I-Premise
endocrine-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
and I-Premise
well-being I-Premise
more I-Premise
effectively I-Premise
than I-Premise
standard I-Premise
care I-Premise
in I-Premise
women I-Premise
with I-Premise
stage I-Premise
0 I-Premise
to I-Premise
III I-Premise
breast I-Premise
cancer I-Premise
, I-Premise
and I-Premise
these I-Premise
results I-Premise
persisted I-Premise
at I-Premise
three I-Premise
months I-Premise
. I-Premise

The B-Premise
average I-Premise
costs I-Premise
of I-Premise
the I-Premise
primary I-Premise
treatment I-Premise
were I-Premise
higher I-Premise
in I-Premise
GM-CSF-treated I-Premise
patients I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
i.e I-Premise
. I-Premise
US I-Premise
$ I-Premise
40782 I-Premise
and I-Premise
US I-Premise
$ I-Premise
34465 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
8.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
8.1-10.4 I-Premise
months I-Premise
) I-Premise
and I-Premise
11.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9.7-12.7 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.247 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.82 I-Premise
) I-Premise
";" I-Premise
the I-Premise
median I-Premise
OS I-Premise
was I-Premise
25.0 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
18.8-not I-Premise
assessable I-Premise
[ I-Premise
N/A I-Premise
] I-Premise
months I-Premise
) I-Premise
and I-Premise
24.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
20.3-N/A I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.475 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.84 I-Premise
) I-Premise
, I-Premise
with I-Premise
PB I-Premise
and I-Premise
PB+G I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Premise
the I-Premise
placebo I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
liver I-Premise
volume I-Premise
increased I-Premise
1.6 I-Premise
% I-Premise
, I-Premise
from I-Premise
4689 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
613-8765 I-Premise
mL I-Premise
) I-Premise
to I-Premise
4895 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
739-9053 I-Premise
mL I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
erlotinib I-Premise
had I-Premise
significantly I-Premise
longer I-Premise
median I-Premise
time I-Premise
to I-Premise
deterioration I-Premise
for I-Premise
all I-Premise
three I-Premise
symptoms I-Premise
( I-Premise
4.9 I-Premise
v I-Premise
3.7 I-Premise
months I-Premise
for I-Premise
cough I-Premise
[ I-Premise
P I-Premise
= I-Premise
.04 I-Premise
] I-Premise
";" I-Premise
4.7 I-Premise
v I-Premise
2.9 I-Premise
months I-Premise
for I-Premise
dyspnea I-Premise
[ I-Premise
P I-Premise
= I-Premise
.04 I-Premise
] I-Premise
, I-Premise
and I-Premise
2.8 I-Premise
v I-Premise
1.9 I-Premise
months I-Premise
for I-Premise
pain I-Premise
[ I-Premise
P I-Premise
= I-Premise
.03 I-Premise
] I-Premise
) I-Premise
. I-Premise

Breast B-Premise
IMRT I-Premise
significantly I-Premise
improved I-Premise
the I-Premise
dose I-Premise
distribution I-Premise
compared I-Premise
with I-Premise
standard I-Premise
radiation I-Premise
. I-Premise

The B-Premise
results I-Premise
were I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

Among B-Premise
all I-Premise
treatment I-Premise
groups I-Premise
, I-Premise
patients I-Premise
who I-Premise
had I-Premise
a I-Premise
mastectomy I-Premise
had I-Premise
the I-Premise
poorest I-Premise
physical I-Premise
functioning I-Premise
at I-Premise
registration I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
at I-Premise
enrollment I-Premise
( I-Premise
P=.05 I-Premise
) I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
was I-Premise
5.5 I-Premise
months I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.04 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.727 I-Premise
) I-Premise
, I-Premise
while I-Premise
ORR I-Premise
was I-Premise
25 I-Premise
% I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
P I-Premise
= I-Premise
1.0 I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
QOL I-Premise
drop-out I-Premise
for I-Premise
any I-Premise
reason I-Premise
was I-Premise
higher I-Premise
for I-Premise
C I-Premise
( I-Premise
53 I-Premise
% I-Premise
) I-Premise
compared I-Premise
to I-Premise
CP I-Premise
( I-Premise
38 I-Premise
% I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
Grade I-Premise
4 I-Premise
toxicity I-Premise
was I-Premise
56 I-Premise
% I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
mitomycin-C I-Premise
and I-Premise
29 I-Premise
% I-Premise
in I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
. I-Premise

Body B-Premise
image I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
cancer-specific I-Premise
posttraumatic I-Premise
distress I-Premise
were I-Premise
notable I-Premise
in I-Premise
their I-Premise
association I-Premise
with I-Premise
subscales I-Premise
of I-Premise
sexual I-Premise
functioning I-Premise
, I-Premise
while I-Premise
a I-Premise
global I-Premise
QOL I-Premise
measure I-Premise
was I-Premise
largely I-Premise
unrelated I-Premise
. I-Premise

Median B-Premise
OS I-Premise
was I-Premise
9.45 I-Premise
and I-Premise
10 I-Premise
months I-Premise
respectively I-Premise
for I-Premise
weekly I-Premise
VNR/CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
one I-Premise
without I-Premise
statistically I-Premise
a I-Premise
significant I-Premise
difference I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
p=0.259 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
weight I-Premise
changes I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
MA I-Premise
( I-Premise
17.1 I-Premise
% I-Premise
v I-Premise
7.6 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
gemcitabine-carboplatin I-Premise
reported I-Premise
significantly I-Premise
faster I-Premise
palliation I-Premise
of I-Premise
abdominal I-Premise
symptoms I-Premise
and I-Premise
a I-Premise
significantly I-Premise
improved I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

This B-Premise
trend I-Premise
for I-Premise
OS I-Premise
benefit I-Premise
for I-Premise
GEM-CAP I-Premise
was I-Premise
consistent I-Premise
across I-Premise
different I-Premise
prognostic I-Premise
subgroups I-Premise
according I-Premise
to I-Premise
baseline I-Premise
stratification I-Premise
factors I-Premise
( I-Premise
stage I-Premise
and I-Premise
performance I-Premise
status I-Premise
) I-Premise
and I-Premise
remained I-Premise
after I-Premise
adjusting I-Premise
for I-Premise
these I-Premise
stratification I-Premise
factors I-Premise
( I-Premise
P I-Premise
= I-Premise
.077 I-Premise
) I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
WHO I-Premise
grade I-Premise
3 I-Premise
or I-Premise
4 I-Premise
anemia I-Premise
, I-Premise
neutropenia I-Premise
and I-Premise
thrombocytopenia I-Premise
was I-Premise
29 I-Premise
, I-Premise
44 I-Premise
and I-Premise
22 I-Premise
% I-Premise
( I-Premise
GE I-Premise
group I-Premise
) I-Premise
, I-Premise
and I-Premise
28 I-Premise
, I-Premise
49 I-Premise
and I-Premise
23 I-Premise
% I-Premise
( I-Premise
GP I-Premise
group I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.75 I-Premise
, I-Premise
0.95 I-Premise
and I-Premise
0.87 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Drain B-Premise
usage I-Premise
, I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
resumption I-Premise
of I-Premise
normal I-Premise
day-to-day I-Premise
activities I-Premise
after I-Premise
surgery I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
axillary I-Premise
operative I-Premise
time I-Premise
was I-Premise
reduced I-Premise
( I-Premise
P I-Premise
= I-Premise
.055 I-Premise
) I-Premise
. I-Premise

Gross-total B-Premise
removal I-Premise
( I-Premise
GTR I-Premise
) I-Premise
was I-Premise
achieved I-Premise
in I-Premise
five I-Premise
patients I-Premise
who I-Premise
underwent I-Premise
SS I-Premise
and I-Premise
in I-Premise
three I-Premise
who I-Premise
underwent I-Premise
SN I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
response I-Premise
rates I-Premise
, I-Premise
with I-Premise
64 I-Premise
% I-Premise
( I-Premise
complete I-Premise
response I-Premise
[ I-Premise
CR I-Premise
] I-Premise
, I-Premise
9 I-Premise
% I-Premise
) I-Premise
for I-Premise
fludarabine I-Premise
versus I-Premise
52 I-Premise
% I-Premise
( I-Premise
CR I-Premise
, I-Premise
7 I-Premise
% I-Premise
) I-Premise
for I-Premise
CVP I-Premise
( I-Premise
P I-Premise
=.72 I-Premise
) I-Premise
. I-Premise

The B-Premise
major I-Premise
World I-Premise
Health I-Premise
Organization I-Premise
grade I-Premise
3-4 I-Premise
toxicities I-Premise
for I-Premise
NP I-Premise
and I-Premise
NIP I-Premise
, I-Premise
respectively I-Premise
, I-Premise
were I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
20.3 I-Premise
% I-Premise
compared I-Premise
with I-Premise
9 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
) I-Premise
, I-Premise
anaemia I-Premise
( I-Premise
4.1 I-Premise
% I-Premise
compared I-Premise
with I-Premise
5 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
) I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
22.2 I-Premise
% I-Premise
compared I-Premise
with I-Premise
19.4 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
and I-Premise
alopecia I-Premise
( I-Premise
5.6 I-Premise
% I-Premise
compared I-Premise
with I-Premise
29.8 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
found I-Premise
between I-Premise
groups I-Premise
regarding I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
complications I-Premise
, I-Premise
drainage I-Premise
time I-Premise
, I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
and I-Premise
survival I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
intervention I-Premise
by I-Premise
subgroup I-Premise
interactions I-Premise
( I-Premise
P I-Premise
> I-Premise
.10 I-Premise
) I-Premise
. I-Premise

Complete B-Premise
remission I-Premise
was I-Premise
achieved I-Premise
in I-Premise
91 I-Premise
% I-Premise
( I-Premise
170/186 I-Premise
) I-Premise
of I-Premise
all I-Premise
patients I-Premise
. I-Premise

Superior B-Premise
survival I-Premise
was I-Premise
observed I-Premise
with I-Premise
the I-Premise
combined I-Premise
paclitaxel I-Premise
regimens I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
9.9 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
38.9 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
7.6 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
31.8 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
48 I-Premise
) I-Premise
. I-Premise

Changes B-Premise
in I-Premise
resting I-Premise
energy I-Premise
expenditure I-Premise
and I-Premise
biochemical I-Premise
tests I-Premise
did I-Premise
not I-Premise
differ I-Premise
during I-Premise
follow-up I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise

The B-Premise
dose-intensified I-Premise
arm I-Premise
was I-Premise
slightly I-Premise
more I-Premise
emetogenic I-Premise
and I-Premise
generated I-Premise
more I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
anemia I-Premise
but I-Premise
less I-Premise
febrile I-Premise
neutropenia I-Premise
episodes I-Premise
. I-Premise

Overall B-Premise
response I-Premise
was I-Premise
54 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
44.1 I-Premise
% I-Premise
-63.9 I-Premise
% I-Premise
) I-Premise
with I-Premise
PVI I-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
compared I-Premise
to I-Premise
38 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
28.3 I-Premise
% I-Premise
-47.7 I-Premise
% I-Premise
) I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
( I-Premise
P I-Premise
= I-Premise
0.024 I-Premise
) I-Premise
. I-Premise

By B-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
treatment I-Premise
period I-Premise
, I-Premise
hot I-Premise
flash I-Premise
scores I-Premise
( I-Premise
frequency I-Premise
x I-Premise
average I-Premise
severity I-Premise
) I-Premise
decreased I-Premise
68 I-Premise
% I-Premise
from I-Premise
baseline I-Premise
to I-Premise
end I-Premise
point I-Premise
in I-Premise
the I-Premise
hypnosis I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Mixed B-Premise
effects I-Premise
models I-Premise
with I-Premise
adjustment I-Premise
for I-Premise
baseline I-Premise
values I-Premise
, I-Premise
study I-Premise
site I-Premise
, I-Premise
treatment I-Premise
at I-Premise
baseline I-Premise
, I-Premise
and I-Premise
age I-Premise
gave I-Premise
intervention I-Premise
effect I-Premise
estimates I-Premise
( I-Premise
intervention I-Premise
minus I-Premise
control I-Premise
) I-Premise
at I-Premise
12 I-Premise
weeks I-Premise
of I-Premise
129 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
83 I-Premise
to I-Premise
176 I-Premise
) I-Premise
for I-Premise
metres I-Premise
walked I-Premise
in I-Premise
12 I-Premise
minutes I-Premise
, I-Premise
182 I-Premise
( I-Premise
75 I-Premise
to I-Premise
289 I-Premise
) I-Premise
for I-Premise
minutes I-Premise
of I-Premise
moderate I-Premise
intensity I-Premise
activity I-Premise
reported I-Premise
in I-Premise
a I-Premise
week I-Premise
, I-Premise
2.6 I-Premise
( I-Premise
1.6 I-Premise
to I-Premise
3.7 I-Premise
) I-Premise
for I-Premise
shoulder I-Premise
mobility I-Premise
, I-Premise
2.5 I-Premise
( I-Premise
1.0 I-Premise
to I-Premise
3.9 I-Premise
) I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
specific I-Premise
subscale I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
and I-Premise
4.0 I-Premise
( I-Premise
1.8 I-Premise
to I-Premise
6.3 I-Premise
) I-Premise
for I-Premise
positive I-Premise
mood I-Premise
. I-Premise

At B-Premise
5 I-Premise
years I-Premise
, I-Premise
the I-Premise
prevalence I-Premise
of I-Premise
new I-Premise
fibroid I-Premise
was I-Premise
60 I-Premise
% I-Premise
in I-Premise
the I-Premise
myomectomy I-Premise
group I-Premise
and I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
UAE I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.008 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
discussed I-Premise
more I-Premise
symptoms I-Premise
over I-Premise
time I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
attention-control I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
and I-Premise
control I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
arms I-Premise
. I-Premise

Before B-Premise
radiotherapy I-Premise
, I-Premise
84 I-Premise
% I-Premise
of I-Premise
patients I-Premise
reported I-Premise
erections I-Premise
adequate I-Premise
for I-Premise
intercourse I-Premise
at I-Premise
least I-Premise
a I-Premise
few I-Premise
times I-Premise
during I-Premise
the I-Premise
previous I-Premise
year I-Premise
. I-Premise

The B-Premise
surviving I-Premise
fraction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
based I-Premise
on I-Premise
Kaplan-Meier I-Premise
analysis I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
intervention I-Premise
groups I-Premise
had I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
levels I-Premise
of I-Premise
endocrine I-Premise
symptoms I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Endocrine I-Premise
Symptoms I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.31-0.52 I-Premise
) I-Premise
and I-Premise
urinary I-Premise
symptoms I-Premise
( I-Premise
Bristol I-Premise
Female I-Premise
Lower I-Premise
Urinary I-Premise
Tract I-Premise
Symptoms I-Premise
Questionnaire I-Premise
";" I-Premise
P=.002 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.29-0.33 I-Premise
) I-Premise
, I-Premise
and I-Premise
they I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
in I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
36-Item I-Premise
Short I-Premise
Form I-Premise
Health I-Premise
Survey I-Premise
physical I-Premise
functioning I-Premise
subscale I-Premise
";" I-Premise
P=.002 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.37-0.46 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
an I-Premise
increase I-Premise
in I-Premise
OS I-Premise
, I-Premise
which I-Premise
reached I-Premise
statistical I-Premise
significance I-Premise
in I-Premise
the I-Premise
EGFR I-Premise
IHC-positive I-Premise
subgroup I-Premise
( I-Premise
p=0.0233 I-Premise
) I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
time I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
17.2 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
15.2 I-Premise
to I-Premise
19.3 I-Premise
months I-Premise
) I-Premise
and I-Premise
the I-Premise
PT I-Premise
arm I-Premise
( I-Premise
19.1 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
16.7 I-Premise
to I-Premise
21.5 I-Premise
months I-Premise
) I-Premise
were I-Premise
also I-Premise
not I-Premise
statistically I-Premise
significantly I-Premise
different I-Premise
";" I-Premise
the B-Premise
same I-Premise
was I-Premise
TRUE I-Premise
of I-Premise
median I-Premise
overall I-Premise
survival I-Premise
time I-Premise
( I-Premise
43.3 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
37.2 I-Premise
to I-Premise
47.8 I-Premise
months I-Premise
versus I-Premise
44.1 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
40.2 I-Premise
to I-Premise
49.4 I-Premise
months I-Premise
, I-Premise
for I-Premise
the I-Premise
TC I-Premise
and I-Premise
PT I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

FACT-B B-Premise
scores I-Premise
increased I-Premise
after I-Premise
treatment I-Premise
began I-Premise
and I-Premise
remained I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
or I-Premise
anastrozole I-Premise
group I-Premise
during I-Premise
the I-Premise
first I-Premise
year I-Premise
( I-Premise
P I-Premise
= I-Premise
0.045 I-Premise
) I-Premise
. I-Premise

The B-Premise
number I-Premise
of I-Premise
patients I-Premise
with I-Premise
an I-Premise
IPSS I-Premise
change I-Premise
of I-Premise
≥ I-Premise
3 I-Premise
over I-Premise
baseline I-Premise
was I-Premise
also I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
degarelix I-Premise
( I-Premise
61.0 I-Premise
vs I-Premise
44.3 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

Best B-Premise
response I-Premise
to I-Premise
induction I-Premise
therapy I-Premise
was I-Premise
complete I-Premise
remission I-Premise
for I-Premise
176 I-Premise
patients I-Premise
( I-Premise
33 I-Premise
% I-Premise
) I-Premise
, I-Premise
partial I-Premise
remission I-Premise
for I-Premise
341 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
15 I-Premise
patients I-Premise
( I-Premise
3 I-Premise
% I-Premise
) I-Premise
had I-Premise
undergone I-Premise
surgical I-Premise
resection I-Premise
. I-Premise

The B-Premise
added I-Premise
benefit I-Premise
of I-Premise
CMF I-Premise
followed I-Premise
by I-Premise
tamoxifen I-Premise
over I-Premise
tamoxifen I-Premise
alone I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
dependent I-Premise
on I-Premise
ER I-Premise
status I-Premise
( I-Premise
tests I-Premise
for I-Premise
interaction I-Premise
: I-Premise
P I-Premise
=.01 I-Premise
for I-Premise
disease-free I-Premise
survival I-Premise
[ I-Premise
DFS I-Premise
] I-Premise
and I-Premise
P I-Premise
=.07 I-Premise
for I-Premise
overall I-Premise
survival I-Premise
[ I-Premise
OS I-Premise
] I-Premise
) I-Premise
. I-Premise

Participants B-Premise
in I-Premise
the I-Premise
Internet I-Premise
group I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
at I-Premise
post-assessment I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
in I-Premise
overall I-Premise
insomnia I-Premise
severity I-Premise
( I-Premise
F I-Premise
( I-Premise
1,26 I-Premise
) I-Premise
= I-Premise
22.8 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
sleep I-Premise
efficiency I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
11.45 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
, I-Premise
sleep I-Premise
onset I-Premise
latency I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
5.18 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
soundness I-Premise
of I-Premise
sleep I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
9.34 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
, I-Premise
restored I-Premise
feeling I-Premise
upon I-Premise
awakening I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
11.95 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
, I-Premise
and I-Premise
general I-Premise
fatigue I-Premise
( I-Premise
F I-Premise
( I-Premise
1,26 I-Premise
) I-Premise
= I-Premise
13.88 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

In B-Premise
limited I-Premise
disease I-Premise
the I-Premise
estimated I-Premise
percentages I-Premise
of I-Premise
survival I-Premise
at I-Premise
2 I-Premise
years I-Premise
were I-Premise
33 I-Premise
% I-Premise
in I-Premise
the I-Premise
early I-Premise
and I-Premise
24 I-Premise
% I-Premise
in I-Premise
the I-Premise
late I-Premise
alternating I-Premise
chemotherapy I-Premise
arms I-Premise
. I-Premise

Good B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
19.5 I-Premise
% I-Premise
vs. I-Premise
49 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
47 I-Premise
% I-Premise
vs. I-Premise
72 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Cox B-Premise
regression I-Premise
models I-Premise
that I-Premise
took I-Premise
TNM I-Premise
staging I-Premise
or I-Premise
the I-Premise
residual I-Premise
tumor I-Premise
classification I-Premise
and I-Premise
tumor I-Premise
site I-Premise
into I-Premise
account I-Premise
also I-Premise
found I-Premise
significant I-Premise
differences I-Premise
at I-Premise
10 I-Premise
years I-Premise
. I-Premise

By B-Premise
contrast I-Premise
, I-Premise
QoL I-Premise
was I-Premise
preserved I-Premise
in I-Premise
the I-Premise
rhTSH I-Premise
group I-Premise
. I-Premise

No B-Premise
QOL I-Premise
difference I-Premise
was I-Premise
found I-Premise
, I-Premise
although I-Premise
more I-Premise
side I-Premise
effects I-Premise
occurred I-Premise
in I-Premise
CAD I-Premise
. I-Premise

Dermatology B-Premise
Life I-Premise
Quality I-Premise
Index I-Premise
( I-Premise
DLQI I-Premise
) I-Premise
scores I-Premise
were I-Premise
assessed I-Premise
for I-Premise
each I-Premise
treatment I-Premise
modality I-Premise
at I-Premise
week I-Premise
4 I-Premise
and I-Premise
were I-Premise
1.95 I-Premise
and I-Premise
1.38 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
.20 I-Premise
) I-Premise
. I-Premise

Other B-Premise
symptoms I-Premise
including I-Premise
sore I-Premise
mouth I-Premise
and I-Premise
hair I-Premise
loss I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
GE I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
0.003 I-Premise
and I-Premise
0.007 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

At B-Premise
the I-Premise
post-treatment I-Premise
assessment I-Premise
, I-Premise
IMCP I-Premise
participants I-Premise
demonstrated I-Premise
significantly I-Premise
greater I-Premise
improvement I-Premise
than I-Premise
the I-Premise
control I-Premise
condition I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
of I-Premise
spiritual I-Premise
well-being I-Premise
( I-Premise
b I-Premise
= I-Premise
0.39 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
, I-Premise
including I-Premise
both I-Premise
components I-Premise
of I-Premise
spiritual I-Premise
well-being I-Premise
( I-Premise
sense I-Premise
of I-Premise
meaning I-Premise
: I-Premise
b I-Premise
= I-Premise
0.34 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.003 I-Premise
and I-Premise
faith I-Premise
: I-Premise
b I-Premise
= I-Premise
0.42 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
b I-Premise
= I-Premise
0.76 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
. I-Premise

Intervention B-Premise
spouses I-Premise
reported I-Premise
higher I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
more I-Premise
self-efficacy I-Premise
, I-Premise
better I-Premise
communication I-Premise
, I-Premise
and I-Premise
less I-Premise
negative I-Premise
appraisal I-Premise
of I-Premise
caregiving I-Premise
, I-Premise
uncertainty I-Premise
, I-Premise
hopelessness I-Premise
, I-Premise
and I-Premise
symptom I-Premise
distress I-Premise
at I-Premise
4 I-Premise
months I-Premise
compared I-Premise
with I-Premise
controls I-Premise
, I-Premise
and I-Premise
some I-Premise
effects I-Premise
were I-Premise
sustained I-Premise
to I-Premise
8 I-Premise
months I-Premise
and I-Premise
12 I-Premise
months I-Premise
. I-Premise

DC/CIK B-Premise
treatment I-Premise
prolongs I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
3.20 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.94-3.50 I-Premise
] I-Premise
vs I-Premise
2.56 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.39-2.73 I-Premise
] I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
adverse I-Premise
events I-Premise
( I-Premise
AE I-Premise
";" I-Premise
78.0 I-Premise
% I-Premise
vs I-Premise
79.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
serious I-Premise
AE I-Premise
( I-Premise
11.1 I-Premise
% I-Premise
vs I-Premise
9.9 I-Premise
% I-Premise
) I-Premise
and I-Premise
discontinuations I-Premise
due I-Premise
to I-Premise
AE I-Premise
( I-Premise
3.8 I-Premise
% I-Premise
vs I-Premise
4.0 I-Premise
% I-Premise
) I-Premise
and I-Premise
serious I-Premise
AE I-Premise
( I-Premise
2.0 I-Premise
% I-Premise
vs I-Premise
1.3 I-Premise
% I-Premise
) I-Premise
were I-Premise
comparable I-Premise
in I-Premise
washout I-Premise
versus I-Premise
direct-switch I-Premise
patients I-Premise
. I-Premise

PIDs B-Premise
were I-Premise
0·9 I-Premise
and I-Premise
0·3 I-Premise
in I-Premise
the I-Premise
oxycodone/paracetamol I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
respectively I-Premise
, I-Premise
on I-Premise
day I-Premise
1 I-Premise
( I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
, I-Premise
and I-Premise
1·5 I-Premise
and I-Premise
0·3 I-Premise
respectively I-Premise
on I-Premise
day I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
. I-Premise

The O
primary O
objective O
of O
this O
study O
was O
to O
compare O
the O
response O
rates O
of O
elderly O
, O
chemonaive O
patients O
with O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
treated O
with O
daily O
oral O
erlotinib O
versus O
oral O
vinorelbine O
. O

To O
compare O
dose-volume O
histogram O
variables O
for O
the O
internal O
and O
external O
urinary O
sphincters O
( O
IUS/EUS O
) O
with O
urinary O
quality O
of O
life O
after O
prostate O
brachytherapy O
. O

This O
article O
reports O
the O
health-related O
quality-of-life O
( O
HRQL O
) O
outcomes O
from O
CO.17 O
. O

Sixty-one O
patients O
were O
enrolled O
from O
the O
Salt O
Lake O
City O
Veterans O
Affairs O
Hospital O
";" O
51 O
completed O
the O
study O
and O
were O
included O
in O
the O
analysis O
. O

Main O
exclusion O
criteria O
were O
brain O
or O
bone O
metastases O
. O

This O
is O
a O
randomized O
phase O
II O
study O
designed O
to O
compare O
the O
toxicity O
profile O
of O
a O
non-platinum-based O
with O
a O
platinum-based O
regimen O
in O
the O
treatment O
of O
advanced O
non-small O
cell O
lung O
cancer O
. O

A O
multicenter O
trial O
was O
conducted O
to O
determine O
the O
efficacy O
and O
toxicity O
of O
escalating O
dosages O
of O
liposomal O
tretinoin O
( O
all-trans-retinoic O
acid O
) O
administered O
once O
or O
three O
times O
weekly O
in O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
-associated O
Kaposi O
sarcoma O
. O

A O
total O
of O
497 O
patients O
with O
previously O
untreated O
metastatic O
colorectal O
cancer O
were O
randomly O
assigned O
to O
receive O
bolus O
FU O
425 O
mg/m2 O
intravenously O
+ O
LV O
20 O
mg/m2 O
on O
days O
1 O
to O
5 O
and O
repeated O
on O
day O
28 O
( O
FU O
+ O
LV O
) O
, O
or O
FU O
2600 O
mg/m2 O
as O
a O
24-hour O
infusion O
alone O
( O
FU24h O
) O
or O
in O
combination O
with O
500 O
mg/m2 O
LV O
( O
FU24h O
+ O
LV O
) O
-all O
given O
weekly O
x6 O
followed O
by O
a O
2-week O
rest O
period O
. O

Sensitivity O
analyses O
were O
also O
performed O
for O
selected O
QOL O
domains O
and O
items O
, O
using O
other O
types O
of O
summary O
measures O
and O
statistics O
. O

This O
international O
, O
randomized O
, O
controlled O
, O
multicenter O
trial O
aimed O
to O
compare O
the O
efficacy O
and O
safety O
of O
recombinant O
human O
TSH O
( O
rhTSH O
) O
to O
prepare O
euthyroid O
patients O
on O
L-thyroxine O
therapy O
( O
euthyroid O
group O
) O
to O
ablate O
remnant O
thyroid O
tissue O
with O
3.7 O
GBq O
( O
100 O
mCi O
) O
131I O
, O
compared O
with O
that O
with O
conventional O
remnant O
ablation O
performed O
in O
the O
hypothyroid O
state O
( O
hypothyroid O
group O
) O
. O

Pain O
was O
assessed O
with O
the O
BPI-SF O
questionnaire O
, O
and O
health-related O
quality O
of O
life O
( O
HRQoL O
) O
with O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Prostate O
( O
FACT-P O
) O
questionnaire O
. O

The O
feasibility O
of O
measuring O
Bcl-2 O
protein O
in O
a O
cooperative O
group O
setting O
is O
hypothesis O
generating O
and O
supports O
further O
study O
as O
a O
marker O
for O
Bcl-2 O
targeted O
therapy O
. O

Paclitaxel O
was O
administered O
as O
a O
3-hour O
intravenous O
infusion O
every O
3 O
weeks O
. O

Gastrointestinal O
( O
GI O
) O
and O
genitourinary O
( O
GU O
) O
toxicity O
was O
evaluated O
before O
RT O
and O
after O
its O
completion O
using O
modified O
late O
effects O
of O
normal O
tissue-subjective O
, O
objective O
, O
management O
, O
analytic O
( O
LENT-SOMA O
) O
scales O
and O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
sexual O
function O
questionnaire O
. O

Patients O
were O
assigned O
to O
12 O
weekly O
injections O
of O
subcutaneous O
epoetin O
alpha O
or O
placebo O
, O
targeting O
Hgb O
levels O
between O
120 O
and O
140 O
g/L O
. O

Most O
patients O
received O
radiotherapy O
in O
the O
adjuvant O
setting O
( O
52 O
of O
the O
83 O
) O
and O
had O
either O
an O
oral O
cavity O
( O
42 O
of O
the O
83 O
) O
or O
an O
oropharyngeal O
( O
16 O
of O
the O
83 O
) O
cancer O
. O

Chronic O
gastrointestinal O
symptoms O
after O
pelvic O
radiotherapy O
are O
common O
, O
multifactorial O
in O
cause O
, O
and O
affect O
patients O
' O
quality O
of O
life O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
a O
novel O
mindfulness O
intervention O
called O
mindfulness-based O
art O
therapy O
( O
MBAT O
) O
versus O
standard O
educational O
support O
, O
on O
indices O
of O
stress O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
with O
high O
stress O
levels O
. O

A O
prospective O
randomized O
, O
controlled O
pilot O
trial O
with O
historical O
control O
. O

Between O
1990 O
and O
1997 O
, O
714 O
patients O
with O
stage O
IC O
grade O
1 O
to O
2 O
or O
IB O
grade O
2 O
to O
3 O
EC O
were O
randomly O
allocated O
to O
pelvic O
external-beam O
radiotherapy O
( O
EBRT O
) O
or O
no O
additional O
treatment O
( O
NAT O
) O
. O

Although O
single- O
and O
multiple-fraction O
radiotherapy O
are O
thought O
to O
provide O
equal O
palliation O
, O
which O
treatment O
schedule O
provides O
better O
value O
for O
the O
money O
is O
unknown O
. O

QOL O
was O
assessed O
over O
a O
1-year O
follow-up O
period O
, O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C-30 O
. O

From O
March O
1995 O
until O
April O
1998 O
, O
812 O
patients O
were O
randomly O
assigned O
to O
receive O
three O
or O
four O
cycles O
: O
of O
these O
, O
681 O
were O
also O
randomly O
assigned O
to O
the O
5-day O
or O
the O
3-day O
schedule O
. O

The O
European O
Study O
Group O
for O
Pancreatic O
Cancer O
( O
ESPAC-1 O
) O
study O
is O
the O
largest O
study O
of O
adjuvant O
treatment O
for O
pancreatic O
ductal O
adenocarcinoma O
to O
date O
and O
confirmed O
a O
survival O
advantage O
for O
adjuvant O
chemotherapy O
but O
not O
for O
chemoradiation O
. O

At O
the O
last O
follow-up O
date O
, O
26 O
patients O
had O
died O
, O
10 O
of O
their O
disease O
and O
none O
of O
toxicity O
, O
with O
no O
differences O
between O
the O
two O
arms O
. O

To O
help O
document O
the O
achievement O
of O
palliation O
and O
to O
characterize O
positive O
and O
negative O
effects O
of O
treatment O
, O
we O
evaluated O
quality-of-life O
( O
QOL O
) O
parameters O
in O
patients O
with O
metastatic O
prostate O
cancer O
who O
were O
randomly O
assigned O
to O
two O
methods O
of O
androgen O
deprivation O
. O

The O
low O
response O
rate O
is O
partly O
related O
to O
the O
number O
of O
patients O
who O
received O
only O
one O
cycle O
of O
chemotherapy O
. O

Pre- O
and O
post-assessment O
data O
were O
collected O
via O
online O
questionnaires O
and O
daily O
sleep O
diaries O
. O

Fifty O
GI O
cancer O
patients O
received O
postoperative O
7 O
days O
of O
isocaloric O
and O
isonitrogenous O
TPN O
after O
operation O
. O

Hence O
, O
we O
did O
this O
study O
to O
evaluate O
the O
effects O
of O
LLLT O
on O
a O
patient O
's O
reported O
measures O
of O
OM O
and O
QOL O
in O
head O
and O
neck O
cancer O
( O
HNC O
) O
patients O
receiving O
CRT O
. O

These O
results O
were O
robust O
to O
sensitivity O
analysis O
. O

Between O
May O
2002 O
and O
January O
2005 O
, O
533 O
patients O
were O
randomly O
assigned O
to O
GEM O
( O
n O
= O
266 O
) O
and O
GEM-CAP O
( O
n O
= O
267 O
) O
arms O
. O

We O
conducted O
a O
multicenter O
, O
randomized O
trial O
to O
compare O
progression-free O
survival O
( O
PFS O
) O
, O
overall O
survival O
( O
OS O
) O
, O
and O
quality O
of O
life O
in O
women O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
receiving O
high-dose O
chemotherapy O
plus O
autologous O
stem-cell O
transplantation O
( O
ASCT O
";" O
HDCT O
) O
compared O
with O
standard-dose O
therapy O
. O

The O
relationship O
between O
change O
in O
self-efficacy O
and O
long-term O
physical O
activity O
( O
PA O
) O
also O
was O
examined O
. O

Double-blind O
, O
randomized O
clinical O
trial O
. O

Patients O
with O
various O
malignancies O
participated O
in O
the O
RCT O
( O
n O
= O
210 O
) O
. O

PP O
group O
received O
pemetrexed O
500 O
mg/m² O
iv O
infusion O
d1 O
and O
cisplatin O
75 O
mg/m² O
iv O
infusion O
d1 O
, O
whereas O
GP O
group O
received O
gemcitabine O
1,000 O
mg/m² O
iv O
infusion O
d1,8 O
and O
cisplatin O
75 O
mg/m² O
iv O
infusion O
d1 O
. O

The O
societal O
values O
of O
life O
expectancies O
were O
assessed O
with O
the O
EuroQol O
classification O
system O
( O
EQ-5D O
) O
questionnaire O
. O

Following O
pretesting O
in O
313 O
patients O
, O
patients O
who O
needed O
district O
nursing O
and O
who O
did O
not O
need O
district O
nursing O
at O
home O
were O
randomly O
assigned O
to O
a O
control O
or O
intervention O
group O
. O

The O
quality O
of O
life O
( O
QoL O
) O
substudy O
tested O
whether O
capecitabine O
treatment O
would O
be O
associated O
with O
a O
better O
QoL O
than O
standard O
chemotherapy O
. O

Data O
were O
collected O
from O
both O
groups O
of O
dyads O
using O
standardized O
assessments O
on O
admission O
and O
1 O
week O
after O
each O
of O
the O
first O
2 O
IDT O
meetings O
in O
which O
these O
dyads O
were O
discussed O
. O

infusion O
and O
5-FU O
, O
1050 O
mg/m2 O
i.v O
. O

All O
patients O
had O
stage O
IV O
or O
relapsed O
disease O
and O
a O
performance O
score O
of O
0 O
or O
1 O
. O

The O
primary O
outcome O
measures O
were O
dysphagia O
, O
quality O
of O
life O
( O
QL O
) O
6 O
weeks O
following O
treatment O
, O
and O
total O
cost O
of O
treatment O
. O

Newly O
diagnosed O
advanced O
cancer O
patients O
undergoing O
radiation O
therapy O
were O
randomized O
to O
active O
QOL O
intervention O
or O
control O
groups O
. O

Multicenter O
, O
randomized O
trial O
. O

Fatigue O
is O
the O
most O
commonly O
reported O
symptom O
in O
all O
cancer O
patients O
. O

Three O
patients O
were O
ineligible O
. O

The O
primary O
endpoint O
was O
change O
in O
Inflammatory O
Bowel O
Disease O
Questionnaire-Bowel O
subset O
score O
( O
IBDQ-B O
) O
at O
6 O
months O
, O
analysed O
by O
intention O
to O
treat O
. O

If O
replicated O
, O
these O
results O
may O
inform O
clinical O
practice O
. O

For O
patients O
who O
received O
thoracic O
radiotherapy O
, O
the O
median O
time O
to O
start O
was O
15 O
days O
in O
the O
immediate O
treatment O
group O
and O
125 O
days O
in O
the O
delayed O
treatment O
group O
. O

In O
a O
phase O
III O
clinical O
trial O
organized O
by O
the O
French O
Federation O
of O
Cancer O
Institutes O
, O
patients O
were O
randomly O
assigned O
to O
receive O
either O
EP O
( O
n O
= O
109 O
";" O
etoposide O
at O
a O
dose O
of O
100 O
mg/m O
( O
2 O
) O
on O
days O
1-3 O
plus O
cisplatin O
at O
100 O
mg/m O
( O
2 O
) O
on O
day O
2 O
) O
or O
PCDE O
( O
n O
= O
117 O
";" O
etoposide O
and O
cisplatin O
given O
as O
in O
EP O
plus O
cyclophosphamide O
at O
400 O
mg/m O
( O
2 O
) O
on O
days O
1-3 O
and O
4'-epidoxorubicin O
at O
40 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
every O
4 O
weeks O
. O

This O
study O
examined O
how O
PRO O
feedback O
had O
an O
impact O
on O
patient-physician O
communication O
over O
time O
to O
gain O
a O
better O
understanding O
of O
how O
it O
may O
influence O
patient O
care O
. O

Between O
Nov O
26 O
, O
2007 O
, O
and O
Dec O
12 O
, O
2011 O
, O
we O
enrolled O
and O
randomly O
allocated O
218 O
patients O
to O
treatment O
: O
80 O
to O
the O
nurse O
group O
, O
70 O
to O
the O
gastroenterologist O
group O
, O
and O
68 O
to O
the O
booklet O
group O
( O
figure O
) O
. O

All O
volunteers O
were O
given O
dl-alpha O
tocopheryl O
acetate O
500 O
mg O
twice O
a O
day O
orally O
plus O
pentoxifylline O
400 O
mg O
twice O
a O
day O
orally O
, O
or O
corresponding O
placebos O
, O
for O
6 O
months O
. O

The O
mean O
number O
of O
hot O
flashes O
per O
day O
was O
reduced O
from O
8.7 O
( O
standard O
deviation O
[ O
SD O
] O
, O
3.9 O
) O
to O
6.2 O
( O
SD O
, O
4.2 O
) O
in O
the O
TRUE O
acupuncture O
group O
and O
from O
10.0 O
( O
SD O
, O
6.1 O
) O
to O
7.6 O
( O
SD O
, O
5.7 O
) O
in O
the O
sham O
group O
. O

If O
the O
intervention O
period O
was O
prolonged O
, O
we O
might O
get O
different O
conclusion O
. O

Of O
the O
analyzable O
patients O
, O
90 O
% O
had O
a O
Karnofsky O
performance O
score O
of O
90-100 O
, O
18 O
% O
had O
weight O
loss O
> O
5 O
% O
, O
37 O
% O
had O
squamous O
cell O
histologic O
features O
, O
and O
54 O
% O
had O
bulky O
N2 O
disease O
. O

Analysis O
of O
the O
overall O
burden O
of O
therapy O
received O
by O
all O
surviving O
children O
( O
including O
primary O
treatment O
and O
treatment O
for O
relapse O
if O
required O
) O
showed O
that O
24 O
% O
( O
28/116 O
) O
were O
treated O
by O
limited O
surgery O
followed O
by O
three O
courses O
of O
IVA O
, O
29 O
% O
( O
34/116 O
) O
were O
treated O
by O
chemotherapy O
alone O
( O
after O
initial O
biopsy O
) O
and O
13 O
% O
( O
15/116 O
) O
received O
chemotherapy O
plus O
conservative O
local O
treatment O
( O
limited O
surgery O
or O
radiotherapy O
for O
residual O
disease O
) O
. O

Symptom O
and O
quality O
of O
life O
( O
QOL O
) O
status O
was O
determined O
with O
use O
of O
questionnaires O
. O

This O
study O
aimed O
to O
determine O
the O
effectiveness O
of O
a O
nurse-delivered O
telephone O
supportive O
intervention O
( O
the O
" O
CONNECT O
" O
intervention O
) O
. O

To O
compare O
the O
efficacy O
and O
tolerability O
of O
ALA-PDT O
and O
imiquimod O
5 O
% O
cream O
for O
the O
treatment O
of O
AKs O
. O

Hot O
flushes O
and O
night O
sweats O
( O
HFNS O
) O
affect O
65-85 O
% O
of O
women O
after O
breast O
cancer O
treatment O
";" O
they O
are O
distressing O
, O
causing O
sleep O
problems O
and O
decreased O
quality O
of O
life O
. O

Breast O
cancer O
patients O
initiating O
adjuvant O
chemotherapy O
( O
n O
= O
242 O
) O
were O
randomly O
assigned O
to O
usual O
care O
( O
n O
= O
82 O
) O
, O
resistance O
exercise O
training O
( O
RET O
";" O
n O
= O
82 O
) O
, O
or O
aerobic O
exercise O
training O
( O
AET O
";" O
n O
= O
78 O
) O
for O
the O
duration O
of O
their O
chemotherapy O
. O

Patients O
were O
mainly O
≥ O
40 O
years O
of O
age O
, O
married O
, O
Caucasian O
, O
and O
diagnosed O
with O
advanced O
breast O
cancer O
. O

We O
report O
on O
the O
quality O
of O
life O
( O
QOL O
) O
outcomes O
for O
this O
trial O
. O

Controls O
had O
no O
prophylactic O
exercises O
and O
were O
referred O
for O
swallowing O
treatment O
after O
completion O
of O
CRT O
if O
indicated O
. O

The O
benefits O
of O
sertraline O
compared O
with O
placebo O
are O
expressed O
on O
a O
range O
from O
100 O
( O
ie O
, O
maximum O
benefit O
) O
to O
-100 O
( O
ie O
, O
maximum O
harm O
) O
";" O
a O
difference O
of O
10 O
was O
deemed O
clinically O
significant O
. O

Compliance O
to O
HRQOL O
assessments O
was O
97 O
% O
at O
baseline O
, O
but O
dropped O
to O
54 O
% O
by O
6 O
months O
. O

A O
phase O
III O
randomized O
trial O
was O
carried O
out O
to O
compare O
two O
schedules O
of O
the O
vinorelbine O
( O
VNR O
) O
-cisplatin O
( O
CDDP O
) O
regimen O
in O
patients O
with O
locally O
advanced O
unresectable O
poor O
prognosis O
stage O
IIIB O
or O
metastatic O
stage O
IV O
non-small O
cell O
lung O
cancer O
. O

Treatment-related O
quality O
of O
life O
was O
assessed O
by O
the O
Breast O
Chemotherapy O
Questionnaire O
( O
BCQ O
) O
before O
, O
during O
, O
and O
4 O
months O
after O
treatment O
in O
163 O
patients O
. O

Intervention O
patients O
had O
access O
for O
up O
to O
12 O
months O
to O
a O
depression O
care O
manager O
who O
was O
supervised O
by O
a O
psychiatrist O
and O
a O
primary O
care O
provider O
and O
who O
offered O
education O
, O
care O
management O
, O
support O
of O
antidepressant O
management O
, O
and O
brief O
, O
structured O
psychosocial O
interventions O
including O
behavioral O
activation O
and O
problem-solving O
treatment O
. O

Patients O
with O
stage O
III O
or O
IV O
cancer O
( O
N O
= O
120 O
) O
were O
randomly O
assigned O
to O
seven O
sessions O
of O
either O
IMCP O
or O
therapeutic O
massage O
( O
TM O
) O
. O

From O
February O
2007 O
to O
July O
2008 O
, O
116 O
patients O
were O
enrolled O
and O
113 O
were O
included O
in O
the O
intent-to-treat O
population O
: O
57 O
patients O
in O
the O
E O
group O
and O
56 O
patients O
in O
the O
V O
group O
. O

Challenges O
with O
capturing O
pain O
data O
were O
identified O
and O
resolved O
. O

Attrition O
was O
assessed O
in O
terms O
of O
the O
percent O
of O
participants O
who O
failed O
to O
complete O
these O
assessments O
, O
and O
demographic O
, O
psychiatric O
, O
medical O
, O
and O
study-related O
correlates O
of O
attrition O
were O
examined O
for O
the O
participants O
in O
each O
of O
these O
categories O
. O

However O
, O
there O
were O
no O
significant O
differences O
in O
total O
response O
rates O
, O
tumor O
progression O
duration O
, O
and O
median O
survival O
rates O
of O
1 O
and O
2 O
years O
. O

To O
assess O
the O
efficacy O
of O
a O
novel O
coloplasty O
colonic O
pouch O
design O
in O
optimizing O
bowel O
function O
after O
ultralow O
anterior O
resection O
. O

QOL O
was O
evaluated O
by O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
and O
subscales O
from O
the O
prostate O
cancer O
module O
, O
PR-25 O
, O
and O
the O
ovarian O
cancer O
module O
, O
OV-28 O
. O

5 O
significance O
level O
. O

The O
aim O
of O
the O
study O
was O
to O
compare O
clinical O
outcomes O
and O
quality O
of O
life O
in O
patients O
undergoing O
surgery O
for O
pilonidal O
disease O
with O
unroofing O
and O
marsupialization O
( O
UM O
) O
or O
rhomboid O
excision O
and O
Limberg O
flap O
( O
RELP O
) O
procedures O
. O

Here O
we O
report O
mature O
HRQoL O
outcomes O
from O
the O
ATAC O
trial O
, O
comparing O
anastrozole O
with O
tamoxifen O
as O
primary O
adjuvant O
therapy O
for O
postmenopausal O
women O
with O
localized O
breast O
cancer O
. O

Patients O
with O
histologically-proven O
unresectable O
MPM O
, O
not O
pretreated O
with O
chemotherapy O
were O
randomly O
assigned O
to O
receive O
cisplatin O
80 O
mg/m2 O
intravenously O
on O
day O
1 O
, O
with O
or O
without O
preceding O
infusion O
of O
raltitrexed O
3 O
mg/m2 O
. O

To O
assess O
the O
efficacy O
of O
prophylactic O
swallowing O
exercises O
on O
swallowing O
function O
in O
patients O
undergoing O
chemoradiation O
therapy O
( O
CRT O
) O
for O
head O
and O
neck O
cancer O
. O

Forty O
patients O
( O
31 O
men O
and O
9 O
women O
) O
were O
enrolled O
and O
received O
3-5 O
courses O
of O
treatment O
. O

The O
primary O
outcome O
was O
QOL O
. O

All O
patients O
who O
underwent O
randomisation O
were O
included O
in O
analyses O
. O

Participants O
, O
identified O
within O
1 O
month O
after O
surgery O
( O
registration O
) O
, O
provided O
demographic O
information O
and O
limited O
measures O
of O
quality O
of O
life O
. O

Sunitinib O
has O
demonstrated O
antitumor O
activity O
in O
metastatic O
renal O
cell O
carcinoma O
( O
mRCC O
) O
when O
given O
at O
50 O
mg/d O
on O
a O
4-weeks-on O
2-weeks-off O
regimen O
. O

Dietary O
intake O
( O
protein O
, O
energy O
, O
fiber O
) O
assessed O
at O
baseline O
and O
at O
4 O
, O
8 O
, O
and O
12 O
weeks O
after O
starting O
radiotherapy O
. O

Regularly O
collecting O
patient-reported O
outcomes O
( O
PROs O
) O
of O
health-related O
quality O
of O
life O
with O
feedback O
to O
oncologists O
may O
assist O
in O
eliciting O
and O
monitoring O
patients O
' O
problems O
during O
cancer O
treatment O
. O

In O
total O
, O
60 O
overweight O
or O
obese O
postmenopausal O
patients O
were O
enrolled O
. O

The O
study O
accrued O
344 O
patients O
";" O
330 O
were O
assessable O
for O
efficacy O
and O
305 O
were O
assessable O
for O
QOL O
. O

It O
is O
well O
documented O
that O
stress O
is O
associated O
with O
negative O
health O
outcomes O
in O
cancer O
patients O
. O

Patients O
completing O
the O
6-month O
, O
double-blind O
period O
were O
eligible O
to O
enter O
the O
long-term O
extension O
";" O
patients O
received O
abatacept O
approximately O
10 O
mg/kg O
, O
plus O
disease-modifying O
antirheumatic O
drugs O
. O

Standardized O
questionnaires O
at O
baseline O
, O
posttreatment O
, O
and O
at O
3-month O
and O
6-month O
follow-up O
assessed O
sexual O
function O
, O
marital O
adjustment O
, O
psychologic O
distress O
, O
and O
utilization O
of O
treatments O
for O
ED O
. O

The O
global O
phase O
III O
SequentiAl O
Tarceva O
in O
UnResectable O
NSCLC O
( O
SATURN O
) O
study O
evaluated O
the O
efficacy O
and O
safety O
of O
the O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
tyrosine-kinase O
inhibitor O
erlotinib O
as O
maintenance O
treatment O
in O
NSCLC O
patients O
without O
progression O
after O
first-line O
chemotherapy O
. O

The O
potential O
long-term O
advantages O
of O
LRP O
over O
ORP O
remain O
to O
be O
determined O
. O

In O
both O
groups O
, O
partners O
completed O
behavioral O
homework O
. O

Patients O
were O
randomly O
assigned O
to O
GEM O
or O
GEM-CAP O
. O

One O
hundred O
eighty-five O
patients O
had O
function O
data O
. O

Premenopausal O
women O
with O
breast O
cancer O
receiving O
adjuvant O
chemotherapy O
are O
at O
risk O
for O
amenorrhea O
. O

They O
had O
also O
received O
morphine O
or O
transdermal O
fentanyl O
patches O
for O
at O
least O
1 O
week O
. O

These O
data O
may O
have O
wider O
implications O
particularly O
in O
respect O
of O
the O
management O
of O
chemotherapy-induced O
neutropenia O
. O

Therefore O
a O
phase O
III O
trial O
was O
implemented O
to O
confirm O
this O
activity O
. O

Recombinant O
human O
TSH O
( O
rhTSH O
) O
has O
become O
the O
modality O
of O
choice O
for O
radioiodine O
remnant O
ablation O
( O
RRA O
) O
in O
low-risk O
thyroid O
cancer O
patients O
. O

Between O
January O
1 O
, O
2007 O
, O
and O
November O
17 O
, O
2007 O
, O
a O
total O
of O
143 O
patients O
were O
randomized O
to O
receive O
either O
EOF O
or O
TOF O
. O

Median O
survival O
time O
was O
19.2 O
months O
( O
95 O
% O
CI O
, O
17.5 O
to O
21.3 O
months O
) O
in O
the O
D3P O
arm O
, O
17.8 O
months O
( O
95 O
% O
CI O
, O
16.2 O
to O
19.2 O
months O
) O
in O
the O
D1P O
arm O
, O
and O
16.3 O
months O
( O
95 O
% O
CI O
, O
14.3 O
to O
17.9 O
months O
) O
in O
the O
MP O
arm O
. O

Eligible O
patients O
had O
previously O
untreated O
stage O
IIIB O
or O
IV O
NSCLC O
suitable O
for O
cisplatin-based O
chemotherapy O
. O

Isotretinoin O
at O
a O
dose O
of O
20 O
mg O
for O
patients O
< O
or O
= O
73 O
kg O
, O
30 O
mg O
for O
patients O
greater O
than O
73 O
kg O
, O
or O
placebo O
daily O
for O
24 O
months O
. O

We O
developed O
Individual O
Meaning-Centered O
Psychotherapy O
( O
IMCP O
) O
to O
address O
the O
need O
for O
brief O
interventions O
targeting O
spiritual O
well-being O
and O
meaning O
for O
patients O
with O
advanced O
cancer O
. O

The O
impact O
of O
the O
side O
effects O
of O
megestrol O
acetate O
on O
the O
quality O
of O
life O
of O
noncachectic O
women O
with O
advanced O
breast O
cancer O
was O
studied O
in O
a O
dose-response O
clinical O
trial O
of O
the O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
8741 O
) O
. O

MRI O
scans O
at O
baseline O
, O
6 O
months O
, O
and O
5 O
years O
were O
independently O
interpreted O
by O
two O
radiologists O
. O

In O
both O
arms O
, O
chemotherapy O
was O
repeated O
at O
day O
29 O
. O

Statistical O
tests O
were O
two-sided O
. O

Subjects O
were O
randomized O
to O
a O
control O
or O
intervention O
group O
";" O
the O
intervention O
was O
performance O
of O
a O
seated O
exercise O
program O
using O
home O
videotape O
three O
times O
per O
week O
for O
four O
cycles O
of O
chemotherapy O
. O

Time O
to O
disease O
progression O
, O
response O
rate O
, O
adverse O
events O
, O
and O
QOL O
were O
secondary O
end O
points O
. O

QOL O
outcomes O
were O
analyzed O
at O
a O
median O
follow-up O
of O
2 O
years O
. O

The O
day O
before O
the O
nutritional O
interventions O
, O
and O
again O
after O
four O
and O
eight O
weeks O
, O
body O
compartments O
were O
determined O
using O
bioelectrical O
impedance O
analysis O
, O
lymphocyte O
subpopulations O
were O
quantified O
using O
flow O
cytometry O
, O
and O
some O
aspects O
of O
the O
quality O
of O
life O
were O
rated O
using O
four O
linear O
analog O
self-assessment O
( O
LASA O
) O
scales O
. O

The O
first O
group O
received O
intrapleural O
bevacizumab O
( O
300 O
mg O
) O
with O
cisplatin O
( O
30 O
mg O
) O
therapy O
and O
the O
second O
group O
received O
intrapleural O
cisplatin O
( O
30 O
mg O
) O
therapy O
alone O
. O

In O
all O
, O
152 O
fatigued O
patients O
with O
advanced O
cancer O
were O
randomly O
assigned O
to O
protocolized O
patient-tailored O
treatment O
( O
PPT O
) O
of O
symptoms O
or O
care O
as O
usual O
. O

After O
the O
administration O
of O
the O
131-I O
dose O
, O
the O
rate O
of O
radiation O
clearance O
from O
blood O
, O
thyroid O
remnant O
, O
and O
whole O
body O
was O
measured O
. O

Breast O
and O
prostate O
cancer O
survivors O
( O
N O
= O
543 O
) O
from O
39 O
US O
states O
and O
two O
Canadian O
provinces O
participated O
in O
the O
FRESH O
START O
intervention O
trial O
. O

The O
trial O
was O
prematurely O
closed O
during O
recruitment O
, O
after O
a O
median O
follow-up O
of O
11.9 O
months O
( O
interquartile O
range O
7.1-19.6 O
, O
total O
6498 O
women O
years O
) O
in O
those O
enrolled O
, O
after O
the O
publication O
of O
early O
results O
from O
the O
women O
's O
health O
initiative O
study O
. O

A O
high O
percentage O
of O
patients O
with O
newly O
diagnosed O
early O
stage O
breast O
cancer O
were O
found O
to O
have O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
. O

To O
assess O
whether O
the O
administration O
of O
recombinant O
human O
erythropoietin O
( O
r-HuEPO O
) O
would O
increase O
the O
hematocrit O
, O
reduce O
the O
requirement O
for O
transfusion O
, O
and O
improve O
the O
quality O
of O
life O
in O
anemic O
cancer O
patients O
receiving O
myelosuppressive O
, O
cisplatin-based O
chemotherapy O
. O

The O
aim O
was O
to O
rule O
out O
a O
5 O
% O
decrease O
in O
the O
2-year O
progression-free O
survival O
( O
PFS O
) O
rate O
. O

Mood O
was O
measured O
by O
the O
Center O
for O
Epidemiological O
Studies O
Depression O
Scale O
( O
range O
, O
0-60 O
) O
. O

The O
proposed O
sample O
size O
was O
300 O
patients O
. O

Patients O
were O
assessed O
before O
and O
after O
completing O
the O
intervention O
and O
2 O
months O
postintervention O
. O

Rehabilitation O
department O
at O
a O
university O
hospital O
. O

However O
, O
few O
studies O
have O
assessed O
whether O
changes O
in O
depression O
symptoms O
are O
associated O
with O
survival O
. O

We O
performed O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
in O
2 O
tertiary O
referral O
centers O
. O

Both O
MLD O
with O
compression O
bandage O
( O
complex O
decongestive O
therapy O
) O
group O
( O
Group O
I O
, O
n=15 O
) O
and O
IPC O
with O
SLD O
group O
( O
Group O
II O
, O
n=15 O
) O
received O
treatment O
for O
LE O
3 O
days O
in O
a O
week O
and O
every O
other O
day O
for O
6 O
weeks O
. O

Factors O
from O
the O
EORTC O
QLQ-C30 O
were O
all O
function O
scales O
, O
fatigue O
, O
nausea/vomiting O
, O
pain O
, O
dyspnoea O
, O
insomnia O
, O
loss O
of O
appetite O
and O
global O
QL O
. O

Although O
infrequent O
, O
other O
similar O
reports O
highlight O
the O
need O
for O
ongoing O
trials O
evaluating O
erythropoietin O
receptor O
agonists O
to O
ensure O
that O
overall O
survival O
is O
monitored O
closely O
. O

Data O
were O
collected O
prior O
to O
intervention O
and O
post-intervention O
( O
3 O
and O
6 O
months O
from O
baseline O
) O
. O

Sensitivity O
analysis O
using O
pattern-mixture O
models O
determined O
the O
effect O
of O
study O
discontinuation O
on/before O
week O
24 O
. O

Secondary O
end O
points O
were O
progression-free O
and O
overall O
survival O
. O

Dose O
escalation O
was O
achieved O
in O
77 O
% O
of O
patients O
who O
had O
≥1 O
cycle O
. O

The O
randomized O
, O
controlled O
BOLERO-2 O
( O
Breast O
Cancer O
Trials O
of O
Oral O
Everolimus O
) O
trial O
demonstrated O
significantly O
improved O
progression-free O
survival O
with O
the O
use O
of O
everolimus O
plus O
exemestane O
( O
EVE O
+ O
EXE O
) O
versus O
placebo O
plus O
exemestane O
( O
PBO O
+ O
EXE O
) O
in O
patients O
with O
advanced O
breast O
cancer O
who O
developed O
disease O
progression O
after O
treatment O
with O
nonsteroidal O
aromatase O
inhibitors O
. O

Primary O
objectives O
were O
to O
record O
changes O
from O
baseline O
KP O
and O
to O
assess O
symptom O
palliation O
. O

One O
hundred O
fifty-nine O
patients O
with O
advanced O
colorectal O
carcinoma O
previously O
untreated O
for O
the O
metastatic O
disease O
( O
34 O
of O
them O
previously O
exposed O
to O
adjuvant O
5-FU O
) O
were O
randomly O
allocated O
to O
receive O
: O
CPT-11 O
, O
200 O
mg/m2 O
i.v O
. O

Two O
hundred O
and O
three O
patients O
, O
recruited O
after O
primary O
treatment O
, O
were O
randomly O
assigned O
either O
to O
a O
treatment O
group O
( O
psycho-educational O
intervention O
) O
or O
to O
a O
waiting-list O
control O
group O
. O

Five O
participants O
( O
exercise=2 O
";" O
usual O
care=3 O
) O
did O
not O
complete O
the O
intervention O
, O
three O
of O
which O
were O
due O
to O
advancing O
disease O
( O
exercise=2 O
";" O
usual O
care=1 O
) O
. O

This O
randomised O
multicentre O
trial O
was O
conducted O
to O
establish O
the O
optimal O
duration O
of O
palliative O
chemotherapy O
in O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

Quality O
of O
life O
was O
the O
primary O
outcome O
measure O
, O
together O
with O
anxiety O
and O
depression O
and O
cost-effectiveness O
. O

Lymphedema O
is O
an O
adverse O
effect O
of O
breast O
cancer O
surgery O
. O

End O
points O
were O
the O
rate O
of O
success O
of O
ablation O
at O
6 O
to O
9 O
months O
, O
adverse O
events O
, O
quality O
of O
life O
, O
and O
length O
of O
hospital O
stay O
. O

It O
is O
not O
known O
whether O
low-dose O
radioiodine O
( O
1.1 O
GBq O
[ O
30 O
mCi O
] O
) O
is O
as O
effective O
as O
high-dose O
radioiodine O
( O
3.7 O
GBq O
[ O
100 O
mCi O
] O
) O
for O
treating O
patients O
with O
differentiated O
thyroid O
cancer O
or O
whether O
the O
effects O
of O
radioiodine O
( O
especially O
at O
a O
low O
dose O
) O
are O
influenced O
by O
using O
either O
recombinant O
human O
thyrotropin O
( O
thyrotropin O
alfa O
) O
or O
thyroid O
hormone O
withdrawal O
. O

The O
secondary O
endpoints O
included O
patient O
reported O
outcome O
measures O
";" O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
, O
Sleep O
disturbances O
( O
MOS-sleep O
questionnaire O
) O
and O
symptoms O
from O
the O
irradiated O
area O
( O
visual O
analogue O
scale O
) O
. O

The O
benefit O
of O
epoetin O
alfa O
in O
maintaining O
hemoglobin O
levels O
in O
cancer O
patients O
with O
hemoglobin O
less O
than O
12 O
g/dL O
has O
not O
been O
evaluated O
. O

The O
aim O
of O
the O
present O
trial O
was O
to O
evaluate O
the O
effects O
of O
chemotherapy O
on O
the O
quality O
of O
life O
and O
survival O
of O
patients O
with O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
( O
stage O
IIIB O
or O
IV O
) O
. O

Intervention O
group O
patients O
received O
the O
Pain O
Education O
Program O
in O
the O
hospital O
, O
and O
3 O
and O
7 O
days O
postdischarge O
by O
telephone O
";" O
this O
was O
done O
by O
nurses O
who O
were O
specially O
trained O
as O
pain O
counselors O
. O

The O
primary O
HRQOL O
scale O
was O
global O
HRQOL O
per O
protocol O
. O

We O
conducted O
a O
randomized O
clinical O
trial O
to O
evaluate O
the O
effects O
of O
ATP O
in O
patients O
with O
advanced O
NSCLC O
( O
stage O
IIIB O
or O
IV O
) O
. O

Patients O
were O
eligible O
if O
they O
were O
asymptomatic O
( O
score O
of O
0 O
or O
1 O
on O
item O
three O
of O
the O
Brief O
Pain O
Inventory O
Short O
Form O
[ O
BPI-SF O
] O
questionnaire O
) O
or O
mildly O
symptomatic O
( O
score O
of O
2 O
or O
3 O
) O
and O
had O
not O
previously O
received O
chemotherapy O
. O

carboplatin O
300 O
mg/m2 O
on O
day O
1 O
and O
etoposide O
120 O
mg/m2 O
orally O
on O
days O
1-5 O
every O
4 O
weeks O
for O
a O
maximum O
of O
eight O
courses O
. O

Study O
Type O
-- O
Therapy O
( O
RCT O
) O
Level O
of O
Evidence O
1b O
. O

In O
a O
previously O
conducted O
randomized O
trial O
comparing O
LRP O
with O
ORP O
, O
60 O
patients O
were O
prospectively O
evaluated O
. O

Two O
hundred O
eighty-nine O
patients O
were O
assessable O
for O
response O
, O
and O
99 O
responders O
were O
assessable O
for O
response O
duration O
( O
RD O
) O
. O

PSA O
decline O
showed O
no O
predictive O
value O
. O

Patients O
with O
bone O
metastasis-related O
pain O
at O
Numeric O
Rating O
Scale O
≥4 O
were O
enrolled O
to O
this O
randomized O
placebo-controlled O
trial O
. O

Of O
260 O
eligible O
patients O
, O
104 O
( O
40 O
% O
) O
agreed O
to O
participate O
, O
and O
93 O
were O
randomised O
. O

During O
2000-2005 O
, O
two O
concomitant O
chemoradiation O
treatment O
methods O
( O
radiotherapy O
with O
5-fluorouracil O
and O
radiotherapy O
with O
gemcitabine O
) O
were O
analyzed O
in O
the O
study O
. O

We O
then O
compared O
the O
FACT-An O
data O
from O
the O
Internet O
survey O
with O
the O
QOL O
data O
of O
a O
375-patient O
randomized O
, O
double-blind O
clinical O
trial O
evaluating O
epoetin O
alfa O
versus O
placebo O
in O
anemic O
cancer O
patients O
. O

To O
perform O
a O
randomized O
trial O
comparing O
70 O
and O
80 O
Gy O
radiotherapy O
for O
prostate O
cancer O
. O

All O
had O
chemotherapy O
. O

Subjects O
completed O
visual O
analog O
scales O
, O
the O
FACIT-Fatigue O
Scale O
and O
the O
Short O
Form-36v2 O
after O
surgery O
and O
again O
3 O
to O
6 O
months O
after O
hospital O
discharge O
. O

Primary O
outcome O
was O
physical O
function O
after O
12 O
months O
estimated O
by O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
QLQ-C30 O
questionnaire O
( O
scale O
0-100 O
) O
. O

Patients O
were O
randomized O
1:1 O
to O
an O
extended O
dosing O
schedule O
( O
EDS O
: O
darbepoetin O
alfa O
300 O
μg O
Q2W O
if O
chemotherapy O
was O
QW O
, O
Q2W O
, O
or O
Q4W O
or O
darbepoetin O
alfa O
500 O
μg O
Q3W O
if O
chemotherapy O
was O
Q3W O
) O
or O
weekly O
( O
150 O
μg O
QW O
regardless O
of O
chemotherapy O
schedule O
) O
. O

We O
compared O
efficacy O
of O
gefitinib O
with O
gemcitabine O
and O
cisplatin O
( O
GP O
) O
chemotherapy O
in O
this O
group O
of O
patients O
as O
first-line O
therapy O
. O

Univariate O
Kaplan O
Meier O
survival O
analysis O
and O
log O
rank O
tests O
were O
used O
to O
compare O
the O
risk O
of O
progression O
. O

Baseline O
symptom O
prevalence O
ranged O
from O
2 O
% O
( O
vaginal O
bleeding O
) O
to O
60 O
% O
to O
70 O
% O
( O
bone/muscle O
aches O
and O
low O
energy O
) O
. O

For O
NSCLC O
lung O
tumors O
≤ O
3 O
cm O
, O
a O
dose O
of O
48 O
Gy O
in O
4 O
fractions O
was O
used O
, O
otherwise O
52 O
Gy O
in O
4 O
fractions O
was O
delivered O
. O

Patients O
with O
advanced O
NSCLC O
with O
no O
evidence O
of O
progression O
after O
four O
cycles O
of O
chemotherapy O
were O
randomized O
to O
receive O
erlotinib O
150 O
mg/day O
or O
placebo O
, O
until O
progressive O
disease O
or O
limiting O
toxicity O
. O

Eligible O
patients O
who O
had O
previously O
completed O
four O
cycles O
of O
platinum-based O
chemotherapy O
were O
randomised O
1:1 O
to O
receive O
erlotinib O
150 O
mg/day O
or O
placebo O
until O
disease O
progression O
, O
unacceptable O
toxicity O
or O
death O
. O

The O
purpose O
of O
this O
study O
was O
to O
test O
the O
efficacy O
of O
a O
comprehensive O
menopausal O
assessment O
( O
CMA O
) O
intervention O
program O
in O
achieving O
relief O
of O
symptoms O
, O
the O
improvement O
in O
quality O
of O
life O
( O
QOL O
) O
, O
and O
sexual O
functioning O
in O
breast O
cancer O
survivors O
. O

Lung O
cancer O
is O
one O
of O
the O
most O
common O
cancers O
in O
the O
United O
States O
and O
is O
associated O
with O
high O
levels O
of O
symptoms O
, O
including O
pain O
, O
fatigue O
, O
shortness O
of O
breath O
, O
and O
psychological O
distress O
. O

Thirty-one O
posttreatment O
cancer O
survivors O
were O
randomized O
in O
groups O
of O
seven O
to O
nine O
to O
either O
the O
8-week O
III O
+ O
ISG O
intervention O
or O
the O
8-week O
III O
condition O
. O

Of O
the O
351 O
patients O
confirmed O
to O
be O
alive O
with O
correct O
address O
, O
246 O
( O
70 O
% O
) O
returned O
the O
questionnaire O
. O

They O
were O
followed O
until O
they O
finished O
primary O
treatment O
( O
enrollment O
) O
, O
at O
which O
time O
they O
completed O
a O
mailed O
baseline O
survey O
that O
included O
standardized O
measures O
of O
quality O
of O
life O
( O
including O
standardized O
scales O
of O
physical O
and O
emotional O
functioning O
) O
, O
mood O
, O
symptoms O
, O
and O
sexual O
functioning O
. O

Secondary O
end O
points O
evaluated O
were O
as O
follows O
: O
clinical O
efficacy O
";" O
quality O
of O
life O
";" O
safety O
";" O
and O
survival O
. O

Stratification O
factors O
included O
chemotherapy O
cycle O
length O
, O
screening O
hemoglobin O
( O
< O
10 O
g/dL O
vs. O
≥10 O
g/dL O
) O
, O
and O
tumor O
type O
( O
lung/gynecological O
vs. O
other O
nonmyeloid O
malignancies O
) O
. O

To O
assess O
whether O
omission O
of O
postoperative O
radiotherapy O
in O
women O
with O
'low-risk O
' O
axillary O
node O
negative O
breast O
cancer O
( O
T0-2 O
) O
treated O
by O
breast-conserving O
surgery O
and O
endocrine O
therapy O
improves O
quality O
of O
life O
and O
is O
more O
cost-effective O
. O

The O
sessions O
included O
education O
on O
prostate O
carcinoma O
and O
sexual O
function O
and O
options O
to O
treat O
ED O
as O
well O
as O
sexual O
communication O
and O
stimulation O
skills O
. O

This O
may O
cause O
cisplatin-induced O
gastrointestinal O
disorders O
and O
hinders O
the O
continuation O
of O
chemotherapy O
. O

Treatment O
was O
delivered O
by O
acupuncturists O
once O
a O
week O
for O
6 O
weeks O
through O
needling O
three O
pairs O
of O
acupoints O
. O

We O
compared O
a O
policy O
of O
three O
vs O
six O
courses O
of O
new-generation O
platinum-based O
combination O
chemotherapy O
with O
regard O
to O
effects O
on O
quality O
of O
life O
( O
QoL O
) O
and O
survival O
. O

Patients O
' O
subjective O
perspective O
should O
be O
taken O
into O
account O
in O
this O
mainly O
palliative O
setting O
. O

They O
were O
randomized O
to O
receive O
marimastat O
10 O
mg O
or O
placebo O
orally O
bid O
for O
up O
to O
2 O
years O
. O

Primary O
-- O
patients O
alive O
and O
without O
moderate O
or O
severe O
cough O
, O
chest O
pain O
, O
haemoptysis O
, O
or O
dyspnoea O
six O
months O
from O
randomisation O
, O
as O
recorded O
by O
clinicians O
. O

Stratified O
by O
chemotherapeutic O
drug O
and O
comorbid O
pain O
risk O
, O
patients O
were O
randomized O
to O
receive O
either O
duloxetine O
followed O
by O
placebo O
or O
placebo O
followed O
by O
duloxetine O
. O

In O
this O
randomized O
phase O
III O
trial O
, O
a O
total O
of O
313 O
Korean O
never-smokers O
with O
stage O
IIIB O
or O
IV O
lung O
adenocarcinoma O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
0 O
to O
2 O
, O
and O
adequate O
organ O
function O
were O
randomly O
assigned O
to O
receive O
either O
gefitinib O
( O
250 O
mg O
daily O
) O
or O
GP O
chemotherapy O
( O
gemcitabine O
1,250 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
";" O
cisplatin O
80 O
mg/m O
( O
2 O
) O
on O
day O
1 O
every O
3 O
weeks O
, O
for O
up O
to O
nine O
courses O
) O
. O

In O
the O
MRC O
OV05/EORTC O
55955 O
collaborative O
trial O
, O
we O
aimed O
to O
establish O
the O
benefits O
of O
early O
treatment O
on O
the O
basis O
of O
increased O
CA125 O
concentrations O
compared O
with O
delayed O
treatment O
on O
the O
basis O
of O
clinical O
recurrence O
. O

Participants O
drank O
4 O
oz O
. O

Thyroid O
ablation O
was O
assessed O
8 O
months O
after O
radioiodine O
administration O
by O
neck O
ultrasonography O
and O
measurement O
of O
recombinant O
human O
thyrotropin-stimulated O
thyroglobulin O
. O

Survival O
was O
the O
primary O
end O
point O
with O
a O
33 O
% O
improvement O
relative O
to O
PC O
considered O
important O
( O
85 O
% O
power O
, O
alpha O
= O
5 O
% O
) O
. O

Two O
hundred O
seventy O
one O
patients O
( O
89 O
% O
of O
randomized O
) O
submitted O
the O
baseline O
QOL O
questionnaires O
and O
were O
included O
in O
the O
QOL O
analysis O
. O

Patients O
completed O
the O
Short O
Form O
36-item O
Health O
Survey O
( O
SF-36 O
) O
and O
the O
Menopause O
Specific O
Quality O
of O
Life O
Questionnaire O
( O
MENQOL O
) O
at O
baseline O
, O
6 O
months O
, O
and O
annually O
. O

At O
9 O
months O
, O
patients O
underwent O
an O
rhTSH O
stimulation O
test O
, O
diagnostic O
( O
131 O
) O
I O
whole O
body O
scan O
( O
dxWBS O
) O
and O
neck O
ultrasonography O
. O

Randomisation O
was O
done O
by O
use O
of O
a O
central O
, O
computerised O
minimisation O
system O
. O

Secondary O
end O
points O
were O
progression-free O
survival O
, O
response O
rate O
, O
response O
duration O
, O
and O
quality O
of O
life O
. O

Quality-of-life O
data O
were O
prospectively O
collected O
. O

Patients O
with O
advanced O
stage O
IIIB O
or O
IV O
NSCLC O
, O
stratified O
by O
sex O
and O
tumor O
histology O
, O
were O
randomly O
assigned O
1:1 O
to O
paclitaxel O
( O
200 O
mg/m O
( O
2 O
) O
) O
and O
carboplatin O
( O
area O
under O
the O
curve O
, O
6.0 O
) O
with O
or O
without O
ASA404 O
( O
1,800 O
mg O
m O
( O
2 O
) O
) O
, O
given O
intravenously O
once O
every O
3 O
weeks O
for O
six O
cycles O
followed O
by O
maintenance O
ASA404 O
or O
placebo O
. O

Patients O
with O
HER2-positive O
MBC O
whose O
disease O
progressed O
during O
prior O
trastuzumab-based O
therapies O
were O
randomly O
assigned O
to O
receive O
lapatinib O
monotherapy O
or O
lapatinib O
in O
combination O
with O
trastuzumab O
. O

Following O
assessment O
of O
mental O
and O
physical O
well-being O
, O
depression O
, O
anxiety O
, O
exercise O
, O
and O
stress O
reduction O
activity O
before O
chemotherapy O
started O
, O
patients O
were O
randomized O
to O
stress O
management O
training O
( O
SM O
) O
, O
exercise O
( O
EX O
) O
, O
combined O
stress O
management O
and O
exercise O
( O
SMEX O
) O
, O
or O
usual O
care O
only O
( O
UCO O
) O
. O

Fifty-one O
patients O
with O
T2 O
, O
N0/N1 O
, O
M0 O
NPC O
took O
part O
in O
a O
randomized O
controlled O
clinical O
study O
and O
received O
IMRT O
or O
CRT O
. O

A O
total O
of O
749 O
patients O
were O
randomized O
and O
697 O
were O
available O
for O
analysis O
. O

One O
hundred O
and O
two O
candidates O
with O
CACS O
were O
randomly O
assigned O
to O
two O
treatment O
groups O
( O
trial O
group O
and O
control O
group O
) O
: O
the O
trial O
group O
received O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
plus O
thalidomide O
( O
50 O
mg O
po O
, O
bid O
) O
, O
while O
the O
control O
group O
received O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
alone O
. O

This O
double-blind O
, O
placebo-controlled O
study O
randomly O
assigned O
patients O
to O
placebo O
or O
epoetin O
alfa O
( O
Ortho O
Biotech O
, O
Bridgewater O
, O
NJ O
) O
40,000 O
U O
subcutaneous O
weekly O
for O
16 O
weeks O
. O

Patients O
in O
Group O
1 O
performed O
pilates O
and O
home O
exercises O
and O
patients O
in O
group O
2 O
performed O
only O
home O
exercises O
. O

Manual O
lymphatic O
drainage O
( O
MLD O
) O
and O
compression O
bandage O
combination O
( O
complex O
decongestive O
therapy O
) O
have O
been O
compared O
with O
intermittent O
pneumatic O
compression O
( O
IPC O
) O
plus O
self-lymphatic O
drainage O
( O
SLD O
) O
. O

Arm O
circumferences O
were O
measured O
before O
and O
the O
1st O
, O
3rd O
, O
and O
6th O
weeks O
of O
the O
treatment O
. O

Moderators O
were O
patient O
preference O
for O
group O
assignment O
, O
marital O
status O
, O
age O
, O
disease O
stage O
, O
and O
chemotherapy O
regimen O
. O

All O
statistical O
tests O
were O
two-sided O
. O

Significance O
was O
set O
at O
alpha O
< O
or O
= O
0.01 O
. O

Outcomes O
were O
assessed O
at O
baseline O
and O
post O
exercise O
. O

Forty-five O
patients O
were O
eligible O
, O
of O
whom O
34 O
were O
randomized O
( O
mean O
( O
s.d O
. O
) O
age O
70 O
( O
11·8 O
) O
years O
) O
. O

Patients O
were O
randomly O
assigned O
to O
the O
following O
four O
chemotherapy O
regimens O
: O
four O
cycles O
of O
anthracycline O
followed O
by O
paclitaxel O
( O
ACP O
) O
, O
four O
cycles O
of O
anthracycline-containing O
regimens O
followed O
by O
docetaxel O
( O
ACD O
) O
, O
eight O
cycles O
of O
paclitaxel O
( O
PTX O
) O
, O
and O
eight O
cycles O
of O
docetaxel O
( O
DTX O
) O
. O

Health-related O
quality O
of O
life O
( O
HRQoL O
";" O
exploratory O
endpoint O
) O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
. O

Single-agent O
therapy O
with O
bicalutamide O
, O
a O
nonsteroidal O
antiandrogen O
, O
was O
compared O
with O
castration O
, O
either O
surgical O
or O
medical O
, O
in O
patients O
with O
untreated O
Stage O
D2 O
prostate O
cancer O
. O

Those O
in O
the O
intervention O
group O
received O
six O
multidisciplinary O
90-minute O
sessions O
designed O
to O
address O
the O
five O
major O
domains O
of O
QOL O
. O

After O
stratification O
according O
to O
performance O
status O
( O
PS O
) O
and O
resection O
of O
the O
primary O
tumor O
, O
72 O
patients O
with O
advanced O
gastric O
carcinoma O
were O
randomized O
to O
2 O
parallel O
Phase O
II O
trials O
with O
5-FU/6S-LV O
and O
EEP-L O
, O
respectively O
. O

Standard O
guidelines O
for O
cancer O
pain O
treatment O
routinely O
recommend O
training O
patients O
to O
reduce O
barriers O
to O
pain O
relief O
, O
use O
medications O
appropriately O
, O
and O
communicate O
their O
pain-related O
needs O
. O

The O
2 O
+ O
2.5 O
dosage O
was O
discontinued O
at O
the O
end O
of O
year O
7 O
. O

Outcome O
measures O
were O
overall O
survival O
( O
OS O
) O
";" O
progression-free O
survival O
( O
PFS O
) O
";" O
-1 O
, O
-2 O
, O
and O
3-year O
survival O
rates O
, O
and O
quality O
of O
life O
( O
QoL O
) O
. O

Treatment-induced O
arm O
lymphoedema O
is O
a O
common O
and O
distressing O
complication O
of O
curative O
surgery O
and O
radiotherapy O
for O
early O
breast O
cancer O
. O

We O
carried O
out O
a O
randomized O
phase O
II O
trial O
to O
select O
one O
of O
the O
following O
treatment O
regimens O
for O
further O
investigation O
: O
weekly O
irinotecan O
at O
a O
dose O
of O
70 O
mg/m O
( O
2 O
) O
days O
1 O
, O
8 O
, O
15 O
, O
22 O
, O
29 O
( O
arm O
A O
) O
or O
3-weekly O
irinotecan O
at O
a O
dose O
of O
300/240 O
mg/m O
( O
2 O
) O
day O
1 O
and O
days O
22 O
( O
arm O
B O
) O
in O
combination O
with O
capecitabine O
1000 O
mg/m O
( O
2 O
) O
twice O
daily O
days O
1-14 O
and O
days O
22-35 O
every O
6 O
weeks O
. O

Transfusion O
use O
was O
low O
during O
the O
study O
in O
both O
groups O
. O

This O
study O
was O
designed O
to O
determine O
whether O
epoetin O
alpha O
would O
decrease O
the O
number O
of O
transfusion O
events O
and O
units O
of O
packed O
erythrocytes O
( O
PRBCs O
) O
transfused O
, O
and O
the O
secondary O
objective O
was O
to O
study O
the O
effects O
of O
epoetin O
alpha O
on O
quality O
of O
life O
( O
QOL O
) O
and O
complete O
remission O
( O
CR O
) O
rates O
. O

To O
prospectively O
evaluate O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
outcomes O
for O
uterine O
artery O
embolization O
( O
UAE O
) O
and O
hysterectomy O
up O
to O
24 O
months O
after O
the O
intervention O
in O
terms O
of O
mental O
and O
physical O
health O
, O
urinary O
and O
defecatory O
function O
, O
and O
overall O
patient O
satisfaction O
. O

QoL O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
questionnaire O
. O

Topical O
photodynamic O
therapy O
( O
PDT O
) O
with O
aminolevulinic O
acid O
( O
ALA O
) O
and O
5 O
% O
imiquimod O
cream O
are O
effective O
therapies O
for O
the O
treatment O
of O
actinic O
keratoses O
( O
AKs O
) O
, O
but O
no O
split-face O
studies O
directly O
comparing O
these O
treatment O
options O
are O
available O
in O
the O
literature O
. O

Patients O
( O
n O
= O
110 O
) O
with O
stage O
II O
, O
III O
, O
or O
IV O
breast O
cancer O
scheduled O
to O
receive O
high O
dose O
chemotherapy O
and O
autologous O
hematopoietic O
stem O
cell O
transplantation O
were O
randomized O
to O
either O
CCSP O
treatment O
or O
control O
group O
. O

Eligible O
patients O
were O
70 O
years O
of O
age O
or O
older O
, O
had O
stage O
IV O
or O
IIIB O
NSCLC O
that O
was O
ineligible O
for O
radiotherapy O
, O
and O
had O
a O
performance O
status O
of O
0-2 O
( O
a O
status O
of O
fully O
active O
to O
a O
status O
of O
capable O
of O
all O
self-care O
but O
unable O
to O
work O
) O
. O

At O
early O
closure O
of O
the O
trial O
, O
56,583 O
had O
been O
screened O
, O
8980 O
entered O
run-in O
, O
and O
5692 O
( O
26 O
% O
of O
target O
of O
22,300 O
) O
started O
treatment O
. O

Using O
a O
computer-generated O
randomisation O
sequence O
, O
we O
randomly O
allocated O
patients O
to O
one O
of O
three O
groups O
( O
1:1:1 O
";" O
stratified O
by O
tumour O
site O
[ O
urological O
, O
gynaecological O
, O
or O
gastrointestinal O
] O
, O
and O
degree O
of O
bowel O
dysfunction O
[ O
IBDQ-B O
score O
< O
60 O
vs O
60-70 O
] O
) O
: O
usual O
care O
( O
a O
detailed O
self-help O
booklet O
) O
, O
gastroenterologist-led O
algorithm-based O
treatment O
, O
or O
nurse-led O
algorithm-based O
treatment O
. O

This O
randomized O
phase O
II O
trial O
evaluated O
two O
docetaxel-based O
regimens O
to O
see O
which O
would O
be O
most O
promising O
according O
to O
overall O
response O
rate O
( O
ORR O
) O
for O
comparison O
in O
a O
phase O
III O
trial O
with O
epirubicin-cisplatin-fluorouracil O
( O
ECF O
) O
as O
first-line O
advanced O
gastric O
cancer O
therapy O
. O

Twenty-three O
moderately O
malnourished O
patients O
with O
gastrointestinal O
carcinomas O
were O
randomized O
to O
receive O
either O
a O
conventional O
diet O
supplying O
35 O
nonprotein O
kcal O
and O
1.1 O
g O
of O
protein/kg O
per O
day O
( O
group O
A O
, O
n O
= O
11 O
) O
or O
a O
fat-enriched O
artificial O
liquid O
diet O
( O
20 O
nonprotein O
kcal/kg O
per O
day O
) O
plus O
normal O
meals O
( O
group O
B O
, O
n O
= O
12 O
) O
for O
a O
period O
of O
eight O
weeks O
, O
i.e. O
, O
from O
the O
first O
to O
the O
third O
chemotherapy O
cycle O
. O

An O
alpha-blocker O
was O
initiated O
either O
prophylactically O
2 O
weeks O
before O
implantation O
and O
continued O
at O
least O
until O
the O
International O
Prostate O
Symptom O
Score O
( O
IPSS O
) O
returned O
to O
normal O
, O
or O
withheld O
until O
the O
onset O
of O
significant O
brachytherapy-related O
urinary O
morbidity O
. O

A O
total O
of O
80 O
patients O
were O
registered O
to O
participate O
in O
a O
randomized O
, O
single-blind O
phase O
III O
trial O
to O
evaluate O
the O
difference O
in O
efficacy O
of O
" O
laying O
on O
of O
hands O
" O
by O
either O
a O
" O
healer O
" O
or O
an O
actor O
. O

Possible O
contributing O
factors O
beyond O
the O
efficacy O
of O
the O
intervention O
were O
the O
inability O
of O
patients O
to O
complete O
an O
8-week O
course O
of O
treatment O
and O
return O
in O
a O
timely O
fashion O
for O
follow-up O
assessment O
, O
and O
because O
the O
patients O
may O
have O
only O
had O
weight O
loss O
possible O
not O
related O
to O
cachexia O
, O
but O
other O
causes O
of O
weight O
loss O
, O
such O
as O
decreased O
appetite O
. O

Few O
RCT O
exercise O
intervention O
studies O
have O
included O
cancer O
patients O
undergoing O
chemotherapy O
. O

Preplanning O
constraints O
included O
prostate O
V100 O
higher O
than O
95 O
% O
, O
V150 O
lower O
than O
60 O
% O
, O
and O
V200 O
lower O
than O
20 O
% O
and O
rectal O
R100 O
less O
than O
1cm O
( O
3 O
) O
. O

All O
patients O
were O
randomly O
assigned O
to O
two O
groups O
, O
the O
55 O
patients O
in O
the O
treated O
group O
were O
treated O
with O
radiotherapy O
combined O
with O
the O
TCM O
therapy O
, O
and O
the O
53 O
in O
the O
control O
group O
were O
given O
radiotherapy O
alone O
. O

Total O
costs O
varied O
between O
treatment O
arms O
but O
these O
findings O
canceled O
out O
when O
SEMSs O
were O
compared O
with O
non-SEMS O
therapies O
( O
95 O
% O
CI O
-845.15-1,332.62 O
) O
. O

Of O
289 O
patients O
screened O
, O
243 O
were O
randomly O
assigned O
and O
164 O
( O
CE O
, O
66 O
of O
95 O
patients O
";" O
THC O
, O
65 O
of O
100 O
patients O
";" O
and O
PL O
, O
33 O
of O
48 O
patients O
) O
completed O
treatment O
. O

The O
follow-up O
assessment O
rate O
was O
73 O
% O
( O
329 O
of O
450 O
) O
. O

Both O
gemcitabine O
( O
GEM O
) O
and O
fluoropyrimidines O
are O
valuable O
treatment O
for O
advanced O
pancreatic O
cancer O
. O

Fifty O
patients O
were O
randomized O
";" O
30 O
patients O
received O
epoetin O
beta O
30,000 O
IU O
once O
weekly O
and O
20 O
received O
20,000 O
IU O
once O
weekly O
. O

Patients O
with O
advanced O
HIV-associated O
KS O
were O
randomly O
assigned O
to O
receive O
paclitaxel O
at O
a O
dose O
of O
100 O
mg/m2 O
intravenously O
( O
iv O
) O
every O
2 O
weeks O
or O
PLD O
at O
a O
dose O
of O
20 O
mg/m2 O
iv O
every O
3 O
weeks O
. O

Eighteen O
patients O
were O
randomized O
to O
GJJ O
and O
21 O
to O
stent O
placement O
. O

The O
immediate O
total O
( O
ie O
, O
> O
90 O
% O
) O
lung O
expansion O
was O
observed O
in O
27 O
patients O
( O
45 O
% O
) O
and O
was O
more O
frequent O
in O
the O
VATS O
group O
( O
60 O
% O
vs O
30 O
% O
, O
respectively O
";" O
p O
= O
0.027 O
) O
. O

The O
recommended O
regimens O
were O
17 O
Gy O
in O
two O
fractions O
one O
week O
apart O
or O
10 O
Gy O
as O
a O
single O
dose O
. O

We O
also O
evaluated O
the O
correlation O
between O
these O
scores O
and O
FACT-G O
, O
-B O
, O
and O
-Taxane O
scores O
at O
each O
time O
point O
. O

CONNECT O
was O
in O
addition O
to O
standard O
clinical O
follow-up O
. O

Eligible O
patients O
had O
measurable O
or O
assessable O
disease O
and O
an O
ECOG O
performance O
status O
of O
0 O
to O
2 O
";" O
stable O
brain O
metastases O
were O
allowed O
. O

Article O
from O
the O
Special O
issue O
on O
Targeted O
Inhibitors O
. O

We O
report O
QOL O
data O
collected O
during O
3 O
years O
after O
random O
assignment O
in O
patients O
without O
disease O
recurrence O
. O

The O
study O
was O
closed O
to O
additional O
accrual O
and O
all O
DPPE O
was O
discontinued O
. O

To O
assess O
the O
QoL O
, O
a O
questionnaire O
in O
reference O
to O
the O
EORTC-QLQ-C30 O
and O
the O
QLQ-OES24 O
was O
administered O
at O
3 O
weeks O
, O
6 O
months O
and O
1 O
year O
after O
surgery O
. O

In O
addition O
, O
the O
long-term O
effectiveness O
was O
investigated O
. O

Twenty-nine O
of O
81 O
pamidronate O
( O
HD/LD O
) O
patients O
first O
received O
600 O
mg/d O
and O
were O
then O
changed O
to O
300 O
mg/d O
";" O
52 O
of O
81 O
pamidronate O
LD O
patients O
received O
300 O
mg/d O
throughout O
the O
study O
. O

Bone-cancer O
pain O
is O
a O
common O
and O
refractory O
cancer O
pain O
. O

The O
differences O
of O
gender O
, O
age O
, O
primary O
GI O
malignancies O
, O
and O
hematological O
and O
biochemical O
data O
between O
the O
two O
compared O
groups O
were O
not O
statistically O
significant O
( O
all O
P O
> O
0.05 O
) O
. O

A O
measure O
of O
3.7 O
GBq O
of O
radioiodine O
was O
given O
to O
both O
groups O
. O

Secondary O
endpoints O
were O
cases O
of O
breakthrough O
pain O
and O
rescue O
morphine O
consumption O
. O

This O
randomized O
, O
multicenter O
, O
phase O
III O
study O
compared O
doxorubicin O
and O
docetaxel O
( O
AT O
) O
with O
doxorubicin O
and O
cyclophosphamide O
( O
AC O
) O
as O
first-line O
chemotherapy O
( O
CT O
) O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O

Safe O
resistance O
exercise O
prescription O
may O
counteract O
this O
effect O
. O

The O
EG O
participants O
kept O
home O
practice O
diaries O
. O

A O
total O
of O
419 O
women O
were O
randomized O
to O
one O
of O
four O
treatments O
: O
once-daily O
1 O
mg O
E2V/2.5 O
mg O
MPA O
( O
1 O
+ O
2.5 O
group O
) O
";" O
1 O
mg O
E2V/5 O
mg O
MPA O
daily O
( O
1 O
+ O
5 O
group O
) O
";" O
2 O
mg O
E2V/2.5 O
mg O
MPA O
daily O
( O
2 O
+ O
2.5 O
group O
) O
";" O
2 O
mg O
E2V/5 O
mg O
MPA O
daily O
( O
2 O
+ O
5 O
group O
) O
( O
Indivina O
, O
Orion O
Pharma O
) O
. O

At O
baseline O
, O
HRQoL O
measures O
were O
comparable O
between O
the O
two O
treatment O
groups O
. O

Twenty-six O
patients O
with O
head O
and O
neck O
cancer O
receiving O
CRT O
. O

To O
assess O
the O
long O
term O
risks O
and O
benefits O
of O
hormone O
replacement O
therapy O
( O
combined O
hormone O
therapy O
versus O
placebo O
, O
and O
oestrogen O
alone O
versus O
combined O
hormone O
therapy O
) O
. O

All O
patients O
were O
to O
receive O
WBRT O
( O
30 O
Gy O
in O
10 O
fractions O
) O
. O

One O
hundred O
forty O
consecutive O
patients O
with O
pilonidal O
sinus O
were O
randomly O
assigned O
to O
receive O
either O
UM O
or O
RELP O
procedures O
. O

A O
total O
of O
219 O
participants O
from O
12 O
oncology O
clinics O
were O
randomly O
assigned O
in O
a O
clinical O
trial O
. O

Pneumocystis O
carinii O
pneumonia O
prophylaxis O
was O
required O
during O
temozolomide O
+ O
radiotherapy O
treatment O
and O
was O
continued O
until O
recovery O
of O
lymphocytopenia O
( O
Common O
Toxicity O
Criteria O
grade O
< O
1 O
) O
. O

The O
potential O
predictive O
value O
of O
plasma O
VEGF-A O
is O
consistent O
with O
findings O
in O
HER2-negative O
LR/MBC O
, O
warranting O
prospective O
evaluation O
. O

This O
study O
addressed O
two O
questions O
: O
the O
dose-response O
relationship O
of O
Taxol O
in O
relapsed O
ovarian O
cancer O
and O
the O
safety O
of O
a O
short O
infusion O
given O
with O
premedication O
. O

Patients O
assigned O
to O
delayed O
treatment O
continued O
masked O
CA125 O
measurements O
, O
with O
treatment O
commencing O
at O
clinical O
or O
symptomatic O
relapse O
. O

The O
World O
Health O
Organization O
( O
WHO O
) O
guidelines O
for O
the O
treatment O
of O
cancer O
pain O
recommend O
nonopioid O
analgesics O
as O
first-line O
therapy O
, O
so-called O
" O
weak O
" O
analgesics O
combined O
with O
nonopioid O
analgesics O
as O
second-line O
therapy O
, O
and O
so-called O
" O
strong O
" O
opioids O
( O
with O
nonopioid O
analgesics O
) O
only O
as O
third-line O
therapy O
. O

Analysis O
was O
by O
intention O
to O
treat O
. O

Esophagogastric O
adenocarcinoma O
mainly O
occurs O
in O
elderly O
patients O
, O
but O
they O
are O
underrepresented O
in O
most O
clinical O
trials O
and O
often O
do O
not O
receive O
effective O
combination O
chemotherapy O
, O
most O
probably O
for O
fear O
of O
intolerance O
. O

Between-group O
differences O
in O
change O
from O
baseline O
were O
assessed O
using O
linear O
mixed O
models O
with O
selected O
covariates O
. O

Primary O
analyses O
were O
done O
by O
intention O
to O
treat O
and O
were O
based O
on O
scale O
scores O
at O
4 O
weeks O
and O
8 O
weeks O
. O

An O
overall O
intent-to-treat O
analysis O
was O
performed O
. O

The O
primary O
outcome O
was O
patient-perceived O
benefits O
, O
using O
the O
emotional O
function O
domain O
of O
the O
EORTC O
quality O
of O
life O
( O
QOL O
) O
QLQC30 O
questionnaire O
evaluated O
after O
12 O
weeks O
. O

Patients O
were O
randomly O
assigned O
to O
FU/LV/placebo O
( O
n O
= O
105 O
) O
or O
FU/LV/bevacizumab O
( O
n O
= O
104 O
) O
. O

The O
primary O
outcome O
measure O
was O
survival O
. O

A O
total O
of O
1308 O
patients O
with O
previously O
untreated O
ovarian O
cancer O
( O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
stages O
IIB-IV O
) O
were O
randomly O
assigned O
to O
receive O
six O
cycles O
of O
paclitaxel O
and O
carboplatin O
followed O
by O
either O
four O
cycles O
of O
topotecan O
( O
TC-Top O
";" O
658 O
patients O
) O
or O
surveillance O
( O
TC O
";" O
650 O
patients O
) O
on O
a O
3-week O
per O
cycle O
schedule O
. O

This O
was O
a O
randomized O
, O
parallel-arm O
, O
active-controlled O
, O
open-label O
, O
multicentre O
trial O
on O
182 O
patients O
treated O
with O
either O
monthly O
degarelix O
( O
240/80 O
mg O
) O
or O
goserelin O
( O
3.6 O
mg O
) O
for O
12 O
weeks O
. O

Costs O
to O
the O
NHS O
associated O
with O
postoperative O
radiotherapy O
were O
calculated O
to O
be O
of O
the O
order O
of O
2000 O
pounds O
per O
patient O
. O

The O
statistical O
calculations O
were O
done O
as O
an O
exploratory O
data O
analysis O
. O

Advanced O
gastric O
cancer O
patients O
were O
randomly O
assigned O
to O
docetaxel O
75 O
mg/m2 O
and O
cisplatin O
75 O
mg/m2 O
( O
day O
1 O
) O
plus O
fluorouracil O
750 O
mg/m2/d O
( O
days O
1 O
to O
5 O
) O
every O
3 O
weeks O
or O
cisplatin O
100 O
mg/m2 O
( O
day O
1 O
) O
plus O
fluorouracil O
1,000 O
mg/m2/d O
( O
days O
1 O
to O
5 O
) O
every O
4 O
weeks O
. O

In O
all O
, O
175 O
patients O
completed O
the O
trial O
( O
96.1 O
% O
) O
. O

Thus O
, O
300 O
patients O
were O
assessable O
for O
toxicity O
and O
to O
determine O
time O
to O
disease O
progression O
( O
TTP O
) O
, O
TTF O
, O
and O
OS O
. O

HRQL O
was O
evaluated O
with O
the O
Short O
Form O
36-Item O
( O
SF-36 O
) O
questionnaire O
";" O
subscales O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
PR25 O
module O
for O
bowel O
and O
bladder O
symptoms O
and O
the O
OV28 O
and O
CX24 O
modules O
for O
sexual O
symptoms O
";" O
and O
demographic O
questions O
. O

However O
, O
whether O
intrapleural O
delivery O
of O
bevacizumab O
can O
be O
used O
to O
treat O
MPE O
remains O
unknown O
. O

We O
designed O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
misoprostol O
in O
patients O
with O
head O
and O
neck O
cancer O
. O

Between O
April O
2010 O
and O
May O
2011 O
, O
patients O
undergoing O
elective O
LCR O
in O
two O
centres O
were O
randomized O
to O
analgesia O
via O
epidural O
or O
WIC O
. O

The O
primary O
outcome O
measures O
were O
arm O
and O
shoulder O
morbidity O
and O
quality O
of O
life O
. O

The O
median O
follow-up O
time O
was O
27.2 O
months O
for O
all O
patients O
and O
49 O
months O
for O
surviving O
patients O
. O

Patient O
HRQoL O
was O
assessed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
questionnaire O
, O
in O
terms O
of O
time O
to O
symptom O
progression O
( O
TSP O
) O
, O
time O
to O
deterioration O
( O
TTD O
) O
in O
Trial O
Outcome O
Index O
( O
TOI O
) O
and O
TTD O
. O

30 O
patients O
received O
exemestane O
( O
EXE O
) O
25 O
mg O
daily O
and O
celecoxib O
( O
CXB O
) O
400 O
mg O
twice O
daily O
( O
group O
A O
) O
, O
24 O
patients O
received O
EXE O
25 O
mg O
daily O
( O
group O
B O
) O
and O
28 O
patients O
received O
letrozole O
( O
LET O
) O
2.5 O
mg O
daily O
( O
group O
C O
) O
. O

Fifty O
patients O
were O
randomly O
assigned O
to O
receive O
12 O
weeks O
of O
acupuncture O
( O
n O
= O
25 O
) O
or O
venlafaxine O
( O
n O
= O
25 O
) O
treatment O
. O

Secondary O
endpoints O
included O
toxicity O
, O
response O
to O
treatment O
, O
quality O
of O
life O
, O
and O
overall O
and O
progression-free O
survival O
time O
. O

Responders O
were O
separately O
compared O
with O
nonresponders O
( O
patients O
with O
SD O
( O
6m O
) O
or O
PD O
) O
and O
with O
patients O
with O
SD O
( O
6m O
) O
, O
and O
patients O
with O
clinical O
benefit O
were O
compared O
with O
patients O
with O
PD O
by O
analysis O
of O
covariance O
with O
adjustment O
for O
baseline O
scores O
. O

A O
total O
of O
438 O
patients O
underwent O
randomization O
";" O
data O
could O
be O
analyzed O
for O
421 O
. O

Four O
weeks O
later O
, O
all O
patients O
received O
pamidronate O
120 O
mg O
. O

Five O
hundred O
seventy-three O
glioblastoma O
multiforme O
patients O
were O
randomized O
to O
receive O
either O
temozolomide O
+ O
radiotherapy O
( O
n O
= O
287 O
) O
or O
radiotherapy O
alone O
( O
n O
= O
286 O
) O
. O

We O
report O
a O
retrospective O
subanalysis O
of O
Asian O
patients O
enrolled O
in O
SATURN O
. O

To O
determine O
the O
long-term O
outcome O
and O
health-related O
quality O
of O
life O
( O
HRQL O
) O
of O
patients O
with O
endometrial O
carcinoma O
( O
EC O
) O
treated O
with O
or O
without O
pelvic O
radiotherapy O
in O
the O
Post O
Operative O
Radiation O
Therapy O
in O
Endometrial O
Carcinoma O
1 O
( O
PORTEC-1 O
) O
trial O
. O

A O
randomized O
controlled O
trial O
of O
five O
high-fluence O
treatments O
( O
intervention O
) O
vs. O
five O
low-fluence O
treatments O
( O
control O
) O
was O
performed O
over O
6 O
months O
in O
a O
National O
Health O
Service O
teaching O
hospital O
. O

Patients O
with O
proven O
metastatic O
colorectal O
cancer O
, O
which O
had O
progressed O
within O
6 O
months O
of O
treatment O
with O
fluorouracil O
, O
were O
randomly O
assigned O
either O
300-350 O
mg/m2 O
irinotecan O
every O
3 O
weeks O
with O
supportive O
care O
or O
supportive O
care O
alone O
, O
in O
a O
2:1 O
ratio O
. O

Endpoints O
included O
the O
QLQ-C30 O
Global O
Health O
Status O
( O
QL2 O
) O
scale O
, O
the O
QLQ-BR23 O
breast O
symptom O
( O
BRBS O
) O
, O
and O
arm O
symptom O
( O
BRAS O
) O
scales O
. O

Prespecified O
outcomes O
were O
three O
genitourinary O
symptoms O
( O
bowel O
function O
tenderness O
, O
frequent O
urination O
, O
and O
erectile O
dysfunction O
[ O
ED O
] O
) O
and O
measures O
of O
physical O
and O
emotional O
function O
. O

Out O
patient O
group O
, O
Department O
of O
Physical O
Medicine O
and O
Rehabilitation O
and O
Medical O
Oncology O
Department O
, O
University O
Hospital O
. O

To O
report O
5-year O
contrast-enhanced O
magnetic O
resonance O
imaging O
findings O
of O
the O
REST O
trial O
recruits O
who O
underwent O
either O
uterine O
artery O
embolization O
( O
UAE O
) O
or O
myomectomy O
. O

L-T4 O
was O
initiated O
in O
both O
groups O
after O
thyroidectomy O
. O

All O
patients O
were O
treated O
with O
the O
same O
CTF O
regimen O
of O
chemotherapy O
for O
21 O
days O
as O
one O
therapeutic O
cycle O
, O
while O
those O
in O
the O
treatment O
group O
were O
given O
SFI O
additionally O
in O
the O
meanwhite O
. O

However O
, O
it O
is O
rarely O
implemented O
given O
its O
limited O
availability O
. O

The O
primary O
endpoint O
was O
changes O
in O
oral O
calorie O
intake O
, O
and O
the O
secondary O
endpoints O
were O
chemotherapy-related O
adverse O
events O
";" O
appetite O
visual O
analog O
scale O
( O
VAS O
) O
scores O
";" O
changes O
in O
gastrointestinal O
hormones O
and O
nutritional O
status O
, O
including O
rapid O
turnover O
proteins O
, O
and O
quality O
of O
life O
( O
QoL O
) O
estimated O
with O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QoL O
core O
questionnaire O
( O
QLQ-C30 O
) O
. O

Radiotherapy O
was O
delivered O
on O
weekdays O
2 O
Gy O
daily O
up O
to O
56 O
Gy O
. O

At O
baseline O
, O
15 O
% O
of O
patients O
were O
sexually O
active O
";" O
this O
increased O
significantly O
to O
39 O
% O
during O
the O
first O
year O
( O
P O
< O
.001 O
) O
. O

The O
majority O
of O
pain O
topics O
had O
to O
be O
discussed O
. O

Patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
lymphoblastic O
lymphoma O
( O
LL O
) O
, O
or O
Burkitt O
lymphoma O
( O
BL O
) O
who O
were O
receiving O
frontline O
myelosuppressive O
chemotherapy O
were O
randomized O
to O
receive O
epoetin O
alpha O
or O
no O
epoetin O
during O
the O
first O
6 O
cycles O
of O
their O
planned O
chemotherapy O
. O

Patients O
with O
stable O
or O
responding O
disease O
were O
then O
randomized O
to O
observation O
or O
four O
cycles O
of O
topotecan O
( O
1.5 O
mg/m O
( O
2 O
) O
/d O
for O
5 O
days O
, O
every O
3 O
weeks O
";" O
step O
2 O
) O
. O

Fifty-two O
patients O
with O
painful O
bone O
metastases O
were O
randomised O
to O
receive O
a O
two-hour O
infusion O
of O
pamidronate O
120 O
mg O
or O
an O
identical O
infusion O
of O
saline O
. O

Patients O
were O
randomly O
assigned O
to O
a O
sunitinib O
starting O
dose O
of O
37.5 O
mg/d O
in O
the O
morning O
( O
AM O
) O
or O
evening O
( O
PM O
) O
. O

To O
assess O
the O
safety O
and O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
of O
continuous O
combined O
hormone O
replacement O
therapy O
( O
ccHRT O
) O
with O
estradiol O
valerate/medroxyprogesterone O
acetate O
( O
E O
( O
2 O
) O
V/MPA O
) O
over O
nine O
years O
and O
at O
follow-up O
one O
year O
after O
discontinuation O
. O

Arm O
lymphoedema O
after O
lymphatic O
radiotherapy O
and O
surgery O
has O
been O
used O
in O
the O
present O
study O
as O
a O
clinical O
system O
for O
testing O
these O
drugs O
in O
a O
double-blind O
placebo-controlled O
randomised O
phase O
II O
trial O
. O

Thirty-six O
patients O
with O
local-regional O
advanced O
H O
& O
amp O
";" O
N O
cancer O
receiving O
chemoradiationtherapy O
( O
CRT O
) O
were O
randomized O
to O
receive O
either O
placebo O
or O
rhDNase O
. O

major O
cardiovascular O
disease O
, O
osteoporotic O
fractures O
, O
and O
breast O
cancer O
. O

Seventy-two O
women O
with O
breast O
cancer O
experiencing O
three O
or O
more O
hot O
flashes O
per O
day O
were O
randomly O
assigned O
to O
receive O
either O
TRUE O
or O
sham O
acupuncture O
. O

Median O
follow-up O
was O
5.2 O
years O
( O
range O
, O
3.2 O
to O
6.5 O
years O
) O
. O

Caloric O
intake O
, O
body O
composition O
( O
dual-energy O
x-ray O
absorptiometry O
) O
, O
and O
respiratory O
gas O
exchanges O
at O
rest O
and O
during O
exercise O
were O
measured O
including O
health-related O
quality O
of O
life O
. O

To O
compare O
the O
effects O
of O
cannabis O
extract O
( O
CE O
) O
, O
delta-9-tetrahydrocannabinol O
( O
THC O
) O
, O
and O
placebo O
( O
PL O
) O
on O
appetite O
and O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
cancer-related O
anorexia-cachexia O
syndrome O
( O
CACS O
) O
. O

We O
aimed O
to O
assess O
the O
effectiveness O
of O
acupuncture O
for O
cancer-related O
fatigue O
( O
CRF O
) O
in O
patients O
with O
breast O
cancer O
. O

To O
determine O
if O
the O
type O
of O
embolic O
material O
used O
for O
uterine O
artery O
embolization O
( O
UAE O
) O
for O
leiomyomas O
has O
an O
impact O
on O
short-term O
recovery O
or O
the O
effectiveness O
of O
embolization O
. O

The O
participants O
who O
dropped O
out O
pretreatment O
reported O
less O
financial O
concerns O
than O
post-treatment O
dropouts O
, O
and O
the O
participants O
who O
dropped O
out O
of O
the O
study O
midtreatment O
had O
poorer O
physical O
health O
than O
treatment O
completers O
. O

Assessments O
were O
done O
at O
baseline O
, O
9 O
weeks O
, O
and O
26 O
weeks O
after O
randomisation O
. O

A O
total O
of O
421 O
patients O
with O
locally O
advanced O
stage O
III O
or O
stage O
IV O
NSCLC O
tumors O
were O
included O
. O

HRQL O
primary O
end O
points O
assessed O
by O
the O
EORTC O
QLQ-C30 O
were O
physical O
function O
( O
PF O
) O
and O
global O
health O
status O
( O
GHS O
) O
";" O
mean O
changes O
from O
baseline O
to O
8 O
and O
16 O
weeks O
were O
assessed O
. O

Our O
primary O
sleep O
endpoint O
was O
global O
sleep O
quality O
assessed O
by O
the O
Pittsburgh O
Sleep O
Quality O
Index O
( O
PSQI O
) O
. O

The O
purpose O
of O
this O
pilot O
study O
was O
to O
examine O
the O
effects O
of O
a O
combined O
cardiorespiratory O
and O
resistance O
exercise O
training O
program O
of O
short O
duration O
on O
the O
cardiorespiratory O
fitness O
, O
strength O
endurance O
, O
task O
specific O
functional O
muscle O
capacity O
, O
body O
composition O
and O
quality O
of O
life O
( O
QOL O
) O
in O
women O
breast O
cancer O
survivors O
. O

This O
study O
is O
registered O
as O
ISRCTN83176944 O
. O

Thirty-two O
women O
with O
breast O
cancer O
were O
randomly O
assigned O
to O
scapula-oriented O
exercise O
group O
( O
n O
= O
16 O
) O
and O
general O
exercise O
group O
( O
n O
= O
16 O
) O
. O

We O
aimed O
to O
determine O
the O
effect O
of O
dietary O
counseling O
or O
oral O
supplements O
on O
outcome O
for O
patients O
with O
cancer O
, O
specifically O
, O
nutritional O
outcome O
, O
morbidity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
, O
during O
and O
3 O
months O
after O
radiotherapy O
. O

The O
present O
study O
extends O
this O
work O
by O
evaluating O
separate O
and O
combined O
effects O
of O
stress O
management O
training O
and O
home-based O
exercise O
. O

Major O
inclusion O
criteria O
were O
a O
history O
of O
systemic O
cancer O
within O
5 O
years O
and O
enhanced O
magnetic O
resonance O
imaging-confirmed O
solitary O
brain O
metastasis O
suitable O
for O
both O
radiosurgery O
and O
surgery O
. O

Clinical O
response O
was O
defined O
as O
complete O
response O
( O
CR O
) O
, O
partial O
response O
( O
PR O
) O
, O
or O
stable O
disease O
( O
SD O
) O
. O

The O
major O
outcome O
measure O
was O
a O
bivariate O
construct O
that O
represented O
hot O
flash O
frequency O
and O
hot O
flash O
score O
, O
which O
was O
analyzed O
by O
a O
classic O
sums O
and O
differences O
comparison O
. O

Participants O
were O
randomly O
assigned O
to O
receive O
a O
10-month O
program O
of O
mailed O
print O
materials O
on O
diet O
and O
PA O
available O
in O
the O
public O
domain O
or O
a O
10-month O
program O
of O
tailored O
materials O
designed O
to O
increase O
fruit O
and O
vegetable O
( O
F O
& O
V O
) O
intake O
, O
decrease O
fat O
intake O
, O
and/or O
increase O
PA. O
Changes O
in O
self-efficacy O
for O
F O
& O
V O
intake O
and O
fat O
restriction O
were O
analyzed O
as O
potential O
mediators O
of O
the O
intervention O
's O
effects O
on O
diet O
at O
2-year O
follow-up O
. O

Secondary O
end-points O
included O
quality O
of O
life O
( O
QOL O
) O
assessed O
using O
the O
EORTC O
QLQ-C30 O
and O
QLQ-LC13 O
questionnaires O
. O

No O
androgen O
deprivation O
was O
allowed O
. O

269 O
patients O
with O
cancer O
";" O
73 O
men O
, O
196 O
women O
, O
mean O
age O
47 O
years O
( O
range O
20-65 O
) O
representing O
21 O
diagnoses O
. O

The O
intervention O
targeted O
couples O
' O
communication O
, O
hope O
, O
coping O
, O
uncertainty O
, O
and O
symptom O
management O
. O

Randomized O
, O
double-blinded O
, O
placebo-controlled O
trial O
. O

Time O
to O
definitive O
deterioration O
of O
QOL O
parameters O
was O
analyzed O
and O
compared O
within O
the O
treatment O
arms O
. O

A O
total O
of O
191 O
women O
were O
enrolled O
, O
stratified O
by O
age O
and O
stress O
level O
, O
and O
randomized O
to O
receive O
either O
an O
8-week O
MBAT O
intervention O
or O
a O
breast O
cancer O
educational O
support O
program O
of O
equal O
time O
and O
duration O
. O

A O
prospective O
randomized O
clinical O
study O
on O
the O
treatment O
of O
patients O
with O
resectable O
and O
unresectable O
pancreatic O
cancer O
was O
conducted O
at O
the O
Department O
of O
Oncology O
of O
Kaunas O
University O
of O
Medicine O
Hospital O
, O
and O
in O
this O
study O
, O
quality O
of O
life O
was O
analyzed O
. O

Patients O
completed O
the O
SWOG O
Quality O
of O
Life O
Questionnaire O
( O
emotional O
, O
physical O
, O
social O
, O
and O
role O
function O
";" O
general O
symptom O
status O
";" O
treatment/disease-specific O
symptoms O
";" O
and O
global O
HRQL O
[ O
GHRQL O
] O
) O
at O
baseline O
, O
6 O
weeks O
, O
6 O
months O
, O
and O
annually O
for O
5 O
years O
. O

Patients O
14 O
to O
70 O
years O
of O
age O
with O
newly O
diagnosed O
GBM O
and O
Karnofsky O
Performance O
Scale O
( O
KPS O
) O
score O
> O
70 O
who O
were O
receiving O
initial O
treatment O
were O
enrolled O
and O
were O
randomized O
into O
2 O
groups O
during O
the O
5-year O
study O
period O
. O

A O
randomised O
controlled O
clinical O
trial O
, O
using O
a O
method O
of O
minimisation O
balanced O
by O
centre O
, O
grade O
of O
cancer O
, O
age O
, O
lymphatic/vascular O
invasion O
and O
preoperative O
endocrine O
therapy O
, O
was O
performed O
. O

The O
present O
study O
aimed O
to O
compare O
FUP O
with O
5-FU O
alone O
, O
which O
was O
the O
control O
arm O
in O
former O
Mayo O
Clinic O
trials O
. O

These O
samples O
were O
analyzed O
using O
six O
polymorphic O
DNA O
markers O
that O
encode O
five O
important O
enzymes O
in O
the O
glutathione O
metabolic O
pathway O
. O

Estramustine O
was O
given O
orally O
, O
280 O
mg O
twice O
daily O
, O
as O
soon O
as O
the O
diagnosis O
was O
established O
, O
during O
and O
after O
the O
radiotherapy O
for O
a O
period O
of O
in O
total O
3 O
months O
. O

Final O
planned O
overall O
survival O
( O
OS O
) O
analysis O
from O
EGF104900 O
is O
reported O
here O
. O

Patients O
were O
randomly O
assigned O
to O
three O
arms O
: O
A O
, O
17 O
Gy O
per O
two O
fractions O
( O
n O
= O
146 O
) O
";" O
B O
, O
42 O
Gy O
per O
15 O
fractions O
( O
n O
= O
145 O
) O
";" O
and O
C O
, O
50 O
Gy O
per O
25 O
fractions O
( O
n O
= O
130 O
) O
. O

We O
aimed O
to O
test O
, O
in O
a O
randomized O
controlled O
trial O
, O
the O
clinical O
and O
cost O
effectiveness O
of O
a O
rehabilitation O
intervention O
for O
patients O
with O
advanced O
, O
recurrent O
cancer O
. O

Improvement O
in O
PCS O
score O
at O
24-month O
follow-up O
was O
significantly O
higher O
for O
patients O
who O
were O
employed O
at O
baseline O
( O
P O
= O
.035 O
) O
. O

In O
the O
randomized O
, O
multinational O
phase O
II/III O
trial O
( O
V325 O
) O
of O
untreated O
advanced O
gastric O
cancer O
patients O
, O
the O
phase O
II O
part O
selected O
docetaxel O
, O
cisplatin O
, O
and O
fluorouracil O
( O
DCF O
) O
over O
docetaxel O
and O
cisplatin O
for O
comparison O
against O
cisplatin O
and O
fluorouracil O
( O
CF O
";" O
reference O
regimen O
) O
in O
the O
phase O
III O
part O
. O

Seven O
days O
of O
diary O
and O
actigraphy O
data O
did O
not O
corroborate O
with O
monthly O
reflections O
( O
PSQI O
) O
. O

An O
outcome O
of O
noninferiority O
of O
short-term O
androgen O
suppression O
as O
compared O
with O
long-term O
suppression O
required O
a O
hazard O
ratio O
of O
more O
than O
1.35 O
for O
overall O
survival O
, O
with O
a O
one-sided O
alpha O
level O
of O
0.05 O
. O

The O
principal O
method O
of O
data O
collection O
was O
by O
questionnaire O
, O
completed O
at O
home O
with O
a O
research O
nurse O
at O
four O
times O
over O
15 O
months O
. O

Also O
, O
we O
evaluated O
their O
effects O
on O
patient O
hormonal O
status O
, O
quality O
of O
life O
( O
QOL O
) O
, O
sexual O
function O
and O
prostate O
specific O
antigen O
relapse-free O
survival O
. O

Breast O
cancer O
patients O
( O
N O
= O
354 O
) O
receiving O
chemotherapy O
were O
randomly O
assigned O
in O
1:1 O
ratio O
to O
epoetin O
alfa O
( O
40,000 O
U O
qw O
) O
or O
standard O
of O
care O
( O
SOC O
) O
. O

The O
levels O
of O
VEGF O
and O
carcinoembryonic O
antigen O
( O
CEA O
) O
in O
the O
pleural O
fluid O
were O
determined O
by O
ELISA O
. O

Secondary O
end O
points O
included O
severity O
and O
duration O
of O
mucositis O
, O
pain O
measurement O
, O
radiation O
therapy O
interruption O
, O
and O
quality O
of O
life O
. O

To O
analyze O
and O
compare O
radiologic O
lung O
expansion O
after O
talc O
pleurodesis O
performed O
either O
by O
videothoracoscopy O
or O
chest O
tube O
and O
correlate O
it O
with O
clinical O
outcome O
. O

Adult O
patients O
with O
anaemia O
( O
Hb O
< O
11 O
g/dL O
) O
were O
randomized O
to O
receive O
epoetin O
beta O
30,000 O
IU O
or O
20,000 O
IU O
once O
weekly O
for O
12 O
weeks O
. O

Randomized O
controlled O
trial O
. O

One O
hundred O
fifty-three O
patients O
were O
randomly O
assigned O
to O
PLD O
( O
n O
= O
76 O
) O
or O
GEM O
( O
n O
= O
77 O
) O
. O

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
, O
where O
available O
, O
the O
EuroQOL O
EQ-5D O
questionnaire O
were O
administered O
every O
8 O
weeks O
from O
baseline O
until O
progression O
and O
then O
every O
3 O
months O
. O

The O
functional O
outcomes O
and O
quality O
of O
life O
in O
patients O
receiving O
esophagectomy O
or O
definitive O
CRT O
is O
uncertain O
. O

We O
therefore O
studied O
the O
effects O
of O
a O
high-fat O
diet O
, O
particularly O
on O
body O
composition O
. O

Before O
CTX O
, O
research O
nurses O
coached O
intervention O
participants O
to O
develop O
a O
BT O
plan O
including O
stimulus O
control O
, O
modified O
sleep O
restriction O
, O
relaxation O
therapy O
, O
and O
sleep O
hygiene O
. O

Data O
from O
these O
patients O
were O
used O
for O
confirmative O
purposes O
. O

Multivariate O
analyses O
were O
used O
to O
evaluate O
the O
association O
of O
the O
genotypes O
on O
the O
four O
endpoints O
. O

The O
aim O
of O
the O
present O
study O
is O
to O
evaluate O
the O
impact O
on O
QoL O
, O
substituting O
cisplatin O
, O
a O
pivot O
drug O
in O
NSCLC O
therapy O
, O
with O
carboplatin O
, O
an O
analogue O
with O
an O
improved O
toxicity O
profile O
. O

The O
purpose O
of O
this O
article O
is O
to O
compare O
quality O
of O
life O
( O
QOL O
) O
and O
menopausal O
symptoms O
among O
premenopausal O
patients O
with O
lymph O
node-negative O
breast O
cancer O
receiving O
chemotherapy O
, O
goserelin O
, O
or O
their O
sequential O
combination O
, O
and O
to O
investigate O
differential O
effects O
by O
age O
. O

213 O
cancer O
patients O
with O
different O
diagnoses O
were O
randomised O
into O
an O
intervention O
group O
or O
wait-list O
control O
group O
. O

In O
our O
randomized O
, O
phase O
3 O
trial O
, O
we O
compared O
two O
thyrotropin-stimulation O
methods O
( O
thyroid O
hormone O
withdrawal O
and O
use O
of O
recombinant O
human O
thyrotropin O
) O
and O
two O
radioiodine O
( O
( O
131 O
) O
I O
) O
doses O
( O
i.e. O
, O
administered O
activities O
) O
( O
1.1 O
GBq O
and O
3.7 O
GBq O
) O
in O
a O
2-by-2 O
design O
. O

This O
phase O
III O
study O
investigated O
the O
effect O
of O
combining O
oxaliplatin O
with O
LV5FU2 O
, O
with O
progression-free O
survival O
as O
the O
primary O
end O
point O
. O

At O
six O
oncology O
clinics O
, O
physicians O
( O
N=22 O
) O
and O
nurses O
( O
N=23 O
) O
enrolled O
patients O
( O
N=93 O
) O
who O
were O
over O
18 O
years O
of O
age O
, O
with O
cancer O
diagnoses O
, O
pain O
, O
and O
a O
life O
expectancy O
of O
at O
least O
6 O
months O
. O

The O
Pain O
Education O
Program O
was O
tailored O
to O
the O
needs O
of O
the O
individual O
patient O
and O
consisted O
of O
three O
elements O
: O
( O
1 O
) O
educating O
patients O
about O
the O
basic O
principles O
regarding O
pain O
and O
pain O
management O
";" O
( O
2 O
) O
instructing O
patients O
how O
to O
report O
their O
pain O
in O
a O
pain O
diary O
";" O
and O
( O
3 O
) O
instructing O
patients O
how O
to O
communicate O
about O
pain O
and O
how O
to O
contact O
health O
care O
providers O
. O

This O
article O
compares O
the O
impact O
on O
HRQOL O
of O
first-line O
treatment O
with O
cisplatin O
versus O
raltitrexed O
and O
cisplatin O
. O

Clinical O
, O
treatment O
and O
dosimetric O
variables O
evaluated O
included O
alpha-blocker O
, O
age O
, O
IPSS O
before O
and O
the O
maximum O
after O
treatment O
, O
prostate O
volume O
on O
ultrasonography O
, O
hormonal O
status O
, O
supplemental O
radiotherapy O
, O
isotope O
, O
urethral O
dose O
, O
V O
( O
100/200 O
) O
, O
D90 O
, O
and O
time O
to O
obtaining O
a O
normal O
IPSS O
. O

Weight O
, O
the O
Schwartz O
Fatigue O
Scale O
, O
and O
the O
Spitzer O
Quality O
of O
Life O
Scale O
were O
also O
measured O
. O

Experimental O
subjects O
live O
and O
interactive O
music O
therapy O
sessions O
, O
including O
a O
pre-operative O
session O
and O
continuing O
with O
daily O
sessions O
until O
the O
patient O
was O
discharged O
home O
. O

Patients O
performed O
5 O
targeted O
swallowing O
exercises O
throughout O
their O
CRT O
and O
participated O
in O
weekly O
swallowing O
therapy O
sessions O
to O
promote O
adherence O
and O
accurate O
technique O
. O

These O
patients O
were O
assigned O
to O
the O
two O
arms O
to O
assess O
the O
value O
of O
low-dose O
CDDP O
when O
added O
to O
a O
continuous O
intravenous O
infusion O
of O
5-FU O
at O
a O
dose O
of O
300 O
mg/m O
( O
2 O
) O
/24 O
hrs O
in O
a O
one-week O
cycle O
consisting O
of O
5 O
days O
of O
treatment O
and O
2 O
days O
of O
rest O
for O
at O
least O
12 O
weeks O
. O

SLNs O
were O
identified O
in O
662 O
of O
697 O
patients O
( O
95 O
% O
) O
and O
positive O
SLNs O
were O
found O
in O
189 O
of O
662 O
patients O
( O
28.5 O
% O
) O
. O

Supervised O
12 O
week O
group O
exercise O
programme O
in O
addition O
to O
usual O
care O
, O
compared O
with O
usual O
care O
. O

Of O
1060 O
registered O
, O
the O
first O
300 O
consecutive O
patients O
were O
included O
in O
the O
current O
utility O
study O
. O

Patients O
, O
and O
investigators O
undertaking O
interventions O
, O
assessing O
outcomes O
, O
and O
analysing O
data O
, O
were O
not O
masked O
to O
group O
assignment O
. O

In O
addition O
, O
our O
study O
was O
to O
determine O
whether O
a O
disease-specific O
module O
has O
greater O
sensitivity O
to O
group O
differences O
than O
a O
generic O
QOL O
questionnaire O
and O
to O
determine O
the O
most O
pragmatic O
approach O
to O
treating O
epidemic O
Kaposi O
's O
sarcoma O
( O
EKS O
) O
in O
Zimbabwe O
. O

Men O
who O
wish O
to O
increase O
their O
odds O
of O
retaining O
sexual O
function O
might O
be O
counseled O
to O
choose O
EBRT O
over O
cryoablation O
. O

All O
participants O
underwent O
assessment O
of O
physical O
activity O
, O
fitness O
, O
physical O
functioning O
, O
fatigue O
and O
exercise O
self-efficacy O
at O
baseline O
and O
after O
the O
16-week O
intervention O
. O

Partial O
responses O
were O
more O
frequent O
in O
patients O
with O
resected O
tumors O
or O
with O
an O
Eastern O
Cooperative O
Oncology O
Group O
PS O
of O
0-1 O
. O

Based O
on O
these O
differences O
between O
the O
embolic O
agents O
, O
enrollment O
in O
this O
study O
was O
terminated O
. O

Exploratory O
analysis O
was O
based O
on O
time O
to O
analgesia O
and O
appearance O
of O
key O
symptoms O
( O
pain O
, O
cough O
and O
dyspnoea O
) O
. O

The O
changes O
in O
the O
BMD O
, O
bone O
turnover O
proteins O
and O
quality-of-life O
( O
QoL O
) O
were O
analyzed O
and O
presented O
here O
. O

We O
evaluated O
safety O
and O
efficacy O
of O
IFNalpha O
and O
isotretinoin O
compared O
with O
IFNalpha O
alone O
as O
adjuvant O
treatment O
in O
patients O
with O
primary O
malignant O
melanoma O
stage O
IIA O
and O
IIB O
. O

In O
phase O
II O
studies O
, O
irinotecan O
is O
active O
in O
metastatic O
colorectal O
cancer O
, O
but O
the O
overall O
benefit O
has O
not O
been O
assessed O
in O
a O
randomised O
clinical O
trial O
. O

We O
conducted O
a O
prospective O
, O
randomized O
, O
multicentre O
clinical O
trial O
comparing O
the O
effects O
and O
costs O
of O
GM-CSF O
as O
an O
adjunct O
to O
intensive O
chemotherapy O
in O
elderly O
patients O
with O
acute O
myeloid O
leukaemia O
( O
AML O
) O
. O

This O
study O
was O
designed O
to O
evaluate O
efficacy O
, O
toxicity O
, O
and O
adverse O
effects O
of O
combination O
of O
chemotherapy O
drugs O
and O
intraperitoneal O
perfusion O
of O
verapamil O
in O
the O
treatment O
of O
malignant O
ascites O
. O

In O
this O
international O
, O
6-month O
, O
open-label O
trial O
, O
patients O
had O
active O
RA O
, O
an O
inadequate O
response O
to O
anti-TNF O
therapy O
for O
3 O
months O
or O
longer O
and O
a O
disease O
activity O
score O
in O
28 O
joints O
( O
DAS28 O
( O
C-reactive O
protein O
";" O
CRP O
) O
of O
5.1 O
or O
greater O
. O

Temozolomide O
( O
TMZ O
) O
is O
an O
alkylating O
agent O
licensed O
for O
treatment O
of O
high-grade O
glioma O
( O
HGG O
) O
. O

Baseline O
global O
health O
status O
scores O
were O
found O
to O
be O
similar O
between O
treatment O
groups O
( O
64.7 O
vs O
65.3 O
) O
. O

Everolimus O
( O
EVE O
) O
+exemestane O
( O
EXE O
";" O
n O
= O
485 O
) O
more O
than O
doubled O
median O
progression-free O
survival O
versus O
placebo O
( O
PBO O
) O
+ O
EXE O
( O
n O
= O
239 O
) O
, O
with O
a O
manageable O
safety O
profile O
and O
no O
deterioration O
in O
health-related O
quality-of-life O
( O
HRQOL O
) O
in O
patients O
with O
hormone-receptor-positive O
( O
HR O
( O
+ O
) O
) O
advanced O
breast O
cancer O
( O
ABC O
) O
who O
recurred O
or O
progressed O
on/after O
nonsteroidal O
aromatase O
inhibitor O
( O
NSAI O
) O
therapy O
. O

A O
total O
of O
93 O
patients O
were O
enrolled O
onto O
the O
trial O
. O

The O
primary O
outcome O
was O
the O
psychological O
subscale O
of O
the O
Supportive O
Care O
Needs O
Survey O
( O
SCNS O
) O
. O

A O
randomised O
controlled O
trial O
of O
radiotherapy O
alone O
versus O
radiotherapy O
with O
concomitant O
and O
adjuvant O
temozolomide O
for O
patients O
with O
glioblastoma O
showed O
that O
survival O
was O
higher O
for O
patients O
assigned O
combination O
treatment O
compared O
with O
those O
assigned O
standard O
radiotherapy O
alone O
. O

Normally O
distributed O
data O
were O
analyzed O
using O
t O
tests O
and O
random-slope/random-intercept O
mixed O
models O
. O

The O
TAX O
327 O
study O
compared O
docetaxel O
administered O
every O
3 O
weeks O
( O
D3 O
) O
, O
weekly O
docetaxel O
( O
D1 O
) O
, O
and O
mitoxantrone O
( O
M O
) O
, O
each O
with O
prednisone O
( O
P O
) O
, O
in O
1,006 O
men O
with O
metastatic O
hormone-resistant O
prostate O
cancer O
( O
HRPC O
) O
. O

To O
determine O
the O
effect O
of O
duloxetine O
, O
60 O
mg O
daily O
, O
on O
average O
pain O
severity O
. O

On O
March O
15 O
, O
2005 O
, O
the O
US O
Food O
and O
Drug O
Administration O
approved O
temozolomide O
( O
Temodar O
capsules O
, O
Schering-Plough O
Research O
Institute O
) O
for O
the O
treatment O
of O
adult O
patients O
with O
newly O
diagnosed O
glioblastoma O
multiforme O
concomitantly O
with O
radiotherapy O
and O
then O
as O
maintenance O
treatment O
. O

The O
setting O
was O
in O
a O
hydrotherapy O
pool O
, O
1.2 O
m O
depth O
, O
and O
a O
temperature O
of O
32-33 O
degrees O
capital O
ES O
, O
Cyrillic O
. O

To O
date O
, O
practice O
guidelines O
for O
the O
prevention O
and O
treatment O
of O
CACS O
are O
lacking O
. O

Pain O
training O
and O
control O
interventions O
were O
matched O
for O
materials O
and O
method O
. O

This O
randomized O
controlled O
trial O
tested O
whether O
acupuncture O
reduces O
vasomotor O
symptoms O
and O
produces O
fewer O
adverse O
effects O
than O
venlafaxine O
. O

Transfusion O
data O
were O
available O
for O
79 O
of O
81 O
evaluable O
patients O
( O
98 O
% O
) O
who O
completed O
the O
treatment/observation O
period O
. O

Patients O
were O
randomly O
assigned O
to O
receive O
either O
nutrition O
intervention O
( O
n=29 O
) O
( O
nutrition O
counseling O
following O
the O
American O
Dietetic O
Association O
[ O
ADA O
] O
medical O
nutrition O
therapy O
[ O
MNT O
] O
protocol O
for O
radiation O
oncology O
) O
or O
standard O
practice O
( O
n=31 O
) O
( O
general O
nutrition O
talk O
and O
booklet O
) O
. O

Randomisation O
was O
by O
use O
of O
a O
computer-generated O
table O
of O
random O
numbers O
in O
blocks O
of O
30 O
. O

Analysis O
was O
by O
intention-to-treat O
. O

Subjects O
were O
randomly O
assigned O
to O
either O
the O
control O
group O
receiving O
no O
music O
intervention O
( O
n O
= O
13 O
) O
or O
the O
experimental O
group O
receiving O
pre O
and O
postoperative O
live O
music O
therapy O
sessions O
( O
n O
= O
14 O
) O
. O

Gefitinib O
has O
shown O
high O
response O
rate O
and O
improved O
progression-free O
survival O
( O
PFS O
) O
in O
never-smokers O
with O
lung O
adenocarcinoma O
( O
NSLAs O
) O
. O

Paclitaxel O
and O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
are O
active O
cytotoxic O
agents O
for O
the O
treatment O
of O
human O
immunodeficiency O
virus O
( O
HIV O
) O
-associated O
Kaposi O
sarcoma O
( O
KS O
) O
. O

Associations O
of O
treatment O
group O
and O
putative O
prognostic O
variables O
with O
survival O
were O
tested O
in O
the O
Cox O
proportional O
hazards O
model O
. O

Study O
follow-up O
was O
completed O
July O
2012 O
. O

Local O
symptoms O
were O
scored O
on O
a O
physician-assessed O
, O
five-point O
categorical O
scale O
and O
summed O
to O
produce O
a O
total O
symptom O
score O
( O
TSS O
) O
. O

This O
double-blind O
phase O
III O
trial O
randomly O
assigned O
731 O
patients O
with O
NSCLC O
who O
had O
progressed O
after O
prior O
chemotherapy O
to O
erlotinib O
150 O
mg O
daily O
or O
placebo O
, O
with O
survival O
as O
the O
primary O
study O
outcome O
. O

They O
were O
randomly O
divided O
to O
receive O
either O
glutamine-enriched O
TPN O
or O
standard O
TPN O
. O

Phase O
III O
EGF104900 O
data O
demonstrated O
that O
lapatinib O
plus O
trastuzumab O
significantly O
improved O
progression-free O
survival O
( O
PFS O
) O
and O
clinical O
benefit O
rate O
versus O
lapatinib O
monotherapy O
, O
offering O
a O
chemotherapy-free O
option O
for O
patients O
with O
heavily O
pretreated O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
-positive O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O

Based O
on O
an O
intention O
to O
treat O
analysis O
, O
there O
was O
no O
statistically O
significant O
difference O
in O
the O
8-week O
lean O
body O
mass O
between O
the O
two O
arms O
. O

Three O
months O
after O
embolization O
, O
contrast O
material-enhanced O
magnetic O
resonance O
imaging O
examinations O
were O
evaluated O
blindly O
to O
determine O
the O
extent O
of O
leiomyoma O
infarction O
. O

Eight O
hundred O
sixty-one O
patients O
were O
accrued O
from O
89 O
sites O
in O
16 O
countries O
. O

Records O
of O
nutritional O
assessments O
, O
inflammatory O
status O
, O
and O
postoperative O
complications O
were O
compared O
between O
the O
two O
groups O
. O

Between O
May O
2003 O
and O
March O
2006 O
, O
107 O
patients O
were O
accrued O
";" O
46 O
had O
limited O
disease O
and O
61 O
extensive O
disease O
. O

Outcome O
data O
were O
collected O
at O
3 O
months O
after O
embolization O
, O
including O
assessment O
of O
clinical O
symptoms O
, O
scores O
from O
a O
fibroid O
tumor-specific O
symptom O
and O
quality O
of O
life O
( O
QOL O
) O
questionnaire O
, O
and O
findings O
on O
contrast O
material-enhanced O
magnetic O
resonance O
( O
MR O
) O
imaging O
, O
including O
the O
degree O
of O
tumor O
infarction O
and O
volume O
reduction O
. O

The O
authors O
conducted O
a O
prospective O
randomized O
study O
in O
which O
45 O
patients O
, O
each O
harboring O
a O
solitary O
contrast-enhancing O
intracerebral O
tumor O
, O
were O
randomized O
for O
surgery O
with O
or O
without O
neuronavigation O
. O

We O
evaluated O
the O
effects O
of O
lanreotide O
, O
a O
somatostatin O
analogue O
, O
in O
patients O
with O
polycystic O
liver O
because O
of O
autosomal-dominant O
( O
AD O
) O
PKD O
or O
autosomal-dominant O
polycystic O
liver O
disease O
( O
PCLD O
) O
. O

All O
treatments O
were O
delivered O
on O
days O
1 O
and O
8 O
every O
3 O
weeks O
for O
a O
maximum O
of O
six O
cycles O
. O

OS O
and O
updated O
PFS O
data O
are O
presented O
using O
Kaplan-Meier O
curves O
and O
log-rank O
tests O
stratified O
for O
hormone O
receptor O
and O
visceral O
disease O
status O
. O

This O
reduction O
in O
hot O
flash O
frequency O
persisted O
for O
up O
to O
6 O
months O
after O
the O
completion O
of O
treatment O
. O

235 O
patients O
completed O
follow-up O
. O

Two O
hundred O
patients O
with O
advanced O
colorectal O
cancer O
received O
PVI O
5-FU O
300 O
mg/m2/day O
for O
a O
maximum O
of O
24 O
weeks O
and O
were O
randomised O
to O
PVI O
5-FU O
alone O
or O
PVI O
5-FU O
+ O
MMC O
10 O
mg/m2 O
( O
7 O
mg/m2 O
from O
June O
1995 O
) O
6 O
weekly O
for O
4 O
courses O
. O

The O
secondary O
endpoints O
were O
also O
not O
significantly O
different O
between O
the O
arms O
. O

An O
EGP O
does O
not O
unequivocally O
affect O
positive O
HRQoL O
outcomes O
. O

The O
fat O
content O
of O
the O
artificial O
diet O
was O
66 O
% O
of O
the O
nonprotein O
calories O
. O

One O
hundred O
and O
twenty-one O
patients O
were O
enrolled O
through O
ten O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
) O
institutions O
";" O
100 O
patients O
had O
breast O
cancer O
and O
21 O
had O
colorectal O
cancer O
. O

During O
the O
first O
week O
of O
study O
, O
patients O
were O
administered O
25 O
mg O
of O
amitriptyline O
or O
equivalent O
drops O
of O
placebo O
at O
night O
for O
3 O
days O
and O
50 O
mg O
for O
the O
following O
4 O
days O
. O

Women O
enrolled O
in O
the O
study O
intervention O
were O
on O
average O
55 O
years O
old O
, O
predominantly O
Caucasian O
( O
79 O
% O
) O
, O
married O
( O
57 O
% O
) O
, O
and O
a O
median O
of O
4 O
years O
postprimary O
treatment O
. O

A O
median O
number O
of O
4 O
cycles O
( O
range O
, O
1-12 O
) O
were O
administered O
per O
patient O
. O

cancer O
survivors O
with O
different O
diagnoses O
, O
and O
cancer-related O
physical O
and O
psychosocial O
problems O
. O

Seventy-two O
patients O
with O
malignant O
ascites O
were O
divided O
into O
two O
study O
groups O
. O

The O
primary O
outcome O
was O
overall O
survival O
. O

These O
patients O
experience O
significant O
functional O
impairment O
and O
muscle O
atrophy O
, O
which O
may O
lead O
to O
an O
increased O
likelihood O
of O
skeletal O
complicaTIOns O
( O
i.e. O
, O
pathological O
fracture O
, O
bone O
pain O
) O
and/or O
falls O
. O

Most O
had O
a O
baseline O
IBDQ-B O
score O
indicating O
moderate-to-severe O
symptoms O
. O

To O
compare O
the O
effectiveness O
and O
tolerability O
of O
gemcitabine O
plus O
cisplatin O
with O
single-agent O
gemcitabine O
as O
first-line O
chemotherapy O
for O
locally O
advanced O
or O
metastatic O
pancreatic O
cancer O
. O

The O
most O
likely O
advantage O
of O
LRP O
is O
the O
superior O
cosmetic O
result O
. O

After O
16 O
of O
the O
first O
65 O
randomized O
patients O
experienced O
febrile O
neutropenia O
( O
FN O
) O
, O
the O
doses O
were O
reduced O
to O
DOX O
40 O
mg/m O
( O
2 O
) O
on O
day O
1 O
and O
VNB O
20 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
versus O
DOX O
60 O
mg/m O
( O
2 O
) O
on O
day O
1 O
. O

From O
January O
2000 O
to O
July O
2004 O
, O
492 O
patients O
were O
enrolled O
. O

SGN-15 O
is O
an O
antibody-drug O
conjugate O
( O
ADC O
) O
, O
consisting O
of O
a O
chimeric O
murine O
monoclonal O
antibody O
recognizing O
the O
Lewis O
Y O
( O
Le O
( O
y O
) O
) O
antigen O
, O
conjugated O
to O
doxorubicin O
. O

In O
addition O
, O
the O
impact O
of O
the O
treatment O
arms O
on O
the O
main O
metabolic O
and O
inflammatory O
parameters O
, O
including O
C-reactive O
protein O
( O
CRP O
) O
, O
interleukin O
( O
IL O
) O
-6 O
, O
tumor O
necrosis O
factor O
( O
TNF O
) O
-α O
, O
leptin O
, O
reactive O
oxygen O
species O
( O
ROS O
) O
, O
and O
glutathione O
peroxidase O
, O
was O
evaluated O
. O

GE/G O
median O
OS O
was O
5.6/5.1 O
months O
";" O
median O
PFS O
was O
3.4/3.0 O
months O
. O

Patients O
received O
LV O
200 O
mg/m O
( O
2 O
) O
( O
2-hour O
infusion O
) O
followed O
by O
FU O
400 O
mg/m O
( O
2 O
) O
( O
bolus O
) O
and O
FU O
600 O
mg/m O
( O
2 O
) O
( O
22-hour O
continuous O
infusion O
) O
on O
days O
1 O
and O
2 O
every O
14 O
days O
( O
LV5FU2 O
";" O
arm O
A O
) O
, O
LV5FU2 O
plus O
cisplatin O
50 O
mg/m O
( O
2 O
) O
( O
1-hour O
infusion O
) O
on O
day O
1 O
or O
2 O
( O
arm O
B O
) O
, O
or O
LV5FU2 O
plus O
irinotecan O
180 O
mg/m O
( O
2 O
) O
( O
2-hour O
infusion O
) O
on O
day O
1 O
( O
arm O
C O
) O
. O

The O
minimum O
follow-up O
time O
was O
5.2 O
years O
for O
the O
surviving O
patients O
. O

In O
one O
of O
these O
trials O
, O
HOVON49 O
, O
a O
prospective O
health-related O
quality-of-life O
( O
HRQoL O
) O
study O
was O
initiated O
in O
order O
to O
assess O
the O
impact O
of O
thalidomide O
on O
QoL O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
specialized O
supportive O
enteral O
and O
parenteral O
feeding O
have O
superior O
effects O
compared O
to O
oral O
nutrition O
on O
recovery O
during O
long-term O
postoperative O
treatment O
of O
cancer O
patients O
with O
preoperative O
weight O
loss O
and O
reduced O
maximum O
exercise O
capacity O
. O

Locally O
advanced O
breast O
cancer O
patients O
were O
randomly O
assigned O
onto O
a O
study O
comparing O
cyclophosphamide O
( O
C O
";" O
75 O
mg/m O
( O
2 O
) O
orally O
days O
1 O
to O
14 O
) O
, O
epirubicin O
( O
E O
";" O
60 O
mg/m O
( O
2 O
) O
intravenously O
[ O
IV O
] O
days O
1 O
, O
8 O
) O
, O
and O
fluorouracil O
( O
F O
";" O
500 O
mg/m O
( O
2 O
) O
IV O
days O
1 O
, O
8 O
) O
six O
cycles O
every O
28 O
days O
versus O
E O
( O
120 O
mg/m O
( O
2 O
) O
IV O
day O
1 O
) O
, O
C O
( O
830 O
mg/m O
( O
2 O
) O
IV O
day O
1 O
) O
, O
and O
granulocyte O
colony-stimulating O
factor O
( O
filgrastim O
";" O
5 O
micro O
g/kg/d O
subcutaneously O
days O
2 O
to O
13 O
) O
six O
cycles O
every O
14 O
days O
. O

The O
findings O
were O
not O
explained O
by O
differences O
in O
adherence O
. O

The O
median O
follow-up O
was O
71 O
months O
. O

There O
were O
fewer O
patients O
with O
a O
performance O
status O
of O
0 O
( O
n O
= O
11 O
v O
20 O
) O
, O
and O
fewer O
had O
CR O
to O
initial O
therapy O
( O
n O
= O
4 O
v O
8 O
) O
in O
the O
vandetanib O
arm O
. O

A O
phase O
III O
randomized O
study O
was O
performed O
to O
establish O
the O
most O
effective O
and O
safest O
treatment O
to O
improve O
the O
key O
symptoms O
in O
advanced O
gynecological O
cancer O
patients O
, O
i.e. O
, O
lean O
body O
mass O
( O
LBM O
) O
, O
resting O
energy O
expenditure O
( O
REE O
) O
, O
fatigue O
, O
and O
QoL O
. O

This O
multicenter O
, O
open-label O
, O
phase O
III O
study O
randomly O
assigned O
patients O
in O
a O
1:2 O
ratio O
to O
irinotecan O
given O
either O
weekly O
( O
125 O
mg/m O
( O
2 O
) O
) O
or O
once O
every O
3 O
weeks O
( O
350 O
mg/m O
( O
2 O
) O
, O
or O
300 O
mg/m O
( O
2 O
) O
in O
patients O
who O
were O
> O
/= O
70 O
years O
of O
age O
, O
who O
had O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
equal O
to O
2 O
, O
or O
who O
had O
prior O
pelvic O
irradiation O
) O
. O

Primary O
end-point O
was O
overall O
response O
to O
first-line O
treatment O
among O
TS O
high O
patients O
. O

At O
the O
fourth O
time O
point O
, O
60 O
% O
of O
living O
patients O
in O
both O
arms O
completed O
a O
QOL O
assessment O
. O

70 O
patients O
were O
treated O
with O
either O
MEV O
( O
Arm O
A O
) O
in O
a O
3-week O
cycle O
or O
CRA/IFN/TAX O
with O
an O
8-week O
cycle O
( O
Arm O
B O
) O
. O

The O
effect O
of O
this O
intervention O
on O
a O
patient O
's O
general O
well-being O
was O
also O
investigated O
. O

Prospective O
studies O
comparing O
the O
two O
methods O
in O
Asian O
people O
are O
few O
. O

A O
phase O
II O
trial O
combining O
DPPE O
and O
doxorubicin O
( O
DOX O
) O
in O
metastatic O
breast O
carcinoma O
showed O
increased O
response O
over O
that O
expected O
with O
DOX O
. O

Randomisation O
was O
done O
in O
blocks O
of O
12-20 O
participants O
, O
stratifying O
by O
age O
( O
younger O
than O
50 O
years O
, O
50 O
years O
or O
older O
) O
, O
and O
was O
done O
with O
a O
computer-generated O
sequence O
. O

One O
hundred O
seven O
patients O
were O
randomly O
assigned O
to O
AM O
( O
n O
= O
54 O
) O
or O
PM O
( O
n O
= O
53 O
) O
dosing O
and O
on O
study O
for O
a O
median O
8.3 O
months O
. O

Our O
primary O
end O
point O
was O
patient-rated O
physical O
functioning O
assessed O
by O
the O
Trial O
Outcome O
Index-Anemia O
. O

The O
trial O
was O
closed O
early O
due O
to O
slow O
accrual O
. O

Women O
( O
N=13388 O
) O
at O
increased O
risk O
for O
breast O
cancer O
because O
they O
1 O
) O
were O
60 O
years O
of O
age O
or O
older O
, O
2 O
) O
were O
35-59 O
years O
of O
age O
with O
a O
5-year O
predicted O
risk O
for O
breast O
cancer O
of O
at O
least O
1.66 O
% O
, O
or O
3 O
) O
had O
a O
history O
of O
lobular O
carcinoma O
in O
situ O
were O
randomly O
assigned O
to O
receive O
placebo O
( O
n=6707 O
) O
or O
20 O
mg/day O
tamoxifen O
( O
n=6681 O
) O
for O
5 O
years O
. O

Consistent O
results O
are O
observed O
across O
subgroups O
of O
patients O
. O

Despite O
this O
, O
it O
remains O
an O
understudied O
, O
underreported O
, O
and O
undertreated O
issue O
in O
the O
field O
of O
cancer O
survivorship O
. O

The O
efficacy O
and O
safety O
of O
letrozole O
therapy O
beyond O
5 O
years O
is O
being O
assessed O
in O
a O
re-randomization O
study O
, O
following O
the O
emergence O
of O
new O
data O
suggesting O
that O
clinical O
benefit O
correlates O
with O
the O
duration O
of O
letrozole O
. O

A O
hot O
flash O
score O
was O
calculated O
at O
each O
time O
point O
. O

Group O
1 O
received O
20 O
mg O
of O
CRO O
, O
group O
2 O
received O
10 O
mg O
of O
CRO O
, O
and O
group O
3 O
received O
a O
placebo O
at O
1 O
hour O
before O
transarterial O
chemoembolization O
( O
T O
( O
0 O
) O
) O
and O
12 O
( O
T O
( O
12 O
) O
) O
and O
24 O
( O
T O
( O
24 O
) O
) O
hours O
after O
T O
( O
0 O
) O
. O

Androgen O
treatment O
for O
prostate O
cancer O
can O
adversely O
affect O
functional O
domains O
of O
quality O
of O
life O
. O

In O
a O
prospective O
randomised O
single-centre O
study O
from O
2007 O
to O
2008 O
, O
104 O
patients O
underwent O
oesophagectomy O
for O
cancer O
. O

There O
was O
a O
month O
of O
washout O
time O
between O
treatments O
. O

Exploratory O
end O
points O
included O
association O
of O
efficacy O
with O
epidermal O
growth O
factor O
receptor O
gene O
copy O
number O
and O
other O
biomarkers O
. O

This O
paper O
reports O
the O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
of O
the O
patients O
in O
this O
trial O
. O

We O
randomised O
149 O
patients O
and O
analysed O
74 O
in O
each O
arm O
. O

Each O
time O
period O
was O
tested O
repeatedly O
against O
the O
baseline O
";" O
an O
overall O
P O
value O
was O
assigned O
for O
each O
reported O
symptom O
. O

The O
phase O
3 O
VISTA O
study O
in O
transplant-ineligible O
myeloma O
patients O
demonstrated O
superior O
efficacy O
with O
bortezomib-melphalan-prednisone O
( O
VMP O
";" O
nine O
6-wk O
cycles O
) O
vs. O
melphalan-prednisone O
( O
MP O
) O
but O
also O
increased O
toxicity O
. O

The O
primary O
outcome O
was O
the O
difference O
in O
the O
change O
in O
Functional O
Assessment O
of O
Cancer O
Therapy-Anemia O
scores O
between O
baseline O
and O
12 O
weeks O
. O

A O
total O
of O
74 O
patients O
were O
enrolled O
for O
the O
study O
. O

Older O
breast O
cancer O
survivors O
( O
BCSs O
) O
are O
at O
risk O
for O
late O
and O
long-term O
treatment O
effects O
on O
quality O
of O
life O
( O
QOL O
) O
, O
including O
lower O
physical O
functioning O
and O
fear O
of O
recurrence O
. O

Group-wise O
randomization O
was O
implemented O
by O
assigning O
one O
half O
of O
the O
patients O
to O
the O
complete O
program O
while O
the O
other O
half O
were O
allowed O
to O
choose O
which O
program O
components O
they O
considered O
relevant O
. O

The O
mean O
age O
of O
the O
participants O
was O
58.8 O
years O
";" O
181 O
( O
65 O
% O
) O
were O
men O
and O
98 O
( O
35 O
% O
) O
were O
women O
. O

and O
What O
does O
the O
study O
add O
? O

The O
primary O
objective O
was O
to O
demonstrate O
better O
overall O
survival O
( O
OS O
) O
for O
gefitinib O
compared O
with O
GP O
in O
chemotherapy-naive O
NSLAs O
. O

To O
explore O
the O
preference O
and O
compliance O
of O
elderly O
patients O
regarding O
p.o O
. O

Using O
a O
single-blinded O
, O
3-armed O
, O
randomized O
controlled O
trial O
, O
450 O
breast O
cancer O
survivors O
were O
randomly O
assigned O
to O
receive O
an O
oncologist O
exercise O
recommendation O
only O
, O
an O
oncologist O
exercise O
recommendation O
plus O
referral O
to O
an O
exercise O
specialist O
, O
or O
usual O
care O
. O

The O
two O
purposes O
of O
the O
study O
were O
to O
describe O
the O
effectiveness O
of O
the O
program O
and O
to O
obtain O
information O
about O
patient O
preferences O
for O
multi O
or O
mono O
dimensional O
rehabilitation O
programs O
. O

Two O
participants O
in O
the O
III O
+ O
ISG O
dropped O
out O
, O
compared O
with O
five O
in O
III O
( O
p O
= O
0.39 O
) O
. O

Patients O
with O
stage O
IIIb O
and O
IV O
NSCLC O
and O
KP O
< O
/= O
70 O
were O
randomly O
assigned O
to O
receive O
gemcitabine O
1,000 O
mg/m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
, O
and O
15 O
of O
each O
28-day O
cycle O
( O
3w4 O
) O
or O
gemcitabine O
1,500 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
of O
each O
21-day O
cycle O
( O
2w3 O
) O
, O
both O
for O
up O
to O
six O
cycles O
. O

Hemoglobin O
responses O
, O
transfusion O
requirements O
, O
and O
prognostic O
factors O
for O
responses O
were O
measured O
. O

There O
was O
also O
no O
difference O
of O
TNM O
stage O
distribution O
and O
type O
of O
operation O
between O
groups O
( O
P O
> O
.05 O
) O
. O

A O
multicenter O
, O
double-blind O
, O
randomized O
clinical O
trial O
was O
performed O
to O
test O
if O
breast O
IMRT O
would O
reduce O
the O
rate O
of O
acute O
skin O
reaction O
( O
notably O
moist O
desquamation O
) O
, O
decrease O
pain O
, O
and O
improve O
quality O
of O
life O
compared O
with O
standard O
radiotherapy O
using O
wedges O
. O

Those O
who O
received O
prednisone O
alone O
could O
have O
mitoxantrone O
added O
after O
6 O
weeks O
if O
there O
was O
no O
improvement O
in O
pain O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
pamidronate O
for O
bone O
pain O
in O
a O
randomised O
double-blind O
trial O
and O
to O
evaluate O
the O
contribution O
of O
new O
markers O
of O
bone O
resorption O
in O
patients O
with O
bone O
metastases O
. O

Exploratory O
analyses O
were O
performed O
on O
a O
data O
set O
from O
a O
previous O
study O
. O

PORTEC-2 O
accrued O
427 O
patients O
between O
2002 O
and O
2006 O
, O
of O
whom O
214 O
were O
randomly O
assigned O
to O
EBRT O
, O
and O
213 O
were O
randomly O
assigned O
to O
VBT O
. O

This O
study O
included O
three O
groups O
of O
patients O
, O
enrolled O
consecutively O
. O

The O
trial O
was O
stopped O
for O
futility O
. O

The O
online O
program O
, O
Sleep O
Healthy O
Using O
The O
Internet O
, O
delivers O
the O
primary O
components O
of O
CBT-I O
( O
sleep O
restriction O
, O
stimulus O
control O
, O
cognitive O
restructuring O
, O
sleep O
hygiene O
, O
and O
relapse O
prevention O
) O
. O

Multicentre O
, O
randomised O
, O
placebo O
controlled O
, O
double O
blind O
trial O
. O

Patients O
and O
clinical O
sites O
were O
informed O
of O
allocation O
to O
early O
treatment O
, O
and O
treatment O
was O
started O
as O
soon O
as O
possible O
within O
28 O
days O
of O
the O
increased O
CA125 O
measurement O
. O

This O
study O
is O
the O
first O
large O
prospective O
RCT O
of O
sentinel O
node O
biopsy O
( O
SNB O
) O
compared O
with O
standard O
axillary O
treatment O
( O
level O
I-III O
axillary O
lymph O
node O
dissection O
or O
four O
node O
sampling O
) O
, O
which O
includes O
comprehensive O
and O
repeated O
quality O
of O
life O
( O
QOL O
) O
assessments O
over O
18 O
months O
. O

The O
intervention O
was O
delivered O
through O
the O
University O
of O
California O
at O
San O
Diego O
";" O
participants O
received O
ten O
phone O
calls O
over O
the O
course O
of O
the O
16-week O
intervention O
. O

National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
CO.17 O
demonstrated O
the O
antiepidermal O
growth O
factor O
receptor O
( O
anti-EGFR O
) O
monoclonal O
antibody O
cetuximab O
improves O
overall O
and O
progression-free O
survival O
in O
patients O
with O
advanced O
, O
chemotherapy-refractory O
colorectal O
cancer O
( O
CRC O
) O
, O
particularly O
in O
patients O
with O
wild-type O
KRAS O
tumors O
. O

After O
chemotherapy O
those O
in O
the O
treatment O
group O
took O
modified O
FJD O
. O

The O
distribution O
of O
bulky O
N2 O
disease O
was O
uniform O
among O
the O
treatment O
arms O
. O

A O
total O
of O
173 O
patients O
( O
82 O
% O
of O
the O
expected O
) O
in O
the O
observation O
arm O
and O
186 O
( O
85 O
% O
of O
expected O
) O
in O
the O
chemotherapy O
arm O
completed O
baseline O
QOL O
assessments O
. O

As O
patients O
with O
pancreas O
and O
periampullary O
cancer O
( O
PPC O
) O
experience O
improved O
survival O
rates O
and O
longevity O
, O
the O
focus O
shifts O
toward O
living O
life O
while O
surviving O
cancer O
. O

A O
total O
of O
322 O
participants O
with O
cancer O
of O
the O
gastrointestinal O
tract O
( O
41 O
% O
";" O
67 O
in O
the O
usual O
care O
group O
vs O
66 O
in O
the O
intervention O
group O
) O
, O
lung O
( O
36 O
% O
";" O
58 O
vs O
59 O
) O
, O
genitourinary O
tract O
( O
12 O
% O
";" O
20 O
vs O
19 O
) O
, O
and O
breast O
( O
10 O
% O
";" O
16 O
vs O
17 O
) O
were O
randomized O
. O

Tumor O
response O
, O
duration O
of O
tumor O
control O
, O
tumor-related O
signs O
and O
symptoms O
( O
TRSS O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
survival O
, O
and O
tolerability O
were O
evaluated O
. O

The O
intervention O
was O
delivered O
on O
an O
individual O
basis O
on O
3 O
occasions O
over O
a O
period O
from O
9 O
weeks O
to O
12 O
weeks O
, O
and O
the O
objective O
of O
the O
intervention O
was O
to O
alter O
fatigue-related O
thoughts O
and O
behavior O
. O

This O
study O
examined O
the O
characteristics O
of O
women O
enrolled O
in O
an O
intervention O
trial O
to O
treat O
sexual O
dysfunction O
, O
and O
explored O
the O
relationship O
between O
sexual O
functioning O
and O
psychological O
well-being O
. O

Twenty O
patients O
completed O
the O
study O
. O

Eligible O
patients O
with O
complete O
response O
( O
CR O
) O
or O
partial O
response O
( O
PR O
) O
to O
combination O
chemotherapy O
( O
+/- O
thoracic O
or O
prophylactic O
cranial O
radiation O
) O
received O
oral O
vandetanib O
300 O
mg/d O
or O
matched O
placebo O
. O

We O
randomly O
assigned O
patients O
who O
had O
completed O
primary O
cancer O
treatment O
within O
the O
past O
24 O
months O
in O
any O
of O
four O
Korean O
hospitals O
and O
had O
reported O
moderate O
to O
severe O
fatigue O
for O
at O
least O
1 O
week O
to O
participate O
in O
a O
12-week O
, O
Internet-based O
, O
individually O
tailored O
CRF O
education O
program O
or O
to O
receive O
routine O
care O
. O

A O
10-point O
change O
in O
QOL O
scores O
from O
baseline O
was O
considered O
clinically O
significant O
. O

All O
parties O
, O
except O
for O
the O
randomisation O
centre O
, O
were O
blinded O
for O
TS O
status O
. O

The O
combination O
of O
radiotherapy O
plus O
long-term O
medical O
suppression O
of O
androgens O
( O
> O
or O
= O
2 O
years O
) O
improves O
overall O
survival O
in O
patients O
with O
locally O
advanced O
prostate O
cancer O
. O

To O
determine O
whether O
the O
impact O
of O
" O
laying O
on O
of O
hands O
" O
on O
the O
well-being O
of O
patients O
with O
advanced O
cancer O
is O
more O
efficient O
when O
performed O
by O
a O
person O
with O
self-declared O
" O
healing O
powers O
" O
as O
compared O
to O
an O
actor O
mimicking O
the O
healer O
in O
close O
detail O
. O

We O
have O
recently O
suggested O
that O
bolus O
5-fluorouracil O
( O
5-FU O
) O
may O
work O
via O
a O
RNA O
directed O
mechanism O
while O
continuous O
infusion O
5-FU O
may O
kill O
cells O
via O
a O
thymidylate O
synthase O
related O
pathway O
. O

One O
hundred O
patients O
were O
randomly O
assigned O
to O
undergo O
UAE O
with O
polyvinyl O
alcohol O
( O
PVA O
) O
particles O
or O
tris-acryl O
gelatin O
microspheres O
. O

EORTC O
QLQ-C30 O
was O
administered O
at O
screening O
, O
on O
day O
1 O
of O
each O
cycle O
, O
at O
the O
end-of-treatment O
visit O
, O
and O
every O
8 O
wk O
until O
progression O
. O

Skin O
care O
, O
30-min O
manual O
lymphatic O
drainage O
, O
1-h O
pneumatic O
compression O
therapy O
, O
application O
of O
a O
short-stretch O
bandage O
or O
K-tape O
for O
each O
group O
, O
and O
a O
20-min O
physical O
therapy O
exercise O
were O
given O
during O
every O
treatment O
session O
. O

Time-to-event O
data O
were O
analyzed O
using O
the O
Kaplan-Meier O
method O
, O
and O
a O
stratified O
log-rank O
test O
was O
used O
to O
compare O
distributions O
between O
treatment O
groups O
. O

Health O
outcomes O
were O
examined O
according O
to O
treatment O
received O
: O
mastectomy O
with O
and O
without O
chemotherapy O
, O
and O
lumpectomy O
with O
and O
without O
chemotherapy O
. O

Patients O
in O
control O
group O
( O
31 O
cases O
) O
received O
conventional O
chemotherapy O
, O
whereas O
patients O
in O
the O
combined O
treatment O
group O
( O
41 O
cases O
) O
were O
given O
verapamil O
intraperitoneally O
in O
addition O
to O
chemotherapy O
drugs O
. O

The O
primary O
end O
point O
was O
time-to-progression O
( O
TTP O
) O
. O

251 O
patients O
were O
randomly O
divided O
into O
pemetrexed O
combined O
with O
cisplatin O
group O
( O
PP O
group O
) O
with O
127 O
cases O
and O
gemcitabine O
combined O
with O
cisplatin O
group O
( O
GP O
group O
) O
with O
124 O
cases O
. O

Thirty O
three O
patients O
( O
16 O
control O
, O
17 O
thalidomide O
) O
were O
evaluated O
at O
four O
weeks O
, O
and O
20 O
patients O
( O
eight O
control O
, O
12 O
thalidomide O
) O
at O
eight O
weeks O
. O

Observational O
studies O
demonstrate O
an O
association O
between O
physical O
activity O
and O
improved O
outcomes O
in O
breast O
and O
colon O
cancer O
survivors O
. O

To O
determine O
functional O
and O
psychological O
benefits O
of O
a O
12 O
week O
supervised O
group O
exercise O
programme O
during O
treatment O
for O
early O
stage O
breast O
cancer O
, O
with O
six O
month O
follow-up O
. O

The O
primary O
endpoint O
was O
investigator-assessed O
overall O
response O
rate O
( O
ORR O
) O
";" O
secondary O
endpoints O
were O
PFS O
, O
overall O
survival O
( O
OS O
) O
, O
safety O
, O
and O
quality O
of O
life O
. O

Vasomotor O
symptoms O
are O
common O
adverse O
effects O
of O
antiestrogen O
hormone O
treatment O
in O
conventional O
breast O
cancer O
care O
. O

Forty-six O
patients O
( O
mean O
age O
, O
66 O
yrs O
";" O
57 O
% O
women O
) O
contributed O
data O
to O
the O
trial O
. O

We O
conducted O
a O
randomized O
trial O
comparing O
uterine-artery O
embolization O
and O
surgery O
in O
women O
with O
symptomatic O
uterine O
fibroids O
. O

Intensity O
of O
service O
was O
measured O
as O
the O
number O
of O
days O
in O
the O
hospital O
and O
in O
the O
intensive O
care O
unit O
( O
ICU O
) O
and O
the O
number O
of O
emergency O
department O
visits O
recorded O
in O
the O
electronic O
medical O
record O
. O

All O
patients O
kept O
a O
daily O
pain O
diary O
. O

From O
September O
1994 O
to O
July O
1997 O
, O
153 O
consecutive O
patients O
were O
randomized O
to O
MVP O
( O
75 O
patients O
) O
or O
MVC O
arm O
( O
78 O
patients O
) O
. O

IFNalpha2a O
was O
given O
daily O
subcutaneously O
, O
starting O
at O
a O
dose O
of O
3 O
million O
units O
( O
MU O
) O
. O

MA.17 O
was O
conducted O
to O
determine O
whether O
letrozole O
improves O
outcome O
after O
discontinuation O
of O
tamoxifen O
. O

The O
primary O
efficacy O
data O
have O
been O
reported O
previously O
. O

KP O
, O
toxicity O
, O
and O
SS14 O
lung O
cancer O
specific O
questions O
were O
recorded O
before O
each O
cycle O
of O
treatment O
. O

Doses O
for O
patients O
aged O
more O
than O
65 O
years O
were O
15 O
mg O
( O
first O
3 O
days O
) O
and O
30 O
mg O
( O
3 O
days O
after O
) O
. O

Patients O
with O
cancer O
are O
characterized O
by O
a O
profound O
impairment O
of O
glucose O
utilization O
, O
with O
lipids O
being O
the O
preferred O
metabolic O
fuel O
. O

We O
investigated O
whether O
dignity O
therapy O
could O
mitigate O
distress O
or O
bolster O
the O
experience O
in O
patients O
nearing O
the O
end O
of O
their O
lives O
. O

The O
primary O
end O
point O
of O
this O
study O
was O
the O
objective O
response O
rate O
and O
based O
on O
the O
statistical O
design O
of O
the O
trial O
, O
the O
3-weekly O
irinotecan O
schedule O
was O
selected O
over O
weekly O
irinotecan O
administration O
. O

Of O
the O
120 O
participants O
randomly O
assigned O
, O
78 O
( O
65 O
% O
) O
completed O
the O
post-treatment O
assessment O
and O
67 O
( O
56 O
% O
) O
completed O
the O
2-month O
follow-up O
. O

To O
determine O
the O
incremental O
cost O
utility O
of O
epoetin-alfa O
versus O
placebo O
in O
anaemic O
patients O
with O
stage O
IV O
breast O
cancer O
from O
a O
UK O
National O
Health O
Service O
perspective O
. O

One O
hundred O
ninety-five O
patients O
were O
enrolled O
and O
showed O
baseline O
characteristics O
well O
balanced O
between O
treatment O
arms O
. O

This O
study O
provides O
prospective O
data O
on O
how O
multiple O
dosing O
regimens O
available O
with O
darbepoetin O
alfa O
can O
be O
synchronized O
with O
chemotherapy O
administered O
across O
a O
range O
of O
dosing O
schedules O
. O

A O
total O
of O
513 O
patients O
were O
enrolled O
when O
a O
planned O
interim O
analysis O
recommended O
early O
closure O
for O
futility O
. O

The O
primary O
end O
point O
was O
progression-free O
survival O
. O

Treosulfan O
, O
an O
alkylating O
agent O
, O
has O
demonstrated O
activity O
in O
recurrent O
ovarian O
carcinoma O
. O

RECIST-defined O
objective O
response O
rate O
( O
ORR O
) O
was O
the O
primary O
end O
point O
. O

Recruited O
were O
167 O
solid O
tumor O
children O
patients O
at O
Department O
of O
Tumor O
, O
Beijing O
Children O
's O
Hospital O
. O

Thalidomide O
with O
melphalan/prednisone O
( O
MPT O
) O
was O
defined O
as O
standard O
treatment O
in O
elderly O
patients O
with O
multiple O
myeloma O
( O
MM O
) O
based O
on O
five O
randomized O
trials O
. O

Baseline O
HRQOL O
scores O
did O
not O
differ O
between O
groups O
. O

Ethics O
committee O
approval O
and O
informed O
consent O
were O
obtained O
for O
the O
Embolisation O
versus O
Hysterectomy O
Trial O
. O

Patients O
were O
randomized O
to O
undergo O
10 O
sessions O
of O
manual O
lymphatic O
drainage O
followed O
by O
10 O
sessions O
of O
low-frequency O
low-intensity O
electrotherapy O
or O
to O
undergo O
first O
low-frequency O
low-intensity O
electrotherapy O
followed O
by O
manual O
lymphatic O
drainage O
. O

The O
primary O
outcomes O
were O
survival O
( O
PCV O
v O
TMZ O
) O
and O
12-week O
progression-free O
survival O
( O
PFS O
";" O
TMZ-5 O
v O
TMZ-21 O
) O
. O

Prospective O
, O
randomized O
, O
controlled O
trial O
. O

After O
16 O
wk O
both O
groups O
suspended O
duloxetine/placebo O
and O
continued O
rehabilitation O
. O

One O
hundred O
twenty-six O
patients O
referred O
for O
resection O
of O
the O
esophagus O
( O
n O
= O
48 O
) O
, O
stomach O
( O
n O
= O
28 O
) O
, O
or O
pancreas O
( O
n O
= O
50 O
) O
were O
considered O
to O
be O
included O
before O
operation O
. O

Consented O
participants O
were O
randomized O
to O
an O
experimental O
group O
( O
EG O
) O
( O
12 O
weekly O
MMP O
sessions O
) O
or O
a O
control O
group O
( O
no O
sessions O
) O
. O

The O
standard O
treatment O
of O
postoperative O
breast O
irradiation O
or O
the O
omission O
of O
radiotherapy O
. O

Participants O
with O
recurrent O
platinum-sensitive O
ovarian O
cancer O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine-carboplatin O
or O
carboplatin O
every O
21 O
days O
. O

Additional O
analyses O
included O
the O
Short O
Form-6 O
Dimensions O
( O
SF-6D O
) O
quality-of-life O
scale O
and O
a O
general O
impression O
( O
GI O
) O
of O
patient O
satisfaction O
with O
treatment O
at O
the O
end O
of O
the O
phase O
. O

In O
a O
previous O
study O
of O
treatment O
for O
advanced O
colorectal O
cancer O
, O
the O
LV5FU2 O
regimen O
, O
comprising O
leucovorin O
( O
LV O
) O
plus O
bolus O
and O
infusional O
fluorouracil O
( O
5FU O
) O
every O
2 O
weeks O
, O
was O
superior O
to O
the O
standard O
North O
Central O
Cancer O
Treatment O
Group/Mayo O
Clinic O
5-day O
bolus O
5FU/LV O
regimen O
. O

The O
aim O
of O
this O
prospective O
controlled O
study O
was O
to O
assess O
the O
efficacy O
of O
two O
different O
combination O
treatment O
modalities O
of O
lymphedema O
( O
LE O
) O
. O

QoL O
was O
assessed O
in O
350 O
patients O
randomly O
assigned O
to O
either O
standard O
chemotherapy O
( O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
[ O
CMF O
] O
or O
doxorubicin O
and O
cyclophosphamide O
[ O
AC O
] O
";" O
n O
= O
182 O
) O
or O
capecitabine O
( O
n O
= O
168 O
) O
. O

Gemcitabine O
for O
advanced O
pancreatic O
cancer O
( O
APC O
) O
is O
palliative O
and O
the O
prognosis O
is O
poor O
, O
making O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
particularly O
important O
. O

Another O
102 O
patients O
, O
97 O
of O
which O
received O
chemotherapy O
, O
were O
subsequently O
included O
in O
the O
study O
on O
an O
individual O
treatment O
preference O
basis O
. O

The O
study O
included O
73 O
analyzable O
patients O
enrolled O
between O
1998 O
and O
2002 O
, O
including O
36 O
in O
the O
paclitaxel O
arm O
and O
37 O
in O
the O
PLD O
arm O
";" O
73 O
% O
of O
patients O
received O
highly O
active O
antiretroviral O
therapy O
( O
HAART O
) O
and O
32 O
% O
had O
an O
undetectable O
viral O
load O
( O
< O
400 O
copies/mL O
) O
. O

The O
interventions O
offered O
dyads O
information O
and O
support O
. O

In O
the O
delayed O
treatment O
group O
, O
48/115 O
( O
42 O
% O
) O
patients O
received O
thoracic O
radiotherapy O
( O
29 O
received O
one O
of O
the O
recommended O
regimens O
) O
";" O
64 O
( O
56 O
% O
) O
died O
without O
receiving O
thoracic O
radiotherapy O
";" O
the O
remaining O
three O
( O
3 O
% O
) O
were O
alive O
at O
the O
end O
of O
the O
study O
without O
having O
received O
the O
treatment O
. O

Women O
with O
ovarian O
cancer O
in O
complete O
remission O
after O
first-line O
platinum-based O
chemotherapy O
and O
a O
normal O
CA125 O
concentration O
were O
registered O
for O
this O
randomised O
controlled O
trial O
. O

The O
success O
of O
blinding O
was O
assessed O
using O
a O
mixed-methods O
approach O
. O

The O
primary O
end O
point O
of O
the O
study O
was O
the O
time O
to O
development O
of O
severe O
mucositis O
from O
the O
start O
of O
radiotherapy O
. O

In O
addition O
, O
folic O
acid O
, O
vitamin O
B12 O
, O
and O
dexamethasone O
were O
administered O
in O
both O
groups O
. O

They O
recorded O
frequency O
, O
duration O
, O
and O
distress O
of O
nausea O
, O
vomiting O
, O
and O
retching O
daily O
, O
beginning O
the O
evening O
of O
chemotherapy O
administration O
and O
continuing O
for O
seven O
days O
. O

Assessments O
were O
conducted O
at O
baseline O
, O
immediately O
before O
every O
treatment O
cycle O
, O
at O
the O
end O
of O
treatment O
, O
and O
every O
six O
weeks O
for O
12 O
months O
. O

The O
objective O
of O
this O
study O
is O
to O
evaluate O
whether O
a O
six-week O
supervised O
multimodal O
exercise O
intervention O
, O
adjunct O
to O
chemotherapy O
and O
standard O
care O
, O
can O
reduce O
the O
patient O
's O
CRF O
level O
. O

We O
investigated O
the O
role O
of O
DC/CIK O
( O
dendritic O
cell/cytokine-induced O
killer O
cells O
) O
immunobiological O
cancer O
therapy O
in O
maintenance O
therapy O
of O
advanced O
non-small O
cell O
lung O
cancer O
. O

All O
statistical O
tests O
were O
two-sided O
and O
were O
performed O
at O
the O
alpha O
= O
. O

All O
patients O
received O
oral O
iron O
supplementation O
. O

182 O
( O
88 O
% O
) O
of O
208 O
men O
in O
the O
radical O
prostatectomy O
group O
, O
167 O
( O
87 O
% O
) O
of O
192 O
men O
in O
the O
watchful-waiting O
group O
, O
and O
214 O
( O
76 O
% O
) O
of O
281 O
men O
in O
the O
population-based O
control O
group O
answered O
the O
questionnaire O
. O

The O
2-year O
risk O
of O
progression O
for O
baseline O
PSA O
< O
50 O
ng/ml O
, O
50 O
to O
< O
500 O
ng/ml O
, O
and O
≥ O
500 O
ng/ml O
was O
25 O
% O
, O
55 O
% O
, O
and O
76 O
% O
( O
P O
= O
0.03 O
) O
in O
CAD O
, O
and O
38 O
% O
, O
64 O
% O
, O
and O
85 O
% O
( O
P O
= O
0.006 O
) O
in O
IAD O
, O
respectively O
. O

We O
assessed O
whether O
such O
patients O
could O
be O
helped O
if O
a O
practitioner O
followed O
an O
investigative O
and O
management O
algorithm O
, O
and O
whether O
outcomes O
differed O
by O
whether O
a O
nurse O
or O
a O
gastroenterologist O
led O
this O
algorithm-based O
care O
. O

Seventy-five O
patients O
with O
head O
and O
neck O
cancer O
who O
were O
referred O
for O
radiotherapy O
( O
RT O
) O
were O
randomized O
to O
the O
following O
groups O
: O
group O
1 O
( O
n O
= O
25 O
) O
, O
patients O
who O
received O
dietary O
counseling O
with O
regular O
foods O
";" O
group O
2 O
( O
n O
= O
25 O
) O
, O
patients O
who O
maintained O
usual O
diet O
plus O
supplements O
";" O
and O
group O
3 O
( O
n O
= O
25 O
) O
, O
patients O
who O
maintained O
intake O
ad O
lib O
. O

We O
therefore O
sought O
to O
assess O
the O
effect O
of O
LAC O
on O
QOL O
in O
the O
short O
and O
long O
term O
, O
using O
individual O
item O
analysis O
of O
multi-item O
QOL O
assessments O
. O

Few O
intervention O
programs O
assist O
patients O
and O
their O
family O
caregivers O
to O
manage O
advanced O
cancer O
and O
maintain O
their O
quality O
of O
life O
( O
QOL O
) O
. O

QOL O
was O
assessed O
at O
baseline O
and O
week O
12 O
. O

This O
study O
took O
place O
at O
the O
Royal O
Prince O
Alfred O
Hospital O
, O
Sydney O
, O
Australia O
. O

Post-surgery O
, O
227 O
breast O
cancer O
patients O
were O
randomized O
to O
intervention O
or O
assessment O
only O
Study O
Arms O
. O

Each O
call O
was O
standardized O
, O
comprising O
the O
assessment O
of O
unmet O
need O
and O
the O
provision O
of O
information O
and O
emotional O
support O
. O

Overall O
disease-related O
symptom O
improvement O
was O
assessed O
using O
an O
eight-item O
questionnaire O
. O

To O
determine O
whether O
drug O
intensification O
improves O
survival O
of O
patients O
with O
extensive O
SCLC O
, O
we O
compared O
this O
treatment O
with O
a O
four-drug O
regimen O
containing O
EP O
plus O
cyclophosphamide O
and O
4'-epidoxorubicin O
( O
PCDE O
) O
. O

A O
total O
of O
769 O
patients O
were O
randomized O
to O
EXE O
25 O
mg/d O
( O
n O
= O
366 O
) O
or O
MA O
( O
n O
= O
403 O
) O
40 O
mg O
four O
times O
daily O
. O

Two O
promising O
approaches O
to O
address O
this O
include O
dance/movement O
therapy O
and O
mindfulness O
. O

One O
hundred O
ninety O
patients O
with O
extremity O
STS O
were O
randomized O
after O
stratification O
by O
tumor O
size O
dichotomized O
at O
10 O
cm O
. O

One O
hundred O
seventy-four O
patients O
were O
enrolled O
. O

The O
maximum O
incidence O
of O
dysuria O
was O
85 O
% O
at O
1 O
month O
after O
brachytherapy O
, O
with O
subsequent O
resolution O
over O
time O
. O

From O
February O
2006 O
to O
March O
2007 O
, O
291 O
patients O
were O
enrolled O
and O
randomized O
, O
after O
total O
thyroidectomy O
: O
( O
1 O
) O
withdrawal O
of O
levothyroxine O
( O
LT4 O
) O
for O
4 O
weeks O
( O
T4-WD O
Group O
, O
n O
= O
89 O
) O
, O
( O
2 O
) O
withdrawal O
of O
LT4 O
for O
4 O
weeks O
plus O
2 O
weeks O
on O
and O
then O
2 O
weeks O
off O
liothyronine O
( O
LT3 O
) O
( O
T3-WD O
Group O
, O
n O
= O
133 O
) O
, O
and O
( O
3 O
) O
rhTSH O
administration O
( O
rhTSH O
Group O
, O
n O
= O
69 O
) O
. O

Median O
age O
was O
61.4 O
years O
for O
BT O
and O
59.4 O
for O
RP O
( O
P O
= O
.05 O
) O
. O

Seventy-six O
patients O
were O
randomly O
assigned O
to O
each O
study O
arm O
. O

Three O
hundred O
nine O
patients O
were O
analyzed O
per O
protocol O
( O
gefitinib O
arm O
, O
n O
= O
159 O
";" O
GP O
arm O
, O
n O
= O
150 O
) O
. O

Subjects O
were O
60 O
years O
or O
older O
with O
major O
depression O
( O
18 O
% O
) O
, O
dysthymic O
disorder O
( O
33 O
% O
) O
, O
or O
both O
( O
49 O
% O
) O
, O
recruited O
from O
18 O
primary O
care O
clinics O
belonging O
to O
8 O
health-care O
organizations O
in O
5 O
states O
. O

Nine O
hundred O
and O
sixty-four O
patients O
were O
recruited O
from O
71 O
centers O
. O

We O
randomized O
122 O
patients O
with O
lymphoma O
to O
usual O
care O
( O
n O
= O
62 O
) O
or O
12 O
weeks O
of O
supervised O
aerobic O
exercise O
training O
( O
AET O
";" O
n O
= O
60 O
) O
. O

We O
recruited O
273 O
participants O
and O
randomly O
assigned O
136 O
to O
the O
intervention O
group O
. O

Patients O
achieving O
complete O
remission O
with O
chemotherapy O
alone O
did O
not O
usually O
receive O
radiotherapy O
or O
undergo O
extensive O
surgery O
, O
but O
patients O
remaining O
in O
partial O
remission O
received O
local O
therapy O
with O
surgery O
and/or O
radiotherapy O
. O

Grade O
3 O
or O
4 O
neutropenia O
was O
more O
frequent O
in O
GEM-treated O
patients O
versus O
PLD-treated O
patients O
( O
P O
= O
.007 O
) O
. O

Postoperatively O
, O
body O
mass O
index O
( O
BMI O
) O
and O
nutritional O
conditions O
were O
measured O
serially O
, O
and O
QOL O
and O
postoperative O
squalor O
scores O
were O
evaluated O
at O
3 O
, O
12 O
, O
and O
60 O
months O
and O
compared O
between O
the O
2 O
groups O
. O

Prospective O
randomized O
study O
that O
included O
60 O
patients O
( O
45 O
women O
, O
15 O
men O
";" O
mean O
age O
, O
55.2 O
years O
) O
with O
recurrent O
malignant O
pleural O
effusion O
between O
January O
2005 O
and O
January O
2008 O
. O

This O
study O
sought O
to O
evaluate O
effectiveness O
of O
autologous O
dendritic O
cell O
vaccine O
( O
immunotherapy O
) O
for O
glioblastoma O
multiforme O
( O
GBM O
) O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

The O
140 O
patients O
included O
were O
in O
a O
good O
clinical O
condition O
with O
a O
median O
age O
of O
55 O
years O
( O
range O
22-87 O
) O
. O

Four O
hundred O
forty-seven O
patients O
were O
randomly O
assigned O
to O
PCV O
( O
224 O
patients O
) O
or O
TMZ O
( O
sub-random O
assignment O
: O
TMZ-5 O
[ O
200 O
mg/m O
( O
2 O
) O
for O
5 O
days O
, O
112 O
patients O
] O
or O
TMZ-21 O
[ O
100 O
mg/m O
( O
2 O
) O
for O
21 O
days O
, O
111 O
patients O
] O
) O
for O
up O
to O
9 O
months O
or O
until O
progression O
. O

Quality O
of O
life O
was O
determined O
at O
the O
time O
of O
randomization O
and O
ablation O
. O

The O
treatment O
could O
be O
incorporated O
into O
breast O
cancer O
survivorship O
programmes O
and O
delivered O
by O
trained O
breast O
cancer O
nurses O
. O

203 O
women O
entered O
the O
study O
";" O
177 O
completed O
the O
six O
month O
follow-up O
. O

Of O
558 O
women O
randomly O
assigned O
to O
treatment O
, O
418 O
completed O
the O
6-month O
assessment O
and O
399 O
completed O
the O
12-month O
assessment O
. O

The O
median O
age O
of O
patients O
was O
70 O
years O
. O

At O
baseline O
, O
no O
significant O
difference O
was O
observed O
among O
the O
three O
groups O
. O

Randomized O
, O
double-blinded O
, O
placebo-controlled O
. O

Ten O
common O
symptoms O
were O
assessed O
by O
self-report O
questionnaire O
administered O
to O
1,614 O
consecutive O
patients O
at O
baseline O
and O
every O
3 O
months O
during O
the O
first O
year O
of O
a O
double-blind O
, O
randomized O
trial O
of O
postmenopausal O
women O
with O
early O
hormone O
receptor-positive O
breast O
cancer O
. O

Further O
investigation O
and O
data O
collection O
will O
allow O
the O
assessment O
of O
this O
procedure O
beyond O
1 O
year O
after O
operation O
. O

Postoperative O
pain O
was O
assessed O
with O
a O
visual O
analog O
scale O
and O
the O
McGill O
Pain O
Questionnaire O
. O

The O
primary O
hypothesis O
was O
that O
duloxetine O
would O
be O
more O
effective O
than O
placebo O
in O
decreasing O
chemotherapy-induced O
peripheral O
neuropathic O
pain O
. O

Discussion O
topics O
were O
predominantly O
raised O
by O
patients/relatives O
, O
regardless O
of O
arm O
allocation O
. O

The O
impact O
of O
the O
addition O
of O
docetaxel O
on O
patients O
' O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
and O
symptoms O
was O
investigated O
. O

The O
sample O
size O
required O
in O
a O
larger O
definitive O
study O
is O
32 O
subjects O
per O
group O
. O

The O
authors O
conducted O
a O
randomized O
study O
to O
confirm O
the O
effectiveness O
and O
safety O
of O
treatment O
of O
CACS O
utilizing O
megestrol O
acetate O
( O
MA O
) O
plus O
thalidomide O
. O

Patients O
aged O
> O
65 O
years O
with O
newly O
diagnosed O
MM O
were O
randomized O
to O
receive O
melphalan O
plus O
prednisone O
( O
MP O
) O
or O
MPT O
, O
followed O
by O
thalidomide O
maintenance O
in O
the O
MPT O
arm O
. O

Between O
April O
1997 O
and O
December O
2000 O
, O
386 O
women O
with O
MBC O
and O
no O
prior O
chemotherapy O
for O
metastatic O
disease O
were O
registered O
. O

However O
, O
previous O
studies O
of O
coping O
skills O
training O
( O
CST O
) O
interventions O
have O
not O
been O
tested O
in O
patients O
with O
lung O
cancer O
nor O
have O
systematically O
included O
caregivers O
. O

The O
intervention O
took O
place O
over O
a O
4-month O
period O
. O

Endpoints O
were O
quality O
of O
life O
( O
QoL O
) O
, O
aerobic O
fitness O
, O
muscular O
strength O
, O
lean O
body O
mass O
, O
and O
body O
fat O
. O

Hazard O
ratios O
( O
HRs O
) O
for O
comparing O
thalidomide O
against O
placebo O
were O
estimated O
using O
Cox O
regression O
modeling O
. O

406 O
eligible O
patients O
were O
entered O
into O
the O
trial O
. O

Symptoms O
were O
analyzed O
by O
repeated-measures O
analysis O
of O
variance O
. O

Eighty O
percent O
of O
patients O
had O
stage O
IV O
NSCLC O
, O
with O
squamous O
cell O
( O
n=21 O
) O
, O
adenocarcinoma O
( O
n=12 O
) O
, O
and O
undifferentiated O
( O
n=7 O
) O
histologies O
. O

Patients O
were O
randomly O
assigned O
( O
2:1 O
) O
to O
GE O
or O
G O
treatment O
";" O
GE O
arm O
: O
E O
500 O
mg O
p.o O
. O

All O
P O
values O
are O
two-sided O
. O

Patients O
watched O
a O
video O
followed O
by O
about O
20 O
min O
of O
manual-standardized O
training O
with O
an O
oncology O
nurse O
focused O
on O
reviewing O
the O
printed O
material O
and O
adapted O
to O
individual O
concerns O
of O
patients O
. O

Shoulder O
range O
of O
motion O
, O
strength O
, O
arm O
circumference O
, O
and O
quality O
of O
life O
measurements O
were O
taken O
prior O
to O
, O
and O
at O
completion O
of O
radiotherapy O
, O
and O
at O
7 O
months O
after O
radiotherapy O
. O

Responsiveness O
to O
treatment O
and O
recurrence O
were O
analyzed O
using O
paired O
t O
tests O
and O
the O
squared O
ratio O
of O
these O
t O
tests O
, O
an O
estimate O
of O
relative O
efficiency O
. O

They O
were O
all O
reconstructed O
with O
stomach O
interposition O
through O
the O
retrosternal O
route O
. O

Psychosocial O
stress O
was O
measured O
using O
the O
Symptoms O
Checklist-90-Revised O
, O
and O
quality O
of O
life O
was O
measured O
using O
the O
Medical O
Outcomes O
Study O
Short-Form O
Health O
Survey O
at O
baseline O
, O
immediately O
post-intervention O
, O
and O
at O
6 O
months O
. O

The O
-1 O
, O
-2 O
, O
and O
3-year O
QOL O
, O
3-year O
survival O
rate O
, O
and O
the O
survival O
life O
of O
dead O
children O
patients O
were O
observed O
. O

In O
Lithuania O
, O
about O
400 O
cases O
of O
pancreatic O
cancer O
are O
diagnosed O
each O
year O
, O
and O
more O
than O
50 O
% O
of O
patients O
are O
diagnosed O
with O
stage O
IV O
disease O
. O

Fatigue O
dimensions O
, O
fatigue O
NRS O
score O
, O
interference O
of O
fatigue O
with O
daily O
life O
, O
symptom O
burden O
, O
quality O
of O
life O
, O
anxiety O
, O
and O
depression O
were O
measured O
at O
baseline O
and O
after O
1 O
, O
2 O
, O
and O
3 O
months O
. O

Of O
131 O
patients O
in O
the O
larger O
randomized O
controlled O
study O
, O
we O
report O
data O
on O
54 O
evaluable O
patients O
( O
16 O
older O
adults O
and O
38 O
younger O
adults O
) O
randomized O
to O
the O
intervention O
. O

The O
primary O
endpoint O
was O
the O
proportion O
of O
patients O
without O
progression O
at O
2 O
years O
. O

For O
this O
three-arm O
randomised O
controlled O
trial O
we O
recruited O
patients O
( O
aged O
≥18 O
years O
) O
from O
clinics O
in O
London O
, O
UK O
, O
with O
new-onset O
gastrointestinal O
symptoms O
persisting O
6 O
months O
after O
pelvic O
radiotherapy O
. O

A O
randomized O
controlled O
trial O
previously O
conducted O
in O
radiation O
oncology O
patients O
demonstrated O
that O
nutrition O
intervention O
had O
a O
beneficial O
impact O
on O
body O
weight O
, O
nutritional O
status O
, O
and O
quality O
of O
life O
compared O
with O
standard O
practice O
, O
but O
it O
did O
not O
report O
on O
dietary O
intake O
data O
. O

At O
baseline O
and O
three O
follow-up O
points O
, O
101 O
of O
125 O
women O
completed O
a O
depression O
symptom O
measure O
. O

HRQoL O
was O
assessed O
with O
the O
EORTC O
Core O
QoL O
Questionnaire O
( O
QLQ-C30 O
) O
and O
the O
myeloma-specific O
module O
( O
QLQ-MY24 O
) O
at O
baseline O
and O
at O
predetermined O
intervals O
during O
treatment O
. O

Secondary O
-- O
quality O
of O
life O
, O
adverse O
events O
, O
survival O
. O

One O
group O
was O
treated O
with O
DC/CIK O
immunobiological O
cancer O
therapy O
, O
and O
the O
other O
was O
taken O
as O
a O
control O
group O
. O

A O
total O
of O
104 O
advanced-stage O
gynecological O
cancer O
patients O
were O
enrolled O
and O
randomly O
assigned O
to O
receive O
either O
megestrol O
acetate O
( O
MA O
) O
plus O
l-carnitine O
, O
celecoxib O
, O
and O
antioxidants O
( O
arm O
1 O
) O
or O
MA O
alone O
( O
arm O
2 O
) O
. O

102 O
men O
completed O
the O
study O
. O

Patients O
with O
cytologically O
proven O
, O
symptomatic O
lung O
cancer O
not O
amenable O
to O
curative O
therapy O
, O
with O
performance O
status O
0-3 O
, O
were O
randomised O
to O
receive O
either O
30 O
Gy O
in O
10 O
fractions O
or O
a O
10 O
Gy O
single O
fraction O
. O

This O
triple O
blinded O
study O
randomized O
220 O
HNC O
patients O
scheduled O
for O
CRT O
( O
three O
weekly O
Cisplatin O
+ O
RT O
= O
66 O
Gray O
( O
2 O
Gy/session O
) O
, O
five O
fractions/week O
for O
6.5 O
weeks O
, O
total O
33 O
fractions O
) O
into O
laser O
( O
110 O
) O
and O
placebo O
( O
110 O
) O
groups O
. O

Previously O
untreated O
patients O
with O
SCLC O
with O
extensive O
disease O
or O
limited O
stage O
with O
poor O
prognostic O
factors O
were O
randomly O
assigned O
to O
six O
3-weekly O
cycles O
of O
GC O
or O
PE O
. O

To O
confirm O
its O
concurrent O
validity O
and O
responsiveness O
to O
treatment O
and O
recurrence O
in O
patients O
with O
breast O
cancer O
, O
emotional O
well-being O
was O
assessed O
every O
3 O
months O
for O
2 O
years O
and O
at O
1 O
and O
6 O
months O
after O
recurrence O
in O
1,169 O
patients O
who O
were O
premenopausal O
and O
960 O
patients O
who O
were O
postmenopausal O
. O

Measures O
included O
psychological O
( O
distress O
) O
, O
biological O
( O
immune O
) O
, O
and O
health O
outcomes O
( O
performance O
status O
and O
evaluations O
of O
patient O
's O
symptomatology O
, O
including O
toxicity O
from O
cancer O
treatment O
, O
lab O
values O
) O
collected O
at O
baseline O
, O
4 O
months O
, O
and O
12 O
months O
. O

Adjustments O
were O
made O
for O
the O
baseline O
score O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
toxicity O
and O
efficacy O
of O
radiation O
therapy O
( O
RT O
) O
for O
localized O
carcinoma O
of O
the O
prostate O
, O
using O
a O
hypofractionated O
( O
55 O
Gy/20 O
fractions/4 O
weeks O
) O
vs. O
a O
conventionally O
fractionated O
( O
64 O
Gy/32 O
fractions/6.5 O
weeks O
) O
dose O
schedule O
. O

Sentinel O
nodes O
were O
located O
using O
blue O
dye O
, O
alone O
or O
with O
technetium-labeled O
antimony O
sulfide O
colloid O
. O

Sensitivity O
, O
false-negative O
rates O
, O
and O
negative O
predictive O
values O
for O
sentinel-lymph-node O
biopsy O
were O
estimated O
in O
the O
RAC O
group O
. O

Embolization O
was O
performed O
in O
a O
standardized O
manner O
. O

Chemotherapy-naïve O
patients O
with O
measurable O
unresectable O
and/or O
metastatic O
gastric O
carcinoma O
, O
a O
performance O
status O
< O
or= O
1 O
, O
and O
adequate O
hematologic O
, O
hepatic O
, O
and O
renal O
function O
randomly O
received O
< O
or= O
eight O
3-weekly O
cycles O
of O
ECF O
( O
epirubicin O
50 O
mg/m O
( O
2 O
) O
on O
day O
1 O
, O
cisplatin O
60 O
mg/m O
( O
2 O
) O
on O
day O
1 O
, O
and O
fluorouracil O
[ O
FU O
] O
200 O
mg/m O
( O
2 O
) O
/d O
on O
days O
1 O
to O
21 O
) O
, O
TC O
( O
docetaxel O
initially O
85 O
mg/m O
( O
2 O
) O
on O
day O
1 O
[ O
later O
reduced O
to O
75 O
mg/m O
( O
2 O
) O
as O
a O
result O
of O
toxicity O
] O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
, O
or O
TCF O
( O
TC O
plus O
FU O
300 O
mg/m O
( O
2 O
) O
/d O
on O
days O
1 O
to O
14 O
) O
. O

The O
content O
of O
consultation O
audio O
recordings O
between O
28 O
oncologists O
and O
198 O
patients O
over O
four O
consecutive O
visits O
( O
792 O
consultations O
) O
was O
analyzed O
. O

The O
control O
group O
received O
normal O
care O
. O

The O
primary O
outcomes O
-- O
reductions O
in O
various O
dimensions O
of O
distress O
before O
and O
after O
completion O
of O
the O
study O
-- O
were O
measured O
with O
the O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
Spiritual O
Well-Being O
Scale O
, O
Patient O
Dignity O
Inventory O
, O
Hospital O
Anxiety O
and O
Depression O
Scale O
, O
items O
from O
the O
Structured O
Interview O
for O
Symptoms O
and O
Concerns O
, O
Quality O
of O
Life O
Scale O
, O
and O
modified O
Edmonton O
Symptom O
Assessment O
Scale O
. O

Forty-one O
patients O
with O
unilateral O
breast-cancer-related O
lymphedema O
for O
at O
least O
3 O
months O
were O
randomly O
grouped O
into O
the O
DLT O
group O
( O
bandage O
group O
, O
N O
= O
21 O
) O
or O
the O
modified O
DLT O
group O
( O
K-tape O
group O
, O
N O
= O
20 O
) O
. O

Patient O
compliance O
with O
respect O
to O
the O
HRQOL O
investigation O
was O
minimum O
74 O
% O
. O

The O
CMA O
intervention O
, O
delivered O
by O
a O
nurse O
practitioner O
, O
focused O
on O
symptom O
assessment O
, O
education O
, O
counseling O
and O
, O
as O
appropriate O
, O
specific O
pharmacologic O
and O
behavioral O
interventions O
for O
each O
of O
the O
three O
target O
symptoms O
. O

The O
purpose O
of O
our O
study O
is O
to O
compare O
the O
effectiveness O
of O
supportive O
care O
vs. O
3 O
intervention O
approaches O
, O
namely O
oral O
Etoposide O
, O
a O
3-drug O
combination O
, O
and O
radiotherapy O
using O
quality O
of O
life O
( O
QOL O
) O
as O
the O
primary O
measure O
of O
success O
. O

EORTC-QLQ O
and O
ASES-tests O
were O
performed O
to O
assess O
the O
quality O
of O
life O
before O
and O
after O
6 O
week-treatment O
. O

Many O
women O
with O
breast O
cancer O
need O
psychological O
help O
to O
cope O
more O
effectively O
after O
treatment O
. O

The O
aim O
of O
this O
study O
is O
to O
explore O
the O
effects O
, O
safety O
, O
and O
quality O
of O
life O
( O
QoL O
) O
of O
Gefitinib O
and O
Pemetrexed O
on O
patients O
with O
advanced O
non-squamous O
NSCLC O
. O

104/115 O
of O
the O
patients O
in O
the O
immediate O
treatment O
group O
received O
thoracic O
radiotherapy O
( O
90 O
received O
one O
of O
the O
recommended O
regimens O
) O
. O

After O
interim O
analysis O
of O
48 O
patients O
, O
the O
study O
was O
closed O
for O
futility O
. O

Outcomes O
included O
safety O
and O
tolerance O
of O
the O
exercise O
program O
, O
physical O
function O
, O
physical O
activity O
level O
, O
body O
composition O
, O
fatigue O
, O
quality O
of O
life O
and O
psychological O
distress O
. O

Patients O
randomly O
received O
docetaxel O
60 O
mg/m2 O
( O
day O
1 O
) O
or O
vinorelbine O
25 O
mg/m2 O
( O
days O
1 O
and O
8 O
) O
every O
21 O
days O
for O
four O
cycles O
. O

To O
explore O
the O
role O
of O
monochemotherapy O
, O
the O
authors O
evaluated O
5-fluorouracil O
( O
5-FU O
) O
, O
modulated O
by O
6S-leucovorin O
( O
6S-LV O
) O
and O
a O
cisplatin-containing O
regimen O
, O
which O
was O
comprised O
of O
epirubicin O
, O
etoposide O
, O
and O
cisplatin O
with O
the O
addition O
of O
the O
reversal O
agent O
lonidamine O
( O
EEP-L O
) O
. O

There O
were O
752 O
patients O
enrolled O
between O
2007 O
and O
2010 O
";" O
92 O
% O
had O
papillary O
cancer O
. O

We O
explored O
the O
quality O
of O
life O
( O
QoL O
) O
of O
such O
patients O
in O
a O
multicenter O
randomized O
trial O
that O
compared O
vinorelbine O
treatment O
with O
supportive O
care O
alone O
. O

Survival O
was O
analyzed O
on O
an O
intent-to-treat O
basis O
. O

Twelve O
patients O
received O
induction O
chemotherapy O
but O
were O
not O
randomized O
to O
RT O
or O
surgery O
thereafter O
. O

For O
the O
last O
six O
months O
, O
all O
received O
the O
1 O
+ O
2.5 O
dosage O
. O

The O
scapula-oriented O
exercises O
were O
designed O
focusing O
on O
scapulothoracic O
movement O
. O

The O
16-week O
regimen O
features O
greater O
doxorubicin O
and O
5-FU O
dose-intensity O
than O
CAF O
and O
improved O
scheduling O
of O
antimetabolites O
with O
sequential O
methotrexate O
and O
5-FU O
, O
as O
well O
as O
infusion O
5-FU O
. O

We O
performed O
a O
randomized O
, O
double-blind O
, O
28-day O
trial O
of O
melatonin O
20 O
mg O
versus O
placebo O
in O
patients O
with O
advanced O
lung O
or O
GI O
cancer O
, O
appetite O
scores O
≥ O
4 O
on O
a O
0 O
to O
10 O
scale O
( O
10 O
= O
worst O
appetite O
) O
, O
and O
history O
of O
weight O
loss O
≥ O
5 O
% O
. O

Objective O
outcome O
measures O
included O
shoulder O
range O
of O
motion O
and O
strength O
. O

The O
primary O
purpose O
of O
this O
study O
was O
to O
compare O
melatonin O
with O
placebo O
for O
appetite O
improvement O
in O
patients O
with O
cancer O
cachexia O
. O

We O
prospectively O
compared O
the O
efficacy O
and O
tolerability O
of O
two O
irinotecan O
regimens O
( O
once O
a O
week O
for O
4 O
weeks O
followed O
by O
a O
2-week O
rest O
period O
[ O
weekly O
] O
v O
once O
every O
3 O
weeks O
) O
in O
such O
patients O
. O

Analysis O
was O
conducted O
after O
intervention O
for O
immediate O
effects O
on O
outcome O
variables O
and O
6 O
weeks O
later O
for O
maintenance O
of O
effects O
. O

Each O
regimen O
was O
repeated O
every O
21 O
days O
and O
each O
included O
cisplatin O
( O
75 O
mg/m O
( O
2 O
) O
) O
. O

Women O
( O
n O
= O
558 O
) O
completed O
psychosocial O
questionnaires O
within O
4 O
weeks O
posttreatment O
and O
again O
2 O
, O
6 O
, O
and O
12 O
months O
later O
. O

Patients O
undergoing O
UAE O
were O
randomly O
assigned O
to O
receive O
TAGMs O
or O
PVA O
. O

We O
evaluated O
thalidomide O
, O
an O
anti-angiogenic O
agent O
, O
when O
combined O
with O
chemotherapy O
and O
as O
maintenance O
treatment O
. O

To O
evaluate O
the O
efficacy O
of O
a O
psychoeducational O
intervention O
in O
improving O
cancer-related O
fatigue O
. O

A O
non-randomised O
cohort O
was O
also O
recruited O
, O
in O
order O
to O
complete O
a O
comprehensive O
cohort O
study O
. O

All O
statistical O
tests O
were O
two-sided O
. O

One O
thousand O
two O
hundred O
ninety-nine O
patients O
were O
randomly O
assigned O
. O

Since O
elderly O
patients O
usually O
have O
several O
concomitant O
diseases O
and O
experience O
more O
treatment O
toxicity O
, O
an O
interim O
safety O
analysis O
was O
planned O
and O
performed O
after O
25 O
patients O
finished O
therapy O
to O
assess O
the O
tolerability O
of O
the O
treatment O
regimens O
. O

The O
primary O
outcome O
was O
the O
adjusted O
mean O
difference O
in O
HFNS O
problem O
rating O
( O
1-10 O
) O
between O
CBT O
and O
usual O
care O
groups O
at O
9 O
weeks O
after O
randomisation O
. O

The O
results O
were O
statistically O
significant O
. O

Peri- O
and O
postoperative O
parameters O
under O
investigation O
included O
the O
following O
: O
duration O
of O
the O
procedure O
";" O
surgeon O
's O
estimate O
of O
the O
usefulness O
of O
neuronavigation O
";" O
quantification O
of O
the O
extent O
of O
resection O
, O
determined O
using O
magnetic O
resonance O
imaging O
";" O
and O
the O
postoperative O
course O
, O
as O
evaluated O
by O
neurological O
examinations O
, O
the O
patient O
's O
quality-of-life O
self-assessment O
, O
application O
of O
the O
Barthel O
index O
and O
the O
Karnofsky O
Performance O
Scale O
score O
, O
and O
the O
patient O
's O
time O
of O
death O
. O

Patients O
with O
untreated O
cytologically O
or O
histologically O
proven O
metastatic O
or O
locally O
advanced O
adenocarcinoma O
of O
the O
pancreas O
were O
deemed O
measurable O
or O
evaluable O
. O

Studies O
on O
quality O
of O
life O
( O
QOL O
) O
among O
women O
with O
endometrial O
cancer O
have O
shown O
that O
patients O
who O
undergo O
pelvic O
radiotherapy O
report O
lower O
role O
functioning O
and O
more O
diarrhea O
and O
fatigue O
. O

Patients O
receiving O
DPPE O
were O
aggressively O
premedicated O
to O
ameliorate O
toxicity O
. O

Ten O
years O
of O
treatment O
planned O
. O

Although O
CP O
has O
recently O
been O
shown O
to O
be O
feasible O
in O
patients O
, O
there O
is O
no O
randomized O
controlled O
trial O
comparing O
bowel O
function O
with O
the O
J-pouch O
. O

We O
studied O
the O
effect O
of O
a O
new O
bisphosphonate O
, O
zoledronic O
acid O
, O
which O
blocks O
bone O
destruction O
, O
on O
skeletal O
complications O
in O
prostate O
cancer O
patients O
with O
bone O
metastases O
. O

1046 O
patients O
were O
treated O
( O
449 O
washout O
, O
597 O
direct-switch O
";" O
baseline O
characteristics O
were O
similar O
between O
groups O
) O
. O

Data O
is O
based O
on O
analyses O
of O
a O
prospective O
randomised O
controlled O
trial O
'The O
Body O
Cancer O
Trial O
' O
. O

These O
patients O
were O
enrolled O
in O
two O
International O
Breast O
Cancer O
Study O
Group O
randomized O
clinical O
trials O
in O
operable O
breast O
cancer O
conducted O
from O
1986 O
to O
1993 O
. O

Molecular O
markers O
to O
predict O
response O
to O
5-fluorouracil O
( O
FU O
) O
-based O
treatment O
of O
recurrent O
or O
metastasised O
colorectal O
cancer O
( O
mCRC O
) O
are O
not O
established O
. O

Secondary O
outcome O
measures O
included O
treatment-associated O
morbidity O
, O
mortality O
, O
survival O
, O
and O
cost-effectiveness O
. O

After O
medical O
treatment O
, O
they O
completed O
baseline O
measures O
and O
were O
randomly O
assigned O
to O
standard O
National O
Cancer O
Institute O
print O
material O
( O
CTL O
) O
";" O
standard O
print O
material O
and O
peer-modeling O
videotape O
( O
VID O
) O
";" O
or O
standard O
print O
material O
, O
videotape O
, O
two O
sessions O
with O
a O
trained O
cancer O
educator O
, O
and O
informational O
workbook O
( O
EDU O
) O
. O

A O
total O
of O
120 O
patients O
were O
randomly O
assigned O
to O
receive O
AM O
, O
and O
122 O
, O
to O
receive O
no O
AM O
( O
one O
patient O
was O
ineligible O
) O
";" O
72 O
% O
received O
AM O
per O
protocol O
or O
with O
a O
minor O
deviation O
. O

Tumor O
treatment O
was O
unrestricted O
. O

230 O
patients O
with O
previously O
untreated O
, O
non-small O
cell O
lung O
cancer O
that O
is O
locally O
too O
advanced O
for O
resection O
or O
radical O
radiotherapy O
with O
curative O
intent O
, O
with O
minimal O
thoracic O
symptoms O
, O
and O
with O
no O
indication O
for O
immediate O
thoracic O
radiotherapy O
. O

Patients O
with O
prior O
cytotoxic O
therapy O
for O
MBC O
were O
ineligible O
. O

The O
documented O
administration O
of O
postoperative O
pain O
medications O
";" O
the O
frequency O
, O
dosage O
, O
type O
, O
and O
how O
it O
was O
given O
was O
also O
compared O
between O
groups O
. O

Rehabilitation O
aims O
to O
address O
these O
needs O
, O
maximize O
psychological O
and O
physical O
function O
, O
and O
enable O
minimum O
dependency O
regardless O
of O
life O
expectancy O
. O

Two O
hundred O
and O
ninety-seven O
patients O
were O
randomised O
( O
C3 O
150 O
, O
C6 O
147 O
) O
. O

HRQOL O
was O
measured O
six O
times O
during O
a O
24-month O
follow-up O
period O
with O
the O
following O
validated O
questionnaires O
: O
Medical O
Outcome O
Study O
Short O
Form O
36 O
( O
SF-36 O
) O
mental O
component O
summary O
( O
MCS O
) O
and O
physical O
component O
summary O
( O
PCS O
) O
, O
Health O
Utilities O
Index O
Mark O
3 O
, O
EuroQol O
5D O
, O
urogenital O
distress O
inventory O
( O
UDI O
) O
, O
incontinence O
impact O
questionnaire O
, O
and O
defecation O
distress O
inventory O
( O
DDI O
) O
. O

All O
patients O
received O
neoadjuvant O
antiandrogen O
therapy O
. O

The O
aims O
of O
the O
present O
prospective O
randomized O
study O
were O
to O
evaluate O
the O
impact O
of O
TSH O
stimulation O
procedure O
( O
hypothyroidism O
vs. O
rhTSH O
) O
on O
quality O
of O
life O
( O
QoL O
) O
of O
thyroid O
cancer O
patients O
undergoing O
RRA O
and O
to O
evaluate O
efficacy O
of O
both O
procedures O
. O

Patients O
were O
randomly O
assigned O
to O
fulvestrant O
500 O
mg O
( O
500 O
mg O
intramuscularly O
[ O
IM O
] O
on O
day O
0 O
, O
then O
500 O
mg O
IM O
on O
days O
14 O
and O
28 O
and O
every O
28 O
days O
thereafter O
) O
or O
250 O
mg O
every O
28 O
days O
. O

Several O
multicomponent O
regimens O
have O
been O
reported O
to O
be O
useful O
in O
advanced O
androgen-independent O
prostate O
cancer O
. O

QOL O
variables O
were O
analyzed O
in O
449 O
randomized O
patients O
from O
the O
COST O
trial O
93-46-53 O
( O
INT O
146 O
) O
. O

Supervised O
exercise O
, O
comprising O
high-intensity O
cardiovascular O
and O
heavy O
resistance O
training O
, O
relaxation- O
and O
body O
awareness O
training O
and O
massage O
, O
9 O
h O
weekly O
for O
6 O
weeks O
. O

Health-related O
quality O
of O
life O
( O
HRQOL O
) O
, O
symptoms O
of O
depression O
, O
and O
adverse O
events O
( O
AEs O
) O
were O
compared O
between O
Japanese O
postmenopausal O
patients O
with O
hormone-sensitive O
breast O
cancer O
( O
BC O
) O
who O
received O
adjuvant O
tamoxifen O
, O
exemestane O
, O
or O
anastrozole O
in O
an O
open-labeled O
, O
randomized O
, O
multicenter O
trial O
designated O
as O
the O
National O
Surgical O
Adjuvant O
Study O
of O
Breast O
Cancer O
( O
N-SAS O
BC O
) O
4 O
substudy O
of O
the O
Tamoxifen O
Exemestane O
Adjuvant O
Multinational O
( O
TEAM O
) O
trial O
. O

Five O
years O
later O
, O
these O
190 O
men O
underwent O
HRQOL O
evaluation O
by O
using O
the O
cancer-specific O
50-item O
Expanded O
Prostate O
Cancer O
Index O
Composite O
, O
the O
Short O
Form O
12 O
Physical O
Component O
Score O
, O
and O
Short O
Form O
12 O
Mental O
Component O
Score O
. O

Included O
patients O
( O
n O
= O
80 O
) O
received O
supportive O
enteral O
or O
parenteral O
nutrition O
postoperatively O
at O
home O
corresponding O
to O
1000 O
kcal/d O
until O
the O
patients O
did O
not O
wish O
to O
continue O
with O
artificial O
nutrition O
for O
any O
reason O
. O

To O
determine O
whether O
a O
new O
agent O
, O
paclitaxel O
, O
would O
further O
improve O
survival O
in O
NSCLC O
, O
the O
Eastern O
Cooperative O
Oncology O
Group O
conducted O
a O
randomized O
trial O
comparing O
paclitaxel O
plus O
cisplatin O
to O
a O
standard O
chemotherapy O
regimen O
consisting O
of O
cisplatin O
and O
etoposide O
. O

The O
trial O
is O
registered O
, O
ISRCTN13771934 O
, O
and O
was O
closed O
March O
15 O
, O
2011 O
. O

The O
American O
College O
of O
Surgeons O
Oncology O
Group O
phase O
III O
Surgical O
Prostatectomy O
Versus O
Interstitial O
Radiation O
Intervention O
Trial O
comparing O
radical O
prostatectomy O
( O
RP O
) O
and O
brachytherapy O
( O
BT O
) O
closed O
after O
2 O
years O
due O
to O
poor O
accrual O
. O

Due O
to O
concerns O
of O
fragility O
fracture O
, O
exercise O
is O
a O
perceived O
contraindication O
for O
prostate O
cancer O
patients O
with O
bone O
metastases O
. O

Both O
regimens O
were O
given O
every O
3 O
weeks O
until O
a O
cumulative O
DOX O
dose O
of O
450 O
mg/m O
( O
2 O
) O
. O

Response O
rate O
( O
RR O
) O
was O
evaluated O
after O
every O
four O
courses O
. O

Fifty O
patients O
with O
advanced O
pancreatic O
cancer O
who O
had O
lost O
at O
least O
10 O
% O
of O
their O
body O
weight O
were O
randomised O
to O
receive O
thalidomide O
200 O
mg O
daily O
or O
placebo O
for O
24 O
weeks O
in O
a O
single O
centre O
, O
double O
blind O
, O
randomised O
controlled O
trial O
. O

Cognitive O
function O
was O
assessed O
by O
Executive O
Interview O
( O
EXIT25 O
) O
and O
Clock O
Drawing O
Tasks O
";" O
mood O
by O
Profile O
of O
Mood O
States O
";" O
anemia-related O
symptoms O
, O
including O
fatigue O
, O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Anemia O
( O
FACT-An O
) O
subscale O
";" O
and O
QOL O
by O
Linear O
Analog O
Scale O
Assessment O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

Quality O
of O
life O
was O
scored O
according O
to O
22 O
daily O
activity O
items O
( O
good O
, O
> O
or O
71 O
";" O
fair O
, O
< O
70 O
";" O
poor O
, O
< O
52 O
) O
. O

Patients O
aged O
65 O
years O
or O
more O
were O
eligible O
provided O
that O
their O
cancers O
were O
considered O
to O
be O
at O
low O
risk O
of O
local O
recurrence O
, O
were O
suitable O
for O
breast-conservation O
surgery O
, O
were O
receiving O
endocrine O
therapy O
and O
were O
able O
and O
willing O
to O
give O
informed O
consent O
. O

This O
study O
aimed O
to O
identify O
which O
patient O
characteristics O
predict O
fatigue O
improvement O
after O
CBT O
. O

Patients O
were O
randomly O
assigned O
to O
receive O
: O
docetaxel O
75 O
mg/m2 O
plus O
cisplatin O
75 O
mg/m2 O
, O
every O
3 O
weeks O
( O
DC O
) O
";" O
docetaxel O
75 O
mg/m2 O
and O
carboplatin O
6 O
mg/ml O
min O
, O
every O
3 O
weeks O
( O
DCb O
) O
";" O
or O
vinorelbine O
25 O
mg/m2/week O
plus O
cisplatin O
100 O
mg/m2 O
, O
every O
4 O
weeks O
( O
VC O
) O
. O

Twenty-one O
centers O
in O
The O
Netherlands O
. O

No O
prospective O
comparison O
with O
nitrosourea-based O
chemotherapy O
exists O
. O

Data O
from O
161 O
patients O
have O
been O
analyzed O
. O

If O
the O
compounds O
work O
, O
they O
would O
offer O
a O
low-cost O
, O
readily O
available O
adjunctive O
treatment O
for O
the O
management O
of O
CINV O
. O

A O
randomized O
, O
wait-listed O
, O
controlled O
trial O
was O
carried O
out O
in O
229 O
women O
after O
surgery O
, O
chemotherapy O
, O
and O
radiotherapy O
for O
breast O
cancer O
. O

In O
this O
project O
, O
the O
QOL O
differences O
between O
older O
adult O
( O
age O
65 O
) O
and O
younger O
adult O
( O
age O
18-64 O
) O
advanced O
cancer O
patients O
in O
response O
to O
a O
multidisciplinary O
intervention O
designed O
to O
improve O
QOL O
were O
examined O
. O

One O
hundred O
thirty-six O
patients O
( O
two O
were O
ineligible O
) O
were O
enrolled O
onto O
the O
randomized O
multicenter O
phase O
II O
trial O
. O

Overall O
, O
88 O
% O
( O
557 O
of O
634 O
) O
of O
expected O
QL O
forms O
were O
received O
. O

Patients O
randomized O
to O
combination O
therapy O
were O
given O
oral O
13-CRA O
1 O
mg/kg/d O
plus O
IFNalpha2a O
. O

A O
total O
of O
157 O
patients O
were O
randomized O
to O
UAE O
or O
surgery O
( O
hysterectomy O
or O
myomectomy O
) O
. O

A O
multicomponent O
, O
psychoeducational O
intervention O
( O
Project O
ENABLE O
[ O
Educate O
, O
Nurture O
, O
Advise O
, O
Before O
Life O
Ends O
] O
) O
conducted O
by O
advanced O
practice O
nurses O
consisting O
of O
4 O
weekly O
educational O
sessions O
and O
monthly O
follow-up O
sessions O
until O
death O
or O
study O
completion O
( O
n O
= O
161 O
) O
vs O
usual O
care O
( O
n O
= O
161 O
) O
. O

Patients O
randomized O
to O
oral O
nutrition O
only O
served O
as O
control O
subjects O
. O

Minimum O
followup O
was O
12 O
months O
. O

A O
recent O
randomized O
trial O
to O
compare O
external O
beam O
radiation O
therapy O
( O
EBRT O
) O
to O
cryoablation O
for O
localized O
disease O
showed O
cryoablation O
to O
be O
noninferior O
to O
external O
beam O
EBRT O
in O
disease O
progression O
and O
overall O
and O
disease-specific O
survival O
. O

Exercise O
therapies O
were O
performed O
for O
one O
session O
per O
week O
for O
eight O
weeks O
. O

The O
oral O
pamidronate O
dose O
was O
600 O
mg/d O
( O
high O
dose O
[ O
HD O
] O
) O
during O
the O
earliest O
study O
years O
, O
then O
changed O
to O
300 O
mg/d O
( O
low O
dose O
[ O
LD O
] O
) O
because O
of O
gastrointestinal O
toxicity O
. O

Administration O
amounts O
of O
nausea O
and O
pain O
medications O
were O
compared O
with O
a O
Two-Way O
ANOVA O
with O
One O
Repeated O
Measure O
resulting O
in O
no O
significant O
differences O
between O
groups O
and O
medications O
, O
F O
( O
1 O
, O
51 O
) O
= O
0.03 O
";" O
p O
> O
.05 O
. O

QoL O
was O
determined O
at O
the O
time O
of O
ablation O
. O

The O
purpose O
of O
our O
study O
was O
to O
evaluate O
the O
effect O
of O
cognitive O
behavioral O
therapy O
( O
CBT O
) O
, O
physical O
exercise O
( O
PE O
) O
, O
and O
of O
these O
two O
interventions O
combined O
( O
CBT/PE O
) O
on O
menopausal O
symptoms O
( O
primary O
outcome O
) O
, O
body O
image O
, O
sexual O
functioning O
, O
psychological O
well-being O
, O
and O
health-related O
quality O
of O
life O
( O
secondary O
outcomes O
) O
in O
patients O
with O
breast O
cancer O
experiencing O
treatment-induced O
menopause O
. O

Considering O
evaluable O
patients O
with O
assessable O
questionnaires O
( O
n O
= O
123 O
) O
, O
neither O
functioning O
nor O
symptom O
parameters O
differed O
significantly O
in O
favor O
of O
one O
of O
the O
two O
treatment O
groups O
. O

Two O
hundred O
fifty O
patients O
were O
randomly O
assigned O
, O
80 O
% O
were O
male O
with O
a O
median O
age O
of O
58 O
years O
, O
WHO O
performance O
status O
0 O
, O
1 O
, O
and O
2 O
, O
in O
25 O
% O
, O
62 O
% O
, O
and O
13 O
% O
of O
cases O
. O

SATURN O
( O
Sequential O
Tarceva O
in O
Unresectable O
NSCLC O
) O
was O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
, O
multicentre O
study O
investigating O
the O
impact O
of O
erlotinib O
maintenance O
therapy O
on O
HRQoL O
in O
patients O
with O
locally O
advanced O
or O
recurrent O
NSCLC O
. O

This O
randomized O
phase O
II O
study O
compared O
two O
treatment O
schedules O
of O
gemcitabine O
in O
patients O
with O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
and O
impaired O
Karnofsky O
performance O
status O
( O
KP O
) O
. O

End O
points O
included O
progression-free O
survival O
( O
PFS O
) O
, O
response O
rate O
( O
RR O
) O
, O
and O
response O
duration O
( O
RD O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
toxicity O
, O
and O
overall O
survival O
( O
OS O
) O
. O

Only O
34 O
% O
( O
39/116 O
) O
received O
intensive O
local O
therapy O
defined O
as O
radical O
wide O
field O
radiotherapy O
or O
radical O
surgery O
or O
both O
. O

Importantly O
, O
none O
of O
the O
QOL O
domains O
were O
worse O
with O
IMRT O
at O
any O
time O
point O
. O

After O
four O
cycles O
of O
platinum-based O
induction O
therapy O
, O
663 O
patients O
with O
stage O
IIIB O
or O
stage O
IV O
NSCLC O
and O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
of O
0 O
or O
1 O
were O
randomly O
assigned O
( O
in O
a O
2:1 O
ratio O
) O
from O
March O
15 O
, O
2005 O
, O
to O
July O
20 O
, O
2007 O
, O
using O
the O
Pocock O
and O
Simon O
minimisation O
method O
to O
receive O
pemetrexed O
( O
500 O
mg/m O
( O
2 O
) O
every O
21 O
days O
";" O
n=441 O
) O
or O
placebo O
( O
n=222 O
) O
plus O
best O
supportive O
care O
until O
disease O
progression O
. O

We O
based O
the O
program O
on O
the O
CRF O
guidelines O
of O
the O
National O
Comprehensive O
Cancer O
Network O
( O
NCCN O
) O
and O
incorporated O
the O
transtheoretic O
model O
( O
TTM O
) O
. O

A O
further O
aim O
was O
to O
investigate O
the O
role O
of O
high-dose O
chemotherapy O
in O
young O
patients O
with O
parameningeal O
primary O
tumours O
. O

Patients O
were O
then O
followed O
for O
6 O
months O
and O
evaluated O
for O
quality O
of O
life O
, O
completion O
of O
adjuvant O
treatment O
, O
and O
depressive O
symptoms O
. O

Quality O
of O
life O
was O
assessed O
from O
the O
responses O
to O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
quality-of-life O
questionnaire O
( O
C30 O
, O
health O
status O
and O
lung O
cancer O
module O
13 O
) O
. O

The O
treatment O
duration O
was O
4 O
months O
. O

Extracellular O
adenosine O
5'-triphosphate O
( O
ATP O
) O
is O
involved O
in O
the O
regulation O
of O
a O
variety O
of O
biologic O
processes O
, O
including O
neurotransmission O
, O
muscle O
contraction O
, O
and O
liver O
glucose O
metabolism O
, O
via O
purinergic O
receptors O
. O

Primary O
end O
point O
was O
overall O
survival O
, O
secondary O
end O
points O
were O
objective O
response O
rate O
( O
ORR O
) O
, O
safety O
, O
symptom O
improvement O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

No O
caregiver O
variables O
changed O
, O
which O
may O
indicate O
a O
need O
for O
a O
focus O
on O
caregivers O
. O

Secondary O
outcomes O
included O
additional O
QOL O
measures O
, O
patient O
satisfaction O
, O
safety O
and O
health O
economics O
. O

The O
primary O
end-point O
was O
acute O
grade O
≥ O
2 O
toxicity O
. O

At O
6-month O
follow-up O
, O
participants O
were O
mailed O
a O
questionnaire O
that O
assessed O
quality O
of O
life O
, O
self-esteem O
, O
fatigue O
, O
anxiety O
, O
depression O
, O
and O
exercise O
behavior O
. O

Primary O
outcome O
measures O
assessed O
at O
baseline O
and O
at O
week O
12 O
included O
the O
Connor O
Davidson O
Resilience O
Scale O
, O
Perceived O
Stress O
Scale O
, O
Smith O
Anxiety O
Scale O
, O
and O
Linear O
Analog O
Self O
Assessment O
Scale O
. O

The O
second O
International O
Society O
of O
Paediatric O
Oncology O
( O
SIOP O
) O
study O
for O
rhabdomyosarcoma O
( O
MMT84 O
) O
had O
several O
goals O
. O

A O
longitudinal O
QoL O
study O
on O
a O
subset O
of O
ESPAC-1 O
patients O
who O
prospectively O
completed O
the O
EORTC O
QLQ O
C-30 O
questionnaire O
during O
treatment O
and O
follow-up O
. O

Median O
age O
was O
47 O
years O
( O
range O
, O
25 O
to O
67 O
years O
) O
. O

Here O
, O
we O
report O
a O
6-month O
follow-up O
of O
exercise O
behavior O
and O
patient-rated O
outcomes O
from O
an O
exercise O
trial O
in O
breast O
cancer O
patients O
. O

Survival O
was O
the O
major O
study O
end O
point O
. O

Randomization O
totaled O
130 O
patients O
( O
GE O
= O
86 O
, O
G O
= O
44 O
) O
";" O
121 O
patients O
were O
treated O
( O
GE O
= O
82 O
, O
G O
= O
39 O
) O
. O

In O
all O
, O
263 O
men O
attended O
47 O
sessions O
. O

Behavioral O
symptoms O
are O
common O
in O
breast O
cancer O
survivors O
, O
including O
disturbances O
in O
energy O
, O
sleep O
, O
and O
mood O
, O
though O
few O
risk O
factors O
for O
these O
negative O
outcomes O
have O
been O
identified O
. O

Drug O
toxicity O
and O
quality O
of O
life O
were O
observed O
. O

Patients O
completed O
questionnaires O
before O
and O
after O
the O
visit O
and O
were O
interviewed O
by O
telephone O
at O
2 O
, O
6 O
, O
and O
12 O
weeks O
. O

Results O
for O
quality O
of O
life O
, O
symptom O
palliation O
, O
and O
tolerability O
are O
presented O
here O
. O

Subjects O
were O
42 O
consecutive O
men O
from O
a O
prospective O
study O
of O
brachytherapy O
as O
monotherapy O
with O
( O
125 O
) O
I O
for O
intermediate-risk O
localized O
prostate O
cancer O
. O

We O
randomly O
assigned O
patients O
with O
locally O
advanced O
prostate O
cancer O
who O
had O
received O
external-beam O
radiotherapy O
plus O
6 O
months O
of O
androgen O
suppression O
to O
two O
groups O
, O
one O
to O
receive O
no O
further O
treatment O
( O
short-term O
suppression O
) O
and O
the O
other O
to O
receive O
2.5 O
years O
of O
further O
treatment O
with O
a O
luteinizing O
hormone-releasing O
hormone O
agonist O
( O
long-term O
suppression O
) O
. O

Two O
hundred O
eighty-four O
patients O
were O
randomized O
to O
treatment O
with O
IFNalpha2a O
plus O
13-CRA O
or O
treatment O
with O
IFNalpha2a O
alone O
. O

Chemonaive O
Taiwanese O
patients O
aged O
70 O
years O
or O
older O
who O
had O
advanced O
NSCLC O
were O
randomized O
to O
receive O
either O
oral O
erlotinib O
150 O
mg O
( O
E O
) O
daily O
or O
oral O
vinorelbine O
60 O
mg/m O
( O
V O
) O
on O
days O
1 O
and O
8 O
every O
3 O
weeks O
. O

Cross-over O
single-blind O
random O
clinical O
trial O
. O

Eligible O
patients O
were O
required O
to O
have O
NSCLC O
unsuitable O
for O
curative O
therapy O
and O
baseline O
hemoglobin O
( O
Hgb O
) O
levels O
less O
than O
121 O
g/L O
. O

Lymphedema O
was O
assessed O
by O
arm O
circumference O
and O
measurement O
of O
arm O
volume O
by O
water O
displacement O
. O

Patients O
received O
traditional O
feeding O
scheme O
until O
resolution O
of O
postoperative O
ileus O
to O
start O
liquid O
diet O
. O

Exercise O
for O
Health O
was O
a O
randomized O
, O
controlled O
trial O
designed O
to O
evaluate O
two O
modes O
of O
delivering O
( O
face-to-face O
[ O
FtF O
] O
and O
over-the-telephone O
[ O
Tel O
] O
) O
an O
8-month O
translational O
exercise O
intervention O
, O
commencing O
6-weeks O
post-breast O
cancer O
surgery O
( O
PS O
) O
. O

Randomized O
controlled O
trial O
. O

Eligibility O
required O
that O
patients O
have O
grade O
1 O
or O
higher O
sensory O
neuropathy O
according O
to O
the O
NCI O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
and O
at O
least O
4 O
on O
a O
scale O
of O
0 O
to O
10 O
, O
representing O
average O
chemotherapy-induced O
pain O
, O
after O
paclitaxel O
, O
other O
taxane O
, O
or O
oxaliplatin O
treatment O
. O

Secondary O
endpoints O
were O
the O
PSQI O
component O
scores O
. O

Between O
1993 O
and O
2002 O
, O
women O
> O
or O
= O
60 O
years O
old O
with O
clinically O
node-negative O
operable O
breast O
cancer O
in O
whom O
adjuvant O
tamoxifen O
was O
considered O
indicated O
regardless O
of O
pathologic O
nodal O
status O
were O
randomly O
assigned O
to O
primary O
surgery O
plus O
axillary O
clearance O
( O
Sx O
+ O
Ax O
) O
followed O
by O
tamoxifen O
( O
Tam O
) O
versus O
Sx O
without O
Ax O
followed O
by O
Tam O
for O
5 O
consecutive O
years O
. O

A O
subset O
of O
166 O
patients O
also O
answered O
additional O
questionnaires O
to O
estimate O
nonradiotherapy O
and O
nonmedical O
costs O
. O

The O
FDA O
reviewed O
raw O
data O
in O
electronic O
format O
from O
a O
randomized O
controlled O
clinical O
trial O
comparing O
erlotinib O
with O
placebo O
in O
patients O
with O
locally O
advanced O
or O
metastatic O
NSCLC O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

Patients O
in O
the O
temozolomide O
+ O
radiotherapy O
arm O
received O
concomitant O
temozolomide O
( O
75 O
mg/m2 O
) O
once O
daily O
for O
the O
duration O
of O
radiation O
therapy O
( O
42-49 O
days O
) O
. O

Patients O
with O
polycystic O
liver O
( O
n O
= O
54 O
) O
were O
randomly O
assigned O
to O
groups O
given O
lanreotide O
( O
120 O
mg O
) O
or O
placebo O
, O
administered O
every O
28 O
days O
for O
24 O
weeks O
. O

In O
this O
study O
, O
we O
aimed O
to O
investigate O
the O
efficacy O
of O
BCAA O
granules O
, O
given O
nocturnally O
, O
in O
improving O
QOL O
in O
these O
patients O
. O

The O
purpose O
of O
this O
study O
is O
to O
compare O
the O
treatment O
and O
retention O
effects O
between O
standard O
decongestive O
lymphatic O
therapy O
( O
DLT O
) O
combined O
with O
pneumatic O
compression O
( O
PC O
) O
and O
modified O
DLT O
, O
in O
which O
the O
use O
of O
a O
short-stretch O
bandage O
is O
replaced O
with O
the O
use O
of O
Kinesio O
tape O
( O
K-tape O
) O
combined O
with O
PC O
. O

After O
catheter O
removal O
, O
112 O
patients O
were O
randomized O
to O
receive O
rehabilitation O
and O
duloxetine O
( O
group O
A O
) O
or O
rehabilitation O
alone O
( O
group O
B O
) O
, O
for O
16 O
wk O
. O

The O
authors O
of O
this O
report O
conducted O
a O
prospective O
, O
randomized O
phase O
2 O
trial O
to O
evaluate O
the O
effects O
of O
exogenous O
ghrelin O
during O
cisplatin-based O
chemotherapy O
. O

By O
March O
2007 O
, O
data O
on O
310 O
additional O
deaths O
were O
obtained O
( O
total O
= O
867 O
deaths O
) O
. O

Continence O
scoring O
, O
anorectal O
manometry O
, O
and O
endoanal O
ultrasound O
assessments O
were O
made O
before O
surgery O
. O

Fifty O
four O
patients O
were O
enrolled O
. O

After O
initial O
lack O
of O
accrual O
, O
a O
multidisciplinary O
educational O
session O
was O
introduced O
for O
eligible O
patients O
. O

Analysis O
was O
completed O
with O
use O
of O
chi O
( O
2 O
) O
analysis O
, O
Fisher O
exact O
tests O
, O
Student O
t O
tests O
, O
and O
analysis O
of O
variance O
as O
appropriate O
. O

WHO O
performance O
status O
was O
0 O
in O
79 O
( O
42 O
% O
) O
patients O
, O
1 O
in O
77 O
( O
41 O
% O
) O
patients O
, O
and O
2 O
in O
32 O
( O
17 O
% O
) O
patients O
. O

It O
is O
not O
clear O
whether O
the O
administration O
of O
radioiodine O
provides O
any O
benefit O
to O
patients O
with O
low-risk O
thyroid O
cancer O
after O
a O
complete O
surgical O
resection O
. O

treosulfan O
for O
the O
treatment O
of O
relapsed O
ovarian O
carcinoma O
, O
women O
aged O
65 O
years O
or O
older O
were O
included O
in O
this O
prospective O
multicenter O
study O
. O

Patients O
in O
the O
three O
groups O
did O
not O
differ O
significantly O
in O
baseline O
characteristics O
or O
tumor O
, O
node O
and O
metastasis O
( O
TNM O
) O
staging O
. O

This O
phase O
2 O
, O
25-week O
, O
open-label O
study O
evaluated O
the O
noninferiority O
of O
darbepoetin O
alfa O
administered O
weekly O
vs. O
as O
an O
extended O
dosing O
schedule O
( O
every O
2 O
or O
3 O
weeks O
) O
in O
patients O
with O
CIA O
. O

To O
further O
evaluate O
EVE O
+ O
EXE O
impact O
on O
disease O
burden O
, O
we O
conducted O
additional O
post-hoc O
analyses O
of O
patient-reported O
HRQOL O
. O

Proinflammatory O
cytokines O
, O
especially O
tumour O
necrosis O
factor O
alpha O
( O
TNF-alpha O
) O
, O
play O
a O
prominent O
role O
in O
the O
pathogenesis O
of O
cancer O
cachexia O
. O

From O
June O
2003 O
to O
December O
2003 O
, O
the O
10-year O
follow-up O
was O
conducted O
. O

Between O
May O
2002 O
and O
April O
2004 O
, O
182 O
patients O
with O
advanced O
GIST O
were O
enrolled O
. O

We O
obtained O
quality-of-life O
information O
from O
872 O
( O
99 O
% O
) O
of O
875 O
eligible O
men O
with O
locally O
advanced O
prostate O
cancer O
( O
T3 O
";" O
78 O
% O
) O
who O
were O
randomly O
assigned O
, O
between O
1996 O
and O
2002 O
, O
to O
3 O
months O
of O
total O
androgen O
blockade O
followed O
by O
continuous O
endocrine O
treatment O
( O
439 O
patients O
) O
or O
the O
same O
hormonal O
treatment O
with O
radiotherapy O
3 O
months O
after O
randomisation O
( O
436 O
patients O
) O
. O

We O
report O
a O
phase O
III O
trial O
comparing O
DOX O
with O
DPPE O
plus O
DOX O
in O
metastatic O
or O
recurrent O
breast O
cancer O
. O

Assessments O
at O
baseline O
, O
one O
, O
three O
, O
and O
6 O
months O
included O
barriers O
, O
the O
Brief O
Pain O
Inventory O
, O
opioid O
use O
, O
and O
physician O
and O
nurse O
ratings O
of O
their O
patients O
' O
pain O
. O

Randomized O
controlled O
trial O
conducted O
from O
November O
2003 O
through O
May O
2008 O
of O
322 O
patients O
with O
advanced O
cancer O
in O
a O
rural O
, O
National O
Cancer O
Institute-designated O
comprehensive O
cancer O
center O
in O
New O
Hampshire O
and O
affiliated O
outreach O
clinics O
and O
a O
VA O
medical O
center O
in O
Vermont O
. O

The O
primary O
end O
point O
was O
overall O
survival O
( O
OS O
) O
. O

The O
proportional O
hazards O
regression O
model O
with O
stratification O
for O
treatment O
, O
and O
the O
logistic O
regression O
model O
adjusting O
for O
treatment O
arm O
were O
used O
for O
univariate O
and O
multivariate O
analyses O
of O
survival O
and O
response O
to O
treatment O
, O
respectively O
. O

To O
assess O
the O
effectiveness O
of O
mindfulness-based O
stress O
reduction O
( O
MBSR O
) O
for O
mood O
, O
breast- O
and O
endocrine-specific O
quality O
of O
life O
, O
and O
well-being O
after O
hospital O
treatment O
in O
women O
with O
stage O
0 O
to O
III O
breast O
cancer O
. O

One O
hundred O
and O
eight O
cancer O
patients O
, O
no O
longer O
responsive O
to O
opioids O
for O
moderate O
pain O
, O
were O
selected O
to O
randomly O
receive O
initial O
daily O
doses O
of O
60 O
mg O
of O
oral O
sustained-release O
morphine O
, O
15 O
mg O
of O
oral O
methadone O
, O
or O
0.6 O
mg O
( O
25 O
microg/h O
) O
of O
transdermal O
fentanyl O
. O

The O
aim O
of O
this O
randomised O
study O
was O
to O
evaluate O
the O
longitudinal O
changes O
in O
body O
composition O
and O
lipid O
profiles O
in O
postmenopausal O
women O
switched O
from O
tamoxifen O
to O
exemestane O
. O

The O
main O
outcomes O
were O
self-reported O
severity O
of O
facial O
hair O
( O
measured O
on O
a O
scale O
of O
1-10 O
) O
, O
depression O
, O
anxiety O
( O
measured O
on O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
) O
and O
quality O
of O
life O
( O
measured O
on O
the O
WHOQOL-BREF O
) O
. O

Palliation O
was O
defined O
as O
an O
improvement O
of O
one O
point O
or O
more O
in O
the O
categorical O
scale O
. O

Secondary O
outcomes O
were O
role O
and O
emotional O
functioning O
and O
feelings O
of O
control O
and O
anxiety O
. O

This O
is O
, O
in O
part O
, O
because O
scales O
and O
measures O
of O
QOL O
are O
still O
relatively O
unfamiliar O
to O
most O
clinicians O
and O
because O
population-based O
reference O
ranges O
are O
lacking O
, O
thus O
making O
clinical O
trial O
results O
difficult O
to O
interpret O
. O

GE O
responses O
: O
1 O
complete O
response O
( O
CR O
, O
1.2 O
% O
) O
, O
6 O
partial O
response O
( O
PR O
, O
7.4 O
% O
) O
, O
and O
33 O
stable O
disease O
( O
SD O
, O
40.7 O
% O
) O
";" O
disease O
control O
rate O
( O
DCR=CR+PR+SD O
, O
49.4 O
% O
) O
. O

Equivalence O
was O
defined O
as O
less O
than O
20 O
% O
difference O
in O
the O
number O
achieving O
an O
improvement O
in O
the O
TSS O
. O

We O
randomly O
assigned O
75 O
patients O
to O
usual O
care O
and O
227 O
patients O
to O
acupuncture O
plus O
usual O
care O
( O
random O
assignment O
of O
1:3 O
respectively O
) O
with O
minimization O
controlling O
for O
baseline O
general O
fatigue O
and O
maintenance O
treatment O
. O

To O
test O
the O
ability O
of O
the O
cytoprotectant O
, O
amifostine O
, O
to O
reduce O
chemoradiotherapy-induced O
esophagitis O
and O
evaluate O
its O
influence O
on O
quality O
of O
life O
( O
QOL O
) O
and O
swallowing O
symptoms O
. O

In O
the O
multivariate O
analysis O
, O
FACIT-TOI O
changes O
were O
only O
affected O
by O
the O
modality O
of O
TSH O
stimulation O
performed O
for O
RRA O
. O

Function O
and O
quality O
of O
life O
were O
measured O
by O
the O
Musculoskeletal O
Tumor O
Society O
Rating O
Scale O
( O
MSTS O
) O
, O
the O
Toronto O
Extremity O
Salvage O
Score O
( O
TESS O
) O
, O
and O
the O
Short O
Form-36 O
( O
SF-36 O
) O
at O
randomization O
, O
6 O
weeks O
, O
and O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
months O
after O
surgery O
. O

Postmenopausal O
women O
aged O
50-69 O
years O
at O
randomisation O
. O

Compliance O
was O
excellent O
, O
with O
7,286 O
questionnaires O
analyzed O
. O

A O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
was O
conducted O
. O

or O
12 O
months O
( O
p.o O
. O
) O
. O

They O
were O
stratified O
by O
radiotherapy O
( O
early O
, O
late O
, O
or O
none O
) O
, O
stage O
( O
extensive O
or O
limited O
) O
, O
response O
( O
complete O
or O
partial O
) O
, O
and O
cooperative O
group O
( O
National O
Cancer O
Institute O
of O
Canada-Clinical O
Trials O
Group O
or O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
) O
. O

After O
a O
median O
follow-up O
of O
5.5 O
years O
, O
277 O
events O
have O
been O
reported O
. O

Patients O
with O
a O
peripheral O
solitary O
lung O
tumor O
( O
NSCLC O
or O
pulmonary O
metastasis O
) O
≤ O
5 O
cm O
were O
eligible O
. O

Anthracycline-naive O
women O
with O
measurable O
metastatic O
disease O
were O
randomly O
assigned O
to O
receive O
, O
every O
21 O
days O
, O
either O
DOX O
60 O
mg/m O
( O
2 O
) O
intravenously O
or O
DOX O
during O
the O
last O
20 O
minutes O
of O
an O
80-minute O
infusion O
of O
DPPE O
( O
5.3 O
mg/kg O
) O
, O
in O
both O
cases O
to O
cumulative O
DOX O
doses O
of O
450 O
mg/m O
( O
2 O
) O
. O

This O
study O
examined O
the O
feasibility O
and O
acceptability O
of O
an O
Individual O
Internet O
Intervention O
( O
III O
) O
embedded O
and O
integrated O
into O
an O
Internet O
Support O
Group O
( O
ISG O
) O
with O
the O
ultimate O
goal O
of O
enhancing O
adherence O
and O
learning O
, O
compared O
with O
an O
individual O
internet O
invention O
alone O
. O

During O
the O
3-day O
efficacy O
phase O
, O
patients O
received O
placebo O
or O
1-3 O
tablets O
of O
oxycodone/paracetamol O
( O
5/325 O
mg O
) O
, O
four O
times O
daily O
for O
3 O
days O
. O

Follow-up O
examinations O
were O
performed O
12 O
months O
after O
ablation O
to O
assess O
ablation O
outcome O
in O
each O
group O
by O
131 O
whole O
body O
scans O
( O
WBSs O
) O
, O
serum O
thyroglobulin O
measurement O
after O
TSH O
stimulation O
, O
and O
neck O
ultrasonography O
. O

However O
, O
there O
is O
a O
wide O
heterogeneity O
in O
the O
clinical O
impact O
of O
hypothyroidism O
. O

We O
report O
, O
to O
our O
knowledge O
, O
the O
first O
randomized O
trial O
of O
procarbazine O
, O
lomustine O
, O
and O
vincristine O
( O
PCV O
) O
versus O
TMZ O
in O
chemotherapy-naive O
patients O
with O
recurrent O
HGG O
. O

No O
significant O
differences O
were O
noted O
at O
baseline O
between O
the O
two O
treatment O
groups O
. O

Between O
April O
1990 O
and O
April O
1994 O
, O
70 O
eligible O
patients O
participated O
in O
a O
phase O
III O
trial O
comparing O
a O
regimen O
containing O
sequential O
chemotherapy O
and O
radiation O
therapy O
versus O
sequential O
chemotherapy O
plus O
surgery O
. O

The O
Southwest O
Oncology O
Group O
( O
SWOG O
) O
intergroup O
trial O
compared O
radical O
prostatectomy O
( O
RP O
) O
plus O
observation O
versus O
RP O
plus O
adjuvant O
radiation O
therapy O
( O
RT O
) O
. O

Radiother O
Oncol O
104:349-354 O
, O
2012 O
) O
. O

In O
addition O
, O
predefined O
AEs O
were O
analyzed O
. O

This O
study O
examined O
factors O
associated O
with O
attrition O
from O
a O
randomized O
controlled O
trial O
comparing O
meaning-centered O
group O
psychotherapy O
( O
MCGP O
) O
, O
an O
intervention O
designed O
to O
help O
advanced O
cancer O
patients O
sustain O
or O
enhance O
their O
sense O
of O
meaning O
to O
the O
supportive O
group O
psychotherapy O
( O
SGP O
) O
, O
a O
standardized O
support O
group O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

Stage O
was O
limited O
for O
279 O
patients O
( O
52 O
% O
) O
and O
extensive O
for O
253 O
( O
48 O
% O
) O
. O

The O
median O
age O
was O
74 O
years O
";" O
80 O
% O
had O
estrogen O
receptor-positive O
disease O
. O

Changes O
in O
mean O
scores O
from O
baseline O
to O
eight O
weeks O
and O
the O
prognostic O
value O
of O
the O
EQ-5D O
were O
evaluated O
. O

There O
was O
no O
difference O
of O
sex O
between O
two O
groups O
( O
IV O
arm O
: O
male/female O
= O
45/29 O
, O
oral O
arm O
: O
male/female O
= O
59/33 O
) O
. O

A O
multi-method O
approach O
was O
used O
in O
which O
verbal O
instruction O
, O
written O
material O
, O
an O
audio O
cassette O
tape O
, O
and O
the O
use O
of O
a O
pain O
diary O
were O
combined O
to O
inform O
and O
instruct O
patients O
about O
pain O
and O
pain O
management O
. O

The O
Medical O
Outcomes O
Trust O
Short-Form O
36 O
Survey O
was O
used O
to O
measure O
quality O
of O
life O
before O
and O
after O
the O
intervention O
. O

To O
examine O
the O
effect O
of O
a O
progressive O
upper-body O
exercise O
program O
on O
lymphedema O
secondary O
to O
breast O
cancer O
treatment O
. O

Generalised O
estimating O
equation O
modelling O
determined O
time O
( O
baseline O
[ O
5 O
weeks O
PS O
] O
, O
mid-intervention O
[ O
6 O
months O
PS O
] O
, O
post-intervention O
[ O
12 O
months O
PS O
] O
) O
, O
group O
( O
FtF O
, O
Tel O
, O
Usual O
Care O
[ O
UC O
] O
) O
and O
time-by-group O
effects O
. O

Planned O
subgroup O
analyses O
were O
also O
conducted O
. O

The O
median O
number O
of O
cycles O
administered O
was O
two O
in O
both O
arms O
( O
range O
0-14 O
) O
. O

Breast O
cancer O
patients O
who O
were O
initiating O
adjuvant O
chemotherapy O
( O
N=242 O
) O
were O
assigned O
randomly O
to O
receive O
usual O
care O
( O
UC O
) O
( O
n=82 O
) O
, O
resistance O
exercise O
training O
( O
RET O
) O
( O
n=82 O
) O
, O
or O
aerobic O
exercise O
training O
( O
AET O
) O
( O
n=78 O
) O
for O
the O
duration O
of O
chemotherapy O
. O

They O
were O
questioned O
on O
the O
topics O
of O
( O
i O
) O
severity O
of O
pain O
, O
( O
ii O
) O
ease O
of O
swallowing O
, O
( O
iii O
) O
satisfaction O
of O
daily O
activities O
, O
( O
iv O
) O
dependence O
on O
medications O
, O
( O
v O
) O
working O
ability O
, O
( O
vi O
) O
fatigue O
, O
( O
vii O
) O
appetite O
, O
( O
viii O
) O
sociality O
, O
( O
ix O
) O
happiness O
and O
( O
x O
) O
self O
respect O
, O
in O
the O
third O
, O
sixth O
and O
twelfth O
month O
. O

The O
primary O
endpoints O
were O
the O
differences O
in O
double O
endometrial O
thickness O
and O
uterine O
volume O
after O
1 O
year O
. O

Although O
treatment O
allocation O
was O
random O
in O
only O
19 O
% O
, O
all O
patients O
received O
identical O
information O
in O
a O
multidisciplinary O
setting O
before O
selecting O
RP O
, O
BT O
, O
or O
random O
assignment O
. O

To O
examine O
health-related O
quality O
of O
life O
, O
we O
investigated O
the O
effect O
of O
adjuvant O
chemotherapy O
regimens O
on O
utility O
scores O
assessed O
by O
the O
EuroQoL-5D O
( O
EQ-5D O
) O
instrument O
in O
a O
randomized O
, O
controlled O
trial O
for O
breast O
cancer O
patients O
after O
surgery O
. O

The O
median O
duration O
of O
therapy O
was O
39 O
weeks O
for O
bicalutamide-treated O
patients O
and O
42 O
weeks O
for O
castrated O
patients O
";" O
treatment O
failure O
occurred O
in O
53 O
% O
and O
42 O
% O
and O
disease O
progression O
in O
43 O
% O
and O
33 O
% O
, O
respectively O
. O

Pemetrexed O
maintenance O
therapy O
significantly O
improved O
overall O
survival O
and O
progression-free O
survival O
compared O
with O
placebo O
, O
and O
had O
a O
good O
safety O
profile O
in O
a O
phase O
3 O
placebo-controlled O
study O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

Mean O
scores O
of O
individual O
domains/scales O
of O
3D-CRT O
and O
IMRT O
were O
compared O
using O
't O
' O
test O
at O
each O
time O
point O
";" O
while O
longitudinal O
change O
in O
mean O
scores O
of O
both O
groups O
over O
time O
was O
evaluated O
by O
repeated O
measurement O
analysis O
of O
variance O
. O

The O
applicant O
has O
committed O
to O
conduct O
post-marketing O
clinical O
trials O
to O
assess O
further O
the O
effect O
of O
epidermal O
growth O
factor O
receptor O
expression O
, O
measured O
with O
immunohistochemical O
staining O
, O
on O
erlotinib O
treatment O
effect O
. O

This O
non-inferiority O
design O
trial O
aimed O
to O
determine O
whether O
the O
combination O
of O
gemcitabine O
and O
carboplatin O
( O
GC O
) O
results O
in O
similar O
survival O
but O
is O
less O
toxic O
with O
better O
quality O
of O
life O
. O

Adjuvant O
chemotherapy O
for O
early O
stage O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
is O
now O
the O
standard O
of O
care O
, O
but O
there O
is O
little O
information O
regarding O
its O
impact O
on O
quality O
of O
life O
( O
QOL O
) O
. O

Patients O
had O
metastatic O
CRC O
and O
one O
of O
the O
following O
characteristics O
: O
age O
> O
or O
= O
65 O
years O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
1 O
or O
2 O
, O
serum O
albumin O
< O
or O
= O
3.5 O
g/dL O
, O
or O
prior O
abdominal/pelvic O
radiotherapy O
. O

EORTC O
QLQ-C30 O
scores O
were O
evaluated O
among O
patients O
with O
a O
valid O
baseline O
and O
at O
least O
one O
post-baseline O
HRQoL O
assessment O
. O

Few O
well-designed O
studies O
have O
investigated O
whether O
these O
impairments O
can O
be O
prevented O
. O

Thirty-six O
women O
with O
chronic O
upper O
limb O
breast O
cancer-related O
lymphoedema O
. O

After O
2 O
weeks O
of O
baseline O
assessment O
, O
all O
participants O
received O
a O
consultation O
plus O
either O
oral O
homeopathic O
medicine O
or O
placebo O
, O
assessed O
every O
4 O
weeks O
for O
16 O
weeks O
. O

Patients O
with O
hormone-refractory O
prostate O
cancer O
and O
a O
history O
of O
bone O
metastases O
were O
randomly O
assigned O
to O
a O
double-blind O
treatment O
regimen O
of O
intravenous O
zoledronic O
acid O
at O
4 O
mg O
( O
N O
= O
214 O
) O
, O
zoledronic O
acid O
at O
8 O
mg O
( O
subsequently O
reduced O
to O
4 O
mg O
";" O
8/4 O
) O
( O
N O
= O
221 O
) O
, O
or O
placebo O
( O
N O
= O
208 O
) O
every O
3 O
weeks O
for O
15 O
months O
. O

Three O
National O
Health O
Service O
oncology O
clinics O
in O
Scotland O
and O
community O
exercise O
facilities O
. O

The O
KS O
Functional O
Assessment O
of O
HIV O
( O
FAHI O
) O
quality O
of O
life O
instrument O
was O
used O
before O
and O
after O
every O
other O
treatment O
cycle O
. O

Baseline O
FACT-H O
& O
amp O
";" O
N O
data O
were O
available O
for O
1,093 O
patients O
and O
missing O
for O
417 O
patients O
. O

Questionnaire O
return O
rates O
for O
this O
study O
never O
dropped O
below O
80 O
% O
";" O
only O
2 O
% O
of O
the O
patients O
did O
not O
submit O
baseline O
QOL O
assessments O
. O

Ninety-four O
patients O
were O
evaluable O
for O
efficacy O
and O
safety O
. O

Sedentary O
( O
engaging O
in O
< O
60 O
min O
of O
recreational O
activity/week O
) O
breast O
and O
colorectal O
cancer O
survivors O
were O
randomized O
to O
a O
telephone-based O
exercise O
intervention O
or O
usual O
care O
control O
group O
. O

To O
compare O
protracted O
venous O
infusion O
( O
PVI O
) O
5-fluorouracil O
( O
5-FU O
) O
with O
and O
without O
mitomycin O
C O
( O
MMC O
) O
in O
a O
prospectively O
randomised O
study O
and O
analyse O
for O
tumour O
response O
, O
survival O
, O
toxicity O
and O
quality O
of O
life O
( O
QL O
) O
. O

A O
secondary O
criterion O
for O
ablation O
, O
an O
rhTSH-stimulated O
serum O
thyroglobulin O
concentration O
less O
than O
2 O
ng/ml O
, O
was O
fulfilled O
by O
23 O
of O
24 O
( O
96 O
% O
) O
euthyroid O
patients O
and O
18 O
of O
21 O
( O
86 O
% O
) O
hypothyroid O
patients O
( O
P O
= O
0.2341 O
) O
. O

Of O
the O
246 O
patients O
in O
the O
intent-to-treat O
set O
, O
89·4 O
% O
completed O
the O
3-day O
efficacy O
phase O
. O

Cost-benefit O
analysis O
was O
based O
on O
hospital O
costs O
. O

We O
investigated O
whether O
patient O
preparation O
using O
rhTSH O
was O
comparable O
to O
conventional O
thyroid O
hormone O
withdrawal O
with O
respect O
to O
efficacy O
of O
postsurgical O
remnant O
ablation O
in O
low-risk O
patients O
receiving O
a O
30 O
mCi O
RI O
. O

A O
specifically O
designed O
questionnaire O
was O
administered O
at O
three O
months O
to O
assess O
time O
from O
the O
operation O
until O
the O
patient O
was O
able O
to O
walk O
, O
return O
to O
daily O
activities O
, O
or O
sit O
without O
pain O
, O
time O
to O
return O
to O
work O
or O
school O
, O
and O
time O
to O
healing O
. O

The O
control O
group O
received O
no O
advice O
about O
exercise O
. O

A O
mixture O
of O
beta-hydroxyl O
beta-methyl O
butyrate O
, O
glutamine O
, O
and O
arginine O
( O
HMB/Arg/Gln O
) O
previously O
showed O
activity O
for O
increasing O
lean O
body O
mass O
( O
LBM O
) O
among O
patients O
with O
cancer O
cachexia O
. O

Participants O
were O
assessed O
before O
cancer O
treatment O
( O
T1 O
) O
, O
postintervention O
( O
T2 O
) O
, O
which O
was O
at O
least O
2 O
months O
after O
cancer O
treatment O
, O
and O
after O
1-year O
follow-up O
( O
T3 O
) O
. O

To O
analyze O
the O
prospectively O
collected O
health-related O
quality-of-life O
( O
HRQOL O
) O
data O
from O
patients O
enrolled O
in O
two O
Radiation O
Therapy O
Oncology O
Group O
randomized O
Phase O
III O
head O
and O
neck O
cancer O
trials O
( O
90-03 O
and O
91-11 O
) O
to O
assess O
their O
value O
as O
an O
independent O
prognostic O
factor O
for O
locoregional O
control O
( O
LRC O
) O
and/or O
overall O
survival O
( O
OS O
) O
. O

Worsening O
of O
symptoms O
was O
defined O
as O
an O
increase O
of O
15 O
mm O
or O
more O
from O
baseline O
on O
a O
100 O
mm O
scale O
for O
each O
LCSS O
item O
. O

Administration O
of O
ESAs O
on O
a O
synchronous O
schedule O
with O
chemotherapy O
administration O
could O
benefit O
patients O
by O
reducing O
clinic O
visits O
and O
potentially O
enhancing O
on-time O
chemotherapy O
delivery O
. O

No O
differences O
between O
groups O
were O
observed O
, O
with O
the O
exception O
of O
PCS O
scores O
at O
6-week O
follow-up O
: O
Patients O
in O
the O
UAE O
group O
had O
significantly O
better O
scores O
than O
did O
patients O
in O
the O
hysterectomy O
group O
( O
P O
< O
.001 O
) O
. O

After O
documentation O
of O
N2 O
disease O
by O
mediastinoscopy O
or O
anterior O
mediastinotomy O
, O
patients O
received O
induction O
chemotherapy O
with O
cisplatin O
, O
vinblastine O
, O
and O
mitomycin-C. O
Mitomycin-C O
was O
later O
dropped O
from O
the O
induction O
regimen O
. O

Before O
and O
after O
the O
intervention O
period O
, O
all O
of O
the O
subjects O
performed O
a O
cardiorespiratory O
test O
to O
measure O
peak O
oxygen O
uptake O
( O
VO2peak O
) O
, O
a O
dynamic O
strength O
endurance O
test O
( O
maximum O
number O
of O
repetitions O
for O
chest O
and O
leg O
press O
exercise O
at O
30 O
- O
35 O
% O
and O
100 O
- O
110 O
% O
of O
body O
mass O
, O
respectively O
) O
and O
a O
sit-stand O
test O
. O

Key O
end O
points O
were O
QoL O
at O
18 O
weeks O
, O
measured O
with O
EORTC O
Quality O
of O
Life O
Questionnaire O
( O
QLQ O
) O
-C30 O
and O
QLQ-LC13 O
, O
and O
overall O
survival O
. O

Sixteen O
advanced O
cancer O
patients O
with O
neuropathic O
pain O
on O
systemic O
morphine O
therapy O
, O
no O
longer O
receiving O
oncologic O
treatment O
, O
presenting O
moderate O
pain O
( O
about O
4 O
or O
more O
, O
but O
less O
than O
7 O
, O
on O
a O
numerical O
scale O
of O
0-10 O
) O
in O
the O
last O
week O
, O
and O
given O
a O
stable O
morphine O
dose O
in O
the O
last O
2 O
days O
were O
admitted O
to O
the O
study O
. O

Neither O
demographic O
nor O
medical O
variables O
explained O
this O
association O
. O

Seventy O
patients O
completed O
the O
4 O
weeks O
period O
of O
study O
. O

Stimulated O
whole O
( O
SWS O
) O
and O
parotid O
( O
SPS O
) O
saliva O
flow O
were O
measured O
and O
Medical O
Outcomes O
Short O
Form O
36 O
( O
SF-36 O
) O
, O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
core O
quetionnaire O
, O
and O
EORTC O
head-and-neck O
module O
( O
QLQ-H O
& O
amp O
";" O
N35 O
) O
were O
completed O
at O
baseline O
and O
2 O
, O
6 O
, O
and O
12 O
months O
after O
radiotherapy O
. O

The O
control O
group O
was O
instructed O
to O
perform O
the O
self-management O
treatment O
. O

A O
clinical O
trial O
tests O
whether O
a O
psychological O
intervention O
for O
cancer O
patients O
can O
do O
so O
, O
and O
also O
tests O
two O
routes O
to O
achieve O
better O
health O
: O
( O
a O
) O
reducing O
patients O
' O
Emotional O
Distress O
, O
and/or O
( O
b O
) O
enhancing O
their O
functional O
immunity O
. O

The O
starting O
dosage O
was O
60 O
mg/m O
( O
2 O
) O
, O
which O
was O
escalated O
to O
90 O
mg/m O
( O
2 O
) O
and O
then O
120 O
mg/m O
( O
2 O
) O
if O
the O
drug O
was O
well O
tolerated O
( O
< O
or= O
Grade O
2 O
toxicities O
[ O
according O
to O
the O
Southwest O
Oncology O
Group O
toxicity O
scale O
] O
) O
. O

Chemotherapy-naïve O
patients O
age O
70 O
years O
or O
older O
with O
stage O
IIIB/IV O
NSCLC O
and O
performance O
status O
2 O
or O
lower O
were O
eligible O
. O

There O
are O
very O
few O
randomized O
controlled O
studies O
on O
exercise O
in O
cancer O
patients O
. O

We O
sought O
the O
extent O
to O
which O
arm O
morbidity O
could O
be O
reduced O
by O
using O
sentinel-lymph-node-based O
management O
in O
women O
with O
clinically O
node-negative O
early O
breast O
cancer O
. O

Paclitaxel O
was O
administered O
at O
two O
different O
dose O
levels O
( O
135 O
mg/m O
( O
2 O
) O
and O
250 O
mg/m O
( O
2 O
) O
) O
, O
and O
etoposide O
was O
given O
at O
a O
dose O
of O
100 O
mg/m O
( O
2 O
) O
daily O
on O
days O
1 O
to O
3 O
. O

formulation O
. O

The O
impact O
of O
psychotherapeutic O
support O
on O
survival O
for O
patients O
with O
gastrointestinal O
cancer O
undergoing O
surgery O
was O
studied O
. O

Gynecological O
neoplastic O
disease O
progression O
is O
characterized O
by O
specific O
energy O
metabolism O
alterations O
and O
by O
symptoms O
including O
fatigue O
, O
anorexia O
, O
nausea O
, O
anemia O
, O
and O
immunodepression O
, O
which O
result O
in O
a O
cachexia O
syndrome O
and O
a O
marked O
decrease O
in O
patient O
quality O
of O
life O
( O
QoL O
) O
. O

This O
was O
followed O
, O
4 O
weeks O
later O
, O
by O
six O
cycles O
of O
temozolomide O
, O
150 O
or O
200 O
mg/m2 O
daily O
for O
5 O
days O
, O
every O
4 O
weeks O
. O

The O
CCSP O
intervention O
was O
taught O
2 O
week O
before O
hospital O
admission O
with O
reinforcement O
at O
specified O
times O
during O
treatment O
and O
3 O
months O
after O
discharge O
. O

A O
total O
of O
75 O
patients O
were O
registered O
";" O
71 O
are O
included O
in O
the O
analysis O
. O

The O
majority O
of O
the O
patient O
loss O
was O
because O
of O
patient O
preference O
( O
45 O
% O
of O
enrolled O
patients O
) O
. O

Adherence O
was O
assessed O
by O
a O
self-reported O
diary O
, O
limb O
volume O
by O
a O
water O
displacement O
device O
, O
quality O
of O
life O
by O
the O
Upper O
Limb O
Lymphedema O
Questionnaire O
( O
ULL27 O
) O
, O
prior O
to O
, O
and O
after O
the O
intervention O
period O
. O

This O
study O
aims O
to O
examine O
the O
effectiveness O
of O
a O
self-management O
multimodal O
comprehensive O
coping O
strategy O
program O
( O
CCSP O
) O
on O
quality O
of O
life O
( O
QOL O
) O
among O
breast O
cancer O
patients O
1 O
year O
after O
treatment O
. O

bolus O
( O
arm O
B O
) O
";" O
or O
MTX O
, O
750 O
mg/m2 O
i.v O
. O

Three O
hundred O
three O
patients O
were O
randomized O
to O
DOX O
50 O
mg/m O
( O
2 O
) O
intravenously O
( O
IV O
) O
on O
day O
1 O
and O
VNB O
25 O
mg/m O
( O
2 O
) O
IV O
on O
days O
1 O
and O
8 O
( O
arm O
1 O
) O
or O
DOX O
70 O
mg/m O
( O
2 O
) O
IV O
on O
day O
1 O
( O
arm O
2 O
) O
. O

It O
can O
have O
debilitating O
and O
dose-limiting O
consequences O
. O

QOL O
was O
assessed O
using O
FACT-Cx O
, O
consisting O
of O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT-G O
) O
plus O
a O
cervix O
cancer-specific O
subscale O
, O
the O
Brief O
Pain O
Inventory-Short O
Form O
( O
BPI-SF O
) O
, O
and O
a O
neurotoxicity O
subscale O
. O

Two O
hundred O
fourteen O
patients O
from O
nineteen O
Italian O
centers O
were O
randomized O
to O
the O
control O
arm O
consisting O
of O
biweekly O
cycles O
of O
MTX O
, O
200 O
mg/m2 O
on O
day O
1 O
, O
followed O
by O
bolus O
5-FU O
600 O
mg/m2 O
on O
day O
2 O
and O
6-S-leucovorin O
rescue O
, O
or O
to O
the O
experimental O
arm O
consisting O
of O
two O
biweekly O
cycles O
of O
the O
same O
regimen O
as O
in O
the O
control O
arm O
alternated O
to O
three O
weeks O
of O
continuous O
infusion O
5-FU O
( O
200 O
mg/m2 O
day O
) O
+ O
weekly O
bolus O
6-S-leucovorin O
, O
20 O
mg/m2 O
. O

Few O
intervention O
studies O
have O
been O
conducted O
to O
help O
couples O
manage O
the O
effects O
of O
prostate O
cancer O
and O
maintain O
their O
quality O
of O
life O
. O

Women O
in O
the O
writing O
group O
wrote O
for O
20 O
min O
on O
four O
consecutive O
days O
. O

Postmenopausal O
women O
with O
hormone O
receptor-positive O
breast O
cancer O
( O
N=5,187 O
) O
were O
randomized O
to O
letrozole O
2.5 O
mg O
or O
placebo O
once O
daily O
for O
5 O
years O
. O

Compare O
GJJ O
and O
stent O
placement O
. O

Exclusion O
criteria O
included O
age O
greater O
than O
70 O
years O
, O
World O
Health O
Organization O
( O
WHO O
) O
performance O
status O
greater O
than O
2 O
, O
prior O
chemotherapy O
for O
metastatic O
disease O
, O
and O
presence O
of O
liver O
metastases O
in O
patients O
younger O
than O
50 O
. O

Mixed O
effects O
regressions O
were O
used O
to O
evaluate O
the O
intervention O
adjusting O
for O
patient O
, O
practice O
, O
and O
site O
characteristics O
. O

Using O
the O
Phoenix O
definition O
, O
the O
5-year O
biochemical O
relapse O
rate O
was O
32 O
% O
and O
23.5 O
% O
, O
respectively O
( O
p O
= O
.09 O
) O
. O

Patients O
with O
completely O
resected O
primary O
tumour O
received O
three O
courses O
of O
IVA O
( O
ifosfamide O
, O
vincristine O
and O
actinomycin O
D O
) O
. O

To O
test O
these O
observations O
with O
a O
large O
, O
randomized O
clinical O
trial O
, O
an O
intervention O
that O
significantly O
impacts O
physical O
activity O
in O
these O
patients O
is O
needed O
. O

Androgen O
deprivation O
therapy O
( O
ADT O
) O
is O
commonly O
used O
as O
a O
primary O
treatment O
for O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
who O
are O
not O
eligible O
for O
radical O
treatment O
options O
. O

Opioid O
consumption O
, O
pain O
intensity O
, O
symptoms O
and O
adverse O
effects O
, O
mood O
, O
sleep O
, O
patient O
's O
preference O
, O
quality O
of O
life O
before O
starting O
the O
study O
, O
the O
first O
week O
after O
and O
the O
second O
week O
after O
were O
recorded O
. O

The O
primary O
outcome O
assessed O
was O
progression-free O
survival O
( O
PFS O
) O
";" O
secondary O
outcomes O
included O
treatment-free O
survival O
( O
TFS O
) O
, O
overall O
survival O
( O
OS O
) O
, O
treatment-related O
toxicity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
according O
to O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
's O
Quality O
of O
Life O
Questionnaire O
C-30 O
version O
1.0 O
instrument O
. O

The O
primary O
endpoint O
was O
increase O
in O
arm O
volume O
from O
baseline O
to O
the O
average O
of O
measurements O
at O
6 O
and O
12 O
months O
. O

This O
resulted O
in O
a O
higher O
need O
to O
remain O
close O
to O
a O
toilet O
and O
, O
as O
a O
consequence O
, O
more O
limitation O
of O
daily O
activities O
because O
of O
bowel O
symptoms O
and O
decreased O
social O
functioning O
. O

Median O
age O
was O
76 O
years O
( O
range O
, O
70 O
years O
to O
86 O
years O
) O
. O

Secondary O
outcome O
measures O
were O
self-reports O
of O
interference O
of O
hot O
flashes O
on O
daily O
activities O
. O

Tumour-related O
symptoms O
were O
present O
in O
134 O
( O
71 O
% O
) O
patients O
and O
weight O
loss O
of O
more O
than O
5 O
% O
was O
seen O
in O
15 O
( O
8 O
% O
) O
patients O
. O

Hot O
flash O
frequency O
was O
evaluated O
at O
baseline O
, O
at O
6 O
weeks O
, O
and O
at O
6 O
months O
after O
initiation O
of O
treatment O
. O

Data O
collection O
occurred O
at O
baseline O
before O
randomization O
and O
at O
4 O
months O
, O
8 O
months O
, O
and O
12 O
months O
. O

Vinorelbine O
was O
given O
intravenously O
on O
days O
1 O
and O
8 O
of O
a O
21-day O
treatment O
cycle O
, O
for O
a O
total O
of O
six O
cycles O
. O

As O
treatment O
for O
mNSCLC O
is O
non-curative O
, O
its O
impact O
on O
patient O
health-related O
quality O
of O
life O
( O
HRQoL O
) O
is O
an O
important O
consideration O
. O

A O
total O
of O
329 O
patients O
from O
10 O
centers O
in O
9 O
countries O
in O
the O
Asia-Pacific O
region O
enrolled O
in O
a O
double-blind O
randomized O
controlled O
trial O
of O
TMX O
120 O
mg/d O
( O
TMX120 O
) O
against O
P O
as O
a O
control O
arm O
with O
an O
intermediate O
dosage O
of O
TMX O
60 O
mg/d O
( O
TMX60 O
) O
to O
assess O
possible O
dose O
response O
. O

To O
describe O
the O
Food O
and O
Drug O
Administration O
( O
FDA O
) O
review O
and O
approval O
of O
erlotinib O
( O
Tarceva O
, O
OSI O
Pharmaceuticals O
, O
Melville O
, O
NY O
) O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

Many O
patients O
with O
advanced O
ovarian O
cancer O
will O
develop O
recurrent O
disease O
. O

The O
primary O
end-point O
was O
the O
effect O
of O
GM-CSF O
on O
the O
percentage O
of O
complete O
remissions O
( O
CR O
) O
. O

Their O
anthropometric O
data O
, O
body O
composition O
, O
including O
fat O
mass O
( O
FM O
) O
and O
fat-free O
mass O
( O
FFM O
) O
, O
and O
lipid O
profiles O
, O
caloric O
intake O
and O
physical O
activity O
were O
assessed O
1 O
week O
before O
randomisation O
, O
and O
6 O
and O
12 O
months O
later O
. O

To O
analyze O
the O
predictive O
value O
of O
PSA O
for O
progression O
and O
the O
role O
of O
testosterone O
for O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
androgen O
deprivation O
therapy O
( O
ADT O
) O
for O
metastatic O
prostate O
cancer O
. O

A O
total O
of O
473 O
patients O
( O
234 O
to O
Sx O
+ O
Ax O
, O
239 O
to O
Sx O
) O
were O
randomly O
assigned O
. O

Patients O
were O
prospectively O
stratified O
on O
the O
basis O
of O
disease O
volume O
. O

Dysuria O
was O
evaluated O
on O
a O
0-10 O
scale O
, O
before O
brachytherapy O
and O
then O
at O
1 O
, O
3 O
, O
6 O
and O
12 O
months O
afterward O
, O
with O
a O
median O
of O
four O
dysuria O
questionnaires O
per O
patient O
. O

It O
may O
thus O
be O
possible O
to O
selectively O
modulate O
each O
schedule O
biochemically O
. O

Evaluation O
at O
baseline O
, O
after O
8 O
sessions O
, O
and O
1 O
month O
after O
programme O
completion O
, O
included O
evaluations O
using O
the O
STAI O
, O
POMS O
, O
MAC O
, O
EORTC O
QLQ-C30 O
and O
EORTC O
QLQ-BR23 O
breast O
module O
scales O
. O

Dosing O
was O
reduced O
to O
25 O
mg/d O
in O
46 O
patients O
( O
43 O
% O
) O
due O
to O
grade O
3/4 O
AEs O
. O

GJJ O
and O
stent O
placement O
. O

The O
stretch O
group O
received O
instruction O
on O
low-load O
, O
prolonged O
pectoral O
stretches O
, O
which O
were O
to O
be O
performed O
daily O
and O
were O
checked O
at O
weekly O
visits O
. O

157 O
patients O
in O
the O
90 O
mg O
group O
and O
156 O
in O
the O
30 O
mg O
group O
were O
included O
in O
the O
primary O
analysis O
. O

Patients O
were O
interviewed O
by O
telephone O
before O
treatment O
( O
baseline O
) O
, O
midtreatment O
, O
within O
1 O
month O
post-treatment O
, O
and O
at O
12 O
, O
18 O
, O
and O
24 O
months O
postbaseline O
by O
using O
questionnaires O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
, O
a O
breast O
systemic O
adverse O
effects O
scale O
( O
EORTC O
BR23 O
) O
, O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
. O

This O
randomized O
, O
phase O
II O
trial O
compared O
bevacizumab O
plus O
fluorouracil O
and O
leucovorin O
( O
FU/LV O
) O
versus O
placebo O
plus O
FU/LV O
as O
first-line O
therapy O
in O
patients O
considered O
nonoptimal O
candidates O
for O
first-line O
irinotecan O
. O

The O
usual O
care O
group O
received O
a O
booklet O
with O
information O
about O
fatigue O
and O
its O
management O
. O

The O
results O
were O
analyzed O
using O
a O
linear O
mixed-effects O
model O
. O

The O
Active O
After O
Cancer O
Trial O
( O
AACT O
) O
was O
a O
multicenter O
pilot O
study O
evaluating O
the O
feasibility O
of O
a O
telephone-based O
exercise O
intervention O
in O
a O
cooperative O
group O
setting O
. O

Few O
exercise O
trials O
in O
cancer O
patients O
have O
reported O
longer-term O
follow-up O
. O

This O
study O
addressed O
the O
effects O
of O
pilates O
exercise O
, O
as O
a O
new O
approach O
, O
on O
functional O
capacity O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
in O
whom O
there O
are O
doubts O
regarding O
the O
efficacy O
and O
usefulness O
of O
the O
exercise O
. O

Patients O
with O
cancer O
( O
n O
= O
178 O
) O
who O
agreed O
to O
participate O
in O
the O
study O
were O
randomized O
to O
the O
intervention O
arm O
( O
n O
= O
89 O
) O
or O
the O
control O
arm O
( O
n O
= O
89 O
) O
. O

infusion O
and O
5-FU O
, O
800 O
mg/m2 O
i.v O
. O

Those O
in O
the O
treatment O
group O
additionally O
took O
FJD O
, O
50 O
-100 O
mL O
each O
time O
, O
twice O
daily O
. O

Five O
patients O
did O
not O
receive O
any O
chemotherapy O
and O
45 O
received O
only O
one O
cycle O
. O

TS O
levels O
were O
available O
for O
147 O
patients O
( O
87.5 O
% O
) O
. O

Sixty O
consecutive O
radiation O
oncology O
outpatients O
( O
51 O
men O
and O
nine O
women O
";" O
age O
61.9+/-14 O
years O
[ O
mean+/-standard O
deviation O
] O
) O
. O

To O
facilitate O
the O
transition O
to O
recovery O
, O
we O
conducted O
the O
Moving O
Beyond O
Cancer O
( O
MBC O
) O
trial O
, O
a O
multisite O
, O
randomized O
, O
controlled O
trial O
of O
psychoeducational O
interventions O
for O
breast O
cancer O
patients O
. O

Seventy-six O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
-associated O
Kaposi O
sarcoma O
were O
randomized O
to O
receive O
the O
study O
drug O
either O
once O
( O
n O
= O
30 O
) O
or O
3 O
times O
weekly O
( O
n O
= O
46 O
) O
. O

Assessments O
were O
made O
on O
4 O
occasions O
: O
at O
baseline O
( O
T0 O
) O
, O
at O
the O
end O
of O
chemotherapy O
( O
T1 O
) O
, O
1 O
month O
after O
chemotherapy O
( O
T2 O
) O
, O
and O
9 O
months O
after O
recruitment O
( O
T3 O
) O
. O

To O
determine O
the O
effectiveness O
of O
the O
Alleviating O
Depression O
Among O
Patients O
With O
Cancer O
( O
ADAPt-C O
) O
collaborative O
care O
management O
for O
major O
depression O
or O
dysthymia O
. O

Treatment O
arms O
were O
compared O
using O
differences O
of O
least O
squares O
mean O
( O
LSM O
) O
changes O
from O
baseline O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
at O
each O
timepoint O
and O
overall O
. O

We O
conducted O
a O
prospective O
, O
multicenter O
, O
randomized O
, O
controlled O
, O
clinical O
trial O
with O
215 O
patients O
followed O
until O
death O
or O
study O
closure O
. O

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
the O
gastric O
module O
STO22 O
were O
administered O
every O
8 O
weeks O
until O
progression O
. O

Time O
to O
definitive O
deterioration O
of O
QOL O
parameters O
was O
analyzed O
. O

HRQOL O
was O
assessed O
at O
baseline O
, O
at O
end O
of O
cycle O
2 O
, O
and O
4 O
, O
6 O
, O
and O
9 O
months O
after O
completion O
of O
RT O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
QLQ-C30 O
) O
and O
the O
EORTC O
QLQ O
Head O
and O
Neck O
Cancer-Specific O
Module O
( O
EORTC O
QLQ-H O
& O
amp O
";" O
N35 O
) O
. O

The O
Intergroup O
conducted O
this O
breast O
cancer O
adjuvant O
trial O
to O
compare O
an O
investigational O
16-week O
regimen O
with O
cyclophosphamide O
, O
doxorubicin O
, O
and O
fluorouracil O
( O
5-FU O
";" O
CAF O
) O
. O

Women O
with O
platinum-pretreated O
epithelial O
ovarian O
cancer O
and O
measurable O
recurrent O
disease O
were O
randomized O
in O
a O
bifactorial O
design O
to O
receive O
either O
175 O
or O
135 O
mg/m2 O
of O
Taxol O
over O
either O
24 O
or O
3 O
hours O
. O

Cycles O
were O
repeated O
as O
rapidly O
as O
possible O
. O

Median O
follow-up O
was O
13.3 O
years O
. O

These O
differences O
all O
resolved O
by O
12 O
months O
. O

Up O
to O
December O
2006 O
, O
eighty-seven O
patients O
of O
stage O
II O
and O
III O
, O
including O
71 O
patients O
of O
middle O
third O
lesions O
and O
16 O
lower O
third O
lesions O
were O
enrolled O
. O

This O
was O
a O
randomized O
, O
double-blind O
, O
parallel-group O
, O
dose-finding O
study O
assessing O
the O
efficacy O
and O
safety O
of O
once-weekly O
epoetin O
beta O
in O
patients O
with O
solid O
tumours O
receiving O
chemotherapy O
. O

Imatinib O
is O
the O
standard O
treatment O
of O
advanced O
GI O
stromal O
tumors O
( O
GISTs O
) O
. O

Between O
1999 O
and O
2002 O
, O
83 O
patients O
were O
recruited O
into O
the O
study O
at O
Westmead O
and O
Nepean O
Hospitals O
, O
Sydney O
. O

The O
final O
sample O
was O
302 O
dyads O
. O

Also O
the O
demographic O
data O
, O
operative O
results O
and O
survival O
were O
recorded O
. O

The O
combination O
of O
cisplatin O
and O
etoposide O
( O
PE O
) O
has O
been O
a O
standard O
treatment O
for O
patients O
with O
poor-prognosis O
small O
cell O
lung O
cancer O
( O
SCLC O
) O
. O

The O
aim O
of O
the O
study O
was O
to O
analyze O
the O
effect O
of O
combined O
treatment O
methods O
on O
quality O
of O
life O
in O
patients O
diagnosed O
with O
pancreatic O
cancer O
. O

Bleomycin O
30 O
mg O
was O
administered O
on O
days O
1 O
, O
8 O
, O
and O
15 O
during O
cycles O
1 O
through O
3 O
. O

A O
regression O
analysis O
with O
interactions O
was O
performed O
to O
determine O
if O
domains O
of O
quality O
of O
life O
( O
EORTC-QLQ-C30 O
) O
functioning O
( O
Health O
Survey O
Short O
Form-36 O
) O
or O
psychological O
distress O
( O
Symptom O
Checklist-90 O
) O
moderated O
the O
effect O
of O
CBT O
on O
fatigue O
. O

The O
efficacy O
and O
safety O
of O
an O
alternative O
regimen O
that O
does O
not O
show O
significant O
neurotoxicity O
were O
evaluated O
by O
comparing O
gemcitabine-carboplatin O
with O
carboplatin O
in O
platinum-sensitive O
recurrent O
ovarian O
cancer O
patients O
in O
a O
Gynecologic O
Cancer O
InterGroup O
trial O
of O
the O
Arbeitsgemeinschaft O
Gynakologische O
Onkologie O
Ovarian O
Cancer O
Study O
Group O
, O
the O
National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
, O
and O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Gynaecological O
Cancer O
Group O
. O

Patients O
were O
randomly O
assigned O
at O
registration O
to O
amifostine O
( O
AM O
) O
500 O
mg O
IV O
four O
times O
per O
week O
or O
no O
AM O
during O
chemoradiotherapy O
. O

Primary O
outcome O
measures O
assessed O
spiritual O
well-being O
and O
quality O
of O
life O
";" O
secondary O
outcomes O
included O
anxiety O
, O
depression O
, O
hopelessness O
, O
symptom O
burden O
, O
and O
symptom-related O
distress O
. O

No O
patient O
received O
antiretroviral O
therapy O
. O

Radiation-induced O
mucositis O
is O
an O
acute O
reaction O
of O
the O
mucosa O
of O
patients O
undergoing O
head O
and O
neck O
radiotherapy O
. O

An O
independent O
data O
review O
board O
recommended O
termination O
of O
recruitment O
because O
of O
insufficient O
differences O
between O
study O
arms O
. O

The O
predefined O
primary O
criterion O
for O
successful O
ablation O
was O
" O
no O
visible O
uptake O
in O
the O
thyroid O
bed O
, O
or O
if O
visible O
, O
fractional O
uptake O
less O
than O
0.1 O
% O
" O
on O
neck O
scans O
performed O
8 O
months O
after O
therapy O
and O
was O
satisfied O
in O
100 O
% O
of O
patients O
in O
both O
groups O
. O

There O
were O
532 O
eligible O
patients O
( O
266 O
marimastat O
and O
266 O
placebo O
) O
. O

Here O
, O
we O
report O
an O
updated O
analysis O
of O
survival O
. O

Thirty O
two O
percent O
of O
women O
randomly O
assigned O
had O
estrogen O
and O
progesterone O
receptor-negative O
breast O
cancer O
, O
42 O
% O
had O
visceral O
metastases O
, O
and O
58 O
% O
had O
bone O
metastases O
. O

This O
study O
examined O
whether O
changes O
in O
self-efficacy O
explain O
the O
effects O
of O
a O
mailed O
print O
intervention O
on O
long-term O
dietary O
practices O
of O
breast O
and O
prostate O
cancer O
survivors O
. O

Satisfaction O
was O
analyzed O
with O
the O
Fisher O
exact O
test O
. O

Further O
investigation O
in O
larger O
numbers O
of O
patients O
is O
warranted O
. O

Fourteen O
breast O
cancer O
survivors O
with O
unilateral O
upper O
extremity O
lymphedema O
were O
randomly O
assigned O
to O
an O
exercise O
( O
n O
= O
7 O
) O
or O
control O
group O
( O
n O
= O
7 O
) O
. O

In O
addition O
, O
the O
data O
comparing O
their O
effects O
on O
the O
quality O
of O
life O
are O
lacking O
. O

Quality O
of O
life O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
( O
EORTC-C30 O
) O
questionnaire O
. O

This O
difference O
( O
7.4 O
) O
was O
clinically O
relevant O
. O

Randomised O
controlled O
trial O
. O

This O
trial O
was O
undertaken O
to O
determine O
whether O
adjuvant O
treatment O
with O
the O
metalloproteinase O
inhibitor O
marimastat O
could O
prolong O
survival O
in O
responding O
patients O
with O
SCLC O
after O
chemotherapy O
. O

We O
examined O
intrusive O
thoughts O
about O
cancer O
at O
the O
baseline O
assessment O
as O
a O
predictor O
of O
fatigue O
, O
sleep O
problems O
, O
pain O
, O
breast O
cancer-specific O
symptoms O
, O
depressive O
symptoms O
, O
negative O
affect O
, O
and O
quality O
of O
life O
using O
growth O
curve O
modeling O
, O
controlling O
for O
study O
condition O
and O
other O
covariates O
. O

Thirty-nine O
patients O
were O
randomly O
assigned O
to O
CONNECT O
and O
36 O
to O
usual O
care O
. O

In O
the O
Asia-Pacific O
region O
and O
elsewhere O
, O
almost O
85 O
% O
of O
patients O
with O
hepatocellular O
carcinoma O
( O
HCC O
) O
are O
inoperable O
at O
diagnosis O
and O
have O
a O
dismal O
prognosis O
. O

We O
also O
investigated O
the O
relationship O
between O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
scale O
scores O
and O
EQ-5D O
utilities O
. O

An O
historical O
control O
group O
( O
n O
= O
18 O
) O
without O
exercise O
was O
enrolled O
from O
breast O
cancer O
survivors O
. O

Forty O
were O
not O
eligible O
for O
randomization O
, O
and O
58 O
patients O
were O
randomly O
assigned O
, O
32 O
and O
26 O
patients O
in O
the O
INT O
and O
CONT O
arms O
, O
respectively O
. O

Questionnaires O
were O
administered O
by O
a O
clinician O
blinded O
to O
treatment O
. O

The O
primary O
end O
points O
were O
response O
and O
overall O
survival O
time O
. O

Twenty-one O
patients O
received O
BCAA O
granules O
three O
times O
a O
day O
( O
one O
sachet O
after O
each O
meal O
: O
the O
daytime O
group O
) O
, O
and O
16 O
patients O
received O
the O
granules O
twice O
a O
day O
( O
one O
sachet O
after O
breakfast O
, O
and O
two O
sachets O
before O
bedtime O
: O
the O
nocturnal O
group O
) O
. O

From O
May O
1999 O
to O
December O
2004 O
, O
patients O
with O
breast O
cancer O
< O
or O
3 O
cm O
were O
randomly O
assigned O
to O
receive O
SLN O
biopsy O
associated O
with O
ALND O
( O
ALND O
arm O
) O
or O
SLN O
biopsy O
followed O
by O
ALND O
only O
if O
the O
SLN O
was O
metastatic O
( O
SLN O
arm O
) O
. O

Differences O
between O
groups O
from O
baseline O
to O
day O
28 O
were O
analyzed O
using O
one-sided O
, O
two-sample O
t O
tests O
or O
Wilcoxon O
two-sample O
tests O
. O

No O
patient O
received O
hormonal O
therapy O
. O

When O
60 O
cases O
of O
non-small O
cell O
lung O
cancer O
patients O
in O
stage O
IIIb O
and O
IV O
reached O
stable O
disease O
after O
treatment O
with O
4 O
cycles O
of O
a O
two-drug O
regimen O
with O
platinum O
, O
they O
were O
randomly O
divided O
into O
two O
groups O
. O

This O
randomised O
non-inferiority O
trial O
was O
designed O
to O
assess O
whether O
radiosurgery O
plus O
adjuvant O
whole O
brain O
radiotherapy O
( O
RS O
+ O
WBRT O
) O
is O
as O
effective O
as O
surgery O
plus O
whole O
brain O
radiotherapy O
( O
S O
+ O
WBRT O
) O
for O
cancer O
patients O
with O
a O
solitary O
brain O
metastasis O
, O
with O
respect O
to O
overall O
survival O
and O
quality O
of O
life O
. O

All O
structures O
including O
the O
IUS O
and O
EUS O
were O
contoured O
on O
T2-weighted O
MRI O
at O
day O
30 O
, O
and O
doses O
received O
were O
calculated O
from O
identification O
of O
seeds O
on O
CT. O
Spearman O
's O
( O
nonparametric O
) O
rank O
correlation O
coefficient O
( O
ρ O
) O
was O
used O
for O
statistical O
analyses O
. O

At O
a O
median O
follow-up O
of O
56 O
months O
, O
there O
were O
more O
locoregional O
recurrences O
in O
the O
SLN O
arm O
, O
and O
the O
5-year O
disease-free O
survival O
was O
89.9 O
% O
in O
the O
ALND O
arm O
and O
87.6 O
% O
in O
the O
SLN O
arm O
, O
with O
a O
difference O
of O
2.3 O
% O
( O
95 O
% O
confidence O
interval O
: O
-3.1 O
% O
to O
7.6 O
% O
) O
. O

Chemotherapy O
was O
first-line O
or O
second-line O
for O
MBC O
. O

Forty-five O
patients O
were O
randomized O
to O
postinduction O
RT O
or O
surgery O
. O

This O
report O
describes O
the O
quality O
of O
life O
( O
QOL O
) O
findings O
of O
a O
randomized O
placebo O
controlled O
study O
of O
erlotinib O
, O
an O
epidermal O
growth O
factor O
receptor O
inhibitor O
, O
in O
patients O
with O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

All O
statistical O
tests O
were O
two-sided O
. O

To O
address O
this O
barrier O
, O
we O
examined O
the O
ability O
of O
an O
easily O
accessible O
online O
CBT-I O
program O
to O
improve O
insomnia O
symptoms O
in O
cancer O
survivors O
. O

Chemotherapy O
with O
a O
platinum O
agent O
and O
a O
taxane O
( O
paclitaxel O
) O
is O
considered O
the O
standard O
of O
care O
for O
treatment O
of O
ovarian O
carcinoma O
. O

Decision O
boundaries O
were O
to O
accept O
the O
null O
hypothesis O
of O
futility O
if O
the O
test O
statistic O
z O
< O
0.39 O
( O
P O
≥ O
.348 O
) O
and O
reject O
the O
null O
hypothesis O
if O
z O
> O
2.54 O
( O
P O
≤ O
.0056 O
) O
. O

A O
randomized O
placebo-controlled O
, O
double-blind O
crossover O
study O
was O
designed O
to O
evidence O
the O
effects O
of O
amitriptyline O
in O
patients O
with O
neuropathic O
cancer O
pain O
. O

Patients O
initially O
randomly O
assigned O
to O
the O
sham O
group O
were O
crossed O
over O
to O
TRUE O
acupuncture O
starting O
at O
week O
7 O
. O

Utility O
scores O
were O
assessed O
using O
the O
EQ-5D O
instrument O
at O
baseline O
";" O
cycles O
3 O
, O
5 O
, O
and O
7 O
";" O
7 O
months O
";" O
and O
1 O
year O
. O

We O
evaluated O
HRQOL O
with O
the O
EuroQol O
( O
EQ-5D™ O
) O
in O
patients O
with O
APC O
participating O
in O
Cancer O
and O
Leukemia O
Group O
B O
80303 O
, O
a O
multicenter O
, O
double-blind O
, O
randomized O
trial O
comparing O
overall O
survival O
( O
OS O
) O
between O
two O
treatment O
arms O
: O
gemcitabine O
with O
bevacizumab O
or O
gemcitabine O
with O
placebo O
. O

The O
primary O
objective O
was O
to O
compare O
complete O
response O
( O
CR O
) O
rates O
. O

The O
aim O
of O
this O
trial O
was O
to O
determine O
the O
value O
of O
thymidylate O
synthase O
( O
TS O
) O
, O
a O
key O
enzyme O
of O
DNA O
synthesis O
and O
target O
of O
5-FU O
, O
to O
predict O
response O
to O
chemotherapy O
of O
mCRC O
. O

Patients O
with O
progressive O
, O
androgen-independent O
prostate O
cancer O
were O
randomly O
assigned O
to O
one O
of O
two O
treatments O
: O
either O
ketoconazole/doxorubicin O
alternating O
with O
vinblastine/estramustine O
( O
KA/VE O
) O
or O
paclitaxel O
, O
estramustine O
, O
and O
oral O
etoposide O
( O
TEE O
) O
. O

One O
hundred O
twenty O
untreated O
patients O
with O
histologically O
confirmed O
HCC O
were O
randomized O
to O
receive O
either O
long-acting O
octreotide O
( O
Sandostation O
LAR O
30 O
mg O
) O
intramuscularly O
every O
4 O
weeks O
or O
placebo O
. O

Two-hundred O
seventeen O
of O
425 O
therapeutic O
trial O
patients O
were O
eligible O
and O
registered O
to O
the O
HRQL O
study O
. O

Patients O
with O
lymphoma O
experience O
sleep O
problems O
that O
may O
be O
managed O
with O
aerobic O
exercise O
but O
no O
previous O
study O
has O
examined O
this O
issue O
. O

Outcome O
parameters O
were O
: O
postoperative O
morbidity O
, O
length O
of O
hospital O
stay O
, O
quality O
of O
life O
, O
long-term O
survival O
, O
and O
local O
recurrences O
. O

Patients O
given O
GC O
received O
more O
chemotherapy O
as O
outpatients O
( O
89 O
% O
GC O
vs O
66 O
% O
PE O
of O
treatment O
cycles O
) O
. O

The O
primary O
outcome O
measure O
is O
quality-adjusted O
life O
years O
( O
QALYs O
) O
. O

Patients O
were O
randomized O
to O
receive O
treatment O
over O
4 O
consecutive O
days O
or O
over O
11 O
days O
. O

The O
experimental O
intervention O
consisted O
of O
reporting O
data O
from O
the O
standardized O
assessments O
to O
the O
IDTs O
. O

From O
1997 O
to O
2001 O
, O
294 O
patients O
were O
included O
. O

To O
determine O
the O
efficacy O
, O
impact O
on O
quality-of-life O
( O
QoL O
) O
and O
tolerability O
of O
two O
different O
irinotecan O
administration O
schedules O
in O
combination O
with O
capecitabine O
as O
first-line O
treatment O
of O
metastatic O
colorectal O
cancer O
. O

Uterine O
and O
quality-of-life O
data O
were O
analyzed O
using O
regression O
methods O
, O
and O
missing O
values O
were O
handled O
using O
multiple O
imputation O
. O

Both O
gastrojejunostomy O
( O
GJJ O
) O
and O
stent O
placement O
are O
commonly O
used O
palliative O
treatments O
of O
obstructive O
symptoms O
caused O
by O
malignant O
gastric O
outlet O
obstruction O
( O
GOO O
) O
. O

However O
, O
the O
survival O
and O
quality-of-life O
( O
QOL O
) O
benefits O
of O
paclitaxel O
used O
as O
a O
single O
agent O
compared O
with O
supportive O
care O
alone O
have O
not O
been O
assessed O
in O
a O
randomized O
clinical O
trial O
. O

Immunobiological O
cancer O
therapy O
plays O
an O
important O
role O
in O
strengthening O
body O
immunological O
surveillance O
function O
and O
killing O
remaining O
tumor O
cells O
in O
the O
body O
. O

Design O
of O
the O
study O
was O
single-blind O
randomized O
clinical O
trial O
. O

Four O
hundred O
twenty O
previously O
untreated O
patients O
with O
measurable O
disease O
were O
randomized O
to O
receive O
a O
2-hour O
infusion O
of O
LV O
( O
200 O
mg/m O
( O
2 O
) O
/d O
) O
followed O
by O
a O
5FU O
bolus O
( O
400 O
mg/m O
( O
2 O
) O
/d O
) O
and O
22-hour O
infusion O
( O
600 O
mg/m O
( O
2 O
) O
/d O
) O
for O
2 O
consecutive O
days O
every O
2 O
weeks O
, O
either O
alone O
or O
together O
with O
oxaliplatin O
85 O
mg/m O
( O
2 O
) O
as O
a O
2-hour O
infusion O
on O
day O
1 O
. O

Primary O
outcomes O
were O
assessed O
as O
follows O
: O
CRF O
using O
the O
Visual O
Analogue O
Scale-Global O
Fatigue O
";" O
physical O
functioning O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality-of-Life O
Core O
30 O
Questionnaire O
, O
and O
CRF-associated O
distress O
using O
the O
Fatigue O
Outcome O
Measure O
. O

The O
primary O
endpoints O
were O
overall O
survival O
( O
OS O
) O
and O
analysis O
of O
toxicity O
, O
while O
secondary O
endpoints O
included O
response O
rates O
, O
time-to-progression O
( O
TTP O
) O
and O
quality O
of O
life O
( O
QoL O
) O
. O

Seventy-eight O
and O
54 O
% O
of O
C3 O
and O
C6 O
patients O
, O
respectively O
, O
completed O
all O
scheduled O
chemotherapy O
courses O
. O

Eighty-nine O
chemotherapy-naïve O
patients O
were O
randomized O
either O
to O
gemcitabine O
( O
1,000 O
mg/m2 O
, O
30-min O
infusion O
on O
days O
1 O
, O
8 O
and O
15 O
) O
and O
oral O
etoposide O
( O
50 O
mg O
, O
days O
1-14 O
";" O
GE O
group O
) O
or O
gemcitabine O
at O
the O
same O
schedule O
and O
cisplatin O
( O
75 O
mg/m2 O
on O
day O
15 O
";" O
GP O
group O
) O
. O

Patients O
were O
randomly O
assigned O
( O
1:1 O
) O
to O
receive O
oral O
abiraterone O
( O
1 O
g O
daily O
) O
plus O
prednisone O
( O
5 O
mg O
twice O
daily O
) O
or O
placebo O
plus O
prednisone O
in O
continuous O
4-week O
cycles O
. O

The O
laser O
group O
received O
LLLT O
( O
Technomed O
Electronics O
Advanced O
Laser O
Therapy O
1000 O
, O
He-Ne O
, O
λ O
= O
632.8 O
nm O
, O
power O
density O
= O
24 O
mW/cm O
( O
2 O
) O
, O
dosage O
= O
3.0 O
J O
at O
each O
point O
, O
total O
dose/session O
= O
36-40 O
J O
, O
spot O
size O
1 O
cm O
( O
2 O
) O
, O
irradiation O
time/point O
125 O
s O
) O
before O
each O
radiation O
session O
, O
while O
the O
placebo O
group O
did O
not O
receive O
laser O
therapy O
. O

The O
upper O
limit O
of O
the O
95 O
% O
confidence O
interval O
was O
less O
than O
the O
prespecified O
limit O
of O
< O
0.75 O
g/dL O
, O
supporting O
noninferiority O
of O
the O
EDS O
dosing O
schedule O
. O

Bone O
resorption O
markers O
measured O
included O
urinary O
calcium O
( O
uCa O
) O
, O
hydroxyproline O
( O
Hyp O
) O
, O
and O
the O
collagen O
breakdown O
products O
: O
NTx O
, O
Crosslaps O
and O
Free O
Dpd O
. O

Participants O
( O
n O
= O
49 O
) O
ranged O
in O
age O
from O
50 O
to O
90 O
years O
( O
average O
, O
65.6 O
years O
) O
and O
were O
at O
9.8 O
years O
since O
diagnosis O
( O
range O
, O
1-32 O
years O
) O
, O
and O
the O
majority O
were O
white O
, O
unpartnered O
, O
and O
retired O
. O

Of O
these O
, O
433 O
are O
known O
to O
be O
dead O
, O
26 O
are O
lost O
to O
follow-up O
and O
11 O
are O
still O
alive O
. O

Group O
CBT O
comprised O
one O
90 O
min O
session O
a O
week O
for O
6 O
weeks O
, O
and O
included O
psycho-education O
, O
paced O
breathing O
, O
and O
cognitive O
and O
behavioural O
strategies O
to O
manage O
HFNS O
. O

The O
primary O
outcome O
was O
depression O
as O
assessed O
by O
the O
Centre O
for O
Epidemiologic O
Studies O
Depression O
scale O
( O
CES-D O
) O
";" O
the O
main O
secondary O
outcomes O
were O
: O
anxiety O
as O
assessed O
by O
Hospital O
Anxiety O
and O
Depression O
Scales O
( O
HADS-A O
) O
";" O
overall O
quality O
of O
life O
and O
fatigue O
as O
assessed O
by O
Functional O
Assessment O
of O
Cancer O
Therapy O
General O
and O
Fatigue O
scales O
( O
FACT-G O
and O
FACT-F O
, O
respectively O
) O
";" O
and O
clinicians O
' O
ratings O
of O
quality O
of O
life O
by O
use O
of O
Spizter O
's O
Quality O
of O
Life O
Index O
( O
SQLI O
) O
. O

Patients O
received O
a O
median O
of O
six O
cycles O
in O
both O
arms O
. O

The O
median O
follow-up O
was O
22.6 O
months O
. O

The O
median O
dose O
intensity O
delivered O
for O
C O
and O
E O
reached O
, O
respectively O
, O
85 O
% O
and O
87 O
% O
of O
that O
planned O
in O
the O
CEF O
arm O
and O
96 O
% O
and O
95 O
% O
of O
that O
planned O
in O
the O
EC O
arm O
. O

Stage O
IV O
breast O
cancer O
therapy O
costs O
were O
collected O
by O
surveying O
UK O
oncologists O
, O
and O
utilities O
for O
associated O
health O
states O
were O
from O
published O
sources O
. O

Secondary O
outcomes O
of O
self-reported O
end-of-life O
experiences O
were O
assessed O
in O
a O
survey O
that O
was O
undertaken O
after O
the O
completion O
of O
the O
study O
. O

To O
compare O
directly O
the O
effect O
of O
intensity-modulated O
radiotherapy O
( O
IMRT O
) O
vs. O
conventional O
radiotherapy O
( O
CRT O
) O
on O
salivary O
flow O
and O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
early-stage O
nasopharyngeal O
carcinoma O
( O
NPC O
) O
. O

We O
evaluated O
the O
role O
of O
glutathione-related O
genotypes O
on O
overall O
survival O
, O
time O
to O
progression O
, O
adverse O
events O
, O
and O
quality O
of O
life O
( O
QOL O
) O
in O
stage O
IIIB/IV O
non-small O
cell O
lung O
cancer O
patients O
who O
were O
stable O
or O
responding O
from O
initial O
treatment O
with O
platinum-based O
chemotherapy O
and O
subsequently O
randomized O
to O
receive O
daily O
oral O
carboxyaminoimidazole O
or O
a O
placebo O
. O

Costs O
were O
in O
British O
pounds O
and O
year O
2000 O
values O
. O

To O
determine O
whether O
patients O
with O
locally O
advanced O
non-small O
cell O
lung O
cancer O
unsuitable O
for O
resection O
or O
radical O
radiotherapy O
, O
and O
with O
minimal O
thoracic O
symptoms O
, O
should O
be O
given O
palliative O
thoracic O
radiotherapy O
immediately O
or O
as O
needed O
to O
treat O
symptoms O
. O

Analysis O
was O
performed O
according O
to O
the O
bifactorial O
design O
. O

We O
conducted O
a O
randomized O
pilot O
study O
in O
patients O
treated O
with O
four O
fractions O
of O
lung O
SBRT O
delivered O
over O
4 O
or O
over O
11 O
days O
. O

Dignity O
therapy O
is O
a O
unique O
, O
individualised O
, O
short-term O
psychotherapy O
that O
was O
developed O
for O
patients O
( O
and O
their O
families O
) O
living O
with O
life-threatening O
or O
life-limiting O
illness O
. O

Regression O
analysis O
was O
used O
to O
analyze O
the O
impact O
on O
outcome O
of O
baseline O
factors O
( O
other O
than O
type O
of O
embolic O
agent O
) O
. O

The O
present O
study O
showed O
that O
ADT O
with O
the O
gonadotropin O
hormone-releasing O
hormone O
( O
GhRH O
) O
antagonist O
degarelix O
is O
non-inferior O
to O
combined O
treatment O
with O
the O
LHRH O
agonist O
goserelin O
and O
bicalutamide O
in O
terms O
of O
reducing O
prostate O
volume O
during O
the O
treatment O
period O
of O
3 O
months O
. O

Third-generation O
aromatase O
inhibitors O
, O
such O
as O
letrozole O
, O
provide O
a O
new O
option O
for O
extended O
adjuvant O
hormonal O
therapy O
after O
5 O
years O
of O
tamoxifen O
. O

Four O
hundred O
eighty-two O
patients O
were O
randomly O
assigned O
on O
JBR.10 O
. O

Analysis O
was O
performed O
after O
a O
29.2-month O
median O
follow-up O
( O
range O
, O
0 O
months O
to O
54.6 O
months O
) O
. O

Overall O
278 O
patients O
were O
enrolled O
into O
the O
trial O
. O

This O
pilot O
trial O
assessed O
the O
feasibility O
of O
a O
randomized O
controlled O
trial O
( O
RCT O
) O
comparing O
epidural O
analgesia O
and O
use O
of O
a O
local O
anaesthetic O
wound O
infusion O
catheter O
( O
WIC O
) O
following O
LCR O
. O

In O
total O
, O
126 O
patients O
from O
East O
and O
South-East O
Asian O
centers O
were O
randomized O
( O
14 O
% O
of O
the O
intent-to-treat O
population O
) O
: O
88 O
from O
Korea O
, O
28 O
from O
China O
and O
10 O
from O
Malaysia O
";" O
one O
patient O
was O
excluded O
from O
this O
analysis O
due O
to O
Indian O
ethnicity O
. O

Testosterone O
kinetics O
and O
QOL O
were O
also O
evaluated O
. O

Treatment O
duration O
was O
8 O
weeks O
. O

From O
1994-1999 O
, O
495 O
EKS O
patients O
were O
accrued O
, O
and O
470 O
were O
evaluable O
. O

Treatment O
arms O
were O
well O
balanced O
for O
clinicopathologic O
characteristics O
. O

Patients O
had O
a O
free O
choice O
of O
treosulfan O
i.v O
. O

Symptom O
intensity O
was O
measured O
by O
the O
Edmonton O
Symptom O
Assessment O
Scale O
( O
score O
range O
, O
0-900 O
) O
. O

Primary O
endpoint O
was O
overall O
survival O
";" O
secondary O
endpoints O
were O
disease-free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

This O
study O
compares O
the O
clinical O
effectiveness O
and O
cost-effectiveness O
of O
self-expanding O
metal O
stents O
( O
SEMSs O
) O
with O
other O
palliative O
therapies O
to O
aid O
clinicians O
in O
making O
an O
evidence-based O
treatment O
choice O
. O

The O
Steering O
Committee O
closed O
the O
trial O
. O

Adverse O
events O
for O
duloxetine O
was O
15.2 O
% O
. O

Randomized O
, O
controlled O
, O
longitudinal O
trial O
. O

We O
compared O
initial O
costs O
and O
costs O
during O
follow-up O
. O

A O
phase O
III O
study O
to O
definitively O
test O
this O
neoadjuvant-concurrent O
strategy O
is O
warranted O
. O

The O
AVEREL O
trial O
[ O
A O
Study O
of O
Avastin O
( O
Bevacizumab O
) O
in O
Combination O
With O
Herceptin O
( O
Trastuzumab O
) O
/Docetaxel O
in O
Patients O
With O
HER2-Positive O
Metastatic O
Breast O
Cancer O
] O
evaluated O
first-line O
bevacizumab-containing O
therapy O
for O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
-positive O
locally O
recurrent/metastatic O
breast O
cancer O
( O
LR/MBC O
) O
. O

Notably O
, O
patients B-Premise
receiving I-Premise
FLO I-Premise
or I-Premise
FLOT I-Premise
as I-Premise
palliative I-Premise
treatment I-Premise
( I-Premise
n I-Premise
= I-Premise
98 I-Premise
) I-Premise
achieved I-Premise
comparable I-Premise
QOL I-Premise
results I-Premise
. I-Premise

Hematologic B-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
( I-Premise
22 I-Premise
% I-Premise
with I-Premise
documented I-Premise
infections I-Premise
compared I-Premise
with I-Premise
8 I-Premise
% I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
";" I-Premise
P I-Premise
=.0038 I-Premise
) I-Premise
, I-Premise
and O
the B-Premise
toxicity-related I-Premise
death I-Premise
rate I-Premise
was I-Premise
9 I-Premise
% I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
versus I-Premise
5.5 I-Premise
% I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
P I-Premise
=.22 I-Premise
) I-Premise
. I-Premise

Urinary B-Premise
function I-Premise
declined I-Premise
when I-Premise
the I-Premise
IUS I-Premise
V285 I-Premise
was I-Premise
0.4 I-Premise
% I-Premise
( I-Premise
ρ=-0.32 I-Premise
, I-Premise
p=0.04 I-Premise
) I-Premise
";" I-Premise
bother B-Premise
worsened I-Premise
when I-Premise
the I-Premise
IUS I-Premise
V35 I-Premise
was I-Premise
99 I-Premise
% I-Premise
( I-Premise
ρ=-0.31 I-Premise
, I-Premise
p=0.05 I-Premise
) I-Premise
or I-Premise
the I-Premise
EUS I-Premise
V240 I-Premise
was I-Premise
63 I-Premise
% I-Premise
( I-Premise
ρ=-0.31 I-Premise
, I-Premise
p=0.05 I-Premise
) I-Premise
";" I-Premise
irritation B-Premise
increased I-Premise
when I-Premise
the I-Premise
IUS I-Premise
V35 I-Premise
was I-Premise
95 I-Premise
% I-Premise
( I-Premise
ρ=-0.37 I-Premise
, I-Premise
p=0.02 I-Premise
) I-Premise
and I-Premise
the I-Premise
EUS I-Premise
V265 I-Premise
was I-Premise
24 I-Premise
% I-Premise
( I-Premise
ρ=-0.32 I-Premise
, I-Premise
p=0.04 I-Premise
) I-Premise
";" I-Premise
and O
urgency B-Premise
worsened I-Premise
when I-Premise
the I-Premise
IUS I-Premise
V35 I-Premise
was I-Premise
99.5 I-Premise
% I-Premise
( I-Premise
ρ=-0.38 I-Premise
, I-Premise
p=0.02 I-Premise
) I-Premise
. I-Premise

The B-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
proved I-Claim
to I-Claim
be I-Claim
feasible I-Claim
: I-Claim
75.0 B-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
had I-Premise
read I-Premise
the I-Premise
entire I-Premise
pain I-Premise
brochure I-Premise
, I-Premise
55.7 I-Premise
% I-Premise
had I-Premise
listened I-Premise
to I-Premise
the I-Premise
audio I-Premise
cassette I-Premise
, I-Premise
and I-Premise
85.6 I-Premise
% I-Premise
of I-Premise
pain I-Premise
scores I-Premise
were I-Premise
completed I-Premise
in I-Premise
the I-Premise
pain I-Premise
diary I-Premise
. I-Premise

Taken B-Premise
together I-Premise
with I-Premise
the I-Premise
broader I-Premise
literature I-Premise
in I-Premise
this I-Premise
area I-Premise
, I-Premise
results B-Claim
from I-Claim
this I-Claim
study I-Claim
suggest I-Claim
that I-Claim
psychosocial I-Claim
interventions I-Claim
can I-Claim
lead I-Claim
to I-Claim
improvements I-Claim
in I-Claim
a I-Claim
range I-Claim
of I-Claim
outcomes I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

For B-Premise
BT I-Premise
versus I-Premise
RP I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
bowel I-Premise
or I-Premise
hormonal I-Premise
domains I-Premise
, I-Premise
but O
men B-Premise
treated I-Premise
with I-Premise
BT I-Premise
scored I-Premise
better I-Premise
in I-Premise
urinary I-Premise
( I-Premise
91.8 I-Premise
v I-Premise
88.1 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
( I-Premise
52.5 I-Premise
v I-Premise
39.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
domains I-Premise
, I-Premise
and I-Premise
in I-Premise
patient I-Premise
satisfaction I-Premise
( I-Premise
93.6 I-Premise
v I-Premise
76.9 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

However O
, O
overall B-Premise
survival I-Premise
from I-Premise
date I-Premise
of I-Premise
randomization I-Premise
on I-Premise
step I-Premise
2 I-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
observation I-Premise
and I-Premise
topotecan I-Premise
arms I-Premise
( I-Premise
8.9 I-Premise
months I-Premise
v I-Premise
9.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.43 I-Premise
) I-Premise
. I-Premise

The O
RRs O
were O
: O
34 O
% O
( O
95 O
% O
confidence O
interval O
( O
95 O
% O
, O
CI O
) O
: O
21 O
% O
-48 O
% O
) O
in O
arm O
A O
, O
including O
3 O
complete O
responses O
( O
CRs O
) O
and O
15 O
partial O
responses O
( O
PRs O
) O
, O
24 O
% O
( O
95 O
% O
CI O
: O
14 O
% O
-38 O
% O
) O
in O
arm O
B O
, O
including O
2 O
CRs O
and O
11 O
PRs O
, O
and O
24 O
% O
( O
95 O
% O
CI O
: O
14 O
% O
-38 O
% O
) O
, O
with O
2 O
CRs O
and O
11 O
PRs O
, O
in O
arm O
C. O
After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
62 I-Premise
( I-Premise
range I-Premise
18-108 I-Premise
) I-Premise
weeks I-Premise
, I-Premise
the I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
38 I-Premise
, I-Premise
25 I-Premise
, I-Premise
and I-Premise
27 I-Premise
weeks I-Premise
for I-Premise
arm I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Triglycerides B-Premise
and I-Premise
high-density I-Premise
lipoprotein I-Premise
cholesterol I-Premise
significantly I-Premise
decreased I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
and O
low-density B-Premise
lipoprotein I-Premise
cholesterol I-Premise
significantly I-Premise
increased I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
1-year I-Premise
study I-Premise
period I-Premise
. I-Premise

However O
, O
intervention B-Premise
patients I-Premise
had I-Premise
significantly I-Premise
better I-Premise
scores I-Premise
at I-Premise
months I-Premise
3 I-Premise
and I-Premise
6 I-Premise
( I-Premise
median I-Premise
3-month I-Premise
intervention I-Premise
score I-Premise
, I-Premise
7 I-Premise
[ I-Premise
range I-Premise
, I-Premise
5-7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
5 I-Premise
[ I-Premise
range I-Premise
, I-Premise
3-7 I-Premise
] I-Premise
[ I-Premise
P I-Premise
= I-Premise
.03 I-Premise
] I-Premise
";" I-Premise
median I-Premise
6-month I-Premise
intervention I-Premise
score I-Premise
, I-Premise
7 I-Premise
[ I-Premise
range I-Premise
, I-Premise
6-7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
6 I-Premise
[ I-Premise
range I-Premise
, I-Premise
3-7 I-Premise
] I-Premise
[ I-Premise
P I-Premise
= I-Premise
.009 I-Premise
] I-Premise
) I-Premise
. I-Premise

Experimental B-Claim
and I-Claim
early I-Claim
clinical I-Claim
investigations I-Claim
have I-Claim
demonstrated I-Claim
encouraging I-Claim
results I-Claim
for I-Claim
estramustine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
malignant I-Claim
glioma I-Claim
. O

This B-Claim
randomised I-Claim
trial I-Claim
encountered I-Claim
the I-Claim
accrual I-Claim
difficulties I-Claim
and I-Claim
consequent I-Claim
low I-Claim
statistical I-Claim
power I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
interdisciplinary I-Claim
studies I-Claim
drawing I-Claim
from I-Claim
a I-Claim
small I-Claim
eligible I-Claim
population I-Claim
, I-Claim
but O
can O
contribute O
to O
future O
overviews O
on O
the O
management O
of O
solitary O
brain O
metastases O
. O

Chemotherapy B-Claim
seems I-Claim
to I-Claim
improve I-Claim
symptoms I-Claim
control I-Claim
, I-Claim
even O
if O
randomised O
studies O
with O
quality O
of O
life O
as O
first O
endpoint O
are O
lacking O
and O
often O
chemotherapy O
toxicity O
compromises O
the O
frail O
cost/benefit O
ratio O
. O

However O
, O
patients B-Premise
with I-Premise
low I-Premise
expression I-Premise
of I-Premise
cytoplasmic I-Premise
pGSK-3β I-Premise
trended I-Premise
toward I-Premise
greater I-Premise
OS I-Premise
with I-Premise
GE I-Premise
treatment I-Premise
. I-Premise

Given O
the O
existing O
evidence O
supporting O
the O
importance O
of O
social O
support O
in O
adjustment O
to O
breast O
cancer O
, O
it B-Claim
seems I-Claim
feasible I-Claim
to I-Claim
suggest I-Claim
that I-Claim
EW I-Claim
may I-Claim
be I-Claim
a I-Claim
cost I-Claim
effective I-Claim
accessible I-Claim
treatment I-Claim
that I-Claim
could I-Claim
be I-Claim
incorporated I-Claim
into I-Claim
the I-Claim
ongoing I-Claim
care I-Claim
of I-Claim
women I-Claim
. I-Claim

Whereas O
patients B-Claim
with I-Claim
early I-Claim
alternating I-Claim
chemotherapy I-Claim
achieve I-Claim
a I-Claim
better I-Claim
subjective I-Claim
adjustment I-Claim
, I-Claim
late B-Claim
alternating I-Claim
chemotherapy I-Claim
allows I-Claim
for I-Claim
a I-Claim
higher I-Claim
RDI I-Claim
of I-Claim
cisplatin I-Claim
, I-Claim
adriamycin I-Claim
and I-Claim
etoposide I-Claim
, I-Claim
which I-Claim
results I-Claim
in I-Claim
a I-Claim
significantly I-Claim
longer I-Claim
median I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
disease I-Claim
. I-Claim

Furthermore O
, O
the B-Premise
most I-Premise
common I-Premise
toxicities I-Premise
in I-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
n=9 I-Premise
, I-Premise
39.13 I-Premise
% I-Premise
) I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
n=8 I-Premise
, I-Premise
34.78 I-Premise
% I-Premise
) I-Premise
, I-Premise
whereas I-Premise
those I-Premise
in I-Premise
the I-Premise
in I-Premise
Gefitinib I-Premise
group I-Premise
were I-Premise
skin I-Premise
rash I-Premise
( I-Premise
n=8 I-Premise
, I-Premise
34.78 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
n=4 I-Premise
, I-Premise
17.39 I-Premise
% I-Premise
) I-Premise
. I-Premise

Patients B-Premise
on I-Premise
Arms I-Premise
A I-Premise
and I-Premise
B I-Premise
had I-Premise
median I-Premise
survivals I-Premise
of I-Premise
31.4 I-Premise
and I-Premise
25.3 I-Premise
weeks I-Premise
, I-Premise
12-month I-Premise
survivals I-Premise
of I-Premise
29 I-Premise
% I-Premise
and I-Premise
24 I-Premise
% I-Premise
, I-Premise
and I-Premise
18-month I-Premise
survivals I-Premise
of I-Premise
18 I-Premise
% I-Premise
and I-Premise
8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. O

Although O
the O
study O
was O
not O
designed O
or O
powered O
to O
evaluate O
survival O
, O
a B-Premise
survival I-Premise
trend I-Premise
was I-Premise
noted I-Premise
favouring I-Premise
epoetin-alfa I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
median I-Premise
survival I-Premise
17 I-Premise
vs I-Premise
11 I-Premise
months I-Premise
[ I-Premise
p I-Premise
= I-Premise
0.126 I-Premise
] I-Premise
) I-Premise
. I-Premise

Specifically O
, O
AET B-Premise
improved I-Premise
global I-Premise
sleep I-Premise
quality I-Premise
in I-Premise
patients I-Premise
with I-Premise
lymphoma I-Premise
who I-Premise
had I-Premise
indolent I-Premise
non-Hodgkin I-Premise
lymphoma I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
were I-Premise
receiving I-Premise
chemotherapy I-Premise
( I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
, I-Premise
were I-Premise
< I-Premise
2 I-Premise
years I-Premise
post-diagnosis I-Premise
( I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
, I-Premise
were I-Premise
obese I-Premise
( I-Premise
P I-Premise
= I-Premise
0.025 I-Premise
) I-Premise
, I-Premise
and I-Premise
were I-Premise
poor I-Premise
sleepers I-Premise
at I-Premise
baseline I-Premise
( I-Premise
P I-Premise
= I-Premise
0.007 I-Premise
) I-Premise
. I-Premise

Although B-Premise
the I-Premise
CR/PR I-Premise
and I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
groups I-Premise
had I-Premise
similar I-Premise
times I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
, I-Premise
patients B-Claim
with I-Claim
CR/PR I-Claim
reported I-Claim
better I-Claim
QL I-Claim
, I-Claim
suggesting I-Claim
more I-Claim
beneficial I-Claim
response I-Claim
to I-Claim
second-line I-Claim
endocrine I-Claim
treatment I-Claim
. I-Claim

In O
particular O
, O
physical B-Premise
functioning I-Premise
remains I-Premise
deteriorated I-Premise
1 I-Premise
year I-Premise
after I-Premise
inclusion I-Premise
for I-Premise
HDC I-Premise
patients I-Premise
comparatively I-Premise
to I-Premise
conventional I-Premise
chemotherapy I-Premise
patients I-Premise
( I-Premise
85.99 I-Premise
vs. I-Premise
76.65 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.021 I-Premise
) I-Premise
, O
and B-Premise
the I-Premise
pain I-Premise
score I-Premise
was I-Premise
still I-Premise
higher I-Premise
in I-Premise
the I-Premise
HDC I-Premise
group I-Premise
at I-Premise
that I-Premise
time I-Premise
( I-Premise
28.32 I-Premise
vs. I-Premise
15.97 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
. I-Premise

Low-frequency B-Premise
low-intensity I-Premise
electrotherapy I-Premise
did I-Premise
not I-Premise
reduce I-Premise
lymphoedema I-Premise
volume I-Premise
( I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
19.77 I-Premise
mL I-Premise
, I-Premise
P I-Premise
= I-Premise
0.36 I-Premise
) I-Premise
, I-Premise
but O
significant B-Premise
reductions I-Premise
were I-Premise
observed I-Premise
in I-Premise
pain I-Premise
, I-Premise
heaviness I-Premise
and I-Premise
tightness I-Premise
( I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
13.1 I-Premise
, I-Premise
16.2 I-Premise
and I-Premise
6.4 I-Premise
mm I-Premise
, I-Premise
respectively I-Premise
) I-Premise
, I-Premise
and I-Premise
FACT-B+4 I-Premise
summaries I-Premise
improved I-Premise
significantly I-Premise
( I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
5.4 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.015 I-Premise
) I-Premise
. I-Premise

After B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
taking I-Premise
prednisone I-Premise
showed I-Premise
no I-Premise
improvement I-Premise
in I-Premise
HQL I-Premise
scores I-Premise
, I-Premise
whereas I-Premise
those I-Premise
taking I-Premise
mitoxantrone I-Premise
plus I-Premise
prednisone I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
, I-Premise
four I-Premise
functioning I-Premise
domains I-Premise
, I-Premise
and I-Premise
nine I-Premise
symptoms I-Premise
( I-Premise
.001 I-Premise
< I-Premise
P I-Premise
< I-Premise
. I-Premise
1 I-Premise
) I-Premise
, I-Premise
and O
the B-Premise
improvement I-Premise
( I-Premise
> I-Premise
10 I-Premise
units I-Premise
on I-Premise
a I-Premise
scale I-Premise
of I-Premise
0 I-Premise
to100 I-Premise
) I-Premise
lasted I-Premise
longer I-Premise
than I-Premise
in I-Premise
the I-Premise
prednisone-alone I-Premise
group I-Premise
( I-Premise
.004 I-Premise
< I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Nonetheless B-Claim
, I-Claim
it I-Claim
is I-Claim
apparent I-Claim
that I-Claim
these I-Claim
first-generation I-Claim
regimens I-Claim
must I-Claim
be I-Claim
applied I-Claim
judiciously I-Claim
, I-Claim
and O
thus B-Claim
we I-Claim
view I-Claim
efforts I-Claim
at I-Claim
better I-Claim
patient I-Claim
selection I-Claim
and I-Claim
the I-Claim
development I-Claim
of I-Claim
more I-Claim
tolerable I-Claim
therapies I-Claim
as I-Claim
higher I-Claim
priorities I-Claim
than I-Claim
carrying I-Claim
either I-Claim
of I-Claim
these I-Claim
regimens I-Claim
to I-Claim
phase I-Claim
III I-Claim
evaluation I-Claim
in I-Claim
the I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim

At O
present O
, O
the B-Claim
J-pouch I-Claim
remains I-Claim
the I-Claim
benchmark I-Claim
for I-Claim
routine I-Claim
clinical I-Claim
practice I-Claim
, I-Claim
and O
due B-Claim
care I-Claim
( I-Claim
including I-Claim
defunctioning I-Claim
stoma I-Claim
) I-Claim
should I-Claim
be I-Claim
exercised I-Claim
in I-Claim
situations I-Claim
requiring I-Claim
CP I-Claim
. I-Claim

However O
, O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
bowel I-Premise
function I-Premise
, I-Premise
continence I-Premise
score I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

The O
decreased O
risk O
occurred O
in O
women O
aged O
49 O
years O
or O
younger O
( O
44 O
% O
) O
, O
50-59 O
years O
( O
51 O
% O
) O
, O
and O
60 O
years O
or O
older O
( O
55 O
% O
) O
";" O
risk B-Premise
was I-Premise
also I-Premise
reduced I-Premise
in I-Premise
women I-Premise
with I-Premise
a I-Premise
history I-Premise
of I-Premise
lobular I-Premise
carcinoma I-Premise
in I-Premise
situ I-Premise
( I-Premise
56 I-Premise
% I-Premise
) I-Premise
or I-Premise
atypical I-Premise
hyperplasia I-Premise
( I-Premise
86 I-Premise
% I-Premise
) I-Premise
and I-Premise
in I-Premise
those I-Premise
with I-Premise
any I-Premise
category I-Premise
of I-Premise
predicted I-Premise
5-year I-Premise
risk I-Premise
. I-Premise

In O
this O
setting O
, O
local B-Claim
control I-Claim
and I-Claim
survival I-Claim
were I-Claim
essentially I-Claim
equal I-Claim
between I-Claim
the I-Claim
surgical I-Claim
and I-Claim
RT I-Claim
arms I-Claim
. I-Claim

Anti-aromatase B-Claim
therapy I-Claim
is I-Claim
important I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
postmenopausal I-Claim
women I-Claim
but O
they O
have O
effects O
on O
the O
bone O
mineral O
density O
( O
BMD O
) O
and O
osteoporosis O
. O

In O
contrast O
, O
coping B-Premise
strategies I-Premise
( I-Premise
MAC I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise

Parenteral B-Claim
feeding I-Claim
was I-Claim
associated I-Claim
with I-Claim
the I-Claim
highest I-Claim
rate I-Claim
of I-Claim
nutrition-related I-Claim
complications I-Claim
, I-Claim
whereas O
enteral B-Claim
feeding I-Claim
reduced I-Claim
quality I-Claim
of I-Claim
life I-Claim
most I-Claim
extensively I-Claim
. I-Claim

There B-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
seen I-Premise
between I-Premise
groups I-Premise
for I-Premise
either I-Premise
activity I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
=-0.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
CI I-Premise
-1.0 I-Premise
to I-Premise
0.2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.17 I-Premise
) I-Premise
or I-Premise
profile I-Premise
scores I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
= I-Premise
-0.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.9 I-Premise
to I-Premise
0.1 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.13 I-Premise
) I-Premise
using I-Premise
this I-Premise
trial I-Premise
design I-Premise
, I-Premise
although B-Claim
post I-Claim
hoc I-Claim
power I-Claim
calculations I-Claim
suggests I-Claim
that I-Claim
65-175 I-Claim
would I-Claim
be I-Claim
needed I-Claim
per I-Claim
group I-Claim
to I-Claim
detect I-Claim
differences I-Claim
of I-Claim
this I-Claim
magnitude I-Claim
with I-Claim
sufficient I-Claim
precision I-Claim
. I-Claim

In O
conclusion O
, O
TMX B-Claim
does I-Claim
not I-Claim
prolong I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
HCC I-Claim
and I-Claim
has I-Claim
an I-Claim
increasingly I-Claim
negative I-Claim
impact I-Claim
with I-Claim
increasing I-Claim
dose I-Claim
. I-Claim

However O
, O
intraoperative B-Premise
blood I-Premise
loss I-Premise
and I-Premise
postoperative I-Premise
hospital I-Premise
stay I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
( I-Premise
Student I-Premise
t-test I-Premise
) I-Premise
. I-Premise

Zoledronic B-Claim
acid I-Claim
at I-Claim
4 I-Claim
mg I-Claim
given I-Claim
as I-Claim
a I-Claim
15-minute I-Claim
infusion I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
but O
the B-Claim
8-mg I-Claim
dose I-Claim
was I-Claim
associated I-Claim
with I-Claim
renal I-Claim
function I-Claim
deterioration I-Claim
. I-Claim

At O
final O
analysis O
, O
there B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
OS I-Premise
seen I-Premise
between I-Premise
ASA404 I-Premise
( I-Premise
n I-Premise
= I-Premise
649 I-Premise
) I-Premise
and I-Premise
placebo I-Premise
( I-Premise
n I-Premise
= I-Premise
650 I-Premise
) I-Premise
arms I-Premise
: I-Premise
median I-Premise
OS I-Premise
was I-Premise
13.4 I-Premise
and I-Premise
12.7 I-Premise
months I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1.01 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.85 I-Premise
to I-Premise
1.19 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.535 I-Premise
) I-Premise
. I-Premise

Particularly O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
regarding I-Premise
time I-Premise
to I-Premise
definitive I-Premise
deterioration I-Premise
of I-Premise
global I-Premise
health I-Premise
status/quality I-Premise
of I-Premise
life I-Premise
from I-Premise
baseline I-Premise
( I-Premise
primary I-Premise
endpoint I-Premise
) I-Premise
. I-Premise

Furthermore O
, O
if B-Claim
offered I-Claim
the I-Claim
choice I-Claim
, I-Claim
the I-Claim
majority I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
seem I-Claim
to I-Claim
prefer I-Claim
multidimensional I-Claim
programs I-Claim
to I-Claim
programs I-Claim
with I-Claim
only I-Claim
one I-Claim
component I-Claim
. I-Claim

Axillary B-Claim
clearance I-Claim
in I-Claim
early I-Claim
breast I-Claim
cancer I-Claim
aims I-Claim
to I-Claim
improve I-Claim
locoregional I-Claim
control I-Claim
and I-Claim
provide I-Claim
staging I-Claim
information I-Claim
but O
is O
associated O
with O
undesirable O
morbidity O
. O

Slowly O
, O
recovery B-Premise
was I-Premise
found I-Premise
at I-Premise
both I-Premise
6 I-Premise
months I-Premise
and I-Premise
1 I-Premise
year I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Experimental B-Claim
surgery I-Claim
on I-Claim
pigs I-Claim
has I-Claim
suggested I-Claim
that I-Claim
a I-Claim
coloplasty I-Claim
pouch I-Claim
( I-Claim
CP I-Claim
) I-Claim
may I-Claim
be I-Claim
a I-Claim
useful I-Claim
alternative I-Claim
. O

These B-Claim
results I-Claim
suggest I-Claim
that I-Claim
sexual I-Claim
functioning I-Claim
may I-Claim
require I-Claim
focused I-Claim
assessment I-Claim
by I-Claim
providers I-Claim
, I-Claim
beyond I-Claim
broad I-Claim
QOL I-Claim
assessments I-Claim
, I-Claim
and O
that O
attention B-Claim
to I-Claim
Sexual/Relationship I-Claim
Satisfaction I-Claim
may I-Claim
be I-Claim
critical I-Claim
in I-Claim
the I-Claim
development I-Claim
and I-Claim
implementation I-Claim
of I-Claim
interventions I-Claim
for I-Claim
this I-Claim
cohort I-Claim
of I-Claim
patients I-Claim
. I-Claim

In O
this O
large O
randomized O
trial O
, O
thalidomide B-Claim
in I-Claim
combination I-Claim
with I-Claim
chemotherapy I-Claim
did I-Claim
not I-Claim
improve I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
SCLC I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
an I-Claim
increased I-Claim
risk I-Claim
of I-Claim
thrombotic I-Claim
events I-Claim
. I-Claim

Gastrointestinal B-Premise
toxicity I-Premise
of I-Premise
pamidronate I-Premise
caused I-Premise
a I-Premise
23 I-Premise
% I-Premise
drop-out I-Premise
rate I-Premise
, I-Premise
but B-Claim
other I-Claim
cancer-associated I-Claim
factors I-Claim
seemed I-Claim
to I-Claim
contribute I-Claim
to I-Claim
this I-Claim
toxicity I-Claim
. I-Claim

Symptom B-Premise
distress I-Premise
was I-Premise
significantly I-Premise
worse I-Premise
for I-Premise
the I-Premise
RP+RT I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
RP I-Premise
alone I-Premise
arm I-Premise
, O
but B-Premise
the I-Premise
treatment I-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
with I-Premise
respect I-Premise
to I-Premise
other I-Premise
general I-Premise
measures I-Premise
of I-Premise
HRQL I-Premise
. I-Premise

Changes O
in O
QOL O
during O
chemotherapy O
were O
relatively O
modest O
";" O
fatigue B-Premise
, I-Premise
nausea I-Premise
, I-Premise
and I-Premise
vomiting I-Premise
worsened I-Premise
, I-Premise
but B-Premise
there I-Premise
was I-Premise
a I-Premise
reduction I-Premise
in I-Premise
pain I-Premise
and I-Premise
no I-Premise
change I-Premise
in I-Premise
global I-Premise
QOL I-Premise
. I-Premise

Nonetheless O
, O
no B-Claim
correlation I-Claim
between I-Claim
immediate I-Claim
lung I-Claim
expansion I-Claim
and I-Claim
clinical I-Claim
outcome I-Claim
was I-Claim
found I-Claim
in I-Claim
this I-Claim
study I-Claim
. I-Claim

Hence O
, O
nurse-led B-Claim
telephone I-Claim
follow-up I-Claim
seems I-Claim
an I-Claim
appropriate I-Claim
way I-Claim
to I-Claim
reduce I-Claim
clinic I-Claim
visits I-Claim
and I-Claim
represents I-Claim
an I-Claim
accepted I-Claim
alternative I-Claim
strategy I-Claim
. I-Claim

Finally O
, O
black B-Premise
women I-Premise
and I-Premise
white I-Premise
women I-Premise
were I-Premise
similar I-Premise
in I-Premise
terms I-Premise
of I-Premise
how I-Premise
they I-Premise
benefited I-Premise
from I-Premise
the I-Premise
MBAT I-Premise
intervention I-Premise
, I-Premise
even I-Premise
though I-Premise
white I-Premise
participants I-Premise
tended I-Premise
to I-Premise
have I-Premise
higher I-Premise
educational I-Premise
level I-Premise
and I-Premise
marital I-Premise
status I-Premise
. I-Premise

In O
view O
of O
the O
improvements O
in O
overall O
and O
progression-free O
survival O
noted O
with O
pemetrexed O
maintenance O
therapy O
, O
such B-Claim
treatment I-Claim
is I-Claim
an I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-squamous I-Claim
NSCLC I-Claim
who I-Claim
have I-Claim
not I-Claim
progressed I-Claim
after I-Claim
platinum-based I-Claim
induction I-Claim
therapy I-Claim
. I-Claim

No B-Premise
between-treatment I-Premise
differences I-Premise
were I-Premise
observed I-Premise
for I-Premise
changes I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
or I-Premise
performance I-Premise
status I-Premise
, I-Premise
but O
patients B-Premise
started I-Premise
on I-Premise
strong I-Premise
opioids I-Premise
had I-Premise
significantly I-Premise
better I-Premise
pain I-Premise
relief I-Premise
than I-Premise
patients I-Premise
treated I-Premise
according I-Premise
to I-Premise
WHO I-Premise
guidelines I-Premise
( I-Premise
P=0.041 I-Premise
) I-Premise
. I-Premise

Both B-Claim
drugs I-Claim
could I-Claim
improve I-Claim
the I-Claim
QoL I-Claim
, I-Claim
but O
Gefitinib B-Claim
showed I-Claim
better I-Claim
overall I-Claim
results I-Claim
than I-Claim
Pemetrexed I-Claim
. I-Claim

Chemotherapy B-Claim
can I-Claim
profoundly I-Claim
affect I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
yet O
few O
clinical O
trials O
in O
advanced O
cervical O
cancer O
have O
included O
QOL O
outcomes O
. O

Overall B-Premise
the I-Premise
treatment I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
. O

Moreover O
, O
adopting B-Premise
a I-Premise
combined I-Premise
aerobic I-Premise
and I-Premise
resistance I-Premise
exercise I-Premise
program I-Premise
after I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
was I-Premise
associated I-Premise
with I-Premise
further I-Premise
improvements I-Premise
in I-Premise
patient-rated I-Premise
outcomes I-Premise
. I-Premise

The B-Premise
use I-Premise
of I-Premise
IMRT I-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
, O
but O
the B-Premise
presence I-Premise
of I-Premise
moist I-Premise
desquamation I-Premise
did I-Premise
significantly I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
and I-Premise
a I-Premise
reduced I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

Alternating O
, O
schedule-specific B-Claim
biochemical I-Claim
modulation I-Claim
of I-Claim
FU I-Claim
is I-Claim
more I-Claim
active I-Claim
than I-Claim
MTX I-Claim
-- I-Claim
> I-Claim
5-FU I-Claim
as I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
. I-Claim

It B-Claim
represents I-Claim
an I-Claim
excellent I-Claim
complement I-Claim
or I-Claim
an I-Claim
alternative I-Claim
to I-Claim
individual I-Claim
psycho-oncologic I-Claim
therapeutic I-Claim
support I-Claim
, I-Claim
widely O
proposed O
in O
France O
, O
and O
should O
now O
be O
tested O
in O
groups O
with O
other O
types O
of O
cancer O
and O
at O
other O
disease O
phases O
. O

The B-Premise
5-year I-Premise
overall I-Premise
mortality I-Premise
for I-Premise
short-term I-Premise
and I-Premise
long-term I-Premise
suppression I-Premise
was I-Premise
19.0 I-Premise
% I-Premise
and I-Premise
15.2 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
the O
observed O
hazard O
ratio O
was O
1.42 O
( O
upper O
95.71 O
% O
confidence O
limit O
, O
1.79 O
";" O
P=0.65 O
for O
noninferiority O
) O
. O

Recruitment O
was O
stopped O
after O
the B-Premise
first I-Premise
planned I-Premise
interim I-Premise
analysis I-Premise
in I-Premise
February I-Premise
2006 I-Premise
( I-Premise
n=150 I-Premise
) I-Premise
showed I-Premise
that I-Premise
survival I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
placebo I-Premise
than I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
sertraline I-Premise
( I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
1.60 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1.04-2.45 I-Premise
] I-Premise
, I-Premise
log-rank I-Premise
p=0.04 I-Premise
";" I-Premise
adjusted I-Premise
hazard I-Premise
ratio I-Premise
1.62 I-Premise
[ I-Premise
1.06-2.41 I-Premise
] I-Premise
, I-Premise
Cox I-Premise
model I-Premise
p=0.02 I-Premise
) I-Premise
. I-Premise

As O
well O
, O
Etoposide B-Claim
resulted I-Claim
in I-Claim
better I-Claim
physical I-Claim
and I-Claim
psychological I-Claim
subscale I-Claim
scores I-Claim
than I-Claim
radiotherapy I-Claim
, I-Claim
3-drugs I-Claim
and I-Claim
supportive I-Claim
care I-Claim
. I-Claim

In O
the O
comparison O
of O
responders O
versus O
patients O
with O
both O
SD O
( O
6m O
) O
and O
PD O
, O
responders B-Premise
indicated I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
4 I-Premise
) I-Premise
and I-Premise
mood I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
at I-Premise
month I-Premise
3 I-Premise
. I-Premise

Local B-Premise
recurrence I-Premise
rate I-Premise
and I-Premise
five-year I-Premise
survival I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
groups I-Premise
";" I-Premise
however B-Claim
, I-Claim
the I-Claim
limited I-Claim
number I-Claim
of I-Claim
patients I-Claim
does I-Claim
not I-Claim
allow I-Claim
firm I-Claim
conclusions I-Claim
. I-Claim

Similarly O
, O
no B-Premise
OS I-Premise
difference I-Premise
was I-Premise
seen I-Premise
in I-Premise
the I-Premise
histologic I-Premise
( I-Premise
squamous I-Premise
or I-Premise
nonsquamous I-Premise
) I-Premise
and I-Premise
sex I-Premise
( I-Premise
male I-Premise
or I-Premise
female I-Premise
) I-Premise
strata I-Premise
. I-Premise

Adverse B-Premise
drug I-Premise
reactions I-Premise
were I-Premise
reported I-Premise
in I-Premise
3 I-Premise
% I-Premise
( I-Premise
9 I-Premise
patients I-Premise
) I-Premise
, I-Premise
and O
8 B-Premise
patients I-Premise
were I-Premise
lost I-Premise
to I-Premise
follow-up I-Premise
. I-Premise

QOL B-Premise
analyses I-Premise
favored I-Premise
Arm I-Premise
A. I-Premise
SGN-15 B-Claim
plus I-Claim
docetaxel I-Claim
is I-Claim
a I-Claim
well-tolerated I-Claim
and I-Claim
active I-Claim
second I-Claim
and I-Claim
third I-Claim
line I-Claim
treatment I-Claim
for I-Claim
NSCLC I-Claim
patients I-Claim
. O

In O
contrast O
, O
no B-Premise
significant I-Premise
improvement I-Premise
was I-Premise
observed I-Premise
in I-Premise
Group I-Premise
2 I-Premise
after I-Premise
the I-Premise
exercise I-Premise
program I-Premise
in I-Premise
any I-Premise
of I-Premise
parameters I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
pre-exercise I-Premise
period I-Premise
( I-Premise
P I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Pain B-Premise
and I-Premise
analgesic I-Premise
scores I-Premise
increased I-Premise
more I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
than I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
, I-Premise
but O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
disease I-Premise
progression I-Premise
, I-Premise
performance I-Premise
status I-Premise
, I-Premise
or I-Premise
quality-of-life I-Premise
scores I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise

However O
, O
we B-Premise
reported I-Premise
a I-Premise
response I-Premise
rate I-Premise
of I-Premise
43.1 I-Premise
and I-Premise
38.6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
MVP I-Premise
and I-Premise
MVC I-Premise
arm I-Premise
( I-Premise
P=0.59 I-Premise
) I-Premise
and I-Premise
a I-Premise
median I-Premise
survival I-Premise
of I-Premise
10.2 I-Premise
and I-Premise
7.2 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
cisplatin I-Premise
and I-Premise
carboplatin I-Premise
arm I-Premise
( I-Premise
P=0.39 I-Premise
) I-Premise
. I-Premise

The B-Claim
effects I-Claim
of I-Claim
Pemetrexed I-Claim
and I-Claim
Gefitinib I-Claim
as I-Claim
second I-Claim
line I-Claim
therapy I-Claim
were I-Claim
similar I-Claim
, I-Claim
although B-Premise
with I-Premise
different I-Premise
AEs I-Premise
. I-Premise

All O
endometrial O
cancers O
in O
the O
tamoxifen O
group O
were O
stage O
I O
( O
localized O
disease O
) O
";" O
no B-Premise
endometrial I-Premise
cancer I-Premise
deaths I-Premise
have I-Premise
occurred I-Premise
in I-Premise
this I-Premise
group I-Premise
. I-Premise

Overall O
, O
QoL B-Claim
scores I-Claim
were I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
treatment I-Claim
groups I-Claim
, I-Claim
but B-Claim
thalidomide I-Claim
was I-Claim
associated I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
diarrhea I-Claim
and I-Claim
more I-Claim
constipation I-Claim
and I-Claim
peripheral I-Claim
neuropathy I-Claim
. I-Claim

The B-Premise
disease-related I-Premise
symptoms I-Premise
improved I-Premise
with I-Premise
time I-Premise
, I-Premise
and O
the B-Premise
benefits I-Premise
lasted I-Premise
for I-Premise
the I-Premise
entire I-Premise
treatment I-Premise
period I-Premise
. I-Premise

Likewise O
, O
emotional B-Premise
, I-Premise
functional I-Premise
well-being I-Premise
, I-Premise
and I-Premise
QoL I-Premise
aspects I-Premise
specifically I-Premise
related I-Premise
to I-Premise
lung I-Premise
cancer I-Premise
were I-Premise
better I-Premise
improved I-Premise
in I-Premise
the I-Premise
Gefitinib I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Thus O
, O
elderly B-Claim
patients I-Claim
in I-Claim
need I-Claim
of I-Claim
intensified I-Claim
chemotherapy I-Claim
may I-Claim
receive I-Claim
FLOT I-Claim
without I-Claim
compromising I-Claim
patient-reported I-Claim
outcome I-Claim
parameters I-Claim
. I-Claim

Thus O
, O
the B-Premise
rate I-Premise
of I-Premise
efficacy I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
combined I-Premise
treatment I-Premise
group I-Premise
( I-Premise
85.36 I-Premise
% I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
vs. I-Premise
control I-Premise
group I-Premise
) I-Premise
. I-Premise

Fulvestrant B-Claim
500 I-Claim
mg I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
increase I-Claim
in I-Claim
PFS I-Claim
and I-Claim
not I-Claim
associated I-Claim
with I-Claim
increased I-Claim
toxicity I-Claim
, I-Claim
corresponding O
to O
a O
clinically O
meaningful O
improvement O
in O
benefit O
versus O
risk O
compared O
with O
fulvestrant O
250 O
mg O
. O

